

- Aalavi, A, 286P(ab)
 Aaron, AD, 1676
 Aaron, LA, 276P(ab)
 Abdel-Dayem, HM, 1662, 242P(ab), 251P(ab), 277P(ab), 301P(ab)
 Abdel-Nabi, H, 9P(ab), 135P(ab), 136P(ab), 238P(ab), 259P(ab)
 Abe, H, 1444
 Abe, R, 294P(ab)
 Abe, S, 955
 Abe, Y, 320
 Abella-Columna, E, 111P(ab), 132P(ab), 136P(ab), 139P(ab)
 Abi-Dargham, A, 33P(ab), 285P(ab)
 Abitbol, C, 23P(ab)
 Abraham, SA, 161P(ab)
 Abramovici, J, 2017
 Abrams, DN, 1589
 Abrams, MJ, 843
 Aburano, T, 5P(ab), 44P(ab), 291P(ab), 292P(ab)
 Acampa, W, 138P(ab), 156P(ab), 159P(ab)
 Achong, D, 267
 Achong, DM, 113P(ab), 240P(ab)
 Ackerman, C, 857
 Ackermann, RJ, 78P(ab), 215P(ab)
 Adachi, I, 263P(ab), 296P(ab)
 Adam, L-E, 221P(ab)
 Adam, LE, 2024
 Adam, M, 36P(ab)
 Adamietz, IA, 1942
 Adams, BK, 1001
 Adams, KF, 80P(ab)
 Adams, S, 121P(ab), 137P(ab)
 Adelson, PD, 269P(ab)
 Adelstein, SJ, 315, 343, 102P(ab), 187P(ab), 229P(ab), 10S, 16S, 19S, 1S
 Adiseshan, P, 179P(ab)
 Adler, B, 302P(ab)
 Adler, LP, 99P(ab)
 Affleck, DJ, 191P(ab)
 Afriyie, MO, 103P(ab), 242P(ab)
 Agis, H, 5P(ab)
 Agnew, JE, 104P(ab)
 Agresti, R, 251P(ab)
 Ahlberg, AW, 37P(ab), 58P(ab), 150P(ab), 177P(ab)
 Ahlman, H, 1519, 2002
 Ahlstrom, H, 32, 1766
 Ahmad, A, 69P(ab)
 Ahmad, K, 457
 Ahmed, M, 993
 Ahn, BC, 268P(ab)
 Ahn, SH, 252P(ab)
 Ahonen, A, 22P(ab)
 Aicher, KP, 463
 Aigbirhio, FI, 141P(ab)
 Aigner, R, 1524
 Aioi, S, 116P(ab)
 Aizawa, Y, 12P(ab)
 Ajami, K, 255P(ab)
 Akabani, G, 89P(ab), 90P(ab), 231P(ab)
 Akbunar, AT, 289P(ab)
 Akerman, KK, 76P(ab)
 Akhtar, M, 993
 Akhurst, T, 1683, 131P(ab), 132P(ab)
 Akinci, H, 289P(ab)
 Akisik, M, 242P(ab), 251P(ab), 277P(ab), 301P(ab)
 Akizawa, H, 7P(ab)
 Aktay, R, 1815
 Akyuz, C, 139P(ab)
 Al-Bunny, A, 289P(ab)
 Al-Hallaq, H, 212P(ab)
 Al-Mohannadi, S, 289P(ab)
 Al-Nabulsi, I, 87P(ab)
 Al-Samrrai, E, 121P(ab)
 Al-Za'abi, K, 289P(ab)
 Alaamer, AS, 1058, 1832
 Alam, MS, 646
 Alarcon, GS, 276P(ab)
 Alauddin, MM, 107P(ab), 193P(ab)
 Alavi, A, 723, 92P(ab), 114P(ab), 117P(ab), 130P(ab), 132P(ab), 148P(ab), 165P(ab), 176P(ab), 246P(ab), 252P(ab), 265P(ab), 276P(ab), 278P(ab), 283P(ab), 284P(ab), 295P(ab), 17N(7)
 Alazraki, NP, 1575, 48P(ab), 84P(ab), 125P(ab), 179P(ab), 293P(ab), 307P(ab)
 Alberto, R, 165P(ab)
 Alberts, KR, 276P(ab)
 Albertson, DA, 1535
 AlbertusPiers, C, 482
 Albin, RL, 164P(ab)
 Albright, RE, 263P(ab)
 Alderson, PO, 5P(ab)
 Aleksandrova, Y, 51P(ab)
 Alexander, E, 158P(ab)
 Alexander, HR, 1690
 Alexander, RW, 276P(ab)
 Alexoff, D, 41P(ab)
 Alfano, B, 260P(ab)
 Algozine, CA, 1575, 47P(ab), 84P(ab)
 Ali, SA, 926, 1356
 Alisauskas, R, 96P(ab)
 Alkan, M, 184P(ab)
 Allada, V, 1717
 Allen, M, 110P(ab), 269P(ab), 301P(ab)
 Allen-Mersh, T, 54P(ab)
 Almeida, P, 217P(ab)
 Aloj, L, 1408, 99P(ab), 118P(ab), 199P(ab), 203P(ab), 204P(ab), 254P(ab)
 Alonso, O, 1919(1e), 266P(ab)
 Alper, E, 159P(ab), 289P(ab)
 Alpert, NM, 950, 33P(ab), 125P(ab), 161P(ab), 239P(ab), 244P(ab)
 Alston, KL, 191P(ab)
 Altieri, P, 565
 Altmann, A, 234P(ab), 235P(ab)
 Alvarez, RD, 1491
 Amano, M, 3P(ab)
 Amanullah, A, 69P(ab), 93P(ab), 181P(ab), 182P(ab)
 Amarencio, P, 1976
 Amato, R, 32P(ab)
 Ambrose, KR, 6P(ab), 193P(ab), 202P(ab)
 Amdur, R, 285P(ab)
 Amerenco, G, 1976
 Amin, TM, 993
 Amyotte, G, 237P(ab)
 Anayat, AR, 147P(ab)
 Anazawa, Y, 1460
 Anderson, BG, 805
 Anderson, CJ, 1294, 61P(ab), 71P(ab), 95P(ab), 128P(ab), 201P(ab), 302P(ab)
 Anderson, JH, 107P(ab)
 Anderson, JR, 227P(ab)
 Anderson, PJ, 1331, 1336
 Andersson, P, 1519, 2002
 Ando, H, 781
 Andre-Fouet, X, 147P(ab)
 Andreaco, M, 85P(ab), 86P(ab)
 Andreas, J, 104P(ab)
 Andrews, D, 157P(ab), 260P(ab)
 Andrich, MP, 1731, 34P(ab), 253P(ab)
 Anesi, E, 185P(ab)
 Angelberger, P, 1480, 1931, 5P(ab), 20P(ab), 251P(ab)
 Angeletti, S, 1452
 Anjilvel, S, 123P(ab)
 Annibale, B, 1452
 Anthony, DC, 270P(ab)
 Antonini, A, 281P(ab)
 Aoyama, T, 179P(ab)
 Appel, M, 265P(ab)
 Appelbaum, FR, 233P(ab)
 Aprile, C, 185P(ab)
 Arai, T, 1819, 64P(ab), 254P(ab)
 Araikum, S, 1323
 Araki, T, 1551, 1819, 64P(ab), 254P(ab)
 Arano, Y, 7P(ab)
 Aras, T, 1662, 177P(ab), 257P(ab), 291P(ab)
 Araujo, LI, 723, 92P(ab), 148P(ab), 176P(ab)
 Arbab, AS, 1551, 1819, 64P(ab), 254P(ab)
 Arbizu, J, 93P(ab)
 Areeda, J, 81P(ab)
 Arildsen, RC, 131P(ab)
 Arimizu, N, 258P(ab), 277P(ab)
 Arisaka, H, 184P(ab)
 Aronochick, JM, 117P(ab)
 Aronsson, EF, 1519
 Arrighi, JA, 282P(ab)
 Arthur, JE, 258P(ab)
 Asenbaum, S, 1931
 Ashburner, J, 271P(ab)
 Ashby, CR Jr, 203P(ab)
 Ashihara, T, 781
 Ashook, G, 46
 Atahan, L, 1956
 Atasever, T, 139P(ab)
 Atay, S, 233
 Atkins, FB, 643, 1639
 Atkins, H, 102P(ab)
 Atkins, HL, 239, 72P(ab)
 Atkins, MS, 209P(ab)
 Atsumi, H, 181P(ab)
 Attie, JN, 242P(ab)
 Aubert, B, 1860
 Aubrey, BA, 174P(ab)
 Augustine, SC, 13S, 90P(ab)
 Auinger, Ch, 241P(ab)
 Aung, MT, 174P(ab)
 Aurell, M, 1872, 1876, 1883
 Aurengo, A, 847, 1773
 Austin-Lane, JL, 284P(ab)
 Avedon, M, 46
 Avril, N, 99P(ab)
 Awata, S, 410
 Awotwi-Pratt, J, 148P(ab)
 Ayyangar, KM, 90P(ab)
 Aziz, M, 242P(ab), 277P(ab)
 Azizi, N, 68P(ab)
 Azuma, M, 244P(ab)
 Baars, JB, 584
 Baas, P, 584
 Babain, R, 296P(ab)
 Babchick, B, 1760
 Babich, JW, 4P(ab), 33P(ab), 143P(ab), 152P(ab), 228P(ab), 239P(ab), 240P(ab), 269P(ab)
 Bacharach, SL, 690, 786, 1557, 1795, 25P(ab), 39P(ab), 60P(ab), 93P(ab), 99P(ab), 160P(ab), 161P(ab), 211P(ab), 253P(ab)
 Bachert, P, 257P(ab), 264P(ab), 296P(ab)
 Bachmann, R, 218P(ab)
 Badawi, RD, 73P(ab)
 Bading, JR, 107P(ab), 155P(ab)
 Baeten, J, 91P(ab)
 Bag, R, 1662
 Bagheri, B, 14P(ab), 149P(ab)
 Bagnara, MC, 243P(ab)
 Bahadur, S, 137P(ab)
 Bahr, A, 1846
 Bahitiarian, EA, 22P(ab), 74P(ab)
 Baidjnath Panday, RKL, 972
 Baidoo, KE, 189P(ab)
 Bailer, H, 115P(ab)
 Bailey, AG, 873
 Bailey, DL, 85P(ab), 148P(ab), 271P(ab)
 Bailey, NO, 19S
 Bair, HJ, 829
 Bajc, M, 622
 Baker, RJ, 84P(ab), 198P(ab)
 Bakheet, S, 26
 Bakheet, SM, 993
 Bakkaloglu, A, 145P(ab)
 Bakker, M, 67P(ab)
 Bakker, WH, 108, 1388, 190P(ab)
 Bal, CS, 137P(ab)
 Baldassari, S, 16S
 Baldwin, D, 2006
 Baldwin, RM, 11, 32P(ab), 33P(ab), 44P(ab), 272P(ab), 285P(ab)
 Balfiore, J, 254P(ab)
 Balkanci, F, 291P(ab)
 Ballinger, JR, 513, 1023, 1578, 1591(ed), 1591(ed), 281P(ab)
 Baltimore, D, 24P(ab)
 Balza, E, 238P(ab)
 Bandy, D, 224P(ab)
 Bangard, M, 100P(ab), 265P(ab)
 Bangerter, M, 262P(ab)
 Banish, MR, 124P(ab)
 Banks, D, 146
 Bannerman, J, 1578
 Banshal, S, 150P(ab)
 Baquey, C, 863
 Bar, RS, 1815
 Bar-Sever, Z, 81, 22P(ab), 28P(ab), 292P(ab)
 Bar-Shalom, R, 139P(ab)
 Baran, Y, 230P(ab)
 Baranowska-Kortylewicz, J, 315, 90P(ab), 150P(ab), 13S, 16S, 19S, 22S
 Barbaras, LG, 172P(ab)
 Barbarics, E, 118P(ab)
 Barber, HB, 53P(ab), 301P(ab)
 Barbet, J, 1853, 129P(ab)
 Barclay, AB, 1891
 Barclay, PD, 315
 Bardet, S, 1853
 Bardies, M, 1853
 Bareille, R, 863
 Bareket, Y, 182P(ab)
 Barendswaard, E, 1052
 Bares, R, 27P(ab), 134P(ab), 137P(ab), 140P(ab)
 Barker, C, 211P(ab)
 Barker, FG II, 157P(ab)
 Barker, WC, 1795
 Barlow, R, 92P(ab)
 Barnes, PD, 81
 Barnes, WE, 275P(ab)
 Baro, ME, 16
 Baron, J, 95
 Baroni, S, 238P(ab)
 Barre, L, 95
 Barrett, HH, 53P(ab), 63P(ab), 124P(ab), 301P(ab)
 Barrett, JA, 117P(ab), 119P(ab), 129P(ab), 151P(ab), 202P(ab), 232P(ab)
 Barrington, S, 87P(ab), 282P(ab)
 Barrington, SF, 1771
 Barrio, JR, 79P(ab), 107P(ab), 147P(ab), 193P(ab)
 Barron, B, 162P(ab), 272P(ab), 292P(ab)
 Barrow, SA, 843, 198P(ab)
 Barsa, J, 251P(ab), 301P(ab)
 Bartelt, KM, 159P(ab)
 Bartenstein, P, 122P(ab), 157P(ab), 278P(ab)
 Barth, I, 218P(ab)
 Bartlett, ML, 1795, 39P(ab), 93P(ab)
 Bartolic, E, 259P(ab)
 Bass, LA, 51P(ab), 61P(ab), 128P(ab), 201P(ab)
 Bassa, P, 931, 1472, 261P(ab)
 Bassett, LW, 269P(ab)

- Bassingtonwaigte, JB, 106P(ab), 110P(ab), 146P(ab)
 Bastidas, D, 673, 1016, 38P(ab), 152P(ab)
 Baudin, E, 912, 1830, 20P(ab)
 Bauer, B, 76P(ab)
 Baum, H, 107P(ab)
 Baum, JK, 74P(ab)
 Baum, RP, 362, 1942, 9P(ab), 121P(ab), 137P(ab)
 Baum, S, 854
 Baumeister, R, 25P(ab)
 Bausart, R, 258P(ab)
 Bautovich, G, 90P(ab)
 Bavisotto, L, 140P(ab)
 Bax, JJ, 1631, 59P(ab), 60P(ab), 176P(ab), 178P(ab), 184P(ab)
 Bazzicalupo, L, 260P(ab)
 Beanlands, RS, 174P(ab)
 Beattie, B, 53P(ab), 54P(ab)
 Beauduin, M, 258P(ab)
 Beaumier, P, 144P(ab)
 Bebe, M, 29P(ab)
 Becherer, A, 1480, 254P(ab)
 Beck, D, 225P(ab)
 Becker, DV, 24N(12)
 Becker, J, 27P(ab), 200P(ab)
 Becker, W, 362, 255P(ab)
 Becker, WS, 829
 Beckurts, KTE, 114P(ab)
 Bednarczyk, EM, 198P(ab)
 Beek, FJA, 289P(ab)
 Beehuis, H, 482
 Beekman, FJ, 62P(ab), 171P(ab), 213P(ab), 216P(ab)
 Beer, S, 172P(ab)
 Beets, AL, 6P(ab), 166P(ab), 193P(ab), 202P(ab)
 Begent, RH, 868
 Behar, P, 136P(ab)
 Behnke, A, 257P(ab)
 Behr, T, 362, 905, 1504
 Behr, TM, 829, 9P(ab), 43P(ab), 44P(ab), 96P(ab), 102P(ab), 168P(ab), 169P(ab), 231P(ab), 232P(ab), 243P(ab)
 Beintema, KD, 21P(ab)
 Bekdik, C, 177P(ab), 257P(ab), 291P(ab)
 Bekdik, CF, 1956
 Bekhechi, D, 229P(ab)
 Belakhlief, A, 209, 1850, 133P(ab)
 Belezzuoli, EV, 92P(ab), 182P(ab)
 Belghiti, J, 113P(ab)
 Belgia, A, 302P(ab)
 Bellanova, B, 250P(ab)
 Belldegrun, A, 141P(ab), 267P(ab)
 Bellemann, ME, 2024, 154P(ab), 221P(ab), 249P(ab), 265P(ab), 266P(ab)
 Beller, GA, 1398, 3P(ab), 69P(ab)
 Bellina, CR, 22S
 Bello, S, 216P(ab)
 Ben-Haim, S, 39P(ab), 139P(ab)
 Benali, H, 217P(ab)
 Benard, F, 130P(ab)
 Benari, B, 93P(ab), 180P(ab)
 Benazzouz, F, 189P(ab)
 Bencherif, B, 7P(ab)0
 Bender, H, 1496, 100P(ab), 134P(ab), 138P(ab), 236P(ab), 252P(ab), 265P(ab)
 Bendriem, B, 5, 118, 1557, 76P(ab), 154P(ab), 170P(ab), 217P(ab), 226P(ab)
 Benjamin, C, 75P(ab)
 Benkfat, C, 113P(ab), 284P(ab)
 Bennett, A, 1749
 Bennett, JA, 87P(ab), 148P(ab)
 Bennett, LR, 306P(ab)
 Bense, S, 99P(ab)
 Benti, R, 37P(ab), 230P(ab)
 Bentourquia, M, 2040, 2046
 Benz, P, 209P(ab)
 Beppu, Y, 1444
 Bera, R, 249P(ab)
 Berardino, S, 13P(ab)
 Berdichevsky, D, 125P(ab)
 Berent, S, 201, 163P(ab), 164P(ab)
 Berg, G, 1519
 Berg, GEB, 228
 Berger, H, 261P(ab)
 Berger, R, 16P(ab)
 Bergman, D, 1487, 135P(ab)
 Bergman, J, 51P(ab)
 Bergman, JB, 387
 Bergmann, SR, 1294, 1723, 39P(ab), 83P(ab), 147P(ab), 221P(ab), 222P(ab)
 Bergstrom, KA, 45P(ab), 76P(ab)
 Bergstrom, M, 32, 1766
 Berk, AJ, 107P(ab)
 Berkefeld, J, 121P(ab)
 Berkenboom, G, 83P(ab)
 Berlangieri, S, 1683
 Berlangieri, SU, 121P(ab), 131P(ab), 132P(ab)
 Berlin, JA, 723
 Berman, DS, 14P(ab), 59P(ab), 68P(ab), 69P(ab), 81P(ab), 93P(ab), 116P(ab), 149P(ab), 176P(ab), 180P(ab), 181P(ab), 182P(ab)
 Berman, KF, 559, 79P(ab), 284P(ab)
 Berman, RM, 315
 Berna, L, 631
 Bernard, AM, 1946
 Bernard, B, 141P(ab)
 Bernard, BF, 1388
 Bernard, E, 34P(ab), 46P(ab)
 Bernard, HF, 190P(ab)
 Bernard, X, 39P(ab)
 Bernas, M, 183P(ab)
 Bernatz, S, 262P(ab)
 Bernstein, ID, 43P(ab), 233P(ab)
 Bernuau, J, 113P(ab)
 Berridge, MS, 11P(ab), 174P(ab)
 Berry, CR, 2011, 200P(ab)
 Berthele, A, 278P(ab)
 Berthold, T, 441, 121P(ab)
 Bertrand-Caix, J, 863
 Besnard, J-C, 186P(ab)
 Best, S, 44P(ab), 272P(ab)
 Better, N, 1618
 Bettman, L, 103P(ab)
 Beutler, JJ, 289P(ab)
 Beyer, GJ, 51P(ab)
 Beyer, J, 104P(ab), 159P(ab)
 Bhargava, K, 199P(ab), 244P(ab)
 Bhattachary, MM, 306P(ab)
 Bhatti, MA, 114P(ab)
 Bhulya, T, 242P(ab)
 Bi, Z, 197P(ab)
 Bianchi, V, 13P(ab)
 Biassoni, P, 243P(ab)
 Biegon, A, 40P(ab)
 Bien, S, 463
 Bier, D, 55P(ab)
 Bierman, H, 46
 Biersack, H-J, 100P(ab), 134P(ab), 138P(ab), 236P(ab), 243P(ab), 252P(ab), 265P(ab), 273P(ab), 280P(ab)
 Biersack, HJ, 626, 1496, 1962
 Bieszk, JA, 149P(ab)
 Bigio, E, 79P(ab)
 Biler, P, 284P(ab)
 Billotey, C, 1773
 Biniakiewicz, DS, 752, 49P(ab), 188P(ab)
 Binkert, B, 1995
 Binkley, D, 86P(ab)
 Biraben, A, 1946
 Birnbaum, EH, 132P(ab)
 Bischof-Delaloye, A, 245P(ab)
 Bishop, J, 1683
 Bisi, G, 26P(ab)
 Bizais, Y, 57P(ab)
 Biziere, K, 77P(ab)
 Bjurling, P, 32
 Black, K, 146P(ab)
 Black, P, 65P(ab), 263P(ab), 265P(ab)
 Black, PMcL, 19S
 Blahd, WH, 53P(ab)
 Blalock, JE, 276P(ab)
 Blank, E, 169P(ab)
 Blankspoor, SC, 218P(ab)
 Blanksma, PK, 1631
 Blasberg, R, 53P(ab), 54P(ab)
 Blasini, R, 126P(ab)
 Blasl, C, 307P(ab)
 Blastos, BP, 231P(ab)
 Blatter, J, 265P(ab)
 Blaufox, D, 1876
 Blaufox, MD, 171, 838, 1883
 Blend, MJ, 252, 211P(ab), 217P(ab)
 Blessing, G, 166P(ab)
 Blevins, WE, 197P(ab)
 Blier, P, 113P(ab)
 Blijham, GH, 38, 244, 465, 1511
 Block, P, 718
 Blohm, K, 170P(ab)
 Bloomfield, PM, 85P(ab)
 Blower, PJ, 166P(ab)
 Berry, CR, 2011, 200P(ab)
 Berthele, A, 278P(ab)
 Berthold, T, 441, 121P(ab)
 Bertrand-Caix, J, 863
 Besnard, J-C, 186P(ab)
 Best, S, 44P(ab), 272P(ab)
 Better, N, 1618
 Bettman, L, 103P(ab)
 Beutler, JJ, 289P(ab)
 Beyer, GJ, 51P(ab)
 Beyer, J, 104P(ab), 159P(ab)
 Bhargava, K, 199P(ab), 244P(ab)
 Bhattachary, MM, 306P(ab)
 Bhatti, MA, 114P(ab)
 Bhulya, T, 242P(ab)
 Bi, Z, 197P(ab)
 Bianchi, V, 13P(ab)
 Biassoni, P, 243P(ab)
 Biegon, A, 40P(ab)
 Bien, S, 463
 Bier, D, 55P(ab)
 Bierman, H, 46
 Biersack, H-J, 100P(ab), 134P(ab), 138P(ab), 236P(ab), 243P(ab), 252P(ab), 265P(ab), 273P(ab), 280P(ab)
 Biersack, HJ, 626, 1496, 1962
 Bieszk, JA, 149P(ab)
 Bigio, E, 79P(ab)
 Biler, P, 284P(ab)
 Billotey, C, 1773
 Biniakiewicz, DS, 752, 49P(ab), 188P(ab)
 Binkert, B, 1995
 Binkley, D, 86P(ab)
 Biraben, A, 1946
 Birnbaum, EH, 132P(ab)
 Bischof-Delaloye, A, 245P(ab)
 Bishop, J, 1683
 Bisi, G, 26P(ab)
 Bonaduce, D, 13P(ab)
 Bonasera, TA, 1009
 Bone, D, 120P(ab), 208P(ab)
 Bongiovanni, J, 171
 Bongiovanni, JA, 838
 Boni, RAH, 441
 Boniface, GR, 1942
 Boning, G, 180P(ab)
 Bonnin, F, 35P(ab), 113P(ab), 231P(ab)
 Bonora, D, 22S
 Bonte, FJ, 79P(ab)
 Booij, J, 65P(ab), 134P(ab)
 Bonstra, H, 263P(ab)
 Bordenave, L, 863
 Borer, JS, 38P(ab), 93P(ab), 184P(ab)
 Borgers, M, 26P(ab)
 Borges-Neto, S, 14P(ab), 74P(ab)
 Bormans, G, 767, 26P(ab), 54P(ab)
 Borously, S, 48P(ab)
 Borovicka, J, 245P(ab)
 Bosch, CMJ, 964
 Bossuyt, A, 718, 1346, 1605, 88P(ab), 211P(ab), 268P(ab)
 Böttcher, HD, 1942
 Bottcher, M, 1626
 Botti, G, 665, 155P(ab), 156P(ab)
 Bottlaender, M, 5
 Bottoncetti, A, 279P(ab)
 Blumenfeld, JD, 838
- Blumenthal, RD, 96P(ab), 102P(ab), 168P(ab), 169P(ab)
 Blundell, P, 17P(ab)
 Boazi, M, 186P(ab)
 Bobba, K, 47P(ab)
 Bobigny, CHU, 274P(ab)
 Bock, E, 248P(ab)
 Bock, F, 241P(ab)
 Bock, M, 296P(ab)
 Bockisch, A, 103P(ab), 104P(ab), 144P(ab), 159P(ab), 209P(ab), 233P(ab)
 Bode, A, 154P(ab)
 Boden, JA, 868
 Bodl, I, 287P(ab)
 Boer, GJ, 134P(ab)
 Boerman, OC, 1392, 169P(ab)
 Boersma, LJ, 584
 Bogdanov, AA Jr, 198P(ab)
 Bogers, AJC, 748
 Bogg, R, 226P(ab)
 Bohuslavizki, KH, 4P(ab), 142P(ab), 246P(ab), 256P(ab), 257P(ab)
 Boissier, B, 233P(ab)
 Bok, B, 35P(ab), 101P(ab), 113P(ab), 217P(ab), 231P(ab)
 Bol, A, 39P(ab)
 Bolasco, P, 565
 Bom, HS, 67P(ab)
 Bonanji, J, 995
 Bonanji, JB, 1828
 Bombardier, E, 250P(ab), 251P(ab)
 Bonab, AA, 33P(ab), 228P(ab)
 Bonaduce, D, 13P(ab)
 Bonasera, TA, 1009
 Bone, D, 120P(ab), 208P(ab)
 Bongiovanni, J, 171
 Bongiovanni, JA, 838
 Boni, RAH, 441
 Boniface, GR, 1942
 Boning, G, 180P(ab)
 Bonnin, F, 35P(ab), 113P(ab), 231P(ab)
 Bonora, D, 22S
 Bonte, FJ, 79P(ab)
 Booij, J, 65P(ab), 134P(ab)
 Bonstra, H, 263P(ab)
 Bordenave, L, 863
 Borer, JS, 38P(ab), 93P(ab), 184P(ab)
 Borgers, M, 26P(ab)
 Borges-Neto, S, 14P(ab), 74P(ab)
 Bormans, G, 767, 26P(ab), 54P(ab)
 Borously, S, 48P(ab)
 Borovicka, J, 245P(ab)
 Bosch, CMJ, 964
 Bossuyt, A, 718, 1346, 1605, 88P(ab), 211P(ab), 268P(ab)
 Böttcher, HD, 1942
 Bottcher, M, 1626
 Botti, G, 665, 155P(ab), 156P(ab)
 Bottlaender, M, 5
 Bottoncetti, A, 279P(ab)
 Blumenfeld, JD, 838
- 106P(ab)
 Bouchard, M, 723
 Boudreau, RJ, 142P(ab), 189P(ab)
 Bourguignon, M, 217P(ab)
 Bourque, JP, 1031
 Bousser, MG, 1976
 Bouville, AC, 24N(12)
 Bowen, WD, 7P(ab), 205P(ab), 267P(ab)
 Boxen, I, 1578
 Boy, C, 113P(ab)
 Boyd, J, 136P(ab), 264P(ab)
 Boyd, SJ, 744
 Boz, A, 1916(le), 1917(le)
 Braams, JW, 897
 Bracco, L, 278P(ab)
 Brachman, M, 46
 Bradley, LA, 276P(ab)
 Brady, F, 191P(ab)
 Brady, J, 289P(ab)
 Brady, LW, 65P(ab), 265P(ab)
 Brady, M, 138P(ab)
 Brady, TJ, 198P(ab)
 Brancato, R, 967
 Brandau, W, 1865, 1990, 49P(ab), 268P(ab)
 Brandt, A, 142P(ab)
 Brandt, T, 122P(ab)
 Brannon, WL, 1595
 Braun, C, 13P(ab)
 Braverman, LE, 991
 Brcke, T, 1931
 Brechbiel, MW, 152P(ab), 234P(ab)
 Breeman, WAP, 108, 1388, 141P(ab)
 Breier, A, 77P(ab)
 Breithardt, G, 106P(ab)
 Breitschwerdt, E, 200P(ab)
 Bremner, JD, 80P(ab)
 Brennan, KM, 130P(ab), 146P(ab)
 Brenner, L, 11
 Brenner, W, 4P(ab), 142P(ab), 246P(ab), 256P(ab), 257P(ab)
 Brensing, A, 243P(ab)
 Bresnick, M, 119P(ab), 129P(ab), 232P(ab)
 Brezinski, DA, 174P(ab)
 Brill, AB, 1583, 23N(6)
 Brill, D, 23N(6)
 Briscoe, E, 926, 1356, 79P(ab)
 Britton, K, 1872
 Britton, KE, 96P(ab)
 Brix, G, 2024, 154P(ab), 221P(ab), 249P(ab), 266P(ab)
 Brizel, DM, 1438
 Brochet, E, 275
 Broderick, TM, 307P(ab)
 Brodin, L-V, 120P(ab)
 Broglia, L, 255P(ab)
 Bronen, RA, 1749
 Bronster, DJ, 467
 Brooks, DJ, 109P(ab), 271P(ab)
 Brotchi, J, 53P(ab)
 Broussard, WF, 32P(ab)
 Brown, A, 191P(ab)
 Brown, CV, 178
 Brown, DJ, 109P(ab)

- Brown, JK, 218P(ab)
 Brown, JW, 302P(ab)
 Brown, K, 818
 Brown, KL, 57P(ab),
 244P(ab)
 Brown, ML, 1903
 Brown, PR, 288P(ab)
 Brown, RS, 1042, 1540,
 64P(ab), 65P(ab)
 Browne, BJ, 292P(ab)
 Browne, G, 31P(ab)
 Browne, JA, 62P(ab)
 Brownell, A-L, 65P(ab),
 66P(ab)
 Brownell, GL, 66P(ab)
 Bruckbauer, T, 155P(ab)
 Brücke, T, 1931
 Brucker-Davis, F, 1690,
 15P(ab)
 Bruckner, JB, 140P(ab)
 Bruels, MC, 229P(ab)
 Brunken, RC, 177P(ab)
 Brunner, F, 108P(ab)
 Bruno, A, 37P(ab), 230P(ab)
 Brust, P, 16P(ab)
 Bubeck, B, 1883
 Buchsbaum, DJ, 186P(ab)
 Buchsbaum, M, 38P(ab)
 Buchtel, HA, 270P(ab)
 Buck, A, 441, 699, 146P(ab),
 207P(ab)
 Budinger, TF, 40P(ab),
 51P(ab), 98P(ab),
 130P(ab), 131P(ab),
 146P(ab)
 Buell, U, 140P(ab)
 Buga, K, 287P(ab)
 Buhler, KR, 151P(ab)
 Buijs, WCAM, 2072
 Bujenovic, LS, 80P(ab)
 Buonocore, E, 279P(ab)
 Buonomo, C, 22P(ab)
 Buralli, S, 16S, 22S
 Burchert, W, 521, 2066
 Burdette, JH, 215P(ab)
 Burg, M, 59P(ab)
 Burger, C, 699, 146P(ab),
 207P(ab)
 Burke, D, 54P(ab)
 Burke, JF, 244P(ab)
 Burns, HD, 307, 288P(ab)
 Burns, L, 66P(ab)
 Burns, RJ, 1918(le)
 Burns, SM, 276P(ab)
 Burns, T, 39P(ab)
 Burris, T, 222P(ab)
 Burris, TG, 1575, 84P(ab),
 305P(ab)
 Burrows, BA, 1922
 Bury, T, 260P(ab)
 Buscombe, JR, 104P(ab)
 Bush, LR, 673, 775,
 204P(ab)
 Bushnell, DL, 31P(ab)
 Butler, J, 1789
 Butler, SP, 744
 Butterworth, E, 70P(ab)
 Buvat, I, 39P(ab), 161P(ab),
 217P(ab)
 Buxton, D, 767
 Buxton, DB, 3P(ab)
 Buxton-Thomas, M, 195
 Buyck, D, 35P(ab), 113P(ab)
 Buyukpamukcu, M, 139P(ab)
 Buzdar, A, 86P(ab)
- Byars, LG, 155P(ab)
 Byrne, MJ, 379
 Cabahug, C, 218P(ab)
 Cabahug, CJ, 239
 Cabico, JA, 69P(ab),
 182P(ab)
 Cadiot, G, 275, 253P(ab),
 256P(ab)
 Cadorette, J, 2040, 170P(ab)
 Caetano, D, 273P(ab)
 Caillou, B, 1830
 Caixas, A, 631
 Calame, W, 241P(ab)
 Calcagno, G, 238P(ab),
 243P(ab), 297P(ab)
 Calderon, C, 287P(ab)
 Caldwell, JC, 106P(ab)
 Caldwell, JH, 70P(ab),
 110P(ab), 146P(ab),
 205P(ab)
 Calguner, M, 290P(ab)
 Callahan, RJ, 843, 198P(ab),
 228P(ab), 239P(ab)
 Callahan, RJ, 2092
 Callans, D, 14P(ab),
 149P(ab)
 Calnon, DA, 3P(ab)
 Calsamiglia, G, 185P(ab)
 Calvitto, M, 55
 Calza, P, 47P(ab)
 Camargo, ECS, 273P(ab)
 Camargo, EE, 273P(ab)
 Camaya, MV, 34P(ab),
 244P(ab)
 Camici, PG, 71P(ab),
 106P(ab)
 Camp, V, 186P(ab),
 191P(ab), 298P(ab)
 Campbell, CE, 123P(ab)
 Campisi, R, 82P(ab)
 Camsari, G, 233
 Caner, B, 177P(ab),
 257P(ab), 291P(ab)
 Cangemi, V, 35P(ab)
 Cannas, P, 35P(ab), 255P(ab)
 Cannizzaro, G, 185P(ab)
 Cantin, J, 75P(ab)
 Canzi, C, 230P(ab)
 Cao, Z, 1740, 2037
 Capa, G, 302P(ab)
 Capasso, I, 155P(ab)
 Caplan, R, 162P(ab)
 Capobianco, D, 264P(ab)
 Caraco, C, 138P(ab),
 156P(ab), 199P(ab),
 254P(ab)
 Cardei, S, 13P(ab), 178P(ab)
 Cardella, JF, 294P(ab)
 Caride, VJ, 91P(ab),
 296P(ab)
 Carles, MC, 144P(ab)
 Carlson, G, 254P(ab)
 Carlson, K, 86P(ab)
 Carney, BI, 1643
 Carnochan, P, 54P(ab),
 166P(ab), 191P(ab)
 Caron, H, 237P(ab)
 Carpenter, S, 91P(ab)
 Carpinelli, A, 133P(ab)
 Carr, AA, 108P(ab)
 Carr, RM, 141P(ab)
 Carrasquillo, JA, 1384,
 29P(ab), 62P(ab),
- 129P(ab), 196P(ab),
 203P(ab), 211P(ab),
 234P(ab)
 Carretta, RF, 1903, 294P(ab),
 25N(1)
 Carrier, LK, 306P(ab)
 Carriero, MV, 665
 Carrio, I, 631, 49P(ab)
 Carroll, FI, 109P(ab)
 Carroll, T, 28P(ab), 119P(ab),
 129P(ab), 151P(ab),
 202P(ab), 232P(ab)
 Carson, JM, 39P(ab),
 93P(ab), 160P(ab)
 Carson, RE, 690, 786,
 10P(ab), 77P(ab), 99P(ab),
 203P(ab), 230P(ab)
 Carter, EA, 239P(ab),
 240P(ab)
 Carton, H, 22P(ab)
 Carvalho, PA, 158P(ab), 19S
 Casale, F, 256P(ab)
 Casati, R, 37P(ab)
 Case, JA, 127P(ab),
 153P(ab), 212P(ab)
 Casey, JL, 868
 Casey, M, 170P(ab)
 Casey, ME, 85P(ab)
 Caspani, S, 205P(ab)
 Castagna, A, 258P(ab)
 Castellani, M, 37P(ab),
 230P(ab)
 Castle, VP, 16
 Castronovo, FP Jr., 19S
 Catena, G, 88P(ab)
 Cave, V, 182P(ab)
 Caymaz, O, 184P(ab)
 Cebon, J, 131P(ab), 132P(ab)
 Ceccarelli, C, 606
 Cekirge, S, 291P(ab)
 Cellar, J, 1749
 Cellier, A, 36P(ab), 120P(ab),
 209P(ab), 219P(ab)
 Censis, DM, 284P(ab)
 Ceriani, R, 169P(ab)
 Cerqueira, MD, 177P(ab)
 Cesani, F, 926, 1356
 Cesaro, P, 274P(ab)
 Cetin, S, 233
 Chabriat, H, 1976
 Chadhuri, TR, 235P(ab)
 Chakrabarti, M, 62P(ab),
 196P(ab)
 Chakrabarti, MC, 1384
 Chakraborty, PK, 51P(ab),
 145P(ab)
 Challeton, C, 598
 Chalon, S, 186P(ab)
 Chaly, T, 209, 216, 1760,
 1850, 133P(ab)
 Champion, P, 36P(ab)
 Champlin, RE, 234P(ab)
 Chan, B, 280P(ab), 283P(ab)
 Chan, G, 131P(ab), 132P(ab)
 Chan, JG, 121P(ab)
 Chan, KH, 77P(ab)
 Chan, KW, 42
 Chan, Y-W, 204P(ab)
 Chandrarlapaty, SKC, 798
 Chandra, R, 1731
 Chandramouli, B, 261P(ab)
 Chandy, B, 489
 Chang, CP, 27P(ab)
 Chang, CS, 245P(ab)
 Chang, CW, 27P(ab),
- 136P(ab)
 Chang, F, 190P(ab), 203P(ab)
 Chang, S, 1349
 Chang, SM, 157P(ab)
 Chang, W, 207P(ab),
 210P(ab)
 ChangLai, SP, 295P(ab)
 Channing, M, 204P(ab),
 230P(ab)
 Chapman, PT, 114P(ab),
 128P(ab)
 Chapman, WC, 131P(ab)
 Chappell, D, 6P(ab)
 Charif, H, 296P(ab)
 Charles, ND, 57P(ab)
 Charles, HC, 1438
 Charney, DS, 11, 32P(ab),
 33P(ab), 44P(ab), 80P(ab),
 272P(ab), 285P(ab)
 Charon, Y, 303P(ab),
 306P(ab)
 Charrier, S, 922
 Chatal, JF, 1853, 72P(ab)
 Chatzioannou, A, 8P(ab)
 Chaudhuri, TK, 288P(ab)
 Chauvel, P, 1946
 Chen, A, 279P(ab), 280P(ab)
 Chen, B, 24P(ab)
 Chen, CC, 1740, 2037,
 15P(ab), 104P(ab),
 118P(ab)
 Chen, CH, 303P(ab)
 Chen, EO, 177P(ab)
 Chen, EQ, 1809, 276P(ab)
 Chen, F, 49P(ab)
 Chen, G, 437
 Chen, GH, 245P(ab)
 Chen, J, 57P(ab)
 Chen, JL, 140P(ab)
 Chen, K, 224P(ab), 304P(ab)
 Chen, KY, 136P(ab),
 262P(ab)
 Chen, M, 332
 Chen, W, 1349
 Chen, WL, 247P(ab)
 Cheng, J, 218P(ab)
 Cheng, KT, 83P(ab)
 Chenggazi, V, 96P(ab)
 Cherif, A, 72P(ab), 86P(ab),
 253P(ab), 264P(ab)
 Cherry, SR, 55P(ab),
 73P(ab), 85P(ab), 86P(ab),
 107P(ab), 130P(ab),
 147P(ab), 193P(ab)
 Chesnut, RW, 194P(ab)
 Chester, KA, 868
 Chevillard, S, 233P(ab)
 Chi, DY, 275P(ab)
 Chia, CY, 298P(ab)
 Chiang, YH, 40P(ab)
 Chiao, PC, 1923
 Chiesa, R, 55
 Childers, SR, 87P(ab)
 Childs, M, 114P(ab),
 246P(ab)
 Chilton, HM, 2092
 Chin, BB, 723
 Chin, CT, 267
 Chingas, GC, 98P(ab)
 Chinol, M, 169P(ab),
 195P(ab), 238P(ab)
 Chiotellis, E, 188P(ab)
 Chiou, PF, 125P(ab)
 Chiou, RK, 13S
 Chirinos, RE, 238P(ab),
- Chiti, A, 250P(ab), 251P(ab)
 Chittenden, S, 228P(ab)
 Cho, BK, 89P(ab), 274P(ab)
 Cho, K, 304P(ab), 308P(ab)
 Choe, YS, 1009, 179P(ab),
 226P(ab), 275P(ab)
 Choi, CW, 248P(ab)
 Choi, NC, 950
 Choi, YB, 179P(ab),
 226P(ab), 252P(ab),
 275P(ab)
 Choi, YY, 252P(ab)
 Chossat, F, 229P(ab)
 Chou, J, 97P(ab)
 Chou, KL, 27P(ab),
 125P(ab), 136P(ab),
 286P(ab)
 Chowdhury, S, 84P(ab),
 142P(ab)
 Choyke, P, 253P(ab)
 Chrem, Y, 293P(ab)
 Christian, PE, 18P(ab),
 97P(ab), 124P(ab)
 Christopher, P, 273P(ab)
 Chu, HB, 1545
 Chu, JMG, 83P(ab)
 Chu, LS, 27P(ab), 262P(ab),
 286P(ab)
 Chu, TS, 174P(ab)
 Chua, K, 104P(ab)
 Chugani, DC, 145P(ab)
 Chugani, HT, 51P(ab),
 145P(ab)
 Chui, C-S, 89P(ab)
 Chumpradit, S, 17P(ab)
 Chun, KJ, 838
 Chung, J, 639, 978
 Chung, J-K, 28P(ab),
 89P(ab), 100P(ab),
 248P(ab), 274P(ab),
 282P(ab)
 Chung, SW, 282P(ab)
 Chung, TS, 426, 551
 Chung, WS, 248P(ab)
 Chyatte, D, 276P(ab)
 Chyr, JS, 286P(ab)
 Cid, E, 58P(ab)
 Cinotti, L, 147P(ab)
 Civelek, AC, 262P(ab)
 Clack, R, 18P(ab), 120P(ab)
 Claessens, RAMJ, 62, 1392,
 72P(ab), 128P(ab),
 241P(ab)
 Clark, J, 225P(ab), 226P(ab)
 Clark, JC, 194P(ab)
 Clark, RD, 40P(ab)
 Clark, RL, 124P(ab)
 Clark, S, 74P(ab)
 Clark, WS, 179P(ab)
 Clarke, CP, 121P(ab)
 Clarke, GA, 995
 Clarke, SEM, 823, 1353,
 297P(ab)
 Clausen, M, 4P(ab),
 142P(ab), 246P(ab),
 256P(ab), 257P(ab)
 Clavo, AC, 502, 64P(ab),
 253P(ab)
 Clemenson, A, 922
 Cleveland, K, 259P(ab)
 Cliffe, IA, 112P(ab)
 Clinthorne, NH, 7P(ab),
 119P(ab), 170P(ab),
 171P(ab)
 Cloughesy, T, 146P(ab)

- Cloutier, D, 117P(ab),
 232P(ab)
 Coates, D, 249P(ab)
 Coenen, HH, 1865, 55P(ab),
 279P(ab)
 Cohen, C, 159P(ab)
 Cohen, CL, 147P(ab)
 Cohen, D, 118P(ab),
 289P(ab)
 Cohen, I, 14P(ab), 59P(ab),
 68P(ab), 69P(ab),
 116P(ab), 181P(ab),
 182P(ab)
 Cohen, M, 14P(ab), 259P(ab)
 Cohen, R, 45P(ab), 105P(ab),
 115P(ab), 284P(ab)
 Cohen, SM, 13S
 Cohen-Solal, A, 70P(ab),
 181P(ab)
 Coit, D, 138P(ab)
 Colao, A, 159P(ab)
 Colas-Linhart, N, 101P(ab),
 231P(ab)
 Colcher, D, 90P(ab),
 150P(ab)
 Cole, GM, 79P(ab)
 Cole, WC, 95P(ab)
 Coletta, AC, 255P(ab)
 Coleman, RE, 498, 1438,
 1906, 2011, 19P(ab),
 22P(ab), 74P(ab),
 120P(ab), 154P(ab),
 160P(ab), 174P(ab),
 200P(ab), 214P(ab),
 216P(ab), 219P(ab),
 295P(ab)
 Collares, M, 273P(ab)
 Collecchi, P, 16S
 Collet, GJ, 259P(ab)
 Collier, A, 274P(ab)
 Collier, BD, 1285, 1903,
 84P(ab)
 Colnaghi, MI, 665
 Colombo, L, 236P(ab)
 Comazzi, V, 188P(ab)
 Combs, MJ, 207P(ab)
 Comet, M, 229P(ab)
 Compierchino, A, 205P(ab)
 Connell, JM, 61P(ab),
 95P(ab)
 Connolly, JL, 74P(ab)
 Connolly, LP, 81, 22P(ab),
 28P(ab), 292P(ab)
 Conrad, B, 278P(ab)
 Conrad, EU, 140P(ab)
 Conti, E, 88P(ab)
 Conti, PS, 107P(ab),
 135P(ab), 140P(ab),
 155P(ab), 193P(ab)
 Contreras, S, 23P(ab)
 Conway, J, 873
 Conway, JJ, 287P(ab),
 20N(7)
 Cook, GJR, 1353, 1359,
 27P(ab), 87P(ab), 297P(ab)
 Cook, SA, 177P(ab)
 Cooke, CD, 48P(ab),
 97P(ab), 179P(ab)
 Cool, V, 53P(ab)
 Cooper, JD, 5P(ab), 135P(ab)
 Coppola, R, 2021
 Coppola, RC, 143P(ab),
 187P(ab)
 Corbelli, C, 88P(ab)
 Corbett, JR, 1923, 70P(ab),
 81P(ab), 148P(ab),
 176P(ab), 179P(ab)
 Cordero, GG, 287P(ab),
 307P(ab)
 Cordes, M, 22
 Cordes, U, 159P(ab)
 Cordobes, MD, 189P(ab)
 Cornel, JH, 748, 1951,
 59P(ab), 176P(ab)
 Correia, JA, 228P(ab),
 239P(ab), 244P(ab)
 Corstens, FHM, 62, 1392,
 2072, 119P(ab), 128P(ab),
 169P(ab)
 Corti, A, 238P(ab)
 Cosimi, AB, 293P(ab)
 Costa, DC, 995, 65P(ab),
 134P(ab)
 Costa, R, 243P(ab), 297P(ab)
 Costa, WLS, 172P(ab),
 223P(ab)
 Couette, J, 606
 Counsell, RE, 1540
 Coupland, DB, 36P(ab)
 Courey, MH, 1913(le)
 Cousins, C, 91P(ab)
 Couthon, HM, 105
 Couturier, O, 57P(ab)
 Cowan, D, 926
 Cowan, RJ, 1535
 Coxson, PG, 131P(ab),
 146P(ab)
 Crabbe, D, 183P(ab)
 Cradduck, TD, 178
 Craig, JC, 46P(ab)
 Crane, PD, 1031, 117P(ab),
 151P(ab), 202P(ab),
 232P(ab)
 Crankshaw, C, 51P(ab),
 71P(ab), 247P(ab)
 Cremonesi, M, 169P(ab)
 Crespo, E, 245P(ab)
 Cristel, ME, 40P(ab),
 128P(ab), 201P(ab)
 Crocker, AC, 129P(ab),
 151P(ab), 202P(ab),
 232P(ab)
 Crommelin, DJA, 1392
 Crompton, N, 54P(ab)
 Cronin, BF, 1771, 282P(ab)
 Croop, JM, 118P(ab)
 Crumrine, P, 269P(ab)
 Csapilar, K, 201P(ab)
 Csernay, L, 273P(ab),
 287P(ab)
 Cuccia, A, 239
 Cucurullo, V, 156P(ab)
 Cukier, A, 294P(ab)
 Culbert, P, 174P(ab)
 Cullom, SJ, 81P(ab),
 149P(ab), 176P(ab),
 210P(ab), 214P(ab),
 215P(ab)
 Culp, R, 80P(ab), 210P(ab)
 Cumming, P, 55P(ab)
 Cunha, ML, 273P(ab)
 Cunningham, B, 259P(ab)
 Cuocolo, A, 735, 13P(ab),
 159P(ab), 178P(ab)
 Curiel, DT, 186P(ab)
 Cutler, PD, 1009, 73P(ab),
 87P(ab)
 Cygne, BV, 134P(ab)
 Cyr, JE, 673
 Czech, T, 1931
 Czernin, J, 1626, 82P(ab),
 130P(ab)
 Czitrom, D, 181P(ab)
 D'Aiuto, G, 155P(ab),
 156P(ab)
 d'Amico, A, 133P(ab),
 258P(ab)
 D'Hondt, AM, 25P(ab),
 126P(ab)
 D'Souza, CD, 32P(ab),
 33P(ab)
 Dachille, MA, 74P(ab),
 224P(ab)
 Dacosta, M, 255P(ab)
 Dadachova, E, 195P(ab)
 Dadparvar, S, 65P(ab),
 114P(ab), 163P(ab),
 259P(ab), 263P(ab),
 265P(ab)
 Dae, MW, 47P(ab), 106P(ab)
 Daenens, F, 250P(ab),
 261P(ab)
 Daghigian, F, 1052, 1557,
 25S, 29S
 Dagli, M, 91P(ab)
 Daher, E, 1783
 Dahl, JR, 216
 Dahlborn, M, 8P(ab),
 73P(ab), 119P(ab),
 170P(ab), 303P(ab)
 Dale, S, 120P(ab), 208P(ab)
 Dalery, K, 150P(ab)
 Dahlberg, ST, 212P(ab)
 Dalrymple, GV, 13S,
 150P(ab)
 Damhaut, P, 21P(ab),
 53P(ab), 83P(ab)
 Damphousse, DJ, 119P(ab),
 129P(ab), 151P(ab),
 202P(ab)
 Dams, R, 1048
 Danek, A, 122P(ab)
 Danforth, DN Jr., 99P(ab)
 Dangas, G, 60P(ab)
 Daniel, GB, 1846
 Daniel, J, 151P(ab)
 Daniel, MJ, 141P(ab)
 Danieli, R, 1452, 35P(ab),
 255P(ab)
 Dann, R, 231P(ab)
 Dannals, RF, 307, 6P(ab),
 11P(ab), 33P(ab), 41P(ab),
 45P(ab), 47P(ab), 77P(ab),
 107P(ab), 112P(ab),
 164P(ab), 192P(ab),
 201P(ab), 280P(ab),
 288P(ab)
 Dansereau, RN, 143P(ab)
 Daou, D, 253P(ab), 256P(ab)
 Das, S, 5P(ab), 178P(ab),
 270P(ab)
 DaSilva, JN, 202P(ab)
 Datz, FL, 97P(ab), 124P(ab)
 Daube-Witherspoon, ME,
 2087, 99P(ab)
 Dauplat, J, 922
 Davenport, A, 104P(ab)
 Davidson, P, 142P(ab)
 Davies, G, 37P(ab), 184P(ab)
 Davies, M, 54P(ab)
 Davila-Garcia, M, 6P(ab)
 Davila-Roman, VG, 82P(ab)
 Davis, BR, 171
 Davis, CM, 60P(ab)
 Davison, A, 17P(ab),
 118P(ab)
 Daya, S, 159P(ab)
 De, D, 96P(ab), 162P(ab),
 240P(ab)
 De Braud, F, 169P(ab)
 de Bruin, W, 213P(ab)
 De Cicco, C, 169P(ab)
 De Cristofaro, MTR,
 278P(ab)
 De Dreux, O, 217P(ab)
 De Geest, H, 767
 De Geeter, F, 473, 718
 De Graff, WG, 1384
 de Jong, BM, 11P(ab),
 21P(ab)
 de Jong, M, 1388, 48P(ab),
 141P(ab), 190P(ab)
 de Jong, PE, 482
 de Klerk, JMH, 38, 244, 465,
 1511, 289P(ab)
 de Kraker, J, 237P(ab),
 287P(ab)
 de Labriolle-Vaylet, C,
 101P(ab)
 de Latour, M, 922
 de Leeuw, PW, 594, 1652
 De Martin, M, 42P(ab)
 de Montigny, C, 113P(ab),
 284P(ab)
 De Roo, M, 22P(ab),
 26P(ab), 54P(ab), 91P(ab),
 175P(ab)
 De Sadeleer, C, 1346
 De Vathaire, F, 598, 606
 de Vries, DJ, 30P(ab),
 153P(ab)
 de Vries, EGE, 1571, 67P(ab)
 de Zeeuw, D, 482
 Deacon, T, 66P(ab)
 Deal, KA, 71P(ab)
 Dean, RT, 673, 775, 1016,
 152P(ab), 204P(ab),
 272P(ab)
 Dearling, JLJ, 166P(ab)
 deBeco, V, 233P(ab)
 DeBruin, S, 97P(ab)
 Debruyne, FMJ, 169P(ab)
 Dec, GW, 144P(ab)
 deCosta, BR, 2021,
 143P(ab), 187P(ab)
 Decristoforo, C, 1912(le)
 Dederichs, B, 137P(ab)
 Deecke, L, 1931
 Deenmamode, M, 148P(ab)
 Defabritiis, A, 88P(ab)
 Deferrari, GM, 37P(ab)
 Defrise, M, 120P(ab)
 DeGrado, TR, 2011, 94P(ab),
 160P(ab), 174P(ab),
 200P(ab), 219P(ab)
 Degre, S, 83P(ab)
 Dehdashti, F, 87P(ab),
 99P(ab), 132P(ab),
 135P(ab)
 deKemp, RA, 174P(ab)
 del Rosario, RB, 1923,
 70P(ab), 192P(ab)
 Del Sole, A, 42P(ab)
 Del Vecchio, S, 665
 Del Vecchio, W, 156P(ab)
 Delahaye, N, 70P(ab),
 181P(ab), 253P(ab)
 Delaney, RC, 1749
 DeLano, DA, 82P(ab),
 161P(ab)
 Delbeke, D, 131P(ab)
 Delforge, J, 5, 118, 70P(ab),
 76P(ab), 226P(ab)
 Delgado, L, 266P(ab)
 Delisle, M, 606
 Delle Fave, G, 1452
 DeLong, DM, 174P(ab)
 Delpassand, ES, 32P(ab)
 Delriego, J, 75P(ab),
 267P(ab), 269P(ab)
 Demaerel, P, 22P(ab)
 DeMan, P, 81P(ab)
 Demez, P, 261P(ab)
 Demirkazik, FB, 1956
 Demonceau, G, 274P(ab)
 Demoor, D, 718
 Demus, DD, 14P(ab)
 den Harder, JM, 216P(ab)
 DeNardo, DA, 146, 1970,
 90P(ab), 232P(ab)
 DeNardo, GL, 146, 451,
 1970, 90P(ab), 128P(ab),
 129P(ab), 167P(ab),
 170P(ab), 232P(ab)
 DeNardo, SJ, 146, 451, 1970,
 90P(ab), 128P(ab),
 129P(ab), 143P(ab),
 167P(ab), 170P(ab),
 199P(ab), 232P(ab)
 Denays, R, 274P(ab)
 Dence, CS, 108P(ab)
 Dendale, P, 718
 DeNovo, R, 1846
 Deo, Y, 362
 DePuey, EG, 13P(ab),
 48P(ab), 69P(ab),
 105P(ab), 115P(ab),
 116P(ab), 125P(ab),
 276P(ab)
 Der, MG, 10P(ab)
 Derbyshire, S, 74P(ab)
 Derebek, E, 302P(ab)
 Derenik, ES, 53P(ab)
 Derenzo, SE, 85P(ab)
 Deriso, GT, 798
 Derksen, J, 270
 DeRogatis, A, 276P(ab)
 DeRook, F, 177P(ab)
 Descamps, X, 685
 DeSisto, WC, 19S
 Detry, R, 258P(ab)
 Deutsch, G, 88P(ab),
 164P(ab), 277P(ab)
 Devillers, A, 1946
 DeVito, R, 97P(ab)
 Dewanjee, M, 96P(ab),
 162P(ab), 240P(ab)
 Devous, Sr., MD, 1735,
 22N(11)
 Dewhurst, MW, 1438
 Dewitte, O, 21P(ab)
 Dey, D, 25N(9)
 Dey, H, 80P(ab), 100P(ab)
 Dey, HM, 282P(ab)
 Dhawan, RT, 1828
 Dhawan, V, 209, 216, 1760,
 1850, 133P(ab), 281P(ab)
 Di Bartolo, N, 195P(ab),
 196P(ab)
 Di Bella, EVR, 1891
 Di Carli, MF, 4P(ab)
 Di Gregorio, F, 156P(ab)
 Di Lieto, E, 264P(ab)
 Di Luca, , 22S

- Di Paola, M, 847
 Di Paola, R, 147P(ab),
 217P(ab)
 Di Sacco, S, 22S
 Di Stefano, R, 22S
 Diamond, GA, 14P(ab),
 68P(ab), 116P(ab)
 Diamond, JA, 60P(ab)
 DiBella, EVR, 153P(ab)
 Dieren, HC, 279P(ab)
 Dieterich, M, 122P(ab)
 DiFabrizio, L, 1662,
 242P(ab)
 Diggle, L, 1789, 230P(ab),
 231P(ab)
 Diksic, M, 55P(ab),
 113P(ab), 284P(ab)
 DiLeo, C, 1655
 Dillehay, G, 878
 Diltsian, V, 690, 1795,
 25P(ab), 39P(ab), 60P(ab),
 93P(ab), 160P(ab),
 161P(ab)
 DiLuca, L, 16S
 Dimitrakopoulou-Strauss, A,
 68P(ab), 147P(ab),
 257P(ab), 264P(ab)
 Ding, HJ, 298P(ab)
 Ding, Y, 554
 Ding, Y-S, 33P(ab), 40P(ab),
 44P(ab)
 Dinh, L, 23P(ab)
 Diril, H, 239P(ab)
 DiSalvo, TG, 144P(ab)
 Discepolo, A, 164P(ab)
 Ditlow, C, 49P(ab)
 Divgi, C, 1922
 Divgi, CR, 43P(ab)
 Dixon, M, 242P(ab)
 Dlouhy, SR, 270P(ab)
 Dobelbower, RR, 90P(ab)
 Dobkin, JA, 1009
 Dodd, LR, 95P(ab)
 Doerr, RJ, 135P(ab),
 238P(ab)
 Dogan, S, 302P(ab)
 Dohmen, BM, 140P(ab)
 Dole, MG, 16
 Doll, J, 68P(ab), 154P(ab),
 221P(ab), 265P(ab)
 Donald, PJ, 136P(ab)
 Donath, A, 51P(ab)
 Dondi, M, 1688, 1876,
 88P(ab)
 Donegan, M, 151P(ab)
 Dong, B, 958
 Donlevy, TM, 196P(ab)
 Donnelly, J, 151P(ab)
 Donnenfeld, H, 277P(ab)
 Donohay, T, 50P(ab)
 Donohoe, KJ, 1903,
 172P(ab), 23N(6)
 Dorcaratto, A, 238P(ab)
 Dortlemez, H, 184P(ab)
 Dortlemez, O, 184P(ab)
 Dose, J, 99P(ab)
 Dosik, D, 169P(ab)
 Dottioni, ME, 236P(ab)
 Doudet, D, 230P(ab)
 Douillard, JY, 1853
 Dowlati, A, 260P(ab)
 Downer, JB, 87P(ab)
 Dragotakes, SC, 240P(ab)
 Drucker, MJ, 252P(ab),
 267P(ab)
- Dubois, EA, 160P(ab)
 Dubovsky, E, 1876
 Dubovsky, EV, 588, 293P(ab)
 Duca, MD, 14P(ab)
 Ducassou, D, 863
 Duet, M, 1773
 duFour, R, 306P(ab)
 Duggaraju, R, 151P(ab)
 Duke, JH, 162P(ab)
 Duncan, D, 252P(ab)
 Duncan, DB, 429
 Duncan, JR, 118P(ab),
 201P(ab), 302P(ab)
 Duncan, R, 661, 1946
 Dunleavy, T, 136P(ab),
 264P(ab)
 Dunn, R, 905, 1504, 9P(ab),
 43P(ab), 44P(ab), 96P(ab),
 102P(ab), 168P(ab),
 169P(ab), 231P(ab),
 239P(ab)
 Dunn, RM, 829
 Dunn, WL, 1456, 243P(ab)
 Dunnwald, LK, 252P(ab),
 267P(ab)
 Dunphy, C, 136P(ab),
 264P(ab)
 Dunphy, F, 136P(ab),
 264P(ab)
 Dupont, JO, 861
 Dupont, P, 22P(ab)
 Durack, LD, 2030
 Durak, H, 302P(ab)
 DuranCordobes, M, 233P(ab)
 Durie, B, 267P(ab), 269P(ab)
 Durski, JM, 135P(ab)
 Duryea, RA, 95P(ab)
 Duscha, BD, 174P(ab)
 Dutka, D, 71P(ab)
 Dutschka, K, 1865
 Dwamena, BA, 111P(ab),
 141P(ab), 158P(ab)
 Dwyer, KM, 1583
 Dykes, JA, 1846
 Dykstra, CJ, 209P(ab)
 Dyling, O, 167P(ab)
 Dynes, AM, 1771, 282P(ab),
 Dzewas, B, 36P(ab)
- Eagle, KA, 14P(ab)
 Early, T, 79P(ab)
 Eary, JF, 2030, 43P(ab),
 67P(ab), 140P(ab),
 233P(ab)
 Easton, E, 249P(ab)
 Eberl, S, 128, 137, 90P(ab),
 147P(ab), 220P(ab)
 Ebert, M, 296P(ab)
 Ebinger, G, 88P(ab)
 Echemendia, E, 251P(ab),
 301P(ab)
 Eckardt, A, 103P(ab)
 Eckblade, MB, 89P(ab),
 90P(ab)
 Eckelman, WC, 1408,
 10P(ab), 77P(ab),
 118P(ab), 129P(ab),
 152P(ab), 197P(ab),
 199P(ab), 203P(ab), 204,
 254P(ab), 279P(ab)
 Eda, R, 296P(ab)
 Edeline, V, 893
 Edell, SL, 74P(ab)
 Edwards, DS, 29P(ab),
 119P(ab), 129P(ab)
- 232P(ab)
 Eersels, J, 184P(ab)
 Efange, SMN, 108P(ab),
 280P(ab)
 Egan, GF, 121P(ab),
 131P(ab), 132P(ab)
 Egashira, S, 781
 Egert, S, 94P(ab)
 Eggli, DF, 294P(ab)
 Egholm, M, 203P(ab)
 Ehrenkaufer, RL, 281P(ab)
 Ehrhardt, GJ, 194P(ab)
 Eichler, HG, 5P(ab)
 Eichstadt, H, 22
 Eidelberg, D, 209, 216, 1760,
 1850, 133P(ab), 281P(ab)
 Eilles, Chr, 248P(ab)
 Eisenberg, B, 57P(ab),
 103P(ab)
 Eisenhut, M, 362, 6P(ab)
 Eisenstein, EL, 14P(ab)
 Eising, EG, 247P(ab)
 Eisner, D, 104P(ab),
 159P(ab), 209P(ab)
 Eisner, RL, 1891, 174P(ab)
 Eisold, J, 854
 EJK, , 533
 El-Shirbiny, A, 102P(ab),
 138P(ab)
 Elahli, N, 1956, 177P(ab)
 Eldin, A, 105P(ab)
 Elgazzar, A, 16P(ab)
 Elgazzar, AH, 858, 60P(ab),
 250P(ab)
 Elger, CE, 100P(ab)
 Elhendy, A, 748, 1951
 Eliashiv, SD, 101P(ab)
 Ell, PJ, 995, 1828, 178P(ab),
 26N(11)
 Eller, D, 46
 Ellerhorst, J, 32P(ab)
 Ellis, G, 252P(ab)
 Elmaleh, D, 269P(ab)
 Elmaleh, DR, 4P(ab),
 33P(ab), 65P(ab), 66P(ab)
 Elmqvist, H, 120P(ab),
 208P(ab)
 Elomaa, I, 256P(ab)
 Elser, H, 362
 Elsinga, PH, 279, 1571,
 11P(ab), 71P(ab)
 Emi, T, 110P(ab)
 Emond, P, 186P(ab)
 Emslander, H-P, 36P(ab)
 Emter, M, 2066
 Enas, JD, 40P(ab), 51P(ab)
 Endo, K, 273, 457, 1981,
 159P(ab), 184P(ab),
 253P(ab)
 Endres, CJ, 77P(ab)
 Engel, H, 441
 Engel, J, 101P(ab)
 Enomoto, K, 279
 Enomoto, M, 641
 Ensing, G, 190P(ab)
 Ensing, K, 11P(ab), 71P(ab),
 108P(ab)
 Epenetos, A, 54P(ab),
 238P(ab)
 Ephron, VJ, 162P(ab),
 272P(ab)
 Erb, D, 9P(ab), 238P(ab)
 Erbas, B, 145P(ab),
 290P(ab), 293P(ab)
 Erdenli, I, 290P(ab)
- Erdil, YT, 233
 Erdos, J, 33P(ab)
 Erel, J, 93P(ab), 149P(ab),
 180P(ab), 182P(ab)
 Ergene, O, 302P(ab)
 Eriksson, B, 32
 Erlandsson, K, 159P(ab)
 Ernst, M, 45P(ab), 284P(ab)
 Eronen, E, 387
 Erwin, WD, 1970, 149P(ab)
 Eshima, D, 1575, 46P(ab),
 47P(ab), 84P(ab),
 186P(ab), 191P(ab),
 222P(ab), 298P(ab),
 305P(ab), 307P(ab)
 Eshima, LA, 1575, 46P(ab),
 47P(ab), 84P(ab),
 186P(ab), 191P(ab),
 222P(ab), 298P(ab),
 305P(ab), 307P(ab)
 Eshuis, SA, 263P(ab)
 Eskin, JD, 53P(ab), 301P(ab)
 Espasandin, J, 266P(ab)
 Esposito, G, 559, 79P(ab),
 284P(ab)
 Esselstyn, CB, 1809, 2000
 Esser, JD, 1323
 Esser, PD, 273P(ab)
 Estorch, M, 631
 Ethier, S, 75P(ab)
 Ethier, SP, 1042, 1540
 Ettori, F, 1300
 Evans, AC, 222P(ab),
 223P(ab), 283P(ab)
 Evans, J, 90P(ab), 102P(ab),
 228P(ab), 229P(ab)
 Evans, K, 1331, 1336
 Everaert, H, 88P(ab),
 211P(ab), 268P(ab)
 Ezquerra, NF, 48P(ab),
 179P(ab)
 Ezuddin, S, 798, 293P(ab)
 Faber, TL, 41P(ab), 97P(ab),
 213P(ab)
 Fadda, G, 633
 Fagret, D, 229P(ab)
 Fahey, FH, 1639, 225P(ab)
 Fahmy, A, 241P(ab)
 Fahrenkamp, A, 1990,
 49P(ab)
 Faigel, DO, 114P(ab),
 246P(ab)
 Faivre-Chauvet, A, 1853
 Falcini, M, 278P(ab)
 Falcone, A, 22S
 Fallanca, F, 264P(ab)
 Fallani, F, 88P(ab)
 Fallon, BA, 270P(ab)
 Fanti, S, 1688, 88P(ab),
 250P(ab)
 Faraggi, M, 275, 181P(ab),
 253P(ab), 256P(ab)
 Farahati, J, 286P(ab)
 Farde, L, 76P(ab), 108P(ab),
 112P(ab), 192P(ab),
 284P(ab)
 Farlow, MR, 270P(ab)
 Farman-Ara, B, 217P(ab)
 Farncombe, T, 219P(ab)
 Farquhar, TH, 73P(ab)
 Farrell, E, 9P(ab), 198P(ab)
 Farrell, JJ, 1595
 Farrell, ML, 293P(ab)
 Farres, MT, 46P(ab)
- Farris, JS, 303P(ab)
 Fashingbauer, P, 2006
 Fataar, A, 1001
 Faulhaber, PF, 99P(ab)
 Faulkner, DB, 305P(ab)
 Fawwaz, RA, 5P(ab),
 270P(ab)
 Fazio, F, 55, 967, 1655,
 42P(ab), 133P(ab),
 205P(ab), 258P(ab)
 Fazzini, PF, 26P(ab)
 Feillel, V, 922
 Fein, T, 142P(ab)
 Feine, U, 463, 1468,
 134P(ab), 137P(ab)
 Feinendegen, DL, 1841
 Feinendegen, LE, 1841
 Feldman, DR, 1682
 Feldmann, H, 157P(ab)
 Felix, R, 22
 Fendrick, AM, 110P(ab),
 111P(ab), 158P(ab)
 Feneley, M, 96P(ab)
 Feng, D, 224P(ab), 227P(ab)
 Feng, T, 207P(ab)
 Feng, YJ, 58P(ab)
 Feroze, H, 105P(ab)
 Ferrant, A, 916
 Ferrari, C, 230P(ab)
 Ferraro, M, 14P(ab)
 Ferrill, K, 143P(ab),
 152P(ab)
 Feske, WI, 140P(ab)
 Fessler, JA, 7P(ab)
 Festa, A, 237P(ab)
 Fetters, JK, 471
 Fiasse, R, 916
 Ficaro, EP, 1562, 78P(ab),
 81P(ab), 98P(ab),
 148P(ab), 176P(ab),
 180P(ab), 215P(ab)
 Fiche, M, 1853
 Fields, ALA, 237P(ab)
 Fields, SD, 554
 Fig, LM, 25P(ab), 285P(ab),
 306P(ab)
 Figlin, RA, 141P(ab)
 Filez, L, 54P(ab)
 Filipchuk, NG, 93P(ab)
 Fimmers, R, 1962
 Fine, E, 1876
 Fine, EI, 838
 Finestone, H, 2098(1e)
 Fink, GR, 429
 Fink, M, 228
 Finley, PA, 6P(ab), 11P(ab),
 112P(ab), 201P(ab),
 279P(ab)
 Finley, RJ, 36P(ab)
 Finn, R, 53P(ab), 54P(ab),
 25S, 29S
 Finn, RD, 1557
 Fiore, F, 260P(ab)
 Fioretti, PM, 748, 1951,
 59P(ab), 60P(ab), 176P(ab)
 Firby, P, 1578
 Firestone, L, 74P(ab)
 Fischer, H, 200P(ab)
 Fischer, KC, 5P(ab)
 Fischer, R, 218P(ab)
 Fischman, A, 843
 Fischman, AJ, 950, 4P(ab),
 24P(ab), 33P(ab), 65P(ab),
 125P(ab), 143P(ab),
 152P(ab), 161P(ab),

- 198P(ab), 228P(ab),
 239P(ab), 240P(ab),
 244P(ab), 269P(ab)
 Fisher, D, 43P(ab)
 Fisher, GA, 1464
 Fisher, MF, 16N(4)
 Fisher, RS, 57P(ab),
 244P(ab)
 Fisher, SJ, 1042, 1540,
 75P(ab)
 Fitt, GJ, 121P(ab)
 Fitz, C, 269P(ab)
 Fixmann, T, 283P(ab)
 Fjälling, M, 2002
 Flamen, P, 88P(ab),
 211P(ab), 268P(ab)
 Flameng, W, 26P(ab)
 Flanagan, FL, 99P(ab),
 132P(ab), 135P(ab)
 Fleming, JS, 873, 1058, 1832
 Fleming, RA, 177P(ab)
 Flesher, JE, 41P(ab)
 Fleshman, JW, 132P(ab)
 Fletcher, A, 112P(ab)
 Fletcher, J, 878, 1876
 Fletcher, JW, 136P(ab),
 249P(ab), 264P(ab),
 303P(ab)
 Flint, A, 65P(ab)
 Flores, LG II, 84, 308P(ab)
 Flores II, LG, 901
 Florio, F, 92P(ab)
 Flower, M, 54P(ab),
 191P(ab)
 Floyd, CE Jr., 295P(ab)
 Fluck, S, 10P(ab)
 Fluks, L, 1571
 Flux, GD, 228P(ab)
 Flyod, BB, 242P(ab)
 Fogarasi, M, 1655
 Foged, C, 76P(ab)
 Fogelman, I, 1353, 1359,
 27P(ab), 87P(ab), 297P(ab)
 Folks, RD, 46P(ab), 48P(ab),
 97P(ab), 179P(ab),
 293P(ab)
 Follansbee, WP, 149P(ab),
 176P(ab)
 Fommei, E, 1876, 1883
 Fontaine, F, 598
 Fontanini, G, 16S
 Fonti, R, 665
 Foo, M, 1828
 Forrest, A, 198P(ab)
 Forrester, JW, 31P(ab)
 Forsher, C, 272P(ab)
 Forsslund-Aronsson, E, 2002
 Forst, T, 104P(ab)
 Forstrom, LA, 1456,
 243P(ab)
 Fortsas, M, 178P(ab)
 Foss, J, 798
 Foster, C, 166P(ab)
 Foster, NL, 163P(ab),
 164P(ab), 270P(ab)
 Fotzsch, R, 283P(ab)
 Foulon, CF, 187P(ab),
 197P(ab), 1S
 Fountain, SW, 1275
 Fowler, JS, 554, 1609,
 33P(ab), 40P(ab), 44P(ab),
 45P(ab), 76P(ab), 281P(ab)
 Fox, PS, 294P(ab)
 Fox, PT, 223P(ab)
 Fox, R, 131P(ab), 132P(ab)
- Frackowiak, RSJ, 42P(ab)
 Fragu, P, 1830
 Frajewicki, V, 1371
 Fraker, D, 253P(ab)
 Fraker, DL, 1690
 Franceschi, D, 446,
 238P(ab), 255P(ab)
 Franceschi, M, 446, 133P(ab)
 Franceschini, R, 169P(ab),
 195P(ab)
 Francescetti, C, 598, 606
 Franchi, R, 88P(ab)
 Francis, I, 289P(ab)
 Francis, IR, 158P(ab)
 Frangin, Y, 186P(ab)
 Franke, W-G, 208P(ab),
 283P(ab)
 Franken, PR, 718, 88P(ab),
 211P(ab), 268P(ab)
 Franklin, J, 141P(ab)
 Franssen, EJF, 1571, 2082,
 67P(ab), 71P(ab), 157P(ab)
 Fratkin, MJ, 243P(ab)
 Frazzini, V, 13P(ab)
 Frederick, D, 17P(ab),
 66P(ab), 201P(ab)
 Freedman, N, 786
 Freedman, NMT, 690,
 99P(ab), 253P(ab)
 Freedman, RS, 1545
 Freeman, LM, 10P(ab),
 74P(ab)
 Freeman, SJ, 241P(ab)
 Freifelder, R, 276P(ab)
 Frenkel, A, 103P(ab),
 139P(ab), 245P(ab)
 Frey, A, 70P(ab)
 Frey, EC, 7P(ab), 30P(ab)
 Frey, KA, 1042, 21P(ab),
 109P(ab), 163P(ab),
 164P(ab), 270P(ab)
 Freyburger, G, 863
 Freyer, R, 208P(ab)
 Frickhofen, N, 262P(ab)
 Fried, M, 245P(ab)
 Friederici, A, 280P(ab)
 Friedland, R, 11P(ab)
 Friedman, HS, 1438, 61P(ab)
 Friedman, JD, 14P(ab),
 59P(ab), 68P(ab), 69P(ab),
 81P(ab), 93P(ab),
 116P(ab), 149P(ab),
 180P(ab), 181P(ab),
 182P(ab)
 Friedman, M, 13P(ab),
 211P(ab)
 Friedman, NC, 275P(ab)
 Friets, E, 100P(ab)
 Friston, K, 42P(ab)
 Friston, KJ, 271P(ab)
 Fritzberg, AR, 29P(ab),
 95P(ab), 166P(ab)
 Frohlich, DEC, 140P(ab)
 Frohmann, JP, 138P(ab)
 Front, A, 245P(ab)
 Front, D, 530, 103P(ab),
 139P(ab)
 Frost, JJ, 41P(ab), 45P(ab)
 Frouin, F, 147P(ab)
 Fry, D, 169P(ab)
 Fujibayashi, Y, 729, 757,
 1403, 1836, 56P(ab),
 95P(ab), 192P(ab),
 257P(ab)
 Fujii, K, 21P(ab)
- Fujino, S, 1622, 179P(ab)
 Fujishima, M, 275P(ab)
 Fujita, H, 12P(ab)
 Fujita, M, 1403, 1836,
 66P(ab), 95P(ab), 285P(ab)
 Fujita, T, 374, 1365, 1600,
 2057, 76P(ab)
 Fujiwara, S, 1289, 181P(ab)
 Fujiwara, T, 761, 175P(ab)
 Fukuchi, K, 761, 1686,
 12P(ab), 94P(ab), 175P(ab)
 Fukuda, H, 320, 410
 Fukuda, T, 111P(ab)
 Fukui, M, 21P(ab)
 Fukuma, H, 1444
 Fukumura, T, 21P(ab),
 36P(ab), 133P(ab),
 271P(ab), 275P(ab)
 Fukuoka, S, 1824
 Fukushi, K, 649
 Fukuyama, H, 1600
 Fukuyama, T, 781
 Fulham, MJ, 128, 137,
 147P(ab), 220P(ab)
 Fulton, RR, 137, 147P(ab),
 220P(ab)
 Fung, C, 82P(ab)
 Furhang, EE, 89P(ab),
 102P(ab)
 Furmanski, P, 169P(ab)
 Furst, S, 138P(ab)
 Furth, EE, 114P(ab),
 246P(ab)
 Furudate, M, 71, 955
 Futami, S, 84, 901, 308P(ab)
 Futatsuya, R, 101P(ab)
 Gacinovic, S, 65P(ab)
 Gaebel, W, 113P(ab)
 Gage, HD, 225P(ab),
 281P(ab)
 Gaggero, B, 238P(ab)
 Gagnon, A, 75P(ab),
 150P(ab)
 Gaillard, N, 1860
 Gal, R, 178P(ab)
 Galle, P, 847
 Galli, M, 735
 Gallo, R, 152P(ab)
 Galt, JR, 214P(ab), 293P(ab)
 Galynker, II, 2098(le)
 Gambhir, SS, 1428, 1428,
 107P(ab), 110P(ab),
 147P(ab), 193P(ab),
 269P(ab), 301P(ab),
 303P(ab)
 Gan, MP, 306P(ab)
 Ganeles, A, 10P(ab)
 Gangopadhyay, S, 69P(ab)
 Gann, DS, 15P(ab)
 Gansow, O, 152P(ab),
 234P(ab)
 Gao, D-W, 106P(ab)
 Gao, P, 107P(ab)
 Garada, B, 17P(ab), 158P(ab)
 Garada, BM, 19S
 Garcia, EV, 41P(ab),
 48P(ab), 81P(ab), 97P(ab),
 125P(ab), 179P(ab),
 213P(ab), 254P(ab),
 305P(ab)
 Garcia, JR, 1476
- Garcia Bolao, I, 93P(ab)
 Garcia Veloso, MJ, 93P(ab)
 Gardet, P, 598, 912
 Gardin, I, 101P(ab),
 217P(ab)
 Garg, PK, 2011, 200P(ab)
 Gariety, J, 199P(ab)
 Garini, P, 185P(ab)
 Garner, BA, 229P(ab)
 Garreau, L, 186P(ab)
 Gately, SJ, 554, 33P(ab),
 44P(ab), 187P(ab),
 203P(ab)
 Gatti, R, 297P(ab)
 Gautheret, E, 1853, 129P(ab)
 Gay, R, 235P(ab)
 Gay, S, 235P(ab)
 Gebauer, H-D, 208P(ab)
 Gebert, J, 87
 Gebhardt, M, 28P(ab)
 Geboes, K, 54P(ab)
 Geleinse, ML, 1951
 Gelfand, MJ, 35P(ab),
 287P(ab)
 Gennari, D, 205P(ab)
 Gentilcore, R, 249P(ab)
 Georgiou, M, 798, 23P(ab),
 289P(ab)
 Gerard, SK, 181P(ab)
 Gerber, B, 25P(ab),
 126P(ab), 39P(ab)
 Gerdzen, I, 283P(ab)
 Gerlach, L, 249P(ab),
 264P(ab), 265P(ab),
 266P(ab)
 Germain, CJ, 61P(ab),
 95P(ab)
 German, C, 234P(ab),
 235P(ab)
 Germano, G, 81P(ab),
 149P(ab)
 Gerson, MC, 752, 49P(ab),
 188P(ab)
 Gerundini, P, 37P(ab),
 230P(ab)
 Gervino, EV, 1618
 Geselowitz, DA, 233P(ab)
 Gestin, JF, 72P(ab)
 Getz, TA, 307P(ab)
 Gewirtz, H, 161P(ab),
 213P(ab)
 Geworski, L, 55P(ab),
 279P(ab)
 Geyer, BC, 7P(ab)
 Geyskes, G, 1876
 Ghali, S, 33N(9)
 Ghesani, M, 13P(ab),
 116P(ab), 276P(ab)
 Ghettii, B, 270P(ab)
 Ghez, C, 281P(ab)
 Ghilardi, FM, 281P(ab)
 234P(ab)
 Giacalone, F, 1853
 Giamarile, F, 912
 Gianchandani, RY, 852
 Gianolli, L, 205P(ab)
 Gibbons, G, 489
 Giblin, MF, 96P(ab),
 198P(ab)
 Gibson, RE, 307, 288P(ab)
 Gierada, DS, 5P(ab)
 Gifford, AN, 187P(ab),
 203P(ab)
 Gil, R, 33P(ab)
 Giladi, N, 245P(ab)
 Gilardi, MC, 205P(ab)
- Gildehaus, F-J, 1990,
 49P(ab)
 Gildersleeve, DL, 1923
 Giles, F, 267P(ab), 269P(ab)
 Gillan, MM, 114P(ab),
 163P(ab), 259P(ab),
 263P(ab), 265P(ab)
 Gilland, DR, 154P(ab),
 212P(ab), 216P(ab)
 Gillispie, SB, 220P(ab)
 Gillooley, J, 242P(ab)
 Gimelli, A, 735
 Ginovart, N, 108P(ab),
 112P(ab), 192P(ab),
 284P(ab)
 Ginsburg, M, 5P(ab)
 Gioia, G, 14P(ab), 149P(ab)
 Gonfriddo, MA, 656
 Giordani, B, 201
 Giordani, BL, 163P(ab),
 164P(ab)
 Giorgetti, A, 735
 Giorgi, MCP, 294P(ab)
 Gisonni, P, 178P(ab)
 Giubbini, R, 1300
 Gjedde, A, 223P(ab),
 283P(ab)
 Gladden, KH, 288P(ab)
 Glahn, DC, 284P(ab)
 Glajchen, N, 297P(ab)
 Glaser, B, 1537
 Glaser, C, 999, 1526,
 266P(ab)
 Glaspy, JA, 99P(ab)
 Glass, D, 54P(ab), 114P(ab),
 148P(ab)
 Glass, EC, 53P(ab), 181P(ab)
 Glatting, G, 160P(ab),
 220P(ab)
 Glick, SJ, 18P(ab), 153P(ab)
 Glikmanas, M, 275
 Glover, DK, 1398, 3P(ab)
 Go, KG, 157P(ab)
 Go, RT, 1809, 177P(ab),
 276P(ab)
 Godbersen, GS, 4P(ab)
 Goes, E, 1346
 Goethals, P, 1048
 Goin, J, 114P(ab)
 Goins, B, 1374
 Gokgoz, L, 184P(ab)
 Golan, H, 513
 Gold, DV, 169P(ab)
 Goldberg, SN, 1310
 Goldenberg, DM, 829, 905,
 1504, 9P(ab), 43P(ab),
 44P(ab), 62P(ab), 96P(ab),
 102P(ab), 151P(ab),
 168P(ab), 169P(ab),
 231P(ab), 232P(ab),
 239P(ab), 243P(ab)
 Goldfarb, CR, 2098(le)
 Goldfine, SM, 38P(ab)
 Goldman, CK, 234P(ab)
 Goldman, S, 21P(ab),
 53P(ab), 83P(ab)
 Goldsmith, SJ, 1528
 Goldstein, DS, 170P(ab)
 Goldstein, S, 216P(ab)
 Gomez, G, 631
 Gona, J, 135P(ab), 136P(ab),
 259P(ab)
 Gong, GY, 252P(ab)
 Gonvers, JJ, 245P(ab)
 Gonzalez, R, 302P(ab)

- Goodman, MM, 6P(ab),
 186P(ab), 191P(ab),
 222P(ab), 298P(ab),
 305P(ab)
 Goodwin, DA, 2092
 Gordon, BM, 307P(ab)
 Gordon, I, 1331, 1336
 Gordon, L, 307P(ab)
 Gorelick, D, 45P(ab)
 Gorenberg, M, 290P(ab),
 297P(ab)
 Gorey, JG, 2021, 143P(ab),
 187P(ab), 281P(ab)
 Gorges, R, 103P(ab),
 144P(ab), 159P(ab)
 Goris, ML, 211P(ab)
 Gormley, JE, 119P(ab),
 170P(ab)
 Gosalbez, R, 23P(ab)
 Goshen, E, 127P(ab)
 Goswami, N, 165P(ab)
 Goto, R, 410
 Gotti, NM, 1575
 Gottlieb, C, 14P(ab),
 149P(ab)
 Gottschalk, A, 577, 1313,
 1636
 Gottschalk, H, 273P(ab)
 Gould, KL, 1701
 Gouliamos, A, 32P(ab)
 Govindan, SV, 62P(ab),
 151P(ab)
 Gowm, AM, 267P(ab)
 Grabb, BC, 76
 Graf, R, 76P(ab)
 Grafton, ST, 135P(ab),
 140P(ab)
 Graham, MC, 695, 1557
 Graham, MM, 178, 2049,
 67P(ab), 220P(ab),
 235P(ab)
 Graham, W, 143P(ab),
 152P(ab), 228P(ab)
 Grahman, MM, 221P(ab)
 Gralow, JR, 252P(ab)
 Grana, C, 169P(ab)
 Granerius, G, 1876
 Graney, W, 146P(ab),
 252P(ab)
 Granowska, M, 96P(ab)
 Grant, C, 48P(ab)
 Grant, S, 293P(ab)
 Grapow, AS, 138P(ab)
 Grassi, F, 42P(ab)
 Gratz, S, 255P(ab)
 Graves, M, 295P(ab)
 Gravina, A, 260P(ab)
 Graziano, FM, 162P(ab)
 Greco, R, 251P(ab)
 Green, AL, 107P(ab)
 Green, L, 1643
 Green, LA, 147P(ab)
 Green, MA, 1003, 1294,
 51P(ab), 308P(ab)
 Green, MV, 204P(ab)
 Green, N, 293P(ab)
 Greenberg, CR, 1589
 Greenes, RA, 178
 Greenwald, F, 1962
 Greer, KL, 498, 154P(ab)
 Gregoire, MC, 147P(ab)
 Grekin, RJ, 852
 Grierson, JR, 67P(ab),
 240P(ab)
 Griffiths, GL, 62P(ab),
- 96P(ab), 151P(ab),
 239P(ab)
 Grimm, W, 144P(ab),
 233P(ab)
 Grivet-Fojaja, MR, 159P(ab),
 164P(ab)
 Grizzle, WE, 1491
 Groch, MW, 1970, 149P(ab),
 211P(ab), 216P(ab)
 Groen, HJM, 67P(ab)
 Groeneveld, ABJ, 1316
 Groothuis, GMM, 482
 Gropler, RJ, 82P(ab),
 83P(ab), 161P(ab),
 222P(ab)
 Gros, M, 157P(ab)
 Groschar, D, 290P(ab),
 297P(ab)
 Grosman, T, 296P(ab)
 Gross, MD, 852, 1540, 1778,
 15P(ab), 25P(ab), 27P(ab),
 141P(ab), 158P(ab),
 285P(ab), 306P(ab)
 Grossi, A, 55
 Grossman, HB, 64P(ab),
 260P(ab), 262P(ab)
 Grossman, MI, 165P(ab)
 Grossman, SJ, 76
 Grossmann, K, 1841
 Groth, W, 137P(ab)
 Grotta, J, 272P(ab)
 Grover-McKay, M, 39P(ab)
 Groves, B, 179P(ab)
 Gruenwald, F, 138P(ab),
 252P(ab)
 Grunbaum, Z, 49P(ab)
 Grunden, G, 77P(ab)
 Grunder, G, 112P(ab)
 Grünwald, F, 626, 1496,
 1962, 100P(ab), 134P(ab),
 243P(ab), 265P(ab),
 273P(ab)
 Gualdi, G, 1452
 Guan, SI, 247P(ab)
 Gucuyener, K, 1755
 Guenther, I, 54P(ab)
 Guerchait, M, 274P(ab)
 Guha, S, 1643
 Guhlmann, A, 262P(ab)
 Guhlmann, CA, 249P(ab)
 Guillaud, C, 188P(ab)
 Guilloteau, D, 186P(ab)
 Guimond, A, 98P(ab)
 Guirao, MA, 80P(ab)
 Gratz, S, 255P(ab)
 Graves, M, 295P(ab)
 Gravina, A, 260P(ab)
 Graziano, FM, 162P(ab)
 Greco, R, 251P(ab)
 Green, AL, 107P(ab)
 Green, L, 1643
 Green, LA, 147P(ab)
 Green, MA, 1003, 1294,
 51P(ab), 308P(ab)
 Green, MV, 204P(ab)
 Green, N, 293P(ab)
 Greenberg, CR, 1589
 Greenes, RA, 178
 Greenwald, F, 1962
 Greer, KL, 498, 154P(ab)
 Gregoire, MC, 147P(ab)
 Grekin, RJ, 852
 Grierson, JR, 67P(ab),
 240P(ab)
 Griffiths, GL, 62P(ab),
- 284P(ab)
 Gur, RE, 283P(ab), 284P(ab)
 Gurney, S, 823
 Gussak, H, 82P(ab)
 Gutzler, F, 68P(ab)
 Guzman, R, 861
 Gwechenberger, M, 115P(ab)
 Gyulai, F, 74P(ab)
 H.Muller, SH, 584
 Højgaard, L, 261
 Haack, K, 87
 Haag, S, 218P(ab)
 Haaparanta, M, 387, 51P(ab),
 256P(ab)
 Haaxma-Reiche, H, 21P(ab)
 Habbab, N, 1662
 Habberema, JDF, 886, 19P(ab)
 Haber, SB, 74P(ab)
 Haber, G, 159P(ab)
 Haberkorn, U, 87, 68P(ab),
 147P(ab), 154P(ab),
 234P(ab), 235P(ab),
 249P(ab), 257P(ab),
 264P(ab), 265P(ab),
 266P(ab)
 Habert, MO, 217P(ab)
 Habib, MP, 35P(ab)
 Hachamovitch, R, 14P(ab),
 68P(ab), 69P(ab),
 116P(ab), 181P(ab),
 182P(ab)
 Hachiya, T, 12P(ab)
 Hackett, MT, 230P(ab)
 Haddad, M, 178P(ab)
 Hagge, RJ, 74P(ab)
 Hahn, K, 1799, 25P(ab),
 34P(ab), 56P(ab),
 156P(ab), 236P(ab),
 252P(ab)
 Haider, N, 144P(ab),
 175P(ab)
 Haim, N, 139P(ab)
 Haines, JL, 79P(ab)
 Hajjar, RJ, 144P(ab)
 Halama, JR, 178
 Hale, CA, 74P(ab)
 Halkar, RK, 293P(ab),
 Hall, A, 54P(ab), 166P(ab)
 Hall, H, 108P(ab), 112P(ab),
 284P(ab)
 Halldin, C, 76P(ab),
 108P(ab), 112P(ab),
 192P(ab), 284P(ab)
 Halpern, SE, 92P(ab),
 182P(ab)
 Halson, P, 873
 Ham, HR, 1281, 1805
 Hamacher, K, 41P(ab),
 142P(ab)
 Hamad, K, 138P(ab),
 252P(ab)
 Hamagami, S, 1679
 Hamamoto, K, 180P(ab)
 Hamberg, LM, 950
 Hamblen, SM, 74P(ab),
 219P(ab)
 Hambye, AS, 175P(ab)
 Hames, W, 245P(ab)
 Hamill, J, 63P(ab)
 Hamill, TG, 307, 288P(ab)
 Hamilton, D, 1649
 Hamlin, DK, 151P(ab)
 Hammami, M, 26
 Hammami, MM, 993
 Hammersley, PAG, 235P(ab)
 Hamzeh, FM, 193P(ab)
 Han, SH, 1511
 Hanaka, NM, 273P(ab)
 Hanuske, A-R, 138P(ab)
 Hancock, RD, 16P(ab)
 Handa, N, 242P(ab)
 Hanein, LG, 74P(ab)
 Hanke, J, 1468
 Hankerson, J, 45P(ab)
 Hankins, D, 197P(ab)
 Hanks, JB, 158P(ab)
 Hanley, D, 905, 9P(ab),
 168P(ab), 169P(ab),
 239P(ab), 243P(ab)
 Hanna, MG, 9P(ab)
 Hannah, A, 1683, 131P(ab),
 132P(ab)
 Hanrahan, SM, 40P(ab)
 Hansen, CL, 183P(ab)
 Hansen, HJ, 62P(ab),
 151P(ab), 239P(ab)
 Hansen, L, 17P(ab), 46P(ab),
 47P(ab), 190P(ab),
 191P(ab)
 Hanson, JM, 162P(ab)
 Hanson, MW, 74P(ab),
 154P(ab), 174P(ab)
 Harada, K, 189P(ab)
 Harapanhalli, RS, 102P(ab)
 Harcke, HT, 23P(ab)
 Hardoff, R, 1371, 245P(ab)
 Hardy, K, 45P(ab), 131P(ab),
 132P(ab)
 Harkness, B, 1639
 Harkness, BA, 225P(ab)
 Harmon, W, 292P(ab)
 Harolds, JA, 1517
 Harrelson, JM, 1438
 Harrington, D, 218P(ab)
 Harrington, E, 272P(ab)
 Harrington, KJ, 54P(ab)
 Harrington, M, 272P(ab)
 Harrington, WN, 241P(ab)
 Harris, AR, 29P(ab),
 232P(ab)
 Harris, T, 119P(ab), 129P(ab)
 Harrison, C, 181P(ab)
 Harrison, KA, 13S, 90P(ab)
 Harrison, RL, 172P(ab)
 Harrop, R, 120P(ab),
 209P(ab), 219P(ab)
 Hart, E, 110P(ab)
 Hartman, JJ, 1294, 39P(ab),
 83P(ab), 221P(ab)
 Hartman, L, 109P(ab)
 Hartman, NG, 1578
 Hartmann, A, 273P(ab)
 Hasegawa, A, 3P(ab)
 Hasegawa, BH, 218P(ab)
 Hasegawa, H, 30P(ab),
 111P(ab), 212P(ab)
 Hasegawa, S, 94P(ab)
 Haseman, MK, 10P(ab),
 111P(ab), 132P(ab),
 139P(ab)
 Hashikawa, K, 12P(ab),
 242P(ab), 285P(ab)
 Hashimoto, J, 30P(ab),
 212P(ab)
 Hashish, AH, 873
 Haskard, DO, 114P(ab),
 128P(ab)
 Hassan, M, 35P(ab)
 Hasselquist, B, 142P(ab)
- Hata, T, 1836, 95P(ab)
 Hatazawa, J, 12P(ab),
 110P(ab), 165P(ab)
 Hattori, N, 1600, 1981, 1985,
 2057, 101P(ab), 150P(ab),
 175P(ab)
 Hauck, RW, 36P(ab)
 Hauser, M, 121P(ab)
 Haustermans, K, 54P(ab)
 Hawk, TC, 22P(ab),
 219P(ab)
 Hawkes, DJ, 208P(ab)
 Hawkins, RA, 506
 Hawkins, RE, 868
 Hawkins, WG, 89P(ab),
 90P(ab), 231P(ab)
 Hay, RV, 25P(ab)
 Hayano, T, 1361
 Hayashi, N, 251P(ab)
 Hayashi, T, 1985, 150P(ab)
 Hayashi, Y, 37P(ab)
 Hayashida, K, 1, 1824,
 277P(ab)
 Hayat, NJ, 48P(ab)
 Hayes, A, 57P(ab)
 Hayes, MJ, 1275
 Hayles, SO, 140P(ab)
 Haynor, DR, 2030
 Hayran, M, 1956, 257P(ab)
 Hazenberg, MP, 108
 He, XS, 2021, 143P(ab),
 187P(ab)
 He, Z-X, 93P(ab), 178P(ab)
 He, ZX, 58P(ab), 69P(ab),
 126P(ab)
 Heard, S, 275P(ab)
 Heesters, MAAM, 157P(ab)
 Heiba, SI, 48P(ab)
 Heidendaal, GAK, 1652
 Heifetz, L, 46
 Heil, W, 296P(ab)
 Heilman, J, 142P(ab)
 Heine, J, 103P(ab)
 Heineman, WR, 205P(ab)
 Heinz, A, 143P(ab),
 187P(ab), 281P(ab)
 Heiss, W, 429
 Heiss, W-D, 76P(ab),
 122P(ab), 270P(ab)
 Helbich, T, 254P(ab)
 Held, J, 1468, 137P(ab)
 Heller, GV, 14P(ab), 37P(ab),
 58P(ab), 68P(ab),
 105P(ab), 149P(ab),
 150P(ab), 176P(ab),
 177P(ab)
 Heller, SL, 838
 Hellman, P, 1766
 Hellman, RS, 1285, 84P(ab)
 Heminway, SJ, 119P(ab),
 129P(ab), 151P(ab),
 202P(ab)
 Hendel, RC, 14P(ab),
 81P(ab), 149P(ab),
 176P(ab), 211P(ab),
 216P(ab)
 Hendershot, I, 249P(ab)
 Hendi, P, 110P(ab),
 269P(ab), 301P(ab)
 Hendrikse, NH, 1571
 Hendry, JH, 336
 Hengstler, JG, 233P(ab)
 Henkin, R, 15N(1)
 Henkin, RE, 1903
 Henneman, P, 1789

- Hennessy, OF, 121P(ab)
 Henry, JW, 1313, 1636
 Henry, TR, 41P(ab),
 222P(ab)
 Henze, E, 4P(ab), 142P(ab),
 246P(ab), 256P(ab),
 257P(ab)
 Henzlova, MJ, 60P(ab)
 Heo, J, 14P(ab), 149P(ab),
 150P(ab), 182P(ab)
 Hercovitch, P, 203P(ab),
 230P(ab)
 Herda, SC, 1575, 84P(ab),
 307P(ab)
 Herholz, K, 122P(ab),
 270P(ab)
 Herman, BE, 854
 Herman, SD, 14P(ab)
 Hermann, G, 297P(ab)
 Hermus, ARMM, 2072
 Herrero, P, 1294, 1723,
 39P(ab), 83P(ab),
 147P(ab), 221P(ab),
 222P(ab)
 Herreros, J, 93P(ab)
 Herrold, EM, 38P(ab)
 Herscheid, JDM, 38P(ab)
 Herschman, H, 107P(ab),
 147P(ab), 193P(ab)
 Herscovitch, P, 10P(ab)
 Herskovic, T, 905, 9P(ab),
 168P(ab), 169P(ab),
 239P(ab), 243P(ab)
 Hertel, A, 121P(ab),
 137P(ab)
 Herz, M, 41P(ab), 99P(ab),
 111P(ab), 138P(ab)
 Herzog, H, 113P(ab),
 166P(ab), 219P(ab),
 222P(ab), 227P(ab),
 283P(ab)
 Hess, EM, 121P(ab)
 Hetherington, HP, 277P(ab)
 Hichwa, RD, 39P(ab),
 199P(ab), 221P(ab),
 225P(ab), 226P(ab)
 Hickey, JJ, 144P(ab),
 166P(ab)
 Hicks, K, 1472, 85P(ab),
 227P(ab)
 Hicks, KW, 931
 Hider, R, 150P(ab)
 Hierholzer, J, 22
 Higashi, K, 17P(ab), 64P(ab),
 122P(ab)
 Higashi, T, 248P(ab)
 Higashi, Y, 246P(ab)
 Higazy, EE, 48P(ab)
 Higginbotham, C, 61P(ab)
 Hiruchi, T, 273
 Hildebrand, J, 21P(ab),
 53P(ab)
 Hilderson, JM, 857
 Hill, TC, 305P(ab)
 Hilson, AJW, 92P(ab),
 104P(ab)
 Hilton, E, 161P(ab)
 Hiltunen, J, 76P(ab)
 Himi, T, 116P(ab)
 Hines, H, 53P(ab), 211P(ab)
 Hirai, J, 179P(ab),
 Hiraike, S, 1819
 Hirakawa, K, 259P(ab)
 Hiraki, Y, 296P(ab)
 Hirano, S, 123P(ab)
- Hirano, T, 273, 457, 1460
 Hirose, Y, 1, 1824, 277P(ab)
 Hirshfeld, A, 277P(ab)
 Hitt, JM, 226P(ab)
 Hitzemann, R, 554
 Hitzemann, RJ, 1609,
 33P(ab), 44P(ab), 45P(ab),
 76P(ab)
 Hnatowich, DJ, 1655, 2092,
 152P(ab), 190P(ab)
 Hnatowski, DJ, 203P(ab)
 Ho, D, 224P(ab)
 Ho, MH, 85P(ab)
 Hobson, D, 1589
 Hobson, LJ, 166P(ab)
 Hock, JC, 167P(ab)
 Hodgson, HJF, 114P(ab)
 Hoefer, G, 1524
 Hoefnagel, CA, 584, 972,
 237P(ab), 287P(ab)
 Hoekstra, A, 38
 Hoekstra, HJ, 257, 984,
 86P(ab)
 Hoekstra, OS, 259P(ab)
 Hoeymans, PAJ, 1951
 Hoffer, PB, 11, 1749,
 33P(ab), 44P(ab),
 272P(ab), 285P(ab)
 Hoffman, EJ, 52P(ab),
 73P(ab), 78P(ab), 130P(ab)
 Hoffman, JM, 41P(ab),
 191P(ab), 222P(ab),
 298P(ab)
 Hoffman, TJ, 61P(ab),
 185P(ab)
 Hofland, LJ, 24P(ab)
 Hofmann, D, 296P(ab)
 Hofstaedter, F, 248P(ab)
 Hogendoorn, PCW, 270
 Hoh, C, 110P(ab), 147P(ab),
 301P(ab)
 Hoh, CK, 506, 1428, 1428,
 1717, 8P(ab), 68P(ab),
 99P(ab), 123P(ab),
 130P(ab), 141P(ab),
 146P(ab), 267P(ab),
 303P(ab)
 Hohenberger, P, 257P(ab)
 Holan, V, 415
 Holdeman, KP, 13S
 Holden, JE, 421, 94P(ab)
 Holder, LE, 1740, 2037,
 15P(ab), 104P(ab),
 118P(ab)
 Holgate, ST, 873
 Holle, L, 615
 Hollema, H, 67P(ab),
 263P(ab)
 Hollenberg, M, 181P(ab)
 Hollinger, EF, 210P(ab)
 Holman, BL, 178, 17P(ab),
 158P(ab)
 Holmberg, ECV, 228
 Holmberg, M, 120P(ab)
 Holmes, RA, 117P(ab),
 232P(ab)
 Holschbach, M, 1841,
 113P(ab), 142P(ab),
 201P(ab), 283P(ab)
 Holt, CS, 225P(ab)
 Holtzman, D, 11N(3)
 Hom, C, 4P(ab)
 Hornsy, Y, 23P(ab)
 Honda, N, 304P(ab)
 Honda, T, 248P(ab)
- Hong, C, 283P(ab)
 Hong, S-C, 127P(ab)
 Honigman, S, 245P(ab)
 Hooper, PK, 128, 147P(ab),
 220P(ab)
 Hopkins, DM, 111P(ab)
 Hör, G, 1942, 9P(ab),
 121P(ab), 137P(ab)
 Hori, M, 1686, 183P(ab)
 Horikoshi, S, 457
 Horn, R, 273P(ab)
 Horoszowski, H, 127P(ab)
 Horowitz, M, 1643
 Horowitz, S, 127P(ab)
 Horti, A, 6P(ab), 11P(ab),
 192P(ab), 208P(ab)
 Hosain, F, 105
 Hoshi, H, 84, 901
 Hoshima, M, 1522
 Hoshizaki, H, 3P(ab),
 184P(ab)
 Hosoda, S, 185P(ab)
 Hosokawa, R, 757, 1403,
 1836
 Hosokawa, T, 95P(ab),
 304P(ab)
 Hosono, M, 304P(ab)
 Hou, N, 296P(ab)
 Houle, S, 202P(ab)
 Houlihan, MJ, 74P(ab)
 Houston, S, 32P(ab), 87P(ab)
 Hove, M, 926
 Howard, RJ, 195
 Howarth, DM, 1456
 Howman-Giles, R, 964,
 34P(ab), 46P(ab)
 Hoyes, KP, 336
 Hr, G, 1942
 Hsiau, HY, 27P(ab)
 Hsu, H, 244P(ab)
 Hsu, L, 96P(ab)
 Hu, G, 85P(ab), 227P(ab)
 Hu, P, 127P(ab)
 Huang, C, 437, 155P(ab)
 Huang, G, 207P(ab),
 210P(ab), 308P(ab)
 Huang, MH, 298P(ab)
 Huang, S, 506, 1717
 Huang, S-C, 55P(ab),
 146P(ab), 163P(ab)
 Huang, SC, 42P(ab),
 109P(ab), 224P(ab),
 304P(ab)
 Huang, WS, 247P(ab)
 Huang, WT, 188P(ab)
 Huang, Y, 145P(ab)
 Hubner, KF, 122P(ab),
 139P(ab), 206P(ab),
 279P(ab)
 Hubsch, P, 20P(ab)
 Hudson, HM, 171P(ab)
 Huerkamp, M, 191P(ab)
 Huesman, MK, 146P(ab)
 Huesman, RH, 8P(ab),
 130P(ab), 131P(ab),
 146P(ab), 155P(ab)
 Huggins, GS, 161P(ab)
 Hughes, JMB, 1275
 Huisman, RM, 482
 Hukuda, T, 3P(ab)
 Hume, SP, 109P(ab),
 224P(ab)
 Humm, J, 1052, 25S
 Humm, JL, 78P(ab),
 102P(ab), 29S
- Hundeshagen, H, 521, 2066
 Hung, JC, 84P(ab), 142P(ab)
 Hunter, GJ, 950
 Hurley, D, 264P(ab)
 Hurwitz, RA, 286P(ab)
 Huse, D, 286P(ab)
 Hussey, D, 202P(ab)
 Hustinx, R, 250P(ab),
 260P(ab), 261P(ab)
 Hutchins, GD, 42P(ab),
 86P(ab), 270P(ab)
 Hutchinson, RJ, 16
 Hutton, B, 1915(l)e
 Hutton, BF, 137, 171P(ab),
 215P(ab)
 Huysmans, DAKC, 2072
 Hwang, D-R, 118P(ab)
 Hwang, GJ, 469
 Hwang, SC, 303P(ab)
 Hwang, T, 1595
 Hwang, YC, 118P(ab)
 Hyun, H, 252
 Hyun, IU, 89P(ab)
 Hyun, IY, 28P(ab), 274P(ab)
 I.Syrbu, SI, 656
 Ichihara, T, 30P(ab),
 212P(ab)
 Ichikawa, A, 186P(ab)
 Ichimiya, A, 275P(ab)
 Ichise, M, 513, 8P(ab),
 77P(ab), 280P(ab),
 281P(ab)
 Ichiya, Y, 21P(ab), 36P(ab),
 133P(ab), 271P(ab),
 275P(ab)
 Ichiyanagi, K, 1622,
 179P(ab)
 Ido, T, 320
 Iftikhar, I, 1306
 Iguchi, N, 185P(ab)
 Iida, H, 12P(ab), 110P(ab)
 Iida, Y, 7P(ab)
 Iimura, O, 1679
 Iizuka, T, 184P(ab)
 Ikeda, A, 101P(ab)
 Ikeda, S, 1343
 Ikegami, T, 248P(ab)
 Ikeno, E, 1289
 Ikeoka, N, 641
 Ikota, N, 649
 Ilgin, N, 45P(ab)
 Im, J-H, 273P(ab)
 Imahori, Y, 1673
 Imai, S, 680
 Imamura, Y, 781
 Imazeki, K, 258P(ab)
 Imbert, B, 98P(ab)
 Imbriaco, M, 1528, 102P(ab)
 Inampudi, C, 89P(ab),
 165P(ab), 277P(ab)
 Inanir, S, 184P(ab)
 Indolfi, P, 256P(ab)
 Ingels, M, 1605
 Ingvar, C, 622
 Innis, RB, 11, 32P(ab),
 33P(ab), 44P(ab), 80P(ab),
 133P(ab), 134P(ab),
 272P(ab), 285P(ab)
 Inobe, Y, 80P(ab)
 Inokuma, T, 248P(ab)
 Inoue, O, 66P(ab)
 Inoue, T, 457, 931, 1472,
 86P(ab), 159P(ab),
 184P(ab), 253P(ab),
 261P(ab)
- Inoue, Y, 183P(ab), 189P(ab)
 Intenzo, CM, 157P(ab),
 260P(ab), 278P(ab)
 Inugami, A, 12P(ab)
 Ionna, F, 138P(ab)
 Iosilevsky, G, 103P(ab)
 Irie, T, 649
 Iriye, T, 975
 Irngartinger, G, 68P(ab)
 Irvin, GL III, 798
 Irwin, AG, 92P(ab)
 Isaacs, RS, 136P(ab)
 Isaacson, O, 66P(ab)
 Isawa, T, 1460
 Ischise, M, 1591(ed),
 1591(ed)
 Ishibashi, K, 244P(ab)
 Ishida, M, 12P(ab), 285P(ab)
 Ishida, Y, 1, 1824, 277P(ab)
 Ishihara, M, 304P(ab),
 308P(ab)
 Ishii, K, 123P(ab), 153P(ab),
 220P(ab), 259P(ab)
 Ishii, S, 123P(ab), 215P(ab)
 Ishii, Y, 192P(ab), 251P(ab),
 257P(ab)
 Ishikawa, T, 209, 216, 1760,
 1850
 Ishikawa, Y, 5P(ab),
 291P(ab), 292P(ab)
 Ishiwata, K, 279, 320,
 123P(ab), 215P(ab),
 259P(ab)
 Ishizu, K, 374, 1600, 2057,
 101P(ab), 123P(ab)
 Isitman, AT, 1285, 84P(ab)
 Iskandrian, AS, 794, 14P(ab),
 37P(ab), 58P(ab), 93P(ab),
 149P(ab), 150P(ab)
 180P(ab), 182P(ab),
 184P(ab)
 Isobe, H, 955
 Isobe, N, 184P(ab)
 Isono, K, 279
 Israel, O, 530, 103P(ab),
 139P(ab), 297P(ab)
 Issaq, E, 290P(ab)
 Itami, J, 258P(ab)
 Ito, H, 410
 Ito, K, 271P(ab)
 Ito, Y, 66P(ab)
 Itoh, K, 71, 955, 16P(ab),
 239P(ab), 290P(ab),
 291P(ab), 293P(ab)
 Itoh, T, 180P(ab)
 Itoh, T, 153P(ab)
 Ivancevic, V, 158P(ab)
 Ivanovic, M, 214P(ab)
 Iwama, T, 277P(ab)
 Iwami, T, 1361
 Iwasaki, T, 680, 3P(ab),
 159P(ab)
 Iwase, T, 304P(ab)
 Iwata, R, 1713
 Iyo, M, 649
 Izaki, M, 294P(ab)
 Izzo, J, 29S
- Jabir, AM, 798
 Jabre, A, 12P(ab)
 Jackson, GE, 379
 Jacob, T, 289P(ab)
 Jacobs, A, 1605
 Jacobs, W, 293P(ab)

- Jacobson, AF, 117P(ab), 177P(ab)
Jacobson, GB, 1766
Jacobsson, H, 1417
Jacquet, N, 250P(ab), 261P(ab)
Jacquier-Sarlin, MR, 1413, 1694
Jadali, F, 220P(ab), 269P(ab)
Jadoga, E, 1408, 10P(ab), 118P(ab), 152P(ab), 197P(ab), 204P(ab), 254P(ab)
Jahn, S, 51P(ab)
Jain, D, 1783, 59P(ab)
jalling, MF, 1519
Jamadar, D, 288P(ab)
Jamal, F, 147P(ab)
Jamar, F, 916, 114P(ab), 128P(ab), 258P(ab)
Jana, S, 137P(ab)
Jang, S, 216P(ab)
Janicke, F, 99P(ab)
Janicki, C, 98P(ab)
Janier, MF, 147P(ab)
Jansen, F, 223P(ab)
Jansen, H, 2082
Jansen, T, 11P(ab), 71P(ab), 108P(ab)
Janssen, AGM, 65P(ab), 134P(ab)
Jaszczak, RJ, 498, 120P(ab), 154P(ab), 212P(ab), 214P(ab), 216P(ab)
Jeanguillaume, C, 847
Jenkin, B, 117P(ab)
Jenkins, B, 66P(ab)
Jeong, JM, 248P(ab), 282P(ab)
Jerabek, PA, 223P(ab)
Jerusalem, G, 250P(ab)
Jewett, DM, 109P(ab)
Jinnouchi, S, 84, 901, 308P(ab)
Jochelson, M, 267P(ab), 269P(ab)
Joensuu, H, 256P(ab)
Johannsen, B, 16P(ab)
Johanson, V, 2002
Johansson, C, 1766
Johansson, VJ, 1519
John, CS, 7P(ab), 205P(ab), 267P(ab)
John, E, 52P(ab), 308P(ab)
John, EK, 489
Johnson, EG, 124P(ab)
Johnson, G III, 107P(ab)
Johnson, LL, 50P(ab)
Johnson, TK, 171P(ab), 206P(ab)
Johnson, W, 97P(ab)
Johnston, RE, 2079, 80P(ab)
Jolles, PR, 243P(ab)
Jolly, D, 55P(ab)
Jonas, M, 1865, 1990, 49P(ab)
Jones, AG, 17P(ab), 118P(ab)
Jones, AKP, 74P(ab)
Jones, DN, 1438
Jones, DW, 2021, 143P(ab), 187P(ab), 281P(ab)
Jones, KL, 1643
Jones, LA, 128P(ab)
Jones, M, 293P(ab)
Jones, PL, 343
Jones, R, 131P(ab), 132P(ab)
Jones, T, 1275, 32P(ab), 85P(ab), 191P(ab)
Jones, W, 85P(ab)
Jones, WF, 86P(ab)
Jones-Wilson, TM, 71P(ab)
Jons, P, 45P(ab)
Jonson, S, 99P(ab)
Jordan, K, 1557
Jorfeldt, L, 208P(ab)
Joshi, R, 53P(ab)
Joshi, V, 150P(ab)
Joubert, F, 188P(ab)
Jousse, F, 39P(ab), 93P(ab), 160P(ab)
Joyce, JM, 76
Jung, TH, 268P(ab)
Jupitner, M, 279P(ab)
Jureidini, IM, 695
Jurisson, SS, 96P(ab), 165P(ab), 198P(ab)
Juweid, M, 905, 9P(ab), 43P(ab), 44P(ab), 168P(ab), 169P(ab), 231P(ab), 232P(ab), 239P(ab), 243P(ab)
Juweid, ME, 829, 1504
Kabalka, GW, 194P(ab), 279P(ab)
Kabasakal, L, 1285
Kachi, R, 126P(ab)
Kado, H, 12P(ab)
Kadrimas, DJ, 7P(ab)
Kagan, M, 117P(ab), 119P(ab), 129P(ab), 232P(ab)
Kagetsu, NJ, 276P(ab)
Kahan, BD, 292P(ab)
Kahn, D, 1583, 1876, 31P(ab)
Kaji, T, 975
Kajiyama, T, 37P(ab)
Kakishita, M, 101P(ab)
Kalaff, A, 280P(ab)
Kalaigian, H, 312, 1557
Kalen, JD, 243P(ab)
Kalf, V, 117P(ab)
Kallenberg, CGM, 21P(ab)
Kamada, T, 285P(ab)
Kamal, T, 9P(ab)
Kamano, T, 304P(ab)
Kamat, V, 69P(ab)
Kamiya, T, 572
Kamphuis, C, 62P(ab), 171P(ab)
Kanagawa, M, 17P(ab)
Kanazawa, N, 184P(ab)
Kanegae, K, 71, 16P(ab), 239P(ab), 290P(ab), 291P(ab)
Kaneko, S, 291P(ab), 292P(ab)
Kang, X, 59P(ab), 81P(ab)
Kanmaz, B, 233
Kanno, I, 137, 110P(ab), 165P(ab)
Kanski, J, 293P(ab)
Kao, C, 437
Kao, C-HK, 189P(ab)
Kao, CH, 145P(ab), 187P(ab), 188P(ab), 241P(ab), 245P(ab), 292P(ab), 294P(ab), 295P(ab), 298P(ab)
Kao, PF, 288P(ab)
Kao, T, 172P(ab)
Kapadia, KM, 114P(ab), 163P(ab), 259P(ab), 263P(ab), 265P(ab)
Kapadvanjwala, M, 96P(ab), 162P(ab)
Kaplan, MS, 2030, 223P(ab)
Kapp, OH, 279P(ab)
Kappeler, C, 55P(ab), 279P(ab)
Kapteijn, BAE, 972
Kapucu, LO, 1755, 139P(ab)
Karacay, H, 151P(ab)
Karaki, A, 116P(ab)
Karamoskos, P, 117P(ab)
Karayalcin, B, 1916(ie), 1917(ie)
Karayalcin, G, 34P(ab), 285P(ab)
Karbe, H, 122P(ab)
Karlsson, P, 284P(ab)
Karp, JS, 1557, 19P(ab), 130P(ab), 172P(ab), 276P(ab)
Karpman, HL, 82P(ab)
Kars, A, 1956
Kasagi, K, 646
Kaserer, K, 20P(ab)
Kashimada, A, 304P(ab)
Kashitani, N, 296P(ab)
Kashiwagi, T, 244P(ab)
Kasina, S, 29P(ab)
Kassis, AI, 315, 343, 102P(ab), 187P(ab), 229P(ab), 10S, 16S, 19S, 1S
Kastis, GA, 301P(ab)
Katayama, M, 975
Kathol, RG, 225P(ab)
Kato, C, 290P(ab), 291P(ab), 293P(ab)
Kato, M, 271P(ab), 273P(ab)
Katoch, C, 16P(ab), 239P(ab), 290P(ab), 291P(ab)
Katona, CLE, 65P(ab)
Katsetos, CD, 65P(ab), 265P(ab)
Katzellenbogen, JA, 1009, 28P(ab), 194P(ab)
Kaufman, CI, 163P(ab)
Kaufman, GE, 275P(ab)
Kaufmann, P, 922
Kaufmann, R, 137P(ab)
Kawabe, K, 304P(ab)
Kawakami, Y, 955
Kawano, S, 1824
Kawashima, R, 410
Kayden, D, 289P(ab), 302P(ab)
Kazumata, K, 1760, 1850, 133P(ab), 281P(ab)
Keast, RK, 212P(ab)
Kee, JW, 1023
Keep, PA, 868
Kehoe, K, 140P(ab), 258P(ab)
Keil, R, 191P(ab), 298P(ab)
Keir, ST, 61P(ab)
Kelham, SA, 302P(ab)
Kellar, KJ, 6P(ab)
Kelley, M, 249P(ab)
Kelly, MJ, 117P(ab)
Kemeny, N, 25S, 29S
Kemerink, GJ, 1652
Kemp, BJ, 213P(ab)
Kempf, JS, 1662, 242P(ab), 251P(ab), 277P(ab), 301P(ab)
Kengen, RAM, 91P(ab)
Kennedy, J, 53P(ab), 78P(ab)
Kerdraon, J, 1976
Kes, S, 177P(ab)
Kessler, DB, 123P(ab)
Kessler, J, 122P(ab)
Kesteloot, D, 1048
Ketring, AR, 61P(ab)
Kettner, B, 20P(ab), 158P(ab)
Khalef, AI, 48P(ab)
Khalkhali, I, 74P(ab)
Khan, SH, 495
Khandekar, S, 177P(ab)
Khare, AB, 108P(ab), 280P(ab)
Khaw, BA, 4P(ab), 49P(ab), 50P(ab), 106P(ab), 119P(ab), 144P(ab), 175P(ab), 269P(ab)
Khazaeli, MB, 1491, 186P(ab)
Kiat, H, 14P(ab), 59P(ab), 68P(ab), 69P(ab), 81P(ab), 93P(ab), 116P(ab), 149P(ab), 176P(ab), 180P(ab), 181P(ab), 182P(ab)
Kido, Y, 111P(ab)
Kiernan, FJ, 105P(ab)
Kiesewetter, DO, 10P(ab)
Kigami, Y, 815, 1567
Kijewski, MF, 18P(ab), 29P(ab), 77P(ab), 124P(ab), 153P(ab), 158P(ab)
Kijima, T, 304P(ab), 308P(ab)
Kikuchi, K, 291P(ab), 292P(ab)
Kilborne, R, 32P(ab)
Kilbourn, MR, 10P(ab), 21P(ab), 109P(ab)
Kilgore, EJ, 1535
Kilroy, K, 276P(ab)
Kilts, C, 186P(ab), 191P(ab), 298P(ab)
Kim, AS, 1626
Kim, BK, 978
Kim, BT, 179P(ab), 226P(ab), 275P(ab)
Kim, C-G, 127P(ab)
Kim, CH, 268P(ab)
Kim, CK, 1487, 16P(ab), 60P(ab), 135P(ab), 255P(ab), 268P(ab), 297P(ab)
Kim, DI, 551
Kim, EE, 931, 1472, 1476, 72P(ab), 86P(ab), 127P(ab), 253P(ab), 261P(ab), 264P(ab), 296P(ab)
Kim, ES, 100P(ab), 305P(ab)
Kim, EY, 2000
Kim, H, 151, 136P(ab), 264P(ab)
Kim, H-J, 201P(ab), 273P(ab)
Kim, HJ, 1965
Kim, IS, 29P(ab), 129P(ab), 203P(ab)
Kim, JH, 50P(ab), 305P(ab)
Kim, JS, 305P(ab)
Kim, JY, 67P(ab)
Kim, KT, 248P(ab)
Kim, M-K, 29P(ab), 129P(ab), 203P(ab)
Kim, MS, 305P(ab)
Kim, S, 28P(ab)
Kim, SE, 307, 179P(ab), 226P(ab), 275P(ab)
Kim, SM, 157P(ab), 260P(ab), 278P(ab)
Kim, SW, 312
Kim, T, 169P(ab)
Kim, YC, 67P(ab)
Kimes, A, 6P(ab), 192P(ab)
Kimiae, S, 1417
Kimmel, M, 4P(ab)
Kimura, T, 248P(ab)
Kimura, Y, 153P(ab), 220P(ab)
King, K, 78
King, MA, 18P(ab), 30P(ab), 63P(ab), 97P(ab), 127P(ab), 153P(ab), 209P(ab), 212P(ab)
King, RB, 106P(ab)
King, SB III, 125P(ab)
Kingstone, D, 92P(ab)
Kinnala, A, 387
Kinoshita, M, 712
Kinthaert, J, 1281
Kinuya, S, 44P(ab), 101P(ab)
Kinzel, D, 157P(ab)
Kira, M, 80P(ab), 189P(ab)
Kira, T, 80P(ab)
Kirby, RJ, 96P(ab)
Kirch, DL, 171P(ab), 206P(ab)
Kirchner, PT, 25N(1), 1815
Kirkby, BS, 79P(ab)
Kirkman, R, 186P(ab)
Kirst, J, 252P(ab)
Kison, P, 98P(ab)
Kison, PV, 36P(ab), 260P(ab), 262P(ab)
Kitano, H, 1600
Kitschenberg, A, 273P(ab)
Kitsiou, AN, 1795, 25P(ab), 39P(ab), 60P(ab), 161P(ab)
Kivlighn, S, 288P(ab)
Klain, M, 159P(ab)
Klein, GJ, 130P(ab), 131P(ab)
Klein, JL, 9P(ab), 97P(ab)
Klein, S, 1789
Klein, WP, 301P(ab)
Klemm, E, 100P(ab), 134P(ab), 138P(ab), 252P(ab), 280P(ab)
Kletter, K, 1480, 1872, 5P(ab), 46P(ab)
Klimke, A, 113P(ab)
Kline, GM, 14P(ab)
Klinkowstein, RE, 61P(ab), 128P(ab)
Klipper, R, 1374
Klocke, FJ, 216P(ab)
Klok, R, 352
Klomp, H-J, 256P(ab)
Kloos, RT, 1778, 15P(ab), 158P(ab)
Kloppenborg, PWC, 2072
Klumb, L, 151P(ab)

- Knable, MB, 2021, 143P(ab),
 187P(ab), 281P(ab)
 Knapp, FF Jr, 6P(ab),
 166P(ab), 184P(ab),
 186P(ab), 193P(ab),
 195P(ab), 202P(ab),
 236P(ab)
 Knapp, WH, 114P(ab)
 Knecht, R, 1942
 Knesaurek, K, 216P(ab),
 38P(ab)
 Knight, J, 46P(ab)
 Knight, LC, 476, 775, 818,
 57P(ab), 244P(ab)
 Knight, RJ, 3P(ab)
 Knight, S, 121P(ab)
 Knoll, GF, 119P(ab),
 170P(ab)
 Knollema, S, 2082
 Knopp, MV, 296P(ab)
 Knust, EJ, 279P(ab)
 Kobashi, T, 304P(ab)
 Kobayashi, H, 29P(ab),
 129P(ab), 185P(ab),
 203P(ab)
 Kobayashi, K, 51, 641,
 66P(ab)
 Kobayashi, Y, 64P(ab)
 Koch, P, 967
 Kocher, F, 249P(ab)
 Kodaira, S, 15P(ab)
 Kodner, IJ, 132P(ab)
 Koenders, E, 169P(ab)
 Koenders, EB, 1392
 Koeppe, RA, 201, 10P(ab),
 21P(ab), 109P(ab),
 164P(ab), 285P(ab)
 Koeppel, JA, 225P(ab),
 226P(ab)
 Koeter, GH, 265P(ab)
 Koffler, SP, 259P(ab)
 Kofoed, KF, 3P(ab)
 Koga, S, 282P(ab)
 Koh, C, 639, 978
 Koh, C-S, 28P(ab), 89P(ab),
 100P(ab), 248P(ab),
 274P(ab), 282P(ab)
 Koh, W-J, 235P(ab)
 Kohlmyer, SK, 223P(ab)
 Koike, S, 807, 248P(ab)
 Koivisto, M, 22P(ab)
 Koizumi, K, 1551, 1819,
 64P(ab), 254P(ab)
 Kojima, A, 80P(ab),
 171P(ab), 189P(ab)
 Kojima, K, 280P(ab)
 Kojima, S, 326
 Kokote, H, 304P(ab)
 Kolachana, B, 77P(ab)
 Kolan, H, 151P(ab)
 Kolar, Z, 72P(ab)
 Kolb, FP, 55P(ab)
 Kolbert, K, 102P(ab)
 Kole, AC, 86P(ab)
 Kolodny, GM, 103P(ab),
 172P(ab), 305P(ab)
 Kolsky, K, 150P(ab),
 167P(ab)
 Komori, T, 263P(ab),
 296P(ab)
 Kondoh, T, 180P(ab)
 Koneru, S, 104P(ab)
 Konishi, J, 374, 572, 646,
 729, 757, 1365, 1403,
 1600, 1836, 1981, 1985,
 2057, 95P(ab), 101P(ab),
 123P(ab), 150P(ab),
 175P(ab), 200P(ab),
 203P(ab), 248P(ab)
 Konopka, LM, 275P(ab)
 Kool, W, 67P(ab)
 Koomans, HA, 289P(ab)
 Koops, HS, 257, 984,
 86P(ab)
 Koper, JW, 108
 Koplan, BA, 1398
 Koponen, H, 45P(ab)
 Koral, KF, 78P(ab)
 Koray, Z, 145P(ab)
 Korf, J, 2082
 Korkmaz, M, 931, 1472,
 1476
 Korn, RL, 92P(ab), 132P(ab)
 Kornblum, HI, 56P(ab)
 Kornek, G, 1480, 20P(ab)
 Kornhuber, J, 1931
 Korobkin, M, 158P(ab)
 Korupolu, G, 10P(ab)
 Kosa, I, 126P(ab)
 Kose, G, 1755
 Koshida, K, 44P(ab)
 Kosinski, AS, 125P(ab)
 Koss, JE, 171P(ab), 206P(ab)
 Kostakoglu, L, 1771, 1956,
 257P(ab), 282P(ab),
 291P(ab), 177P(ab)
 Kosten, TR, 44P(ab)
 Kosuda, S, 975, 260P(ab),
 262P(ab)
 Kotoo, Y, 26P(ab), 58P(ab),
 126P(ab), 185P(ab)
 Kotz, D, 11N(4), 20N(5),
 27N(5), 15N(6), 19N(9),
 19N(10), 21N(11), 17N(12)
 Kotzerke, J, 2066, 160P(ab),
 249P(ab)
 Koutelou, M, 1306
 Kouyoumdji, JC, 233P(ab)
 Kovaniikaya, A, 286P(ab)
 Kowalsky, W, 1662
 Koyama, H, 1522, 246P(ab)
 Koyama, K, 304P(ab)
 Koyama, M, 410, 12P(ab)
 Koyanagi, T, 71
 Kozan, O, 302P(ab)
 Kozarek, RA, 57P(ab)
 Kozawa, S, 67P(ab)
 Kraan, J, 11P(ab), 71P(ab),
 108P(ab)
 Kramer, EL, 169P(ab)
 Kramis, M, 55P(ab)
 Krasenbaum, DN, 77P(ab),
 112P(ab)
 Krasnow, AZ, 1285, 84P(ab)
 Krause, BJ, 9P(ab)
 Krause, T, 218P(ab)
 Krausz, T, 1275
 Krausz, Y, 1537
 Krawczynska, EG, 48P(ab),
 125P(ab), 179P(ab)
 Krebs, D, 626
 Kreis, JM, 95P(ab)
 Kreissig, I, 137P(ab)
 Krems, B, 257P(ab),
 264P(ab)
 Krenning, E, 748
 Krenning, EP, 108, 886,
 1388, 19P(ab), 24P(ab),
 48P(ab), 60P(ab),
 141P(ab), 190P(ab),
 268P(ab)
 Krevsky, B, 818
 Krishna, L, 65P(ab),
 163P(ab), 259P(ab),
 263P(ab), 265P(ab)
 Krishnamurthy, GT, 35P(ab),
 72P(ab), 95P(ab)
 Kroger, LA, 451, 129P(ab),
 167P(ab)
 Krohn, KA, 2049, 43P(ab),
 49P(ab), 67P(ab), 70P(ab),
 106P(ab), 110P(ab),
 146P(ab), 194P(ab),
 205P(ab), 235P(ab)
 Krois, D, 20P(ab)
 Kroiss, A, 241P(ab)
 Kroker, B, 4P(ab)
 Kroll, K, 49P(ab), 70P(ab),
 106P(ab)
 Kronauge, JF, 118P(ab)
 Kronik, G, 115P(ab)
 Kroode, HFJ, 1511
 Kroon, BBR, 972
 Kropp, A, 6P(ab)
 Kroser, JA, 246P(ab)
 Krouwer, HGJ, 465
 Kruijter, PS, 38P(ab)
 Kruschke, C, 111P(ab)
 Krynycky, BR, 1995,
 10P(ab), 162P(ab)
 Krystal, J, 33P(ab), 285P(ab)
 Krystal, JH, 11
 Kuang, L-R, 72P(ab),
 86P(ab), 264P(ab)
 Kubo, A, 15P(ab), 30P(ab),
 212P(ab)
 Kubota, K, 320, 1713,
 67P(ab)
 Kubota, R, 320, 1713
 Kudoh, T, 729, 1981, 1985,
 150P(ab), 175P(ab)
 Kuhl, DE, 201, 10P(ab),
 21P(ab), 109P(ab),
 163P(ab), 164P(ab),
 215P(ab), 270P(ab)
 Kuhle, W, 767
 Kuikka, JT, 45P(ab),
 76P(ab), 1911Ie
 Kuker, RA, 255P(ab)
 Kukis, DL, 128P(ab),
 129P(ab), 167P(ab)
 Kulago, A, 194P(ab)
 Kumar, V, 83P(ab)
 Kumazaki, T, 304P(ab),
 308P(ab)
 Kume, N, 807, 1361
 Kumita, S, 304P(ab),
 308P(ab)
 Kumpe, D, 295P(ab)
 Kung, HF, 151, 513, 1965,
 17P(ab), 66P(ab),
 190P(ab), 201P(ab),
 219P(ab), 281P(ab)
 Kung, M, 151
 Kung, M-P, 17P(ab),
 66P(ab), 190P(ab),
 201P(ab)
 Kung, MP, 1965
 Kunst, E, 54P(ab)
 Kunzi, G, 51P(ab)
 Kurczak, S, 167P(ab)
 Kurita, T, 246P(ab)
 Kuroda, T, 116P(ab)
 Kurogane, H, 37P(ab)
 Kuroki, M, 84
 Kuroki, T, 51, 641
 Kurtaran, A, 1480, 5P(ab),
 20P(ab), 46P(ab), 251P(ab)
 Kuruc, A, 155P(ab)
 Kusakabe, K, 185P(ab)
 Kusama, Y, 304P(ab),
 308P(ab)
 Kusano, S, 975
 Kushner, SA, 66P(ab),
 201P(ab), 219P(ab)
 Kusic, Z, 446
 Kusuoka, H, 761, 1686,
 66P(ab), 94P(ab), 175P(ab)
 Kuwabara, H, 55P(ab),
 223P(ab)
 Kuwabara, Y, 21P(ab),
 36P(ab), 116P(ab),
 133P(ab), 271P(ab),
 275P(ab)
 Kuwert, T, 268P(ab)
 Kuyama, J, 258P(ab)
 Kuyvenhoven, JD, 857
 Kwan, W, 534
 Kwekkeboom, DJ, 108, 886,
 19P(ab), 141P(ab)
 Kwok, CG, 165, 2062
 Kwong, JS, 36P(ab)
 L'Abbate, A, 735
 La Rue, A, 79P(ab)
 Labarbera, J, 92P(ab)
 LaBombardi, V, 242P(ab)
 Labrouche, S, 863
 Lacey, J, 232P(ab)
 LaCroix, KJ, 78P(ab),
 80P(ab), 210P(ab)
 Lacy, JL, 52P(ab), 308P(ab)
 Lade, K, 233P(ab)
 Ladner, RC, 152P(ab)
 Lafair, J, 1537
 Lagerwaard, A, 24P(ab)
 Lago, G, 1919Ie, 266P(ab)
 Laguna, R, 287P(ab)
 Lakkis, NM, 58P(ab),
 126P(ab)
 Lally, KP, 162P(ab)
 Lalush, DS, 63P(ab),
 80P(ab), 210P(ab)
 Lambert, C, 167P(ab)
 Lambert, R, 1368, 23P(ab),
 75P(ab), 180P(ab)
 Lamberts, SWJ, 108, 886,
 19P(ab), 24P(ab)
 Lamberty, GJ, 225P(ab)
 Lamborn, KR, 1970,
 129P(ab), 170P(ab)
 Lambrecht, RM, 1557
 Lameire, N, 1048
 Lamki, L, 162P(ab),
 272P(ab), 292P(ab)
 Lammertsma, AA, 71P(ab),
 106P(ab), 109P(ab),
 224P(ab)
 Lamonica, D, 135P(ab)
 Lan, R, 187P(ab)
 Lanahan, MV, 128P(ab),
 201P(ab)
 Landau, B, 95
 Lands, EL, 149P(ab)
 Lang, J, 287P(ab)
 Lang, L, 1408, 118P(ab),
 197P(ab), 203P(ab),
 204P(ab)
 Lang, S, 999, 1526, 266P(ab)
 Langason, RB, 108P(ab),
 280P(ab)
 Langen, K-J, 201P(ab)
 Langhammer, HR, 36P(ab)
 Langstrom, B, 32, 1766
 Laniec, P, 303P(ab),
 306P(ab)
 Lanman, T, 272P(ab)
 Lansmies, E, 45P(ab)
 Lapela, M, 256P(ab)
 Lapidus, A, 47P(ab)
 Lapke, J, 1516
 Laprovitera, A, 156P(ab)
 Laragh, JH, 838
 LaRiccia, P, 278P(ab)
 Larkin, R, 171P(ab)
 Larsen, RH, 197P(ab)
 Larson, SM, 312, 695, 1052,
 1528, 1557, 43P(ab),
 78P(ab), 102P(ab),
 138P(ab), 25S, 29S
 Larsson, SA, 1417
 Laruelle, M, 32P(ab),
 33P(ab), 272P(ab),
 285P(ab)
 Lasku, A, 238P(ab)
 Lassen, NA, 13P(ab),
 164P(ab)
 Lassmann, S, 246P(ab)
 Lastoria, S, 665, 138P(ab),
 155P(ab), 156P(ab),
 199P(ab)
 Latour, Y, 69P(ab)
 Lattanand, C, 252P(ab),
 278P(ab)
 Laubenbacher, C, 99P(ab),
 114P(ab), 1918Ie
 Lauchart, W, 200P(ab)
 Laureys, S, 88P(ab)
 Lavigne, GJ, 271P(ab)
 Lawson, M, 224P(ab),
 304P(ab)
 Lay Ergun, E, 291P(ab)
 Layfield, L, 1438
 Lazewatsky, J, 117P(ab),
 119P(ab), 129P(ab),
 232P(ab)
 Lazzarin, A, 258P(ab)
 Le, D, 847
 Le, N, 1384, 29P(ab),
 129P(ab), 196P(ab),
 203P(ab), 234P(ab)
 Le Bouedec, G, 922
 Le Doussal, JM, 129P(ab)
 Le Guludec, D, 70P(ab),
 181P(ab), 253P(ab),
 256P(ab)
 Le Poncin, M, 274P(ab)
 Leach, C, 142P(ab)
 Leahy, R, 155P(ab)
 Lear, JL, 95P(ab), 295P(ab)
 Leb, G, 1524
 Lebesque, JV, 584
 LeBlanc, JW, 170P(ab)
 Lebtahi, R, 275, 253P(ab),
 256P(ab)
 Leclerc, J, 912
 Lecloirec, J, 1946
 Lecomte, R, 2040, 2046,
 170P(ab)
 Lee, B, 426
 Lee, D, 978
 Lee, DS, 639, 28P(ab),
 89P(ab), 100P(ab),
 248P(ab), 274P(ab),
 282P(ab)

- Lee, H, 1016
 Lee, HH, 82P(ab)
 Lee, HK, 252P(ab), 273P(ab)
 Lee, J, 268P(ab), 293P(ab)
 Lee, JD, 426, 469, 551
 Lee, JR, 226P(ab)
 Lee, JS, 303P(ab)
 Lee, JY, 305P(ab)
 Lee, KB, 179P(ab), 268P(ab)
 Lee, KH, 639, 179P(ab),
 226P(ab), 275P(ab)
 Lee, KS, 551, 2021,
 143P(ab), 187P(ab),
 281P(ab)
 Lee, L, 278P(ab)
 Lee, M, 978
 Lee, M-J, 273P(ab)
 Lee, MC, 639, 28P(ab),
 89P(ab), 100P(ab),
 248P(ab), 274P(ab),
 282P(ab), 305P(ab)
 Lee, MT, 205P(ab)
 Lee, RJ, 1003
 Lee, SH, 179P(ab)
 Lee, SK, 100P(ab), 194P(ab)
 Lee, WS, 551
 Lee, YJ, 248P(ab)
 Leenders, K, 54P(ab)
 Lefebvre, F, 863
 Legal, JD, 1860
 LeGuludec, D, 275
 Lehikoinen, P, 256P(ab)
 Lehmann, WD, 362
 Lehner, H, 20P(ab)
 Lehr, HA, 267P(ab)
 Lei, K, 190P(ab), 203P(ab)
 Leibenhaut, MH, 139P(ab)
 Leichner, PK, 89P(ab),
 90P(ab), 231P(ab), 13S
 Leimer, M, 1480, 5P(ab),
 20P(ab), 251P(ab)
 Leinonen, E, 45P(ab)
 Leitha, T, 1526, 46P(ab),
 115P(ab), 254P(ab),
 266P(ab)
 Leitho, T, 999
 Lelcuk, S, 259P(ab)
 Lemmens, JAM, 62
 Lenaers, A, 83P(ab)
 Leners, C, 916
 LeonardJr., MH, 926
 Leonidas, J, 34P(ab)
 Leonzi, O, 1300
 Lepola, U, 45P(ab)
 Leppo, JA, 160P(ab)
 Lequen, H, 893
 Lerch, H, 106P(ab)
 Leskinen, S, 256P(ab)
 Leslie, WD, 861, 1589
 Leung, A, 117P(ab),
 288P(ab)
 Leung, JY, 1042, 65P(ab)
 Leung, W, 100P(ab)
 Levchenko, A, 312
 Leveille, J, 1368, 75P(ab),
 180P(ab)
 Lever, JR, 193P(ab)
 Lever, SZ, 189P(ab)
 Levi, H, 211P(ab)
 Levi, L, 242P(ab)
 Levin, CS, 52P(ab), 78P(ab)
 Levin, Z, 125P(ab)
 Levine, A, 4P(ab)
 Levine, TB, 4P(ab)
 Levivier, M, 21P(ab),
- 53P(ab)
 Levy, AV, 41P(ab)
 Lewellen, B, 67P(ab)
 Lewellen, TK, 2030,
 67P(ab), 172P(ab),
 223P(ab), 224P(ab),
 235P(ab)
 Lewington, VJ, 1058
 Lewis, DH, 12P(ab)
 Lewis, DP, 80P(ab),
 210P(ab)
 Lewis, J, 138P(ab)
 Lewis, JS, 166P(ab)
 Lewis, PJ, 100P(ab),
 271P(ab)
 Lewis, R, 142P(ab)
 Lexa, RN, 210P(ab)
 Ley, A, 152P(ab), 205P(ab)
 Leyton, M, 113P(ab),
 284P(ab)
 Li, J, 489, 498, 30P(ab),
 151P(ab), 205P(ab),
 214P(ab)
 Li, N, 61P(ab)
 Li, PY, 665
 Li, S, 1480, 92P(ab)
 Li, SR, 20P(ab), 251P(ab)
 Li, X, 227P(ab)
 Li, Y, 10P(ab), 127P(ab)
 Li, Z, 106P(ab), 110P(ab),
 146P(ab)
 Liang, P, 958
 Liang, Z, 218P(ab)
 Liberzon, I, 285P(ab)
 Licata, AA, 1809
 Lich, LL, 1009, 226P(ab)
 Licho, R, 127P(ab), 275P(ab)
 Lidov, M, 467
 Lie, KI, 1631
 Liebeg, J, 211P(ab)
 Lieberman, J, 44P(ab)
 Lieberman, R, 13S
 Liebes, L, 169P(ab)
 Liedtke, AJ, 94P(ab)
 Lieg, JL, 144P(ab)
 Liegner, KB, 270P(ab)
 Liem, IH, 972
 Lietzenmayer, R, 1468,
 134P(ab), 137P(ab)
 Ligtenauer-Kaligis, EGR,
 24P(ab)
 Lillehei, C, 292P(ab)
 Lim, BB, 7P(ab)
 Lim, J, 16P(ab)
 Lim, JL, 282P(ab)
 Lim, S, 131P(ab), 146P(ab),
 267P(ab), 269P(ab)
 Lim, SK, 469
 Lim, SM, 248P(ab)
 Limouris, GS, 32P(ab)
 Lin, C, 1349
 Lin, CH, 1749
 Lin, HM, 136P(ab)
 Lin, KP, 130P(ab)
 Lin, Q, 6P(ab)
 Lin, W, 332
 Lin, WY, 145P(ab),
 163P(ab), 234P(ab),
 288P(ab), 294P(ab)
 Lin, Z, 57P(ab)
 Lindauer, M, 87
 Lindholm, P, 256P(ab)
 Lindner, KJ, 32
 Lindroos, M, 51P(ab)
 Lindstedt, G, 1519
- Lindstrom, C, 120P(ab),
 208P(ab)
 Line, BR, 87P(ab), 117P(ab),
 143P(ab), 148P(ab),
 232P(ab)
 Line, SW, 281P(ab)
 Link, JM, 2049, 67P(ab),
 70P(ab), 194P(ab),
 205P(ab)
 Link, M, 110P(ab), 146P(ab)
 Linke, R, 56P(ab)
 Linse, KH, 166P(ab)
 Liow, J-S, 73P(ab), 227P(ab)
 Lipowska, M, 17P(ab),
 46P(ab), 190P(ab),
 191P(ab)
 Lipp, RW, 1524
 Lipszyc, H, 673, 1016,
 38P(ab), 152P(ab),
 272P(ab)
 Lisbona, A, 1853
 Lister-James, J, 673, 775,
 1016, 20P(ab), 138P(ab),
 152P(ab), 204P(ab),
 272P(ab)
 Little, EP, 171P(ab),
 206P(ab)
 Liu, A, 209P(ab)
 Liu, HG, 88P(ab), 89P(ab),
 165P(ab), 235P(ab),
 276P(ab), 277P(ab)
 Liu, J, 207P(ab)
 Liu, L, 81P(ab), 210P(ab),
 215P(ab)
 Liu, R, 78, 1349
 Liu, RS, 27P(ab), 125P(ab),
 136P(ab), 172P(ab),
 262P(ab), 286P(ab)
 Liu, S, 29P(ab), 119P(ab),
 129P(ab), 232P(ab)
 Liu, T, 1491
 Liu, WG, 308P(ab)
 Liu, Y-H, 81P(ab)
 Liu, YF, 196P(ab)
 Liu, YH, 62P(ab)
 Liu, Z, 107P(ab)
 Livingston, DA, 252P(ab)
 Livni, E, 65P(ab), 66P(ab)
 Lo, JM, 188P(ab)
 Lobbezoo, F, 271P(ab)
 Lobmann, R, 104P(ab)
 LoBuglio, AF, 1491
 Locati, EH, 37P(ab)
 Lodewijks, H, 268P(ab)
 Loeffler, JS, 158P(ab)
 Loessner, A, 252P(ab)
 Logan, J, 554, 33P(ab),
 41P(ab), 44P(ab), 45P(ab),
 281P(ab)
 Logothetis, C, 32P(ab)
 Loi, G, 565
 Lombardi, G, 159P(ab)
 Lommatsch, B, 236P(ab)
 Lomuscio, G, 236P(ab)
 Loncaric, S, 207P(ab),
 214P(ab)
 London, ED, 6P(ab),
 11P(ab), 192P(ab),
 201P(ab), 279P(ab)
 Longford, CPD, 194P(ab),
 279P(ab)
 Lonn, AHR, 80P(ab),
 210P(ab)
 Lonneux, M, 258P(ab)
 Looby, RJ, 29P(ab)
- Look, R, 267P(ab), 269P(ab)
 Lopalco, L, 238P(ab)
 Lopresti, B, 109P(ab),
 145P(ab)
 Lorberboym, M, 415, 467,
 1487, 1528, 16P(ab),
 60P(ab), 135P(ab),
 255P(ab), 297P(ab)
 Lorenz, M, 9P(ab)
 Lorenz, S, 34P(ab)
 Lorenz, WJ, 2024, 154P(ab),
 221P(ab), 249P(ab),
 266P(ab), 296P(ab)
 Losman, MJ, 62P(ab)
 Lottgen, J, 429
 Loucif, E, 129P(ab)
 Low, PS, 1003
 Lowe, VJ, 136P(ab),
 249P(ab), 264P(ab),
 303P(ab)
 Lowellen, TK, 146P(ab)
 Lowenberg, B, 19P(ab),
 268P(ab)
 Lu, P, 38P(ab)
 Lu, W, 85P(ab), 227P(ab)
 Lubin, E, 259P(ab)
 Lubushitzky, R, 103P(ab)
 Lucht, R, 221P(ab)
 Lucignani, G, 42P(ab),
 133P(ab), 258P(ab)
 Ludlum, D, 207P(ab)
 Ludwig, T, 154P(ab)
 Luger, A, 1931
 Lugo, CE, 74P(ab)
 Lui, W, 332
 Lukasiewicz, R, 117P(ab),
 148P(ab), 232P(ab)
 Lukinac, L, 446
 Lumbroso, J, 598, 893, 912,
 20P(ab), 52P(ab)
 Lumenta, C, 157P(ab)
 Lundkvist, C, 108P(ab),
 112P(ab), 192P(ab),
 284P(ab)
 Lung-Kurt, S, 615
 Luo, D-S, 63P(ab)
 Luo, H, 6P(ab), 193P(ab),
 202P(ab)
 Luong, A, 513
 Luthra, SK, 109P(ab),
 191P(ab)
 Lutrin, CL, 139P(ab)
 Lutz, S, 122P(ab)
 Luxen, A, 53P(ab)
 Luzi, S, 633
 Lyster, DM, 36P(ab),
 219P(ab)
 Lythgoe, MF, 1331, 1336
- M'Kacher, R, 1860
 Ma, Y, 222P(ab), 223P(ab)
 Maas, K, 23P(ab)
 Macapinlac, H, 1528,
 102P(ab)
 Macapinlac, HA, 25S, 29S
 Macaulay, RD, 1826
 MacDonald, LR, 52P(ab),
 78P(ab), 119P(ab)
 Macey, DJ, 1970, 207P(ab),
 232P(ab), 234P(ab)
 Mach, RH, 87P(ab),
 281P(ab)
 Machac, J, 415, 16P(ab),
 38P(ab), 60P(ab),
 152P(ab), 216P(ab),
 250P(ab), 255P(ab),
 272P(ab), 297P(ab)
 Machecourt, J, 229P(ab)
 Machida, K, 304P(ab)
 Machulla, H-J, 27P(ab),
 200P(ab)
 MacIntyre, WJ, 1809,
 177P(ab), 276P(ab)
 Macke, HR, 29P(ab)
 MacMullan, J, 100P(ab)
 Macrae, IM, 661
 Macrum, B, 181P(ab)
 Madar, I, 1428, 1428
 Maddahi, J, 1428, 1428,
 68P(ab), 99P(ab),
 141P(ab), 267P(ab),
 301P(ab)
 Madras, BK, 17P(ab),
 65P(ab)
 Madsen, M, 39P(ab)
 Maecke, H, 20P(ab)
 Maecke, HR, 967
 Maeda, G, 1444
 Maeda, T, 296P(ab)
 Maekawa, M, 1673
 Maes, A, 767, 26P(ab)
 Maffioli, L, 251P(ab)
 Magata, Y, 572, 729, 1600,
 123P(ab), 175P(ab),
 192P(ab), 248P(ab)
 Magid, NM, 38P(ab)
 Magnani, P, 967, 1655
 Magoun, S, 1913(le)
 Mahe, M, 1853, 1970
 Mahmarian, JJ, 1306,
 58P(ab), 69P(ab), 93P(ab),
 126P(ab), 178P(ab)
 Mahmood, A, 17P(ab)
 Mahmood, K, 145P(ab)
 Mahmoud, S, 289P(ab)
 Mahmud, AM, 1460
 Mahoney, DW, 142P(ab)
 Mahraj, RPM, 294P(ab)
 Mainenti, PP, 164P(ab)
 Mainolfi, C, 260P(ab)
 Maintz, JBA, 213P(ab)
 Maisey, MN, 1771, 27P(ab),
 87P(ab), 208P(ab),
 282P(ab)
 Maish, D, 151P(ab)
 Majd, M, 1731, 34P(ab)
 Makihara, S, 296P(ab)
 Makriyannis, A, 187P(ab)
 Makuch, R, 1783
 Maldonado, A, 93P(ab),
 Malholtra, S, 115P(ab)
 Malhotra, S, 105P(ab)
 Mali, WPThM, 289P(ab)
 Malik, AB, 1545
 Malison, R, 201P(ab)
 Malison, RT, 44P(ab),
 272P(ab)
 Mallin, W, 798
 Mallmann, P, 626, 265P(ab)
 Malone, KM, 123P(ab)
 Maloof, J, 943
 Malveaux, E, 46P(ab),
 97P(ab), 191P(ab),
 298P(ab)
 Mamiya, T, 304P(ab)
 Mammone, GL, 178
 Mandal, AK, 118P(ab)
 Mandel, F, 209, 216, 1760
 Mandel, S, 278P(ab)
 Mandelkern, MA, 53P(ab),

- 79P(ab), 123P(ab)
 Mandell, GA, 23P(ab)
 Mandell, L, 255P(ab)
 Mandigers, CMPW, 270
 Manetou, A, 32P(ab)
 Manetti, C, 129P(ab)
 Mangner, TJ, 4P(ab),
 51P(ab), 145P(ab)
 Maniam, S, 80P(ab),
 210P(ab)
 Maniawski, PJ, 209P(ab),
 214P(ab)
 Manil, L, 893
 Mankoff, DA, 2049, 67P(ab),
 140P(ab), 252P(ab),
 267P(ab)
 Mann, JJ, 123P(ab),
 273P(ab)
 Mannino, T, 100P(ab),
 305P(ab)
 Manolidis, S, 136P(ab)
 Mansi, L, 156P(ab),
 256P(ab), 264P(ab)
 Mantil, JC, 118P(ab)
 Mantwill, K, 142P(ab)
 Mar, W, 282P(ab)
 Maragliano, C, 243P(ab),
 297P(ab)
 Marcassa, C, 735
 Marcel, R, 160P(ab)
 Marchetti, D, 9P(ab)
 Marchlinski, F, 14P(ab),
 149P(ab)
 Marcus, C, 230P(ab),
 231P(ab)
 Marcus, CS, 1789
 Mardirossian, G, 1583,
 190P(ab), 203P(ab)
 Marek, K, 133P(ab),
 134P(ab)
 Marek, KL, 272P(ab)
 Marek, MJ, 236P(ab)
 Marengo, M, 88P(ab)
 Maresca, K, 152P(ab)
 Margeneau, WH, 61P(ab)
 Margouleff, C, 209, 216,
 1760, 1850
 Margouleff, D, 1850
 Mariani, G, 536, 47P(ab),
 238P(ab), 243P(ab),
 297P(ab), 16S, 19S, 22S
 Marienhagen, J, 248P(ab)
 Marino, G, 256P(ab)
 Marinone, MG, 185P(ab)
 Mariotti, S, 565
 Markham, J, 1723
 Markham, J, 1294
 Markowitz, AL, 9P(ab),
 169P(ab)
 Marks, DG, 53P(ab),
 301P(ab)
 Markstein, R, 113P(ab)
 Marmuse, JP, 253P(ab)
 Marotta, G, 37P(ab),
 230P(ab)
 Marsden, PK, 73P(ab),
 85P(ab)
 Marshall, RC, 149P(ab)
 Marshall, RS, 273P(ab)
 Martin, A, 79P(ab)
 Martin, CC, 206P(ab),
 223P(ab)
 Martin, GV, 49P(ab)
 Martin, M, 129P(ab)
 Martin, MY, 276P(ab)
- Martin, WG, 114P(ab)
 Martinez, M, 266P(ab)
 Martini, L, 88P(ab)
 Martonen, TB, 873
 Maruyama, I, 257P(ab)
 Marwin, S, 241P(ab)
 Marx, D, 2006
 Marzilli, LG, 17P(ab),
 46P(ab), 190P(ab),
 191P(ab)
 Marzullo, P, 735
 Masaki, H, 781
 Masaki, K, 641
 Mascitelli, VA, 37P(ab),
 177P(ab)
 Masdeu, J, 277P(ab)
 Mash, DC, 108P(ab)
 Mason, G, 1789, 277P(ab)
 Mason, M, 256P(ab)
 Massarino, F, 243P(ab)
 Mastrangelo, R, 237P(ab)
 Mastrangelo, S, 237P(ab)
 Mastripolito, R, 303P(ab),
 306P(ab)
 Mastrofrancesco, P, 50P(ab)
 Masuda, I, 1985, 150P(ab)
 Masuda, K, 815, 21P(ab),
 36P(ab), 133P(ab),
 271P(ab), 275P(ab)
 Masuda, Y, 116P(ab)
 Masuyama, M, 1522
 Matiffas-Guiu, X, 631
 Mataalka, KZ, 343
 Matheja, P, 268P(ab)
 Matheoud, R, 230P(ab)
 Maher, SJ, 96P(ab),
 150P(ab)
 Matherson, KJ, 53P(ab),
 301P(ab)
 Mathews, WB, 307, 33P(ab),
 41P(ab), 45P(ab), 47P(ab),
 112P(ab), 192P(ab),
 288P(ab)
 Mathias, CJ, 1003
 Mathieu, JP, 229P(ab)
 Mathis, CA, 109P(ab),
 145P(ab), 231P(ab)
 Matoba, M, 1622
 Matoba, Y, 66P(ab)
 Matochik, J, 45P(ab)
 Marshall, BJ, 207P(ab)
 Matsubara, S, 248P(ab)
 Matsubara, T, 26P(ab),
 58P(ab), 126P(ab),
 185P(ab)
 Matsuda, H, 17P(ab)
 Matsui, R, 263P(ab),
 296P(ab)
 Matsumori, A, 572
 Matsumoto, M, 12P(ab),
 242P(ab), 285P(ab)
 Matsumoto, T, 807, 163P(ab)
 Matsumura, K, 282P(ab)
 Matsumura, Y, 220P(ab)
 Matsunaga, N, 807, 1361
 Matsunari, I, 1622, 179P(ab),
 180P(ab)
 Matsuno, K, 116P(ab)
 Matsuno, N, 258P(ab)
 Martin, A, 26P(ab),
 58P(ab), 126P(ab),
 185P(ab)
 Matsuo, H, 26P(ab), 58P(ab),
 126P(ab), 185P(ab)
 Matsuo, S, 712
- Matsushima, Y, 1613
 Mattera, JA, 81P(ab)
 Matters, J, 1783
 Mattes, MJ, 239P(ab)
 Matteucci, F, 22S
 Matthew, E, 270P(ab)
 Matthews, DC, 233P(ab)
 Matthews, WB, 107P(ab)
 Maublant, J, 922
 Maouny, C, 2037,
 104P(ab)
 Maurea, S, 159P(ab),
 260P(ab)
 Maurer, AH, 476, 775, 818,
 57P(ab), 244P(ab)
 Mausner, LF, 72P(ab),
 128P(ab), 150P(ab),
 167P(ab), 195P(ab)
 Maxted, D, 15P(ab)
 May, A, 279P(ab)
 May, CC, 304P(ab)
 Mayberg, HS, 223P(ab)
 Mayer, EA, 123P(ab)
 Mazaika, T, 129P(ab),
 151P(ab), 202P(ab),
 232P(ab)
 Mazza, SM, 193P(ab),
 282P(ab)
 Mazzuotta, JC, 79P(ab)
 Mazzucchelli, L, 236P(ab)
 McAndrews, P, 46
 McBride, BJ, 1016
 McBride, JG, 4P(ab)
 McCallum, RW, 57P(ab)
 McCarron, JA, 112P(ab)
 McCarthy, A, 34P(ab)
 McCarthy, DW, 61P(ab),
 71P(ab), 128P(ab)
 McCarthy, TJ, 40P(ab),
 108P(ab)
 McCarthy, WH, 964
 McCartney, WH, 80P(ab)
 McClellan, JM, 92P(ab),
 148P(ab), 176P(ab)
 McCool, D, 104P(ab)
 McCormick, T, 263P(ab)
 McCowage, GB, 1438
 McCready, VR, 235P(ab)
 McCullough, SP, 232P(ab)
 McDevitt, M, 78P(ab)
 McDonough, E, 136P(ab),
 264P(ab)
 McDougall, IR, 2062
 McElgin, W, 151
 McElgin, WT, 1965,
 201P(ab), 219P(ab)
 McEllin, K, 15P(ab)
 McEwan, AJB, 237P(ab)
 McFalls, EO, 2006
 McGhie, J, 748
 McGoron, AJ, 752, 49P(ab),
 188P(ab), 205P(ab)
 McGowan, DG, 237P(ab)
 McGuffie, E, 1052
 McHarg, D, 90P(ab)
 McIlvain, TR, 29P(ab)
 McKay, RG, 105P(ab)
 McKay, WJ, 1683, 121P(ab),
 131P(ab), 132P(ab)
 McKusick, KA, 1906
 McLean, S, 186P(ab)
 McLeish, A, 131P(ab),
 132P(ab)
 McMahon, M, 105P(ab),
 177P(ab)
- McNeill, G, 183P(ab)
 McNerney, A, 167P(ab)
 McNulty, PH, 50P(ab)
 McPeck, M, 239
 McPherson, DW, 6P(ab),
 186P(ab), 193P(ab),
 202P(ab)
 Mdaka, T, 1323
 Meadors, K, 86P(ab)
 Meares, CF, 451, 128P(ab),
 167P(ab)
 Mease, RC, 72P(ab),
 167P(ab)
 Mechanick, JI, 1487, 1528,
 135P(ab)
 Meegalla, S, 151
 Meegalla, SK, 17P(ab)
 Mehldorn, HM, 257P(ab)
 Mehling, R, 118P(ab)
 Mehta, BM, 312
 Mehta, HH, 161P(ab),
 241P(ab), 285P(ab)
 Meier, DA, 1745
 Meijer, S, 259P(ab)
 Meikle, SR, 128, 220P(ab)
 Meinken, GE, 72P(ab),
 195P(ab)
 Mekhmandarov, S, 259P(ab)
 Mele, FM, 296P(ab)
 Melega, WP, 55P(ab),
 109P(ab), 163P(ab)
 Melhem, E, 12P(ab)
 Melin, J, 25P(ab), 39P(ab),
 126P(ab)
 Melissano, G, 55
 Meller, J, 255P(ab)
 Meltzer, CC, 269P(ab),
 71P(ab), 128P(ab)
 Meltzer, PC, 17P(ab)
 Memsic, L, 250P(ab)
 Ménard, JF, 1976
 Menard, S, 665
 Mendes, D, 116P(ab)
 Meneghetti, JC, 294P(ab)
 Menendez, LR, 140P(ab)
 Menendez, M, 245P(ab)
 Menzel, C, 1496, 1962,
 100P(ab), 134P(ab),
 138P(ab), 243P(ab),
 252P(ab), 273P(ab)
 Meredith, RF, 1491
 Merlet, P, 70P(ab)
 Merlini, G, 185P(ab)
 Merrick, MV, 42
 Mertz, JE, 189P(ab)
 Messa, C, 133P(ab),
 258P(ab)
 Mestas, D, 922
 Metroka, CE, 276P(ab)
 Mettler, L, 142P(ab)
 Mettler, FH, 24N(12)
 Metz, CE, 160, 30P(ab)
 Metz, DC, 114P(ab),
 246P(ab)
 Meunier, J, 98P(ab)
 Meyer, E, 42P(ab)
 Meyer, G, 34P(ab), 156P(ab),
 236P(ab)
 Meyer, GJ, 521
 Meyer, MA, 226P(ab)
 Meyer, P, 1853
 Meylaerts, SAG, 1449
 Meyringer, R, 248P(ab)
 Michanek, A, 1519
 Michanek, AMK, 228
 Michel, C, 39P(ab)
- Michiels, P, 91P(ab)
 Michigishi, T, 101P(ab)
 Michotte, A, 88P(ab)
 Middleton, ML, 171
 Miedema, AR, 1449
 Miers, LA, 128P(ab),
 129P(ab), 167P(ab)
 Mignon, M, 253P(ab),
 256P(ab)
 Mikami, Y, 116P(ab)
 Miki, M, 1460
 Mikuni, N, 101P(ab)
 Milan, E, 1300
 Milas, L, 72P(ab), 253P(ab)
 Milko, DL, 74P(ab)
 Millard, RW, 752, 49P(ab),
 188P(ab)
 Miller, DD, 14P(ab),
 68P(ab), 69P(ab)
 Miller, JH, 286P(ab)
 Miller, MA, 57P(ab),
 244P(ab)
 Miller, MM, 63P(ab)
 Miller, RF, 995
 Miller, S, 31P(ab)
 Miller, SD, 209P(ab),
 214P(ab)
 Miller, TR, 63P(ab),
 217P(ab)
 Milo, TJ, 275P(ab)
 Minami, C, 1789, 230P(ab),
 231P(ab)
 Minard, TL, 259P(ab)
 Minn, H, 256P(ab)
 Minosako, Y, 94P(ab)
 Minoshima, S, 21P(ab),
 163P(ab), 164P(ab),
 215P(ab), 270P(ab),
 277P(ab), 278P(ab),
 285P(ab)
 Minster, J, 136P(ab),
 264P(ab)
 Minturn, MA, 74P(ab),
 80P(ab), 109P(ab),
 145P(ab), 220P(ab),
 224P(ab), 231P(ab),
 269P(ab)
 Miola, UJ, 1649
 Miotti, S, 665
 Miraldi, F, 11P(ab), 174P(ab)
 Mirick, GR, 451
 Mirzadeh, S, 166P(ab),
 195P(ab)
 Misaki, T, 646
 Mishani, E, 40P(ab)
 Mitchell, DA, 233P(ab)
 Mitchell, DS, 16
 Mitchell, R, 42
 Mitsuoka, W, 781
 Miura, H, 815
 Miura, S, 110P(ab)
 Miyahara, Y, 1343
 Miyamoto, C, 259P(ab),
 263P(ab), 265P(ab)
 Miyamoto, K, 1679
 Miyamoto, S, 646
 Miyaoka, RS, 2030,
 172P(ab), 223P(ab)
 Miyashita, K, 1824
 Miyatake, S, 200P(ab)
 Miyauchi, T, 36P(ab),
 64P(ab)
 Miyazawa, Y, 51
 Mizrachi, H, 169P(ab)
 Mizumura, S, 304P(ab),

- 308P(ab)
 Mizunaga, M, 291P(ab)
 Mochizuki, T, 180P(ab),
 239P(ab), 290P(ab),
 291P(ab)
 Mochoviac, S, 11
 Mock, BH, 40P(ab)
 Modorati, G, 967
 Moeller, JR, 281P(ab)
 Moffat, FL, 238P(ab)
 Moger, AS, 278P(ab)
 Mohamadiyah, M, 33P(ab),
 164P(ab)
 Mohammadtahgi, S, 54P(ab),
 91P(ab)
 Mohammed, A, 6P(ab)
 Moin, K, 97P(ab)
 Molea, N, 297P(ab)
 Molenaar, WM, 257, 984
 Molinari, AS, 798
 Mollenstadt, S, 262P(ab)
 Molloy, PT, 265P(ab),
 286P(ab)
 Molls, M, 157P(ab)
 Momen, A, 211P(ab)
 Momomura, S, 38P(ab),
 82P(ab)
 Momomura, SI, 1937
 Momose, M, 185P(ab)
 Momose, T, 189P(ab),
 280P(ab)
 Monclus, M, 53P(ab)
 Monetti, N, 1688, 88P(ab),
 250P(ab)
 Montane, B, 23P(ab)
 Monticciolo, D, 254P(ab)
 Montplaisir, JY, 271P(ab)
 Moody, T, 204P(ab),
 254P(ab)
 Moog, F, 249P(ab), 262P(ab)
 Moon, DH, 99P(ab),
 141P(ab), 267P(ab)
 Moore, A, 55P(ab)
 Moore, E, 873
 Moore, MJ, 1578
 Moore, SC, 18P(ab),
 29P(ab), 77P(ab),
 124P(ab), 153P(ab)
 Morales, A, 240P(ab)
 Morel, C, 51P(ab)
 Moresco, RM, 133P(ab)
 Moretti, JL, 233P(ab),
 274P(ab)
 Moretti, M, 189P(ab)
 Morey, SS, 35P(ab)
 Morgan, HT, 209P(ab),
 210P(ab), 214P(ab)
 Morgenroth, C, 268P(ab)
 Mori, H, 186P(ab)
 Mori, M, 37P(ab)
 Morimitsu, T, 1343
 Morin, C, 237P(ab)
 Morishita, K, 94P(ab)
 Morita, R, 815, 1567
 Moriwaki, H, 12P(ab),
 242P(ab), 285P(ab)
 Morozumi, T, 1686, 183P(ab)
 Morr, I, 87, 234P(ab),
 235P(ab), 264P(ab),
 265P(ab)
 Morell, AC, 276P(ab)
 Morris, ED, 125P(ab)
 Morris, G, 146
 Morris, ID, 336
 Morris, JC, 1487, 135P(ab)
- Morris, S, 58P(ab)
 Morrish, PK, 271P(ab)
 Morrison, JC, 302P(ab)
 Morrison, V, 302P(ab)
 Morrissey, GJ, 197P(ab)
 Mortelmans, L, 767, 26P(ab),
 91P(ab)
 Mortimer, JE, 99P(ab)
 Morton, K, 1876
 Morton, KA, 46P(ab)
 Morton, TE, 281P(ab)
 Mosca, F, 22S
 Moser, E, 67P(ab), 218P(ab)
 Moser, R, 156P(ab),
 252P(ab)
 Moses, WW, 85P(ab)
 Mosesson, R, 255P(ab)
 Moshin, J, 723
 Moskovitz, B, 290P(ab)
 Mothe, G, 245P(ab)
 Motomura, N, 30P(ab),
 212P(ab)
 Motta, C, 238P(ab),
 243P(ab), 297P(ab)
 Moulopoulou, A, 32P(ab)
 Mountz, JD, 276P(ab)
 Mountz, JM, 88P(ab),
 89P(ab), 164P(ab),
 165P(ab), 235P(ab),
 276P(ab), 277P(ab)
 Mousa, D, 1649
 Movassaghi, N, 34P(ab)
 Moyer, BR, 673, 775, 1016,
 204P(ab)
 Moyers, C, 85P(ab), 86P(ab)
 Mozley, LH, 283P(ab)
 Mozley, PD, 151, 1965,
 66P(ab), 165P(ab),
 201P(ab), 219P(ab),
 276P(ab), 278P(ab),
 283P(ab), 284P(ab),
 286P(ab)
 Mozzillo, N, 138P(ab)
 Msaki, P, 2040, 2046
 Mu, M, 1965, 66P(ab),
 201P(ab)
 Muenz, LR, 1965
 Muenzing, W, 56P(ab)
 Mugitani, T, 1522
 Muhlesiepen, H, 113P(ab),
 201P(ab)
 Mukai, T, 374
 Mukherjee, J, 50P(ab),
 193P(ab), 211P(ab)
 Mukherji, SK, 2079
 Mukhopadhyay, SK, 70P(ab)
 Mulholland, GT, 40P(ab)
 Mullan, BP, 1456, 84P(ab),
 116P(ab)
 Mullani, N, 1701
 Muller, D, 158P(ab)
 Muller, E, 67P(ab)
 Muller, H, 286P(ab)
 Muller, NL, 36P(ab)
 Muller, SP, 18P(ab), 29P(ab),
 55P(ab), 124P(ab),
 153P(ab), 279P(ab)
 Muller-Berg, M, 137P(ab)
 Muller-Gartner, HW,
 113P(ab), 201P(ab),
 219P(ab), 222P(ab),
 227P(ab), 283P(ab)
 Muller-Schauenburg, W, 463,
 1468, 134P(ab), 137P(ab)
 Mumcuoglu, E, 86P(ab),
- 130P(ab)
 Munakata, JA, 123P(ab)
 Munakata, K, 304P(ab),
 308P(ab)
 Munch, G, 107P(ab)
 Mundler, O, 1773
 Mundy, J, 54P(ab)
 Munz, DL, 20P(ab),
 158P(ab), 255P(ab)
 Munz, F, 131P(ab), 154P(ab)
 Murakami, N, 901
 Murakami, T, 1937
 Murakumo, M, 71
 Murano, A, 256P(ab)
 Murase, K, 180P(ab),
 223P(ab), 2232
 Murata, I, 26P(ab), 58P(ab),
 126P(ab), 185P(ab)
 Murata, K, 1567
 Murata, Y, 1613
 Murayama, S, 36P(ab)
 Mure, A, 275
 Murman, DL, 270P(ab)
 Murray, DR, 307P(ab)
 Murthy, S, 1487, 135P(ab)
 Musachio, JL, 6P(ab),
 41P(ab), 45P(ab),
 107P(ab), 112P(ab),
 192P(ab)
 Muswick, GJ, 685
 Mut, F, 1919(le), 266P(ab)
 Muto, P, 138P(ab), 155P(ab),
 156P(ab)
 Muzi, M, 220P(ab), 221P(ab)
 Muzic, RF Jr, 685, 11P(ab),
 174P(ab)
 Muzik, O, 4P(ab), 145P(ab)
 Myers, AM, 1965
 Myers, M, 148P(ab)
 Myers, MJ, 91P(ab)
 Myers, RW, 111P(ab),
 132P(ab), 139P(ab)
 Mzengeza, S, 55P(ab),
 284P(ab)
 Mzengeza, S, 113P(ab)
 Na, DL, 275P(ab)
 Nabi, H, 198P(ab)
 Naddaf, S, 242P(ab),
 251P(ab), 277P(ab),
 301P(ab)
 Nader, MA, 281P(ab)
 Nadkarni, R, 162P(ab),
 240P(ab)
 Naeem, M, 48P(ab)
 Nagai, R, 3P(ab)
 Nagamachi, S, 84, 901, 1626,
 308P(ab)
 Nagaoka, H, 3P(ab)
 Nagasawa, M, 244P(ab)
 Nagatsuka, S, 649
 Nagle, CE, 1745, 17N(7)
 Nagren, K, 256P(ab)
 Nahmias, C, 432
 Nair, S, 263P(ab)
 Naito, M, 244P(ab)
 Naito, T, 1343
 Naito, Y, 123P(ab)
 Nakada, H, 200P(ab)
 Nakada, K, 16P(ab),
 239P(ab), 290P(ab),
 291P(ab)
 Nakagawa, T, 282P(ab)
 Nakagawara, J, 276P(ab)
 Nakahara, H, 901, 308P(ab)
- Nakajima, S, 51
 Nakamoto, Y, 200P(ab),
 203P(ab), 248P(ab)
 Nakamura, J, 276P(ab)
 Nakamura, K, 15P(ab)
 Nakamura, Y, 712
 Nakao, K, 1985, 150P(ab)
 Nakashima, H, 282P(ab)
 Nakashima, R, 80P(ab)
 Nakata, T, 1679
 Nakata, Y, 263P(ab),
 296P(ab)
 Nakayama, H, 189P(ab)
 Nakayama, M, 189P(ab),
 200P(ab)
 Nallamothu, N, 149P(ab),
 182P(ab)
 Nally, J, 1876
 Namavari, M, 107P(ab),
 147P(ab), 193P(ab)
 Namba, H, 649
 Namba, R, 263P(ab)
 Namba, Y, 200P(ab)
 Nampoory, MRA, 289P(ab)
 Napolitano, C, 37P(ab)
 Nappi, A, 13P(ab), 178P(ab)
 Narabayashi, I, 263P(ab),
 296P(ab)
 Narayan, M, 1749
 Narayana, S, 221P(ab)
 Nariai, T, 259P(ab)
 Narita, Y, 110P(ab)
 Naruki, Y, 246P(ab)
 Narula, J, 4P(ab), 49P(ab),
 106P(ab), 144P(ab),
 175P(ab), 269P(ab)
 Naruse, H, 1783
 Nasel, C, 999, 266P(ab)
 Nassim, MA, 873
 Natale, D, 1783
 Nativ, O, 290P(ab)
 Naylor, I, 6P(ab)
 Neal, CE, 74P(ab)
 Needle, MN, 265P(ab),
 286P(ab)
 Neff, S, 31P(ab), 92P(ab)
 Nekolla, SG, 70P(ab),
 131P(ab), 154P(ab),
 172P(ab), 180P(ab),
 218P(ab)
 Nelleman, P, 53P(ab)
 Nellis, SH, 94P(ab)
 Nelp, W, 1583
 Nelson, AD, 685, 174P(ab)
 Nelson, CA, 1031
 Nelson, DL, 234P(ab)
 Nemoto, M, 280P(ab)
 Netto, ICV, 288P(ab)
 Neuhold, N, 20P(ab),
 251P(ab)
 Neumann, DR, 1809, 2000,
 177P(ab)
 Neumann, FJ, 126P(ab)
 Neumann, RD, 1408,
 62P(ab), 118P(ab),
 228P(ab), 233P(ab),
 254P(ab)
 Neumann, U, 283P(ab)
 Neumayr, A, 241P(ab)
 Neumeyer, J, 1760, 133P(ab)
 Neumeyer, JL, 284P(ab)
 Neverve, J, 218P(ab)
 Newell, DW, 12P(ab)
 Newhouse, H, 182P(ab)
 Newport, D, 85P(ab)
- Newton, MA, 213P(ab)
 Ng, C, 282P(ab)
 Ng, C-y, 171P(ab)
 Ng, CK, 50P(ab), 80P(ab)
 Nguyen, A, 136P(ab)
 Nguyen, K, 75P(ab),
 250P(ab), 272P(ab),
 273P(ab)
 Nguyen, KN, 107P(ab)
 Nguyen, N, 94P(ab),
 107P(ab)
 Niccoli, L, 1300
 Nicholl, C, 6P(ab)
 Nichols, D, 16N(1), 20N(1),
 18N(8), 34N(10), 44N(11),
 24N(12)
 Nichols, K, 48P(ab),
 105P(ab), 115P(ab),
 116P(ab)
 Nichols, TE, 74P(ab),
 220P(ab), 224P(ab)
 Nicholson, GL, 127P(ab)
 Nicholson, RL, 213P(ab)
 Nickel, O, 209P(ab)
 Nickerson, LDH, 223P(ab)
 Nickles, RJ, 94P(ab),
 206P(ab)
 Nicolai, A, 178P(ab)
 Nicolai, E, 13P(ab)
 Nicolosi, A, 565
 Niederle, B, 20P(ab)
 Niehoff, T, 1865
 Nielson, JB, 199P(ab)
 Niesen, A, 1942
 Nieweg, OE, 257, 972, 984,
 86P(ab)
 Nijhof, MW, 128P(ab)
 Nikkels, PGJ, 897
 Nili, M, 103P(ab)
 Nilsson, O, 1519, 2002
 Nishida, Y, 26P(ab), 58P(ab),
 126P(ab), 185P(ab)
 Nishide, H, 1622
 Nishiguchi, K, 807, 1361
 Nishigori, H, 326, 1698
 Nishiguchi, S, 51
 Nishijima, K, 1343
 Nishikawa, J, 1937, 38P(ab),
 82P(ab), 183P(ab),
 189P(ab), 280P(ab)
 Nishikawa, M, 280P(ab)
 Nishikawa, T, 64P(ab),
 122P(ab), 180P(ab)
 Nishimura, T, 1, 761, 1686,
 1824, 12P(ab), 26P(ab),
 66P(ab), 94P(ab),
 175P(ab), 183P(ab),
 242P(ab), 277P(ab),
 285P(ab)
 Nishino, M, 246P(ab)
 Nishioeda, Y, 1, 1824
 Nishiura, M, 66P(ab)
 Nishizawa, S, 374, 113P(ab),
 123P(ab), 284P(ab)
 Nizami, MA, 1001
 Nobuyoshi, M, 26P(ab)
 Nofzinger, EA, 80P(ab)
 Noguchi, J, 215P(ab)
 Noguchi, K, 12P(ab)
 Noguchi, S, 901
 Noguera, C, 245P(ab)
 Noguera, G, 245P(ab)
 Nohara, R, 572, 729, 757,
 1403, 1836, 1981, 95P(ab)
 Nonomura, A, 298P(ab)

- Nonomura, K, 71
 Nordman, E, 256P(ab)
 Novak, S, 96P(ab), 162P(ab),
 240P(ab)
 Nowak, DJ, 1891
 Noz, M, 169P(ab)
 Nozaki, T, 215P(ab)
 Nquyen, K, 267P(ab),
 269P(ab)
 Nukiwa, T, 1460
 Numata, H, 111P(ab)
 Nunez, M, 266P(ab)
 Nurmoahmed, SA, 38P(ab)
 Nusynowitz, ML, 144P(ab)
 Nutt, R, 85P(ab), 86P(ab),
 170P(ab)
 Nutter, F, 200P(ab)
 Nuutinen, J, 256P(ab)
 Nuyts, J, 767, 26P(ab)
 Nyberg, S, 108P(ab)
- O'Brien, C, 964
 O'Brien, JT, 195
 O'Donnell, RT, 451,
 232P(ab)
 O'Donoghue, JA, 102P(ab),
 3S
 O'Dowd, T, 211P(ab)
 O'Keefe, GJ, 121P(ab)
 O'Mara, RE, 1903
 O'Neil, JP, 1009
 O'Reilly, P, 1872
 O'Sullivan, F, 220P(ab),
 221P(ab), 224P(ab)
 O'Tuama, LA, 12P(ab),
 270P(ab)
 Oates, E, 267, 113P(ab)
 Oberdorfer, F, 87, 341,
 68P(ab), 147P(ab),
 257P(ab), 265P(ab)
 Oberg, K, 32
 Oberhausen, E, 615
 Oberhofer, MT, 139P(ab)
 Obreanovich, GT, 294P(ab)
 Obuchowski, NA, 1809
 Ochi, H, 51, 641, 304P(ab)
 Ochoa, AV, 306P(ab)
 Ochrymowycz, LA, 61P(ab)
 Oda, H, 26P(ab), 58P(ab),
 126P(ab), 185P(ab)
 Oda, K, 1698, 123P(ab),
 153P(ab), 215P(ab),
 220P(ab)
 Oehme, L, 208P(ab),
 283P(ab)
 Oei, HY, 1876, 19P(ab),
 268P(ab)
 Oesch, F, 233P(ab)
 Offord, R, 51P(ab)
 Offord, SJ, 11, 112P(ab)
 Ogawa, K, 30P(ab),
 212P(ab), 215P(ab),
 225P(ab)
 Ogawa, T, 12P(ab), 110P(ab)
 Ogawa, Y, 291P(ab),
 292P(ab)
 Ogihara-Umeda, I, 326, 1698
 Ogino, M, 1403, 1836,
 95P(ab)
 Oguchi, M, 64P(ab),
 122P(ab)
 Ogunbiyi, OA, 132P(ab)
 Ogura, S, 955
 Oguz, A, 139P(ab)
 Oh-hori, K, 1679
- Ohashi, H, 26P(ab), 126P(ab)
 Ohlenschlaeger, U, 1841
 Ohmori, Y, 1673
 Ohnaka, Y, 815
 Ohnishi, H, 815, 1567
 Ohnishi, T, 84, 901, 308P(ab)
 Ohshima, S, 3P(ab)
 Ohta, K, 76P(ab)
 Ohta, M, 258P(ab)
 Ohta, Y, 997
 Ohtake, E, 111P(ab)
 Ohtake, T, 1937, 38P(ab),
 82P(ab), 183P(ab),
 189P(ab)
 Ohtomo, K, 1444
 Ohyama, Y, 189P(ab)
 Oian, J, 97P(ab)
 Okada, J, 258P(ab)
 Okada, RD, 107P(ab)
 Okamura, T, 304P(ab)
 Okazawa, H, 374, 729, 1600,
 2057, 101P(ab), 123P(ab)
 Okazumi, S, 279
 Okimura, T, 64P(ab),
 122P(ab)
 Oku, N, 12P(ab), 285P(ab)
 Okuda, K, 757, 1403, 1836,
 95P(ab)
 Olalde, L, 301P(ab)
 Old, LJ, 1052
 Oliner, C, 37P(ab)
 Olinger, R, 208P(ab)
 Ollinger, JM, 226P(ab)
 Olmos, RAV, 584
 Olshen, A, 221P(ab)
 Olsson, RA, 142P(ab)
 Omar, WS, 242P(ab),
 277P(ab)
 Omata, M, 1937, 38P(ab),
 82P(ab)
 Ommeslag, DJ, 857
 Ongseg, F, 2098(ie)
 Onishi, Y, 374
 Ono, K, 1622
 Ono, M, 7P(ab)
 Ono, S, 410
 Onsel, C, 233
 Onthank, DC, 151P(ab),
 202P(ab)
 Oohashi, H, 185P(ab)
 Oosterhof, GON, 169P(ab)
 Oosterwijk, E, 169P(ab)
 Oosterwijk-Wakka, JC,
 169P(ab)
 Orduna, E, 287P(ab)
 Oren, R, 39P(ab),
 Oriuchi, N, 273, 457,
 72P(ab), 86P(ab), 264P(ab)
 Orlandi, C, 37P(ab), 93P(ab),
 150P(ab), 184P(ab)
 Osada, H, 304P(ab)
 Oser, U, 218P(ab)
 Oshima, S, 680, 184P(ab)
 Osiecki, A, 215P(ab)
 Osipova, TA, 52P(ab)
 Osman, AF, 81P(ab)
 Osman, S, 109P(ab),
 112P(ab)
 Osmont, A, 95
 Osorio, L, 169P(ab)
 Oster, Z, 218P(ab)
 Oster, ZH, 24P(ab)
 Ostertag, H, 221P(ab)
 Ostrem, JL, 79P(ab)
 Ota, T, 815, 1567
- Otsuka, M, 271P(ab)
 Otsuka, S, 246P(ab)
 Ott, R, 54P(ab), 191P(ab),
 228P(ab)
 Otte, R, 100P(ab)
 Otten, EW, 296P(ab)
 Overall, J, 1609, 76P(ab)
 Overbeck, B, 243P(ab),
 273P(ab)
 Overkamp, D, 463
 Ovize, M, 147P(ab)
 Ovunc, K, 177P(ab)
 Owunwanne, A, 289P(ab)
 Oya, S, 190P(ab)
 Oyama, Y, 80P(ab)
 Oyen, WJC, 62, 1392,
 119P(ab), 128P(ab)
 Ozaki, S, 244P(ab)
 Ozbilek, E, 302P(ab)
 Ozdemir, S, 130P(ab)
 Ozker, K, 1285, 84P(ab)
 Özyar, E, 1956, 257P(ab)
 Paans, AMJ, 257, 279, 984,
 2082, 11P(ab), 71P(ab),
 86P(ab), 157P(ab),
 225P(ab), 265P(ab),
 306P(ab)
 Paberzs, A, 36P(ab)
 Pace, L, 735, 178P(ab)
 Packard, AB, 270P(ab)
 Padhy, AK, 137P(ab)
 Padurean, A, 152P(ab)
 Paganelli, G, 55, 967, 1655,
 169P(ab), 195P(ab),
 238P(ab)
 Page, MPA, 195
 Pagliarulo, A, 78P(ab)
 Paik, CH, 1384, 29P(ab),
 129P(ab), 196P(ab),
 203P(ab), 234P(ab)
 Pajkrt, D, 24P(ab)
 Pak, C, 49P(ab)
 Pak, CYK, 175P(ab)
 Pak, KY, 119P(ab)
 Palant, A, 224P(ab)
 Palestro, CJ, 34P(ab),
 103P(ab), 161P(ab),
 199P(ab), 241P(ab),
 242P(ab), 244P(ab),
 285P(ab)
 Palevsky, H, 295P(ab)
 Palkovic, S, 268P(ab)
 Palmedo, H, 626, 1496,
 100P(ab), 134P(ab),
 138P(ab), 243P(ab),
 252P(ab), 265P(ab)
 Palmer, EL, 1310
 Palmer, J, 622
 Palmer, LB, 239
 Palmon, S, 33P(ab)
 Pan, T-S, 18P(ab), 63P(ab),
 97P(ab), 153P(ab)
 Panaro, V, 238P(ab)
 Pancholy, S, 149P(ab)
 Pandit, N, 415, 467
 Pang, IW, 301P(ab)
 Panico, MR, 260P(ab)
 Panther, R, 178P(ab)
 Panyutin, I, 62P(ab),
 228P(ab)
 Papadopoulos, M, 188P(ab)
 Papageorgiou, S, 5
 Papatheofanis, FJ, 31P(ab)
 Papatheofanis, FP, 92P(ab)
 Papatheofanis, PP, 92P(ab)
- Papos, M, 287P(ab)
 Pappas, N, 1609, 33P(ab),
 44P(ab), 45P(ab), 76P(ab),
 281P(ab)
 Paracchi, A, 230P(ab)
 Paredes, A, 23P(ab)
 Parekh, JS, 158P(ab)
 Parikh, A, 59P(ab)
 Park, CH, 157P(ab),
 260P(ab)
 Park, CY, 426, 469, 551
 Park, HM, 137P(ab),
 236P(ab)
 Park, JM, 252P(ab)
 Park, KO, 67P(ab)
 Park, R, 178P(ab)
 Park, S, 978
 Park, S-G, 15P(ab)
 Park, YH, 137P(ab),
 236P(ab)
 Parker, D, 166P(ab)
 Parker, JA, 178, 1618, 1906,
 2087, 172P(ab)
 Parkes, SL, 744
 Parkman, HP, 57P(ab),
 244P(ab)
 Parmentier, C, 598, 606, 912,
 1860, 20P(ab), 52P(ab)
 Parodi, O, 735
 Parra, LC, 124P(ab)
 Parsai, EI, 90P(ab)
 Partridge, EE, 1491
 Parwaresh, MR, 142P(ab)
 Pascani, K, 1609, 45P(ab),
 76P(ab)
 Pascual, M, 293P(ab)
 Pascuavalca, D, 45P(ab)
 Pasqualini, R, 107P(ab),
 188P(ab), 189P(ab)
 Pasquet, A, 25P(ab),
 126P(ab)
 Passath, A, 1524
 Pastan, I, 29P(ab), 129P(ab),
 152P(ab), 203P(ab),
 204P(ab)
 Pastore, V, 264P(ab)
 Pastores, G, 297P(ab)
 Patel, B, 252
 Patel, D, 272P(ab)
 Patel, M, 241P(ab),
 Patel, SL, 272P(ab)
 Pathare, PM, 151P(ab)
 Pathmaraj, K, 121P(ab)
 Patlak, C, 209
 Patsis, G, 188P(ab)
 Patterson, GA, 135P(ab)
 Patterson, J, 661, 79P(ab)
 Patterson, M, 81P(ab)
 Patterson, R, 6P(ab)
 Patterson, RE, 1891,
 174P(ab)
 Pattillo, R, 182P(ab)
 Patton, DD, 301P(ab)
 Patton, JA, 31P(ab)
 Pau, A, 238P(ab)
 Paulesu, E, 42P(ab),
 133P(ab)
 Pauley, DR, 307P(ab)
 Paulik, SG, 249P(ab)
 Paulus, M, 85P(ab), 86P(ab),
 119P(ab)
 Paulus, P, 250P(ab),
 260P(ab), 261P(ab)
 Pauwels, S, 916, 258P(ab)
 Papatheofanis, PP, 92P(ab)
- Pavics, L, 273P(ab),
 280P(ab)
 Pawitan, Y, 224P(ab)
 Pawlik, G, 429
 Payne, JK, 1735
 Pechmann, M, 156P(ab),
 252P(ab)
 Peck, GE, 197P(ab)
 Pecorale, A, 195P(ab)
 Pecori, B, 156P(ab)
 Pedenovi, P, 26P(ab)
 Pedley, B, 868
 Pedrini, L, 49P(ab), 88P(ab)
 Peifer, JW, 97P(ab)
 Pelegrini, M, 217P(ab)
 Peltier, P, 1853
 Peluso, P, 205P(ab)
 Pemberton, CC, 307P(ab)
 Penney, BC, 211P(ab),
 212P(ab)
 Penninckx, F, 54P(ab)
 Pentlow, KS, 1557
 Perani, D, 42P(ab)
 Pereira, J, 273P(ab)
 Pereira, M, 905
 Perenboom, RM, 1392
 Pericak-Vance, MA, 79P(ab)
 Perkeges, JL, 57P(ab)
 Perlman, SB, 162P(ab)
 Pernezky, G, 241P(ab)
 Perry, JR, 80P(ab)
 Perry, R, 2079
 Perrymore, WD, 1517
 Persson, M, 120P(ab)
 Pescatore, F, 1662
 Petegnief, Y, 256P(ab)
 Peterdy, AE, 861
 Peter, BM, 14N(7)
 Peters, AM, 54P(ab),
 91P(ab), 114P(ab),
 128P(ab), 148P(ab)
 Peters, W, 4P(ab)
 Peterson, J, 169P(ab)
 Peterson, LM, 235P(ab)
 Peterson, NP, 78P(ab)
 Petiet, A, 101P(ab), 231P(ab)
 Petit-Taboue, M, 95
 Petrakis, I, 285P(ab)
 Petras, S, 847
 Petretta, M, 13P(ab)
 Petrosino, T, 155P(ab)
 Petrov, A, 4P(ab), 175P(ab),
 269P(ab)
 Pettigrew, RI, 125P(ab)
 Pettit, W, 31P(ab)
 Pezzullo, L, 138P(ab)
 Pfaffendorf, M, 160P(ab)
 Pfeffer, M, 1537
 Pfluger, T, 34P(ab)
 Pham, HL, 230P(ab),
 231P(ab)
 Phaneuf, DC, 180P(ab)
 Phelps, ME, 506, 1428,
 1428, 1626, 1717, 42P(ab),
 55P(ab), 56P(ab), 68P(ab),
 79P(ab), 82P(ab), 86P(ab),
 99P(ab), 107P(ab),
 109P(ab), 110P(ab),
 141P(ab), 146P(ab),
 147P(ab), 163P(ab),
 193P(ab), 267P(ab),
 269P(ab), 301P(ab),
 303P(ab)
 Phillips, E, 250P(ab)
 Phillips, PC, 265P(ab),

- 286P(ab)
 Phillips, RL, 284P(ab)
 Phillips, WT, 1374, 247P(ab)
 Philpott, GW, 61P(ab)
 Picardi, V, 35P(ab), 255P(ab)
 Piccardo, P, 270P(ab)
 Piccini, P, 109P(ab)
 Piccolo, S, 155P(ab),
 156P(ab)
 Pickering, AD, 195
 Piepsz, A, 1281, 1346, 1805,
 1883
 Piera, J, 631
 Pieri, PL, 49P(ab)
 Piers, DA, 67P(ab)
 Pierson, R Jr., 878
 Pier, M, 201, 27P(ab),
 200P(ab)
 Pietrzky, U, 122P(ab),
 137P(ab), 155P(ab)
 Pietzsch, H-J, 16P(ab)
 Piga, M, 565
 Pijpers, R, 259P(ab)
 Pike, VW, 112P(ab),
 141P(ab), 191P(ab)
 Pimstone, N, 160
 Pinchera, A, 606
 Pinchuk, AN, 1540
 Pinkert, J, 283P(ab)
 Pinot, L, 303P(ab), 306P(ab)
 Pinson, CW, 131P(ab)
 Pinto, CD, 301P(ab)
 Pipolo, F, 40P(ab)
 Pippin, J, 93P(ab), 184P(ab)
 Piriz, JM, 37P(ab), 58P(ab),
 105P(ab)
 Pirker, W, 1931
 Pirmettis, I, 188P(ab)
 Pirotte, B, 21P(ab)
 Pitt, SR, 81P(ab)
 Piwnica-Worms, D, 51P(ab),
 71P(ab), 247P(ab)
 Plossl, K, 17P(ab)
 Plott, G, 1491
 Ploux, L, 303P(ab), 306P(ab)
 Plukker, JTM, 86P(ab)
 Plutckoh, J, 270P(ab)
 Podoloff, DA, 931, 1472,
 1476, 32P(ab), 72P(ab),
 86P(ab), 127P(ab),
 207P(ab), 232P(ab),
 234P(ab), 253P(ab),
 261P(ab), 264P(ab),
 296P(ab)
 Podreka, I, 1931
 Poewe, W, 22
 Pointon, O, 121P(ab),
 131P(ab)
 Poldermans, D, 60P(ab)
 Polgar, M, 287P(ab)
 Polla, BS, 1413, 1694
 Pollard, KR, 2030
 Polulak, D, 222P(ab),
 305P(ab)
 Pomeranz, SJ, 263P(ab),
 307P(ab)
 Pomper, MG, 41P(ab)
 Ponto, JA, 2092
 Ponto, LLB, 39P(ab),
 199P(ab), 221P(ab),
 225P(ab), 226P(ab)
 Poppe, G, 767
 Porenta, G, 178P(ab)
 Porter, D, 55P(ab)
 Porter, JK, 143P(ab)
- Postiglione, A, 164P(ab)
 Postma-Tjoa, J, 748
 Potena, MI, 665
 Pounds, TR, 111P(ab),
 132P(ab), 136P(ab),
 139P(ab), 157P(ab)
 Poussaint, TY, 270P(ab)
 Powe, J, 993
 Powers, TA, 131P(ab)
 Powers, WJ, 1668, 226P(ab)
 Powsner, R, 12P(ab)
 Pozniakoff, TA, 273P(ab)
 Prados, MD, 157P(ab)
 Prat, L, 49P(ab)
 Prato, FS, 213P(ab)
 Pratt, JP, 95P(ab), 295P(ab)
 Prauer, H, 111P(ab)
 Prekeges, JL, 103P(ab)
 Prenant, C, 341
 Prescod, N, 823
 Prescott, DM, 1438
 Press, OW, 43P(ab)
 Pretorius, HT, 263P(ab),
 307P(ab)
 Pretorius, PH, 97P(ab),
 153P(ab)
 Preumont, N, 83P(ab)
 Price, JC, 690, 786
 Price, JE, 264P(ab)
 Price, JP, 109P(ab)
 Price, LH, 44P(ab)
 Priori, SG, 37P(ab)
 Probst, R, 70P(ab)
 Procaccini, E, 156P(ab)
 Pruckmayer, M, 999, 1526,
 115P(ab), 266P(ab)
 Pruijn, J, 257, 897, 984,
 111P(ab), 211P(ab), 71P(ab),
 86P(ab), 157P(ab),
 263P(ab), 265P(ab),
 306P(ab)
 Prvulovich, EM, 995
 Puig, M, 631
 Puig, S, 266P(ab)
 Pulawski, P, 1865
 Puntieri, P, 264P(ab)
 Pupi, A, 278P(ab), 279P(ab)
 Puschel, W, 615
 Puskas, C, 49P(ab)
 Put, E, 1605
 Put, T, 1605
 Pyzalski, RW, 162P(ab)
 Qaim, SM, 166P(ab)
 Qazi, UA, 207P(ab)
 Qing, F, 1275
 Qu, T, 152P(ab), 190P(ab),
 203P(ab)
 Quadri, SM, 1545
 Quaife, RA, 179P(ab),
 295P(ab)
 Querin, S, 1368
 Quick, D, 32P(ab)
 Quinn, GA, 852
 Quinn, KB, 265P(ab)
 Quinn, MJ, 964
 Quinn, RJ, 744
 Quinn, TP, 96P(ab), 198P(ab)
 Quion, JV, 37P(ab)
 Quirijnen, JMS, 244, 1511
 Quirk, S, 197P(ab)
 Quyyumi, AA, 25P(ab)
 Rabin, MSZ, 212P(ab)
- Rabito, CA, 293P(ab)
 Rabkin, G, 4P(ab)
 Raderer, M, 1480, 20P(ab),
 251P(ab)
 Radosavljevic, I, 20P(ab)
 Raffel, DM, 1923, 70P(ab)
 Ragland, JD, 283P(ab),
 284P(ab)
 Ragland, T, 186P(ab)
 Rahi, S, 1946
 Raijmakers, PGHM, 1316
 Rain, JD, 1773
 Raina, A, 182P(ab)
 Rajendran, J, 12P(ab),
 117P(ab)
 Rajopadhye, M, 28P(ab),
 119P(ab), 129P(ab)
 Rajvanshi, P, 244P(ab)
 Rakshi, JS, 271P(ab)
 Raleigh, MJ, 55P(ab),
 109P(ab), 163P(ab)
 Raltz, SL, 57P(ab)
 Ramanna, L, 46
 Rambaldi, PF, 156P(ab),
 256P(ab), 264P(ab)
 Rambaldi, R, 60P(ab)
 Rammohan, R, 175P(ab)
 Ramos, CD, 273P(ab)
 Ramos-Gabatin, A, 301P(ab),
 302P(ab)
 Rampy, MA, 1540
 Ramsingh, KK, 263P(ab)
 Ramsingh, PS, 263P(ab),
 307P(ab)
 Rancurel, G, 1976
 Rank, BM, 294P(ab)
 Ranner, G, 1524
 Rao, V, 71P(ab)
 Rapoport, E, 4P(ab),
 269P(ab)
 Rapun, R, 251P(ab),
 301P(ab)
 Rasey, JS, 235P(ab)
 Rashti, F, 1731
 Rasse, M, 999, 1526,
 266P(ab)
 Rassidakis, A, 32P(ab)
 Rastad, J, 1766
 Rau, V, 308P(ab)
 Raubitschek, AA, 209P(ab)
 Rauch, SL, 33P(ab)
 Rauth, AM, 1023
 Ravad, GA, 182P(ab)
 Ravert, HT, 307, 11P(ab),
 33P(ab), 41P(ab), 45P(ab),
 47P(ab), 77P(ab),
 107P(ab), 112P(ab),
 164P(ab), 192P(ab),
 201P(ab), 280P(ab),
 288P(ab)
 Ravn, U, 51P(ab)
 Rawwas, JB, 16
 Raylman, RR, 1562, 36P(ab),
 52P(ab), 98P(ab), 1914(le)
 Reba, RC, 279P(ab)
 Reddy, NK, 279P(ab)
 Redfern, MG, 142P(ab)
 Reed, J, 85P(ab), 130P(ab)
 Reed, NL, 10P(ab)
 Reeves, F, 69P(ab)
 Rehm, K, 227P(ab)
 Rehm, PK, 643, 1676
 Reich, H, 278P(ab)
 Reichart, B, 70P(ab)
 Reichert, D, 16P(ab),
- 71P(ab)
 Reid, R, 8P(ab), 197P(ab)
 Reid, WS, 279P(ab)
 Reidel, G, 157P(ab)
 Reijis, AEM, 1951, 48P(ab),
 60P(ab)
 Reilly, RM, 199P(ab)
 Reiman, E, 224P(ab),
 304P(ab)
 Reiman, RE, 471
 Reiners, Chr, 286P(ab)
 Reinhardt, CP, 160P(ab)
 Reinhardt, M, 67P(ab)
 Reinhold, U, 138P(ab)
 Reisinger, I, 20P(ab),
 158P(ab)
 Relyea, B, 577, 1636
 Rendl, J, 286P(ab)
 Reno, JM, 29P(ab), 166P(ab)
 Renstrom, B, 94P(ab)
 Repp, R, 362
 Resche, I, 32P(ab)
 Reschini, E, 37P(ab),
 230P(ab)
 Reske, SN, 160P(ab),
 220P(ab), 249P(ab),
 262P(ab)
 Reuland, P, 463
 Reutens, DC, 42P(ab)
 Reuter, S, 81P(ab)
 Reutter, BW, 131P(ab)
 Reveiz, MC, 199P(ab)
 Reyes, GA, 126P(ab)
 Reynolds, JC, 1690, 15P(ab),
 234P(ab)
 Rezai, K, 1815
 Rezani, C, 177P(ab)
 Rhoden, S, 926
 Rhodes, B, 1789
 Rhodes, BA, 24P(ab)
 Rhodes, C, 106P(ab)
 Rhodes, CG, 1275, 71P(ab),
 106P(ab)
 Ribbe, T, 120P(ab)
 Ribeiro, L, 223P(ab)
 Ricard, M, 598, 1830,
 52P(ab)
 Ricaurte, GA, 112P(ab)
 Riccabona, G, 1912(le)
 Ricci, S, 22S
 Rice, KC, 2021, 143P(ab),
 187P(ab)
 Rich, D, 80P(ab)
 Rich, DA, 282P(ab)
 Richards, JS, 277P(ab)
 Richardson, DD, 1310
 Richardt, G, 107P(ab)
 Richenbacher, W, 39P(ab)
 Richie, JP, 315
 Richmond, JCW, 225P(ab),
 226P(ab)
 Richter, JA, 93P(ab)
 Richter, WS, 22
 Riedl, M, 1931
 Riese, K, 861
 Riggan, S, 276P(ab)
 Redfern, MG, 142P(ab)
 Rigo, P, 250P(ab), 260P(ab),
 261P(ab)
 Rijnstjes, M, 55P(ab)
 Ringelstein, JG, 275P(ab)
 Rini, JN, 243P(ab)
 Rinne, D, 137P(ab)
 Ritsema, GH, 594
 Riva, P, 49P(ab)
 Rizzo, G, 133P(ab),
- Robbins, J, 1690, 15P(ab)
 Robbins, R, 102P(ab)
 Robert, A, 25P(ab), 126P(ab)
 Roberts, D, 271P(ab)
 Roberts, TG, 279P(ab)
 Robeson, W, 209, 216, 1850,
 133P(ab)
 Robeson, WR, 1557
 Robidoux, A, 75P(ab)
 Robinson, R, 1749
 Robson, L, 868
 Rocchisani, JM, 274P(ab)
 Rocco, TP, 1618
 Roche, A, 912
 Roche, T, 141P(ab)
 Rodriguez, S, 170P(ab)
 Roelandt, JRTC, 748, 1951
 Roelants, V, 25P(ab),
 126P(ab)
 Roelcke, U, 54P(ab)
 Rogers, BE, 95P(ab),
 186P(ab)
 Rogers, JG, 161P(ab)
 Rogers, WL, 7P(ab),
 119P(ab), 170P(ab),
 171P(ab)
 Rogulski, MM, 301P(ab)
 Rohe, RC, 77P(ab)
 Rohlen, DA, 283P(ab)
 Rohrlich, P, 35P(ab)
 Rolfs, RJ, 263P(ab)
 Rolla, D, 243P(ab)
 Rolleman, E, 141P(ab)
 Rolleman, EJ, 1388
 Romano, JE, 476
 Rombach, M, 218P(ab)
 Romeo, A, 88P(ab), 250P(ab)
 Romer, W, 36P(ab), 99P(ab),
 111P(ab), 138P(ab)
 Rommelfanger, S, 94P(ab)
 Roncevic, S, 446
 Roodenburg, JLN, 897
 Rooney, BC, 166P(ab)
 Rosa, E, 312
 Rosch, F, 166P(ab), 227P(ab)
 Rose, DJ, 152P(ab)
 Rose, PA, 70P(ab), 81P(ab),
 148P(ab), 176P(ab)
 Rosen, G, 272P(ab)
 Rosen, PJ, 267P(ab)
 Rosenberg, JM, 280P(ab)
 Rosenblatt, W, 33P(ab)
 Rosenthal, L, 1872
 Roses, AD, 79P(ab)
 Rossmuller, B, 236P(ab)
 Rosner, D, 238P(ab)
 Ross, R, 57P(ab)
 Ross, SG, 8P(ab)
 Rössler, K, 1431
 Roszell, NJ, 49P(ab),
 188P(ab)
 Rota-Kops, E, 113P(ab),
 283P(ab)
 Rothfusz, BC, 293P(ab)
 Rotman, M, 234P(ab)
 Rottenberg, DA, 73P(ab),
 227P(ab)
 Roubin, GS, 277P(ab)
 Rougier, P, 20P(ab)
 Rouleau, D, 170P(ab)
 Rousset, O, 283P(ab)
 Rouvier, E, 1853, 129P(ab)
 Roy, LP, 46P(ab)
 Royal, H, 878
 Royal, HD, 1903, 1906

- Royal, HJ, 2087, 2092
 Royen, EA, 1449
 Rozanski, A, 105P(ab), 115P(ab)
 Rssler, K, 1931
 Rubas, B, 211P(ab)
 Rubin, A, 168P(ab), 169P(ab), 239P(ab)
 Rubin, AD, 905, 9P(ab), 43P(ab), 243P(ab)
 Rubin, PJ, 39P(ab), 82P(ab), 161P(ab), 221P(ab)
 Rubin, RH, 843, 24P(ab), 33P(ab), 239P(ab)
 Rubin, S, 183P(ab)
 Rubinstein, M, 274P(ab)
 Rubio, L, 93P(ab)
 Rubow, S, 283P(ab)
 Rubulotta, MR, 156P(ab)
 Rudas, M, 254P(ab)
 Ruddy, TD, 174P(ab)
 Rudello, F, 205P(ab)
 Rudolfstigung, KA, 241P(ab)
 Rueschoff, J, 248P(ab)
 Rufini, V, 633, 1464, 1778, 237P(ab)
 Ruhmann, J, 134P(ab), 138P(ab), 252P(ab)
 Ruiz, E, 245P(ab)
 Ruiz, M, 1398, 3P(ab)
 Ruotsalainen, U, 387, 256P(ab)
 Ruskowski, M, 1655, 152P(ab), 190P(ab), 203P(ab)
 Rushton, HG, 1731
 Russel, FGM, 2082
 Russell, A, 105P(ab)
 Russell, C, 1876, 1883
 Russell, CD, 588, 1491, 293P(ab)
 Russell, K, 114P(ab)
 Rust, M, 121P(ab)
 Ruszkiewicz, JA, 74P(ab)
 Rutgers, DH, 38
 Ruth, F, 262P(ab)
 Ruth, TJ, 421
 Ryan, A, 137
 Ryan, J, 185
 Ryan, JW, 212P(ab)
 Ryan, PJ, 1353, 297P(ab)
 Rybicki, F, 124P(ab)
 Ryu, JS, 252P(ab), 273P(ab)
 Ryu, YH, 551
- Saatci, U, 145P(ab)
 Sacher, M, 415
 Sadato, N, 123P(ab), 192P(ab), 251P(ab), 257P(ab)
 Sadek, AH, 165P(ab), 265P(ab), 278P(ab)
 Sadik, A, 1662
 Saenz, A, 1595
 Safer, JR, 176P(ab)
 Saffer, JR, 19P(ab)
 Saga, T, 179P(ab), 200P(ab), 203P(ab)
 Saha, GB, 177P(ab), 2276P(ab)
 Sahu, SK, 187P(ab)
 Sain, JD, 301P(ab)
 Saito, T, 116P(ab)
 Saito, Y, 291P(ab)
 Saitoh, M, 258P(ab)
- Sakahara, H, 200P(ab), 203P(ab)
 Sakamoto, H, 111P(ab)
 Sakamoto, K, 304P(ab)
 Sakata, I, 17P(ab)
 Sala-Trepot, M, 101P(ab)
 Salako, P, 146
 Salako, Q, 129P(ab), 143P(ab), 167P(ab), 199P(ab)
 Saleh, Z, 48P(ab)
 Salensky, H, 48P(ab), 105P(ab), 115P(ab), 116P(ab)
 Saletnick, I, 633
 Salk, D, 252
 Salman, HS, 48P(ab)
 Salman, UA, 247P(ab)
 Salmassi, A, 142P(ab)
 Salminen, E, 256P(ab)
 Salvadori, PA, 22S
 Salvatore, M, 665, 13P(ab), 138P(ab), 155P(ab), 156P(ab), 159P(ab), 164P(ab), 178P(ab), 260P(ab)
 Salvatori, M, 633
 Salzmann, JK, 112P(ab)
 Sambuceti, G, 735
 Samson, Y, 5, 1976, 76P(ab)
 Samuel, A, 55
 Samuels, RS, 103P(ab)
 San Pedro, EC, 88P(ab), 89P(ab), 165P(ab), 276P(ab), 277P(ab)
 Sand, A, 2017
 Sandbank, J, 259P(ab)
 Sandler, MP, 31P(ab), 131P(ab)
 Sandrock, D, 158P(ab), 255P(ab)
 Sanger, J, 169P(ab)
 Sano, J, 308P(ab)
 Sano, M, 123P(ab)
 Santoro, GM, 26P(ab)
 Saoudi, A, 303P(ab)
 Saponaro, R, 185P(ab)
 Saran, F, 1942
 Sarda, L, 275, 253P(ab), 256P(ab)
 Sarfati, E, 1773
 Sarti, G, 49P(ab)
 Sarwar, M, 457
 Sasaki, M, 21P(ab), 36P(ab), 133P(ab), 271P(ab), 275P(ab)
 Sasaki, T, 279, 326, 1698, 123P(ab)
 Sasaki, Y, 680, 1289, 1937, 38P(ab), 82P(ab), 183P(ab), 189P(ab), 246P(ab), 280P(ab)
 Sasayama, S, 572, 729, 757, 1403, 1836, 95P(ab)
 Sassaman, M, 204P(ab)
 Sasso, D, 196P(ab)
 Sasso, DE, 656
 Satake, S, 15P(ab)
 Sato, J, 5P(ab), 291P(ab), 292P(ab)
 Sato, K, 410
 Sato, M, 410
 Sato, S, 17P(ab)
 Satoh, H, 153P(ab)
 Satoh, T, 165P(ab)
- Satta, L, 565
 Satyamurthy, N, 107P(ab), 193P(ab)
 Saunders, AM, 79P(ab)
 Saunders, R, 77P(ab)
 Saunders, RC, 281P(ab)
 Savelli, G, 250P(ab), 251P(ab)
 Savi, A, 205P(ab)
 Saxena, S, 79P(ab)
 Sayed, ME, 48P(ab)
 Sayman, H, 233
 Scanlan, DR, 161P(ab)
 Scarborough, E, 94P(ab)
 Scarfone, C, 498, 214P(ab), 216P(ab)
 Schabel, SI, 1682
 Schackert, HK, 87
 Schad, D, 111P(ab), 154P(ab)
 Schad, LR, 296P(ab)
 Schaefer, T, 137P(ab)
 Schafer, H, 104P(ab)
 Schafers, M, 71P(ab), 106P(ab), 268P(ab)
 Scharko, AM, 162P(ab)
 Scheff, AM, 74P(ab)
 Scheffel, U, 307, 6P(ab), 11P(ab), 33P(ab), 41P(ab), 107P(ab), 112P(ab), 201P(ab), 279P(ab)
 Scheidhauer, K, 137P(ab)
 Scheinberg, DA, 695, 78P(ab)
 Scheithauer, W, 1480, 20P(ab), 251P(ab)
 Schelbert, H, 767
 Schelbert, HR, 1626, 1717, 3P(ab), 82P(ab)
 Scheid, HH, 1990
 Schelosky, L, 22
 Schemman, F, 1942
 Schenker, C, 16P(ab)
 Scheubeck, M, 286P(ab)
 Scheunemann, C, 16P(ab)
 Schicha, H, 137P(ab)
 Schiepers, C, 767, 22P(ab), 54P(ab)
 Schiepers, CW, 306P(ab)
 Schierlinger, S, 172P(ab)
 Schillaci, O, 1452, 35P(ab), 255P(ab)
 Schirmer, B, 57P(ab)
 Schlag, P, 257P(ab)
 Schlom, J, 1491
 Schlumberger, M, 598, 606, 912, 1830, 1860, 20P(ab), 52P(ab)
 Schnall, B, 204P(ab)
 Schmidlin, P, 154P(ab), 221P(ab)
 Schmidt, S, 615
 Schmidt, U, 144P(ab)
 Schmitt, T, 208P(ab)
 Schnakenberg, H, 167P(ab)
 Schnakenberg, J, 222P(ab)
 Schneider-Eicke, J, 126P(ab), 180P(ab)
 Schneiderman, GS, 6S
 Schneiderman, MH, 13S, 6S
 Schnitt, SJ, 74P(ab)
 Schnur, KC, 99P(ab)
 Schober, O, 1865, 1990, 49P(ab), 71P(ab), 106P(ab), 268P(ab)
 Schoder, H, 3P(ab)
- Schoenberger, JA, 248P(ab)
 Schofield, L, 50P(ab)
 Schomburg, A, 626, 1496, 138P(ab), 243P(ab), 252P(ab), 265P(ab), 273P(ab)
 Schomig, A, 126P(ab)
 Schonauer, M, 131P(ab)
 Schosser, R, 147P(ab)
 Schrag, A, 22
 Schramm, M, 142P(ab)
 Schreij, G, 594, 1652
 Schrotte, W, 1799
 Schuller, M, 142P(ab)
 Schulz, C, 36P(ab)
 Schulze, PE, 22
 Schulzer, M, 421
 Schumaker, R, 78P(ab)
 Schuth, G, 222P(ab)
 Schwabe, U, 142P(ab)
 Schwaiger, M, 1923, 36P(ab), 41P(ab), 70P(ab), 94P(ab), 99P(ab), 107P(ab), 111P(ab), 114P(ab), 122P(ab), 126P(ab), 131P(ab), 138P(ab), 154P(ab), 157P(ab), 172P(ab), 180P(ab), 218P(ab), 262P(ab), 278P(ab), 1918(ie)
 Schwarz, TH, 230P(ab)
 Schwartz, AM, 267P(ab)
 Schwartz, JG, 247P(ab)
 Schwartz, JR, 1826
 Schwartz, M, 1826
 Schwartz, PJ, 37P(ab)
 Schwartz, RB, 158P(ab)
 Schwartzman, DS, 14P(ab), 149P(ab)
 Schwarz, SW, 61P(ab), 95P(ab)
 Schwizer, W, 245P(ab)
 Sciagra, R, 26P(ab)
 Sciuji, J, 1865, 1990, 55P(ab), 247P(ab), 279P(ab)
 Scopinaro, F, 1452, 35P(ab), 255P(ab)
 Scott, A, 1052
 Scott, AM, 695, 1683, 43P(ab), 121P(ab), 131P(ab), 132P(ab)
 Scott, JA, 1310
 Scott-Moncrieff, C, 197P(ab)
 Scovill, WA, 15P(ab)
 Scully, SP, 1438
 Seabold, JE, 1815
 Sedelnikova, OA, 228P(ab)
 Seeman, P, 113P(ab)
 Segal, D, 415
 Segall, GM, 165
 Seibyl, J, 33P(ab), 44P(ab), 100P(ab), 133P(ab), 134P(ab), 246P(ab), 272P(ab), 305P(ab)
 Seibyl, JP, 11
 Seidel, J, 204P(ab)
 Seike, Y, 12P(ab), 285P(ab)
 Seitz, RJ, 219P(ab)
 Seki, C, 280P(ab)
 Seki, H, 64P(ab), 122P(ab)
 Sekito, Y, 276P(ab)
 Seliskar, CJ, 205P(ab)
 Selland, DG, 267
- Semigran, MJ, 144P(ab)
 Semmler, W, 257P(ab), Sen, C, 415
 Senda, M, 279, 1698, 123P(ab), 153P(ab), 215P(ab), 220P(ab), 259P(ab)
 Senekowitsch-Schmidtke, R, 41P(ab), 138P(ab), 262P(ab)
 Sennma, J, 179P(ab)
 Seo, IS, 4P(ab)
 Serafini, A, 798, 32P(ab), 96P(ab), 162P(ab), 238P(ab), 240P(ab), 255P(ab), 302P(ab)
 Sergeant, P, 26P(ab)
 Setna, FJ, 1828
 Seto, H, 101P(ab)
 Setyono-Han, B, 108
 Seybold, S, 307P(ab)
 Seymour, KM, 70P(ab)
 Sfakianakis, G, 1876, 23P(ab), 96P(ab), 162P(ab), 238P(ab), 240P(ab), 255P(ab), 289P(ab), 293P(ab), 302P(ab)
 Sfakianakis, GN, 798
 Sgouros, G, 695, 43P(ab), 78P(ab), 89P(ab), 96P(ab), 102P(ab)
 Shah, JH, 72P(ab), 95P(ab)
 Shaker, R, 1285
 Shalaby-Rana, E, 34P(ab)
 Shan, YF, 308P(ab)
 Shao, L, 132P(ab), 252P(ab)
 Shao, Y, 85P(ab), 86P(ab)
 Shapiro, B, 633, 852, 1464, 1778, 15P(ab), 25P(ab), 141P(ab), 158P(ab), 288P(ab)
 Shapiro, S, 197P(ab)
 Sharfstein, S, 107P(ab), 147P(ab)
 Sharkey, R, 1504
 Sharkey, RM, 829, 905, 9P(ab), 43P(ab), 44P(ab), 96P(ab), 102P(ab), 168P(ab), 169P(ab), 231P(ab), 232P(ab), 239P(ab), 243P(ab)
 Sharma, HL, 336
 Sharma, S, 24P(ab)
 Sharma, V, 51P(ab), 71P(ab)
 Sharp, JG, 13S
 Shaw, HM, 964
 Shaw, LJ, 14P(ab), 68P(ab), 116P(ab)
 Shaw, P, 34P(ab)
 Shaw, SM, 197P(ab)
 Shaya, E, 77P(ab)
 Shea, C, 203P(ab)
 Shedwick, LA, 231P(ab)
 Shefer, RE, 61P(ab), 128P(ab)
 Sheff, K, 133P(ab), 134P(ab), 272P(ab)
 Shehata, AR, 14P(ab), 58P(ab), 177P(ab)
 Shelton, DK, 214P(ab)
 Shelton, ME, 222P(ab)
 Shen, MYH, 81P(ab)
 Shen, S, 146, 1970, 90P(ab), 128P(ab), 232P(ab)

- Shenk, RR, 99P(ab)
 Sheridan, CM, 105P(ab)
 Sherman, ELC, 108P(ab), 128P(ab)
 Sherman, PS, 50P(ab)
 Shettar, S, 165P(ab)
 Shi, B, 186P(ab), 298P(ab)
 Shi, R, 127P(ab)
 Shiba, K, 186P(ab)
 Shibasaki, H, 101P(ab)
 Shibasaki, T, 457
 Shibasaki, T, 273
 Shields, AF, 2049, 67P(ab), 240P(ab)
 Shields, SC, 56P(ab)
 Shiga, T, 276P(ab), 290P(ab), 291P(ab), 293P(ab)
 Shih, L, 151P(ab)
 Shih, WJ, 1913(le), 230P(ab)
 Shimada, S, 66P(ab)
 Shimizu, M, 101P(ab)
 Shimizu, T, 263P(ab)
 Shimizu, Y, 304P(ab)
 Shimonishi, Y, 304P(ab)
 Shimosegawa, E, 12P(ab)
 Shimotsu, Y, 1824
 Shin, SA, 226P(ab)
 Shinbata, H, 180P(ab)
 Shiomi, S, 51, 641
 Shiraishi, M, 55P(ab)
 Shirakami, Y, 94P(ab)
 Shirazi, P, 275P(ab)
 Shoup, TM, 33P(ab), 222P(ab)
 Shreeve, WW, 1841
 Shreve, P, 15P(ab), 25P(ab), 27P(ab)
 Shreve, PD, 36P(ab), 141P(ab)
 Shuke, N, 5P(ab), 44P(ab), 291P(ab), 292P(ab)
 Shulkin, BL, 16, 1464, 288P(ab)
 Sibomana, M, 258P(ab)
 Siccaldi, AG, 967, 169P(ab), 238P(ab)
 Siddiqui, A, 286P(ab)
 Sides, K, 168P(ab)
 Sidoli, A, 238P(ab)
 Siebert, R, 303P(ab), 306P(ab)
 Sieckman, GL, 61P(ab), 185P(ab)
 Siegel, A, 271P(ab)
 Siegel, AH, 100P(ab)
 Siegel, BA, 1906, 87P(ab), 99P(ab), 132P(ab), 135P(ab)
 Siegel, J, 905, 9P(ab)
 Siegel, JA, 495, 9P(ab), 44P(ab), 90P(ab), 102P(ab), 168P(ab), 231P(ab), 232P(ab)
 Siegel, JS, 1504
 Siegel, S, 85P(ab), 86P(ab)
 Siemion, J, 279P(ab)
 Siewert, JR, 114P(ab)
 Siggelkow, H, 255P(ab)
 Signorini, M, 42P(ab)
 Silberman, A, 250P(ab)
 Silberstein, E, 881
 Silberstein, EB, 185, 102P(ab), 23N(6)
 Sill, H, 1524
 Silva, F, 287P(ab)
- Silver, S, 23N(8)
 Silverman, DHS, 123P(ab)
 Silverman, DS, 99P(ab)
 Silverman, ED, 854
 Silverman, J, 75P(ab)
 Silverman, RW, 85P(ab), 86P(ab)
 Simakhodski, I, 283P(ab)
 Simkin, P, 991
 Simon, AJ, 86P(ab)
 Simons, M, 1618
 Simpson, G, 136P(ab)
 Simpson, LJ, 72P(ab)
 Simpson, N, 109P(ab), 145P(ab)
 Simpson, NR, 231P(ab)
 Simsek, U, 289P(ab)
 Sinboku, H, 1343
 Sinclair, RA, 121P(ab)
 Singer, PA, 135P(ab)
 Singh, PR, 28P(ab)
 Sinnige, LGF, 21P(ab)
 Shimizu, R, 1789
 Sinusas, A, 1783
 Sinusas, AJ, 62P(ab), 81P(ab)
 Sippel, C, 246P(ab), 257P(ab)
 Sisyan, R, 250P(ab)
 Sisson, JC, 16, 852, 1464, 288P(ab)
 Sitek, A, 120P(ab)
 Skarulis, MC, 1690
 Skibo, LK, 165
 Skinner, RS, 25P(ab)
 Skinner, RWS, 1540
 Skopicki, HA, 161P(ab)
 Slade, SA, 191P(ab)
 Slaton, JW, 292P(ab)
 Slavin, A, 261P(ab)
 Slivka, T, 149P(ab)
 Slizofski, WJ, 65P(ab), 114P(ab), 163P(ab), 259P(ab), 263P(ab), 265P(ab)
 Slomka, PJ, 8P(ab), 25N(9)
 Sloane, RM, 5P(ab)
 Sloof, GW, 184P(ab)
 Slooff, TJH, 62
 Slosky, JJ, 72N(2)
 Slosman, DO, 1413, 1694
 Smaldone, GC, 239
 Small, GW, 42P(ab), 79P(ab)
 Smarkey, S, 6P(ab)
 Smart, S, 1285
 Smellie, JM, 823
 Smilowitz, HM, 656
 Smit, EF, 67P(ab), 265P(ab)
 Smith, AM, 155P(ab), 220P(ab)
 Smith, CR, 87P(ab), 281P(ab)
 Smith, E, 191P(ab), 298P(ab)
 Smith, EM, 288P(ab)
 Smith, EO, 1749, 100P(ab), 222P(ab)
 Smith, F, 301P(ab)
 Smith, G, 554, 145P(ab), 220P(ab)
 Smith, GS, 109P(ab), 231P(ab)
 Smith, GT, 1846, 122P(ab), 139P(ab), 206P(ab), 279P(ab)
 Smith, KF, 4P(ab)
- Smith, MF, 212P(ab)
 Smith, RJ, 19P(ab), 130P(ab), 132P(ab), 172P(ab), 276P(ab), 283P(ab), 284P(ab)
 Smith, SM, 307P(ab)
 Smith, SV, 195P(ab), 196P(ab)
 Smith, T, 1331, 1336
 Smith, WS, 24N(9), 29N(10), 34N(11), 30N(12)
 Smith, WH, 3P(ab)
 Smola, R, 207P(ab)
 Smylie, M, 237P(ab)
 Snow, BJ, 421
 Snow, DA, 673
 Snow, GB, 352
 Snyder, SE, 10P(ab), 21P(ab)
 So, Y, 28P(ab)
 Soares, EJ, 30P(ab)
 Soares, J Jr, 294P(ab)
 Sohn, SK, 268P(ab)
 Soil, A, 245P(ab)
 Solbach, M, 200P(ab)
 Solin, O, 387, 51P(ab)
 Solzabach, U, 218P(ab)
 Som, P, 24P(ab)
 Sommer, H, 156P(ab), 252P(ab)
 Somsen, GA, 160P(ab)
 Song, HC, 67P(ab)
 Song, IS, 639
 Songini, C, 967
 Sonmezoglu, K, 233
 Sonnenberg, F, 113P(ab)
 Soricelli, A, 164P(ab)
 Sostman, HD, 1438, 1906
 Soucy, J-P, 98P(ab), 271P(ab)
 Soufer, R, 50P(ab), 59P(ab), 80P(ab), 282P(ab)
 Soulén, M, 132P(ab)
 Soulez, G, 1368
 Sparks, RB, 229P(ab)
 Spath, G, 1496
 Spaulding, MB, 135P(ab), 136P(ab), 259P(ab)
 Speckter, H, 209P(ab)
 Speelman, JD, 134P(ab)
 Spelle, L, 5, 76P(ab)
 Spence, A, 221P(ab)
 Spencer, RP, 105
 Spencer, SS, 100P(ab), 305P(ab)
 Sperling, B, 13P(ab)
 Spetsieris, P, 216
 Spicer, KM, 83P(ab), 208P(ab), 307P(ab)
 Spies, H, 16P(ab)
 Spies, SM, 211P(ab), 216P(ab)
 Spies, WG, 216P(ab)
 Spinks, TJ, 85P(ab)
 Spaetels, SEC, 748
 Spradau, TW, 28P(ab)
 Springer, J, 65P(ab)
 Spyra, L, 218P(ab)
 Squire, O, 25S
 Sridhar, K, 255P(ab)
 Srinivasan, A, 147P(ab), 193P(ab), 420
 Srinivasan, G, 1795, 25P(ab), 39P(ab), 60P(ab), 93P(ab), 160P(ab), 161P(ab)
 Srivastava, SC, 72P(ab), Srivastava, V, 252P(ab), 295P(ab)
 Srur, S, 290P(ab)
 Stabin, M, 1995
 Stabin, MG, 538, 2079, 90P(ab), 162P(ab), 228P(ab), 229P(ab), 231P(ab)
 Stackhouse, M, 186P(ab)
 Stadalmik, RC, 160, 1896, 202P(ab)
 Stadler, E, 172P(ab)
 Stahlschmidt, A, 200P(ab)
 Staib, L, 80P(ab)
 Staib-Sebler, E, 9P(ab)
 Stallings, L, 83P(ab)
 Stalteri, MA, 96P(ab), 150P(ab)
 Stanowsky, A, 137P(ab)
 Stanus, E, 21P(ab)
 Starken, NF, 47P(ab)
 Starzec, A, 189P(ab), 233P(ab)
 Stathis, M, 6P(ab), 11P(ab), 41P(ab), 201P(ab), 279P(ab)
 Staub, A, 281P(ab)
 Steele, DL, 206P(ab)
 Steele, PP, 171P(ab)
 Stefanini, S, 735
 Steffens, MG, 169P(ab)
 Stegen, M, 274P(ab)
 Stein, PD, 577, 1313, 1636
 Steinbrenner, L, 135P(ab), 259P(ab)
 Steiner, B, 266P(ab)
 Steinert, H, 441, 121P(ab)
 Steinstrasser, A, 362
 Stephens, S, 122P(ab)
 Stephens, TS, 139P(ab)
 Stephenson, MT, 118P(ab), 202P(ab), 302P(ab)
 Steuer, J, 11N(2), 15N(3)
 Stevens, JS, 46P(ab)
 Stevens, S, 206P(ab)
 Stevenson, A, 302P(ab)
 Stevenson, DA, 17P(ab), 66P(ab), 190P(ab)
 Stevenson, R, 285P(ab)
 Stewart, JSW, 54P(ab)
 Stewart-Henney, PA, 60P(ab)
 Steivenart, JL, 35P(ab), 217P(ab), 113P(ab)
 Stillson, CA, 106P(ab)
 Stipp, VH, 230P(ab)
 Stocklin, G, 41P(ab), 113P(ab), 142P(ab), 227P(ab)
 Stodilka, R, 213P(ab)
 Stoeter, P, 209P(ab)
 Stoll, B, 245P(ab)
 Stoller, M, 92P(ab)
 Stollfus, J, 218P(ab)
 Stollfuss, J, 180P(ab)
 Stone, CK, 94P(ab), 206P(ab)
 Stone, D, 29P(ab)
- Stoof, JC, 134P(ab)
 Storck, M, 249P(ab)
 Storm, G, 1392
 Stout, DB, 109P(ab), 163P(ab)
 Stowe, LA, 306P(ab)
 Strassmann, G, 121P(ab)
 Stratton, JR, 29P(ab)
 Strauss, HW, 534, 1921
 Strauss, J, 23P(ab)
 Strauss, LG, 68P(ab), 147P(ab), 154P(ab), 257P(ab), 264P(ab)
 Stray, JE, 151P(ab)
 Striano, G, 42P(ab)
 Strittmatter, W, 362
 Strother, SC, 73P(ab), 227P(ab)
 Strotman, NA, 24P(ab)
 Strul, D, 154P(ab)
 Struttman, M, 61P(ab)
 Stubbs, J, 102P(ab), 230P(ab), 231P(ab)
 Stubbs, JB, 151
 Studebaker, R, 40P(ab)
 Studholme, C, 100P(ab), 208P(ab)
 Stumpf, MJ, 45P(ab)
 Stundzia, A, 8P(ab)
 Sturtz, GL, 105
 Su, F-M, 144P(ab), 166P(ab)
 Su, T, 77P(ab)
 Sudati, F, 55, 967, 1655
 Suematsu, K, 276P(ab)
 Suetens, P, 767
 Sueyoshi, K, 263P(ab), 296P(ab)
 Suga, K, 807, 1361
 Sugawara, I, 15P(ab)
 Sugimoto, K, 251P(ab), 257P(ab)
 Suh, JH, 551
 Suhonen-Polvi, H, 387
 Sukekawa, H, 1289
 Sulla, M, 245P(ab)
 Sullivan, K, 252
 Sullivan, MJ, 174P(ab)
 Sullo, P, 178P(ab)
 Sumiya, H, 186P(ab), 298P(ab)
 Summers, RM, 25P(ab)
 Sumner, A, 261P(ab)
 Sun, K, 224P(ab)
 Sun, KT, 1626, 82P(ab)
 Sundaresan, SR, 135P(ab)
 Sunder-Plassmann, L, 249P(ab)
 Sundin, A, 32, 1766
 Surkau, R, 296P(ab)
 Surova-Trojanova, H, 211P(ab)
 Sutherland, DR, 141P(ab)
 Suto, Y, 997
 Sutter, CW, 214P(ab)
 Suzuki, H, 273, 457
 Suzuki, N, 17P(ab)
 Suzuki, S, 1613
 Suzuki, T, 680, 1567, 1981, 3P(ab), 184P(ab)
 Suzuki, Y, 3P(ab)
 Swahn, C-G, 108P(ab), 112P(ab), 192P(ab), 284P(ab)
 Swailem, FM, 72P(ab)
 Swanson, DP, 2092,

- 231P(ab)
 Swayne, AN, 168P(ab)
 Swayne, LC, 905, 1504,
 1826, 9P(ab), 168P(ab),
 169P(ab), 243P(ab)
 Sweeney, TJ, 110P(ab)
 Sweet, MP, 72P(ab),
 167P(ab)
 Swirsky, D, 148P(ab)
 Swischuk, LE, 1356
 Sy, WM, 4P(ab)
 Sychra, JJ, 217P(ab)
 Syhre, R, 16P(ab)
 Synovec, RE, 205P(ab)
 Syrota, A, 5, 118, 70P(ab),
 76P(ab), 170P(ab),
 226P(ab)
 Szabo, K, 33P(ab), 164P(ab)
 Szabo, Z, 307, 33P(ab),
 47P(ab), 112P(ab),
 164P(ab), 262P(ab),
 288P(ab)
 Szeimies, U, 156P(ab)
 Szekely, C, 274P(ab)
 Szonn, B, 256P(ab)
 Szulc, M, 38P(ab)
 Szymanski, S, 112P(ab)
 Tabuchi, K, 296P(ab)
 Tachibana, S, 263P(ab)
 Tada, M, 1713
 Tadamura, E, 572, 729, 1981,
 1985, 150P(ab)
 Taddei, G, 238P(ab),
 297P(ab)
 Taguchi, A, 220P(ab)
 Tai, Y-C, 73P(ab), 130P(ab)
 Taillefer, R, 1368, 37P(ab),
 68P(ab), 69P(ab), 74P(ab),
 75P(ab), 93P(ab),
 150P(ab), 180P(ab),
 184P(ab)
 Taillon, LA, 104P(ab)
 Tait, JF, 29P(ab)
 Takada, A, 1522
 Takahashi, J, 320
 Takahashi, M, 712, 80P(ab),
 189P(ab), 276P(ab)
 Takahashi, N, 160P(ab)
 Takahashi, T, 1522, 1713,
 304P(ab)
 Takami, H, 15P(ab)
 Takano, K, 807
 Takao, M, 1343
 Takarada, A, 37P(ab)
 Takashio, T, 5P(ab),
 291P(ab), 292P(ab)
 Takatoku, K, 66P(ab)
 Takayama, T, 291P(ab)
 Takeda, K, 282P(ab)
 Takeda, T, 51, 641
 Takeishi, Y, 1289, 181P(ab)
 Takekawa, H, 955
 Takeuchi, A, 282P(ab)
 Takeyama, H, 296P(ab)
 Taki, J, 1622, 298P(ab)
 Takikawa, S, 1850
 Tal, I, 172P(ab)
 Tall, J, 1639
 Talusani, S, 295P(ab)
 Tamagami, H, 649
 Tamaki, N, 572, 729, 757,
 1365, 1403, 1600, 1836,
 1981, 1985, 2057, 16P(ab),
 95P(ab), 101P(ab),
 123P(ab), 150P(ab),
 175P(ab), 239P(ab),
 248P(ab), 276P(ab),
 290P(ab), 291P(ab),
 293P(ab)
 Tamamura, H, 122P(ab)
 Tamarapalli, N, 293P(ab)
 Tamgac, F, 289P(ab)
 Tamir, A, 245P(ab)
 Tamura, M, 273, 457
 Tan, ES, 1631
 Tan, TX, 287P(ab)
 Tan, W, 278P(ab)
 Tanabe, H, 285P(ab)
 Tanabe, Y, 997
 Tanada, S, 180P(ab)
 Tanaka, F, 374, 1600, 2057,
 101P(ab)
 Tanaka, H, 1522, 180P(ab)
 Tanaka, K, 1365
 Tanaka, S, 1679
 Tanaka, Y, 244P(ab),
 277P(ab)
 Tang, HR, 218P(ab)
 Taniguchi, H, 1522
 Taniguchi, K, 3P(ab),
 184P(ab)
 Taniguchi, M, 122P(ab)
 Tanihata, S, 26P(ab),
 58P(ab), 126P(ab),
 185P(ab)
 Tanishima, Y, 1622
 Taniuchi, H, 192P(ab)
 Tansey, W, 1472, 72P(ab),
 86P(ab), 253P(ab)
 Tantayakom, S, 211P(ab)
 Tapnio, P, 273P(ab)
 Tardif, CP, 1731
 Tarditi, L, 169P(ab)
 Tarquini, A, 565
 Tateno, M, 680, 1981, 1985,
 150P(ab), 159P(ab),
 175P(ab)
 Tatsch, K, 1799, 1965,
 25P(ab), 56P(ab),
 156P(ab), 236P(ab),
 252P(ab)
 Tatsu, Y, 263P(ab), 296P(ab)
 Tatsukawa, K, 56P(ab)
 Tatter, S, 66P(ab)
 Taub, R, 46
 Tauxe, WN, 180P(ab)
 Tavolaro, R, 1452, 35P(ab),
 255P(ab)
 Taylor, A, 1872, 1876, 1883
 Taylor, A Jr, 881, 46P(ab),
 17P(ab), 190P(ab),
 191P(ab), 293P(ab)
 Taylor, AT, 588, 1575,
 47P(ab), 84P(ab),
 125P(ab), 307P(ab)
 Taylor, C, 144P(ab)
 Taylor, RJ, 13S
 Taylor, SE, 146P(ab)
 Taylor, SF, 285P(ab)
 Teates, CD, 158P(ab)
 Tehan, AM, 15P(ab)
 Teigen, EL, 1535
 Tellmann, L, 219P(ab)
 Telsey, J, 38P(ab)
 Tempere, MA, 90P(ab),
 150P(ab), 13S
 ten Bokum, AMC, 24P(ab)
 TenCate, FJ, 1951
 Tennison, J, 142P(ab)
- Terada, K, 101P(ab)
 Teras, M, 387
 Terauchi, T, 1444
 Terra Filho, M, 294P(ab)
 Terui, S, 1444
 Terzi, A, 1300
 Tesar, RD, 111P(ab),
 132P(ab)
 Teshima, T, 1460
 Testa, T, 1872
 Tetsuou, Y, 304P(ab)
 Tettenborn, B, 209P(ab)
 Teule, GJJ, 1316, 1631,
 38P(ab), 184P(ab),
 259P(ab)
 Teusch, M, 140P(ab)
 Thadani, V, 271P(ab)
 Thakur, ML, 489, 1789,
 151P(ab), 205P(ab)
 Theobald, A, 341
 Theriault, R, 127P(ab)
 Thie, J, 122P(ab)
 Thie, JA, 206P(ab)
 Thiel, A, 270P(ab)
 Thierens, H, 1048
 Thijis, LG, 1316
 Thodtmann, R, 138P(ab)
 Thomas, D, 121P(ab),
 131P(ab), 132P(ab)
 Thomas, R, 155P(ab),
 156P(ab)
 Thomashow, B, 5P(ab)
 Thomason, D, 249P(ab)
 Thome, M, 103P(ab)
 Thompson, C, 104P(ab)
 Thompson, JF, 964
 Thompson, NW, 852
 Thomsen, HS, 1883
 Thrall, R, 196P(ab)
 Thrall, RS, 656
 Tian, J, 958
 Tiblier, ES, 126P(ab)
 Tieku, S, 1942
 Tiel-van Buul, MMC,
 24P(ab), 287P(ab)
 Tiihonen, J, 45P(ab), 76P(ab)
 Tikofsky, RS, 273P(ab)
 Tiling, R, 156P(ab), 252P(ab)
 Tillett, I, 95
 Timar, E, 287P(ab)
 Timmann, D, 55P(ab)
 Ting, G, 332
 Tisell, LE, 1519
 Tissuing, G, 134P(ab)
 Titsch, U, 6P(ab)
 Tjuvajev, J, 53P(ab)
 Tluczek, L, 50P(ab), 70P(ab)
 TMzyar, E, 1956
 Tobes, MC, 4P(ab)
 Tochon-Danguy, H,
 131P(ab), 132P(ab)
 Tochon-Danguy, HJ,
 121P(ab)
 Todd-Pokropek, AE, 2087
 Toftdahl, DB, 261
 Tohyama, M, 66P(ab)
 Tokcaer, AB, 1755
 Tokuda, O, 807
 Tokunaga, M, 457
 Tolle, TR, 278P(ab)
 Toma, P, 297P(ab)
 Tomas, MB, 103P(ab),
 242P(ab)
 Tomassetti, P, 250P(ab)
 Tennison, J, 142P(ab)
- Terada, K, 101P(ab)
 Tomita, K, 298P(ab)
 Tomiyoshi, K, 457, 159P(ab)
 Tomoike, H, 1289, 181P(ab)
 Tompkins, RG, 239P(ab),
 240P(ab), 244P(ab)
 Tonami, N, 1622, 44P(ab),
 101P(ab), 186P(ab),
 291P(ab), 298P(ab)
 Tondeur, M, 1281
 Top, LE, 234P(ab)
 Topaloglu, R, 145P(ab)
 Torchilin, VP, 106P(ab)
 Torizuka, T, 1365, 64P(ab),
 248P(ab), 253P(ab)
 Tornai, MP, 52P(ab), 78P(ab)
 Tornesello, A, 237P(ab)
 Torniainen, P, 22P(ab)
 Torres, MA, 199P(ab),
 242P(ab)
 Touber, ME, 1773
 Tourassi, GD, 295P(ab)
 Touya, E, 266P(ab)
 Towbin, RB, 269P(ab)
 Townsend, CE, 995
 Townsend, DW, 74P(ab)
 Towson, J, 90P(ab)
 Toyama, H, 1698, 123P(ab),
 153P(ab), 215P(ab),
 220P(ab), 259P(ab),
 282P(ab)
 Toyama, K, 1551, 1819,
 64P(ab), 254P(ab)
 Toyama, S, 203P(ab)
 Toyama, T, 3P(ab), 184P(ab),
 244P(ab)
 Toyoda, H, 304P(ab)
 Toyohara, J, 17P(ab)
 Trampert, L, 615
 Trask, DD, 132P(ab),
 135P(ab)
 Trate, DM, 57P(ab),
 244P(ab)
 Travagli, J, 598
 Travagli, JP, 912, 1830,
 52P(ab)
 Travlin, MI, 14P(ab),
 105P(ab)
 Trebossek, R, 170P(ab),
 217P(ab)
 Treves, ST, 81, 22P(ab),
 28P(ab), 270P(ab),
 292P(ab)
 Triana-Alexander, M,
 276P(ab)
 Tricoire, H, 303P(ab),
 306P(ab)
 Tripp, B, 23P(ab)
 Trisjono, F, 153P(ab)
 Tristam, M, 1058
 Trivedi, MH, 1735
 Troch, ME, 857
 Trojan, H, 221P(ab),
 265P(ab)
 Uren, R, 34P(ab), 46P(ab)
 Uren, RF, 964
 Uribe, J, 85P(ab), 227P(ab)
 Usui, I, 233
 Utech, CI, 307P(ab)
 Uysal, U, 1956, 177P(ab),
 257P(ab), 290P(ab)
 Uzal, D, 1956, 257P(ab)
 Uzun, A, 233
 v. Ammon, K, 54P(ab)
 V. de Beco, JL, 189P(ab)
 Vaalburg, W, 257, 279, 897,

- 984, 1571, 1631, 11P(ab),
 71P(ab), 86P(ab),
 108P(ab), 157P(ab),
 225P(ab), 263P(ab),
 265P(ab), 306P(ab)
 Vachier, J-L, 83P(ab)
 Vagg, RC, 168P(ab)
 Vaidyanathan, G, 61P(ab),
 160P(ab), 191P(ab)
 Vaigneur, K, 85P(ab)
 Vainionpaa, L, 22P(ab)
 Valda Ochoa, A, 303P(ab)
 Valdes Olmos, RA, 972,
 237P(ab)
 Valdivia, S, 97P(ab)
 Valent, P, 5P(ab), 20P(ab)
 Valente, CM, 202P(ab)
 Valentini, L, 303P(ab),
 306P(ab)
 Valentine, JD, 77P(ab)
 Valerius, T, 362
 Valk, PE, 111P(ab),
 132P(ab), 136P(ab),
 139P(ab), 157P(ab)
 Valkama, M, 22P(ab)
 Valkema, R, 19P(ab),
 48P(ab), 60P(ab), 268P(ab)
 Vallabhajosula, S, 673, 1016,
 38P(ab), 60P(ab),
 152P(ab), 204P(ab),
 272P(ab)
 van Baalen, JR, 23P(ab)
 van Beek, JHGM, 38P(ab)
 van Bloois, L, 1392
 van de Lagemaat, L,
 219P(ab)
 van de Ven, MTP, 2072
 van de Ven, PJG, 289P(ab)
 Van den Abeele, AD, 315,
 140P(ab), 258P(ab),
 261P(ab), 305P(ab), 19S
 van den Anker-Lugtenburg,
 PJ, 19P(ab), 268P(ab)
 van den Broek, WJM, 2072
 van den Elsen, PA, 213P(ab)
 van den Hoff, J, 521, 2066
 van der Duin, LV, 2082
 van der Graaf, WTA, 1571,
 67P(ab)
 van der Kleij, AJ, 287P(ab)
 van der Linden, JGM,
 72P(ab)
 van der Mark, TW, 11P(ab),
 71P(ab), 108P(ab),
 265P(ab)
 van der Meer, JWM, 1392,
 128P(ab)
 van der Mey, AGL, 270
 van der Pluijm, ME, 108
 van der Vliet, JA, 119P(ab)
 Van der Zee, AGJ, 263P(ab)
 van der Schors, R, 352
 van Deventer, SJH, 24P(ab)
 van Dieren, EB, 38
 van Dijk, A, 38, 244, 465,
 1511
 van Domburg, RT, 1951
 van Dongen, AJ, 23P(ab)
 van Dongen, GAMS, 352
 Van Dort, ME, 50P(ab)
 van Dyck, CH, 1749,
 33P(ab), 272P(ab)
 van Eijken, M, 1048
 van Es, PN, 1652
 Van Every, B, 117P(ab)
- van Gennip, A, 287P(ab)
 van Gils, APG, 270
 van Ginkel, RJ, 257, 984
 van Gog, FB, 352
 van Hagen, PM, 24P(ab)
 Van Heertum, RL, 5P(ab),
 123P(ab), 270P(ab),
 273P(ab)
 van het Schip, AD, 38, 244,
 465, 1511
 Van Horn, JD, 559, 79P(ab),
 284P(ab)
 van Horn, JR, 62
 van Isselt, JW, 289P(ab)
 van Kaick, G, 87, 68P(ab),
 147P(ab), 234P(ab),
 235P(ab), 257P(ab),
 264P(ab), 265P(ab),
 296P(ab)
 van Kampen, A, 128P(ab)
 van Kroonenburgh, MJPG,
 1652
 van Leyen-Pilgram, K,
 270P(ab)
 van Lingen, A, 1631,
 59P(ab), 60P(ab),
 176P(ab), 178P(ab)
 Van Mullekom, A, 498
 van Peski, J, 48P(ab),
 60P(ab)
 Van Renterghem, D, 473
 van Rijk, PP, 38, 244, 465,
 1511, 23P(ab), 62P(ab),
 216P(ab), 231P(ab),
 289P(ab)
 van Roermund, PM, 23P(ab)
 van Royen, EA, 65P(ab),
 134P(ab), 160P(ab)
 Van Train, K, 81P(ab)
 van Waarde, A, 11P(ab),
 71P(ab), 108P(ab)
 van Zandwijk, N, 584
 van Zwieten, PA, 160P(ab)
 Vanbilloen, H, 91P(ab)
 VanBrocklin, HF, 40P(ab),
 51P(ab)
 Vande Streek, PR, 294P(ab)
 Vandenberghe, R, 22P(ab)
 Vandermeiren, R, 175P(ab)
 vanDie, J, 465
 VanHagen, MP, 108
 Vannoy, SD, 172P(ab)
 Vanoverschelde, JL, 25P(ab),
 39P(ab), 126P(ab)
 Vansant, JP, 1575, 48P(ab),
 84P(ab), 125P(ab),
 159P(ab), 213P(ab),
 254P(ab), 307P(ab)
 VanTol, H, 113P(ab)
 Vanzetto, G, 3P(ab),
 229P(ab)
 Vargas, FS, 294P(ab)
 Vargo, JJ, 854
 Varkonyi, a, 287P(ab)
 Varma, VM, 205P(ab)
 Varella, P, 138P(ab),
 156P(ab)
 Varrone, A, 164P(ab)
 Varvares, M, 136P(ab),
 264P(ab)
 Vasconcelos, AG, 273P(ab)
 Vaughan, SN, 265P(ab),
 286P(ab)
 Vavrek, MT, 40P(ab)
 Veening, MA, 1631, 60P(ab)
- Vellante, C, 237P(ab)
 Velu, T, 53P(ab)
 Vemulakonda, US, 1639
 Vender, J, 65P(ab), 265P(ab)
 Vento, J, 196P(ab)
 Venugopal, R, 205P(ab)
 Vera, DR, 160, 1896,
 202P(ab)
 Vera, P, 1976, 35P(ab),
 113P(ab), 217P(ab)
 Verani, MS, 1306, 37P(ab),
 58P(ab), 69P(ab), 93P(ab),
 126P(ab), 178P(ab),
 184P(ab)
 Verbeke, K, 175P(ab)
 Verberckmoes, R, 91P(ab)
 Verbruggen, A, 91P(ab),
 175P(ab)
 Verdesca, SA, 50P(ab)
 Vergara, E, 138P(ab),
 156P(ab)
 Verhaar, MJ, 868
 Verhoeft, NPLG, 1449
 Verhorst, PMJ, 38P(ab)
 Verma, RC, 306P(ab)
 Vermeeren, PC, 16N(2)
 Vermey, A, 897
 Vermiglio, F, 1830
 Veronikis, IE, 991
 Vessella, RL, 151P(ab)
 Vessotskje, J, 201P(ab)
 Vessotskje, JM, 66P(ab)
 Veyre, A, 922
 Vezina, W, 197P(ab)
 Viale, G, 238P(ab)
 Viergever, MA, 62P(ab),
 213P(ab), 216P(ab)
 Viggiano, J, 148P(ab),
 176P(ab)
 Vignal, JP, 1946
 Vignati, A, 236P(ab)
 Villa, G, 47P(ab), 238P(ab),
 243P(ab)
 Villanueva-Meyer, J, 926,
 1356, 74P(ab), 79P(ab)
 Villar, C, 272P(ab)
 Villegas, BJ, 97P(ab)
 Villemagne, V, 6P(ab),
 11P(ab), 262P(ab)
 Villena-Heinsen, CE, 615
 Vilmer, E, 35P(ab)
 Vilner, BJ, 7P(ab), 267P(ab)
 Vincent, D, 302P(ab)
 Vinci, J, 239P(ab)
 Vinci, P, 47P(ab)
 Vines, D, 513, 281P(ab)
 Vingerhoets, FJG, 421
 Vini, L, 235P(ab)
 Vink, A, 38P(ab)
 Violon, P, 21P(ab)
 Virgolini, I, 1480, 5P(ab),
 20P(ab), 251P(ab)
 Virzì, F, 1655
 Visscher, CA, 482
 Visser, CA, 1631, 38P(ab),
 59P(ab), 60P(ab),
 178P(ab), 178P(ab),
 184P(ab)
 Visser, GM, 1571, 11P(ab),
 71P(ab), 108P(ab)
 Visser, GWM, 352
 Visser, TJ, 108, 1388,
 11P(ab), 71P(ab),
- 108P(ab), 141P(ab),
 190P(ab)
 Visser-Wisselaar, HA, 108
 Vitola, JV, 131P(ab)
 Vlahos, L, 32P(ab)
 Voderholzer, WA, 1799
 Voisin, P, 1860
 Volkert, WA, 61P(ab),
 185P(ab)
 Volkow, ND, 554, 1609,
 33P(ab), 40P(ab), 41P(ab),
 44P(ab), 45P(ab), 76P(ab),
 187P(ab), 203P(ab),
 281P(ab)
 Vollet, B, 1990, 49P(ab),
 268P(ab)
 Volonte, MA, 133P(ab)
 Volpi, JD, 273P(ab)
 Volpino, P, 35P(ab)
 Volterrani, D, 1883, 22S
 Voltini, F, 37P(ab)
 von der Ohe, MR, 247P(ab)
 von Scheidt, W, 70P(ab)
 von Schulthess, GK, 441,
 699, 121P(ab)
 Votaw, D, 222P(ab),
 254P(ab), 298P(ab)
 Votaw, J, 191P(ab),
 254P(ab), 298P(ab)
 Votaw, JR, 41P(ab), 222P(ab)
 Voute, PA, 237P(ab)
 Vreugdenhil, G, 594
 Vriesendorp, HM, 1545
 Vrolix, M, 767
 Vural, G, 1755, 139P(ab)
 Vural, I, 106P(ab), 175P(ab)
 Waack, M, 122P(ab)
 Wachholz, BW, 24N(12)
 Wachsner, RY, 306P(ab)
 Wackers, FJT, 1783, 59P(ab),
 62P(ab), 81P(ab)
 Waddington, W, 65P(ab)
 Wagenaar, DJ, 178, 305P(ab)
 Wagnberg, B, 2002
 Wagner, B, 46P(ab)
 Wagner, HN Jr., 262P(ab),
 11N(8), 18N(10)
 Wagner, R, 121P(ab),
 137P(ab)
 Wagner, TOF, 2066
 Wahl, L, 432
 Wahl, RL, 371, 502, 1042,
 1540, 1562, 27P(ab),
 36P(ab), 43P(ab), 52P(ab),
 64P(ab), 65P(ab), 75P(ab),
 98P(ab), 110P(ab),
 111P(ab), 141P(ab),
 253P(ab), 260P(ab),
 262P(ab), 1914(1e)
 Wainer, N, 19P(ab)
 Wakabayashi, S, 259P(ab)
 Wakamatsu, S, 184P(ab)
 Wakasugi, T, 179P(ab)
 Waki, A, 56P(ab), 192P(ab),
 251P(ab), 257P(ab)
 Wakisaka, K, 7P(ab)
 Wakita, S, 183P(ab)
 Waldmann, TA, 234P(ab)
 Walicka, MA, 229P(ab)
 Walker, M, 79P(ab)
 Walker, S, 65P(ab)
 Wall, F, 46
 Wallace, S, 72P(ab), 86P(ab),
 253P(ab), 264P(ab)
- Wallis, JW, 178, 63P(ab),
 217P(ab)
 Walsh, C, 171P(ab)
 Walsh, TK, 35P(ab), 72P(ab),
 95P(ab)
 Wanet, PM, 2017
 Wang, G, 554
 Wang, G-J, 33P(ab), 41P(ab),
 44P(ab), 45P(ab), 76P(ab),
 281P(ab)
 Wang, GJ, 1609
 Wang, H, 120P(ab),
 214P(ab), 216P(ab),
 260P(ab)
 Wang, J, 2057, 24P(ab),
 114P(ab), 163P(ab),
 259P(ab)
 Wang, JK, 125P(ab),
 172P(ab)
 Wang, KC, 89P(ab),
 274P(ab)
 Wang, QJ, 1031
 Wang, S, 332, 437, 1003
 Wang, SC, 5P(ab)
 Wang, SJ, 145P(ab),
 163P(ab), 187P(ab),
 188P(ab), 234P(ab),
 241P(ab), 245P(ab),
 288P(ab), 292P(ab),
 294P(ab), 298P(ab)
 Wang, X, 958, 149P(ab)
 Wang, XY, 196P(ab)
 Wang, Y, 6P(ab)
 Wängberg, B, 1519, 2002
 Ward, H, 2006
 Warwick, T, 1916(1e)
 Washburn, LC, 752, 49P(ab)
 Washino, K, 17P(ab)
 Wasserheit, C, 169P(ab)
 Wassmann, H, 268P(ab)
 Watanabe, H, 285P(ab)
 Watanabe, K, 84, 901,
 53P(ab), 308P(ab)
 Watanabe, N, 273, 457,
 101P(ab)
 Watanabe, S, 26P(ab),
 58P(ab), 126P(ab),
 185P(ab)
 Watanabe, T, 189P(ab)
 Watanabe, Y, 761, 12P(ab),
 175P(ab)
 Waters, D, 14P(ab), 37P(ab),
 105P(ab), 195P(ab)
 Waters, DJ, 1003
 Waters, SL, 141P(ab)
 Watkins, GL, 39P(ab),
 199P(ab), 225P(ab),
 226P(ab)
 Watson, D, 69P(ab)
 Watson, DD, 1398, 3P(ab)
 Watzlowik, P, 70P(ab)
 Wawrzynski, PE, 81P(ab),
 148P(ab), 176P(ab)
 Waxman, A, 75P(ab),
 101P(ab), 250P(ab),
 267P(ab), 269P(ab),
 272P(ab), 273P(ab)
 Waxman, AD, 46
 Weaver, JP, 127P(ab),
 275P(ab)
 Webb, E, 285P(ab)
 Webb, S, 228P(ab)
 Webber, KO, 29P(ab),
 129P(ab), 152P(ab),
 203P(ab), 204P(ab)

- Weber, C, 159P(ab)
 Weber, DA, 214P(ab)
 Weber, K, 87
 Weber, W, 99P(ab), 111P(ab),
 138P(ab), 157P(ab)
 Weber-Luxenburger, G,
 122P(ab)
 Webner, PJ, 858, 250P(ab)
 Weder, W, 121P(ab)
 Weemaes, AA, 1571
 Wegelius, U, 387, 256P(ab)
 Wehage, J, 181P(ab)
 Wehe, DK, 119P(ab),
 170P(ab)
 Weichert, JP, 1540
 Weiland, FL, 294P(ab)
 Weiller, C, 55P(ab), 279P(ab)
 Weinbaum, DL, 76
 Weinberger, DR, 559, 2021,
 79P(ab), 143P(ab),
 187P(ab), 281P(ab),
 284P(ab)
 Weinberger, J, 272P(ab)
 Weiner, MF, 79P(ab)
 Weiner, R, 196P(ab)
 Weiner, RE, 656
 Weinheimer, CJ, 1723
 Weinlaender, G, 1480
 Weinreich, R, 54P(ab)
 Weintraub, BD, 1690,
 15P(ab)
 Weintraub, WS, 125P(ab)
 Weinzapfel, BT, 42P(ab)
 Weisman, MH, 242P(ab)
 Weismuller, S, 82P(ab)
 Weiss, M, 25P(ab)
 Weiss, MJ, 1799
 Weiss, S, 287P(ab)
 Weissleder, R, 198P(ab)
 Welch, A, 8P(ab), 18P(ab),
 120P(ab)
 Welch, MJ, 1009, 1294,
 16P(ab), 40P(ab), 51P(ab),
 61P(ab), 71P(ab), 87P(ab),
 95P(ab), 99P(ab),
 108P(ab), 118P(ab),
 128P(ab)
 Weller, S, 27P(ab)
 Welsh, PC, 191P(ab)
 Welt, S, 1052
 Wen, PYC, 19S
 Wenger, DE, 1456
 Wenzel, R, 122P(ab)
 Werner, E, 307P(ab)
 Wernikoff, R, 213P(ab)
 Wessell, D, 78P(ab)
 West, DJ, 823
 West, T, 181P(ab)
 Westera, G, 699, 146P(ab)
 Wey, SP, 51P(ab)
 Weyand, M, 1990, 49P(ab)
 Whatley, M, 15P(ab)
 Wheeler, KT, 87P(ab)
 Wheeler, RH, 1491
 Whipple, C, 23N(12)
 Whirrett, B, 87P(ab)
 White, CL III, 79P(ab)
 White, JD, 234P(ab)
 White, M, 37P(ab)
 White, ML, 81P(ab),
 210P(ab), 215P(ab)
 White, T, 124P(ab)
 Wichter, T, 106P(ab)
 Wiegert, DA, 276P(ab)
 Wiegman, T, 225P(ab)
 Wiegner, R, 83P(ab),
 208P(ab)
 Wieland, D, 70P(ab),
 107P(ab)
 Wieland, DM, 16, 1923,
 50P(ab), 70P(ab), 192P(ab)
 Wienhard, K, 76P(ab),
 122P(ab), 155P(ab)
 Wiersma, AM, 119P(ab)
 Wiersma, A, 2082
 Wierzbinski, B, 1913(Ie)
 Wiesler, M, 264P(ab)
 Wijers, AA, 306P(ab)
 Wikler, D, 21P(ab), 83P(ab)
 Wilbur, DS, 151P(ab)
 Wilderman, SJ, 119P(ab),
 170P(ab)
 Wilk, M, 19P(ab)
 Wilkinson, RA, 24P(ab),
 240P(ab)
 Wilkinson, RH Jr., 636
 Willemsen, ATM, 2082
 Willemsen, ATM, 984, 1631,
 225P(ab), 265P(ab),
 306P(ab)
 Williams, BB, 77P(ab)
 Williams, CC, 307P(ab)
 Williams, D, 197P(ab)
 Williams, J, 43P(ab)
 Williams, KA, 93P(ab),
 104P(ab), 105P(ab)
 Williams, LE, 209P(ab)
 Williams, R, 57P(ab)
 Williams, SC, 304P(ab)
 Williams, W, 183P(ab)
 Williamson, PD, 100P(ab),
 271P(ab)
 Willingham, MC, 1052
 Wilson, AA, 202P(ab)
 Wilson, D, 202P(ab)
 Wilson, DW, 63P(ab),
 301P(ab)
 Winek, R, 1516
 Winkle, W, 40P(ab), 86P(ab)
 Winkler, K, 261
 Winn, HR, 12P(ab)
 Winnick, S, 312
 Winter, E, 27P(ab)
 Winter, PF, 1516, 307P(ab)
 Wirth, M, 429
 Wise, M, 165P(ab)
 Wiseman, GA, 1456,
 116P(ab)
 Wiseman, MB, 224P(ab)
 Wishart, JM, 1643
 Wisner, ER, 202P(ab)
 Wisniewski, G, 1749,
 100P(ab)
 Witjes, JA, 169P(ab)
 Witmeyer, PE, 147P(ab)
 Witt, C, 20P(ab)
 Witte, C, 183P(ab)
 Witte, M, 183P(ab)
 Wittry, MD, 303P(ab)
 Woessler, B, 268P(ab)
 Wohrle, H, 1468
 Wojno, K, 64P(ab)
 Wolf, FG, 829
 Wolf, H, 4P(ab), 142P(ab),
 246P(ab), 256P(ab),
 257P(ab)
 Wolfenden, PJ, 1717
 Volkov, HB, 139P(ab)
 Wollenweber, SD, 226P(ab)
 Wolpers, HG, 521
 Wolters, EC, 134P(ab)
 Won, JH, 426
 Wong, CYO, 177P(ab),
 276P(ab)
 Wong, DF, 77P(ab),
 107P(ab), 112P(ab),
 279P(ab), 280P(ab),
 283P(ab)
 Wong, FC, 127P(ab),
 207P(ab), 296P(ab)
 Wong, FCL, 931, 1472,
 1476, 261P(ab)
 Wong, JCH, 1771, 208P(ab),
 282P(ab)
 Wong, W, 931, 1472, 1476
 Wong, W-H, 261P(ab)
 Wong, WH, 85P(ab),
 227P(ab)
 Woo, KS, 248P(ab)
 Woolfenden, JM, 53P(ab),
 301P(ab)
 Worsley, DF, 36P(ab),
 117P(ab)
 WP, , 533
 Wright, KL, 46P(ab)
 Wrobel, MC, 7P(ab)
 Wu, A, 58P(ab)
 Wu, C, 152P(ab)
 Wu, E, 178
 Wu, H, 506, 1717
 Wu, HM, 68P(ab)
 Wu, HP, 302P(ab)
 Wu, KN, 127P(ab)
 Wu, L, 107P(ab)
 Wu, LC, 125P(ab), 136P(ab),
 172P(ab), 286P(ab)
 Wu, S, 96P(ab), 162P(ab),
 240P(ab)
 Wu, YH, 196P(ab)
 Wunderlich, G, 113P(ab)
 Wutz, W, 142P(ab)
 Wynne, J, 4P(ab)
 Xia, W, 18P(ab), 97P(ab)
 Xing, A, 298P(ab)
 Xiong, CY, 129P(ab),
 167P(ab)
 Xu, B, 958
 Xu, JC, 1896
 Xu, LC, 189P(ab)
 Xu, M, 1009, 108P(ab)
 Yaakob, W, 307P(ab)
 Yachiku, S, 291P(ab),
 292P(ab)
 Yadagar, J, 250P(ab)
 Yadav, S, 89P(ab), 277P(ab)
 Yamada, I, 1613
 Yamada, R, 304P(ab)
 Yamada, S, 320, 1713,
 67P(ab)
 Yamamichi, Y, 94P(ab)
 Yamamoto, I, 815, 1567,
 64P(ab), 122P(ab)
 Yamamoto, K, 251P(ab),
 257P(ab)
 Yamamoto, S, 56P(ab),
 179P(ab)
 Yamamoto, W, 5P(ab),
 291P(ab), 292P(ab)
 Yamamura, Y, 1567
 Yamanouchi, H, 123P(ab)
 Yamanouchi, M, 116P(ab)
 Yamaoka, Y, 1365
 Yamashina, I, 200P(ab)
 Yamashita, T, 71
 Yamazaki, M, 277P(ab)
 Yan, JT, 251P(ab)
 Yang, A, 78
 Yang, CC, 298P(ab)
 Yang, DJ, 931, 1472, 1476,
 72P(ab), 86P(ab),
 253P(ab), 261P(ab),
 264P(ab)
 Yang, J, 42P(ab), 146P(ab),
 303P(ab)
 Yang, JY, 1398
 Yang, Q, 20P(ab), 251P(ab)
 Yang, RC, 298P(ab)
 Yang, S-O, 252P(ab),
 273P(ab)
 Yang, ZY, 50P(ab), 193P(ab)
 Yao, R, 170P(ab)
 Yao, W, 506
 Yao, WJ, 68P(ab)
 Yao, Z, 200P(ab), 203P(ab)
 Yasaka, Y, 37P(ab)
 Yaster, M, 279P(ab)
 Yasue, H, 80P(ab)
 Yavasaooglu, I, 289P(ab)
 Ye, J, 218P(ab)
 Yeh, S, 78, 1349, 138P(ab)
 Yeh, SDJ, 102P(ab)
 Yeh, SH, 27P(ab), 125P(ab),
 136P(ab), 172P(ab),
 262P(ab), 286P(ab),
 303P(ab)
 Yeh, SJ, 187P(ab)
 Yen, SH, 136P(ab), 262P(ab)
 Yen, T, 78, 1349
 Yeo, E, 286P(ab)
 Yeo, J, 978
 Yester, MV, 2087
 Yeung, DW, 31P(ab),
 92P(ab), 182P(ab),
 242P(ab)
 Yeung, H, 102P(ab),
 138P(ab)
 Yeung, HW, 858
 Yeung, HWD, 1528
 Yin, G, 214P(ab)
 Ying, Z, 9P(ab), 168P(ab),
 231P(ab)
 Yipintsoi, T, 110P(ab),
 146P(ab)
 Yokoi, F, 77P(ab), 112P(ab),
 279P(ab), 280P(ab),
 283P(ab)
 Yokokawa, T, 975
 Yokoyama, A, 757, 7P(ab),
 56P(ab), 192P(ab)
 Yokoyama, H, 975
 Yokoyama, I, 1937, 38P(ab),
 82P(ab), 280P(ab)
 Yokoyama, K, 44P(ab),
 101P(ab)
 Yokoyama, R, 1444
 Yonekura, Y, 374, 572, 729,
 757, 1365, 1403, 1600,
 1985, 2057, 56P(ab),
 101P(ab), 123P(ab),
 150P(ab), 175P(ab),
 192P(ab), 248P(ab),
 251P(ab), 257P(ab)
 Yoo, TM, 29P(ab), 129P(ab),
 203P(ab)
 Yoon, BW, 274P(ab)
 Yoon, K, 248P(ab)
 Yoshiabayashi, M, 572
 Yoshida, A, 37P(ab)

- Yoshida, K, 1701
 Yoshida, M, 257P(ab)
 Yoshida, T, 21P(ab), 36P(ab),
 133P(ab), 271P(ab),
 275P(ab)
 Yoshida, Y, 37P(ab)
 Yoshino, E, 1673
 Yoshioka, N, 183P(ab)
 Yost, P, 249P(ab)
 Young, CS, 307P(ab)
 Young, ET, 53P(ab)
 Young, G, 293P(ab)
 Young, H, 54P(ab), 148P(ab)
 Young, I, 251P(ab), 301P(ab)
 Young, J, 85P(ab), 86P(ab)
 Young, K, 1846
 Young, S, 284P(ab)
 Young, SN, 113P(ab)
 Young, VR, 244P(ab)
 Yu, D, 210P(ab)
 Yu, MD, 197P(ab)
 Yu, SM, 286P(ab)
 Yu, X, 155P(ab)
 Yu, Y-M, 244P(ab)
 Yuan, A, 146, 1970, 90P(ab),
 232P(ab)
 Yuasa, K, 3P(ab), 64P(ab)
 Yueh, TC, 127P(ab)
 Yuh, I, 1567
 Yukihiro, M, 1981, 159P(ab)
 Yun, LS, 224P(ab)
 Yung, TH, 247P(ab)
 Yurekli, Y, 302P(ab)
 Yusen, RD, 5P(ab)
 Yutani, K, 94P(ab)
 Yuu, I, 815
 Yves, N, 1773
 Zabalegui, A, 169P(ab)
 Zaers, J, 221P(ab)
 Zaidi, H, 1421
 Zalcberg, J, 131P(ab),
 132P(ab)
 Zalutsky, MR, 2011, 61P(ab),
 160P(ab), 191P(ab),
 197P(ab), 200P(ab)
 Zamecnik, PC, 4P(ab),
 269P(ab)
 Zametkin, A, 45P(ab),
 284P(ab)
 Zamora, PO, 1962, 236P(ab)
 Zanzi, I, 1760
 Zanzonic, P, 1995, 38P(ab)
 Zanzonic, PB, 1921
 Zapf, A-O, 233P(ab)
 Zardi, L, 238P(ab)
 Zaret, BL, 59P(ab), 81P(ab)
 Zasadny, KR, 371, 43P(ab),
 65P(ab), 78P(ab)
 Zea-Ponce, Y, 11, 44P(ab),
 272P(ab)
 Zelitt, D, 162P(ab)
 Zeng, GL, 206P(ab)
 Zeng, SQ, 127P(ab)
 Zerausche, F, 26P(ab)
 Zhang, J, 958, 108P(ab),
 25S, 29S
 Zhang, JJ, 312, 1528,
 157P(ab), 260P(ab),
 278P(ab)
 Zhang, M, 200P(ab),
 203P(ab)
 Zhang, N, 98P(ab)
 Zhang, Y, 7P(ab), 171P(ab),
 223P(ab)

Zhao, HY, 308P(ab)	Ziegler, M, 232P(ab)	Zilleruelo, G, 23P(ab)	Zoet-Nugteren, S, 748	Zuckerman, , 1323
Zhao, QH, 38P(ab), 152P(ab)	Ziegler, P, 259P(ab)	Zimmer, AM, 216P(ab)	Zoghbi, SS, 32P(ab),	Zuckier, LS, 1995, 162P(ab)
Zhao, XD, 78P(ab)	Ziegler, S, 94P(ab), 99P(ab),	Zimmerman, RE, 17P(ab),	33P(ab), 44P(ab),	Zuger, J, 249P(ab)
Zhen, J, 308P(ab)	107P(ab), 111P(ab),	29P(ab), 77P(ab),	272P(ab), 285P(ab)	Zukerberg, BW, 132P(ab)
Zheng, GL, 153P(ab)	122P(ab), 138P(ab),	158P(ab), 305P(ab), 19S	Zollner, TM, 137P(ab)	Zurakowski, D, 292P(ab)
Zheng, L, 174P(ab)	154P(ab), 157P(ab),	Zinn, KR, 235P(ab)	Zonnenberg, BA, 38, 244,	Zuurbier, C, 146P(ab)
Zheng, M, 67P(ab)	180P(ab), 278P(ab)	Zito, F, 967, 133P(ab),	465, 1511	Zwas, ST, 127P(ab)
Zheng, Q-H, 40P(ab)	Ziegler, SI, 70P(ab),	258P(ab)	Zubal, IG, 91P(ab),	Zweit, J, 54P(ab), 166P(ab),
Zhou, FC, 40P(ab)	131P(ab), 147P(ab)	Zivanovic, MA, 1058	100P(ab), 246P(ab),	191P(ab)
Zhou, Y, 146P(ab)	Ziessman, HA, 643, 1639	Zoar, S, 290P(ab)	305P(ab)	Zwinderman, AH, 533
Zhu, N, 11P(ab), 174P(ab)	Ziffer, JA, 125P(ab)	Zoboli, S, 88P(ab), 169P(ab),	Zubieta, J, 152P(ab)	
Zhu, YY, 47P(ab)	Zifko, UA, 8P(ab)	250P(ab)	Zubieta, JK, 45P(ab)	
Zhu, ZH, 196P(ab)	Zilbovicius, M, 1976	Zoccarato, O, 1300	Zucker, J, 893	

A

- A1 receptor**, potential use of ^{11}C -KF15372 for detecting degeneration of presynaptic neurons, 1203
- Abdominal carcinoid tumors**, accuracy of somatostatin receptor scintigraphy in visualization of ^{11}In -pentetetreotide SPECT, 1452
- Absorbed dose**, ^{1-11}C -glucose estimates in adults, effects of hyperinsulinemia, 1668
- Absorptiometry**, dual-energy x-ray, measurements of bone mineral density, 103P(ab)
- Abstracts**, record number at SNM annual meeting, 27N(5)
- Acetate dialysate**, effect on plasma renin activity and level changes, hemodialysis, 145P(ab)
- Acetazolamide**
 - ^{99m}Tc HMPAO brain perfusion SPECT enhanced with, vertebrobasilar insufficiency patients, 88P(ab)
 - assessment of vascular reserve in patients with carotid artery disease, compared with dipyridamole SPECT, 1595
 - effects of high flow on ^{99m}Tc -HMPAO uptake, comparison of ^{99m}Tc -HMPAO and ^{133}Xe measurements of regional cerebral blood flow, SPECT, 1735
 - one-day protocol for cerebral perfusion reserve, ^{99m}Tc -ECD, 2057
- PET evaluation of cerebral hemodynamics, chronic occlusive cerebral arteries, 21P(ab)
- Acetazolamide test**
 - ^{99m}Tc HMPAO SPECT and, dementia, 273P(ab)
 - cerebral vascular reserve, quantification with ^{15}O water, 282P(ab)
- Acetylcholine**, synthesis, tracer of, brain uptake of ^{11}C choline, 283P(ab)
- Acetylcholinesterase**
 - ^{11}C CP-126 N998 studies of, 41P(ab)
 - delivery-dependent brain distributions, 10P(ab)
 - early diagnosis of Alzheimer's disease using radioactive analog method, PET, 649
- Achalasia**, idiopathic, botulinum toxin efficacy in, scintigraphy, 57P(ab)
- ACNP**, *see* American College of Nuclear Physicians
- Acquired immunodeficiency syndrome**
 - ^{67}Ga imaging of pericardial lymphoma, 995
 - brain lymphoma in, ^{201}Tl SPECT detection of, 258P(ab)
 - dementia
 - peptide T and glucose metabolism, FDG-PET, 1177
 - differential diagnosis of cerebral toxoplasmosis and CNS lymphoma, ^{201}Tl SPECT, 1150
 - dual-isotope methods in diagnosis of, 302P(ab)
 - intracranial lesions in, ^{201}Tl chloride and ^{99m}Tc sestamibi SPECT comparison in, 277P(ab)
 - lymphoma or infectious intracranial lesions in, ^{201}Tl SPECT for differentiation, 276P(ab)
 - sequential thallium and gallium chest scans, opportunistic infections, 1662
 - untreated *Pneumocystis carinii* pneumonia, diagnosis with gallium scintigraphy, 293P(ab)
- Acquisition**, optimization of, performance of ^{99m}Tc brain SPECT, 273P(ab)
- Acromegaly**, octreotide in, growth hormone response and ^{11}In pentetetreotide uptake in, 159P(ab)

Activated-platelet imaging, evaluation of ^{99m}Tc -P280, 775

Acupuncture, objective assessment of effects on brain functions, ^{99m}Tc HMPAO SPECT imaging, 278P(ab)

Acute myocardial infarction, reverse redistribution of ^{99m}Tc -sestamibi following PTCA, prediction of successful revascularization and wall motion status, 1289

Acute stroke, clinical utilization of SPECT imaging and thrombolytic therapy, 1259

Adenocarcinoma

- gastrointestinal tract, ^{131}I VIP receptor scanning of, 20P(ab)
- intestinal, binding of ^{123}I -labeled VIP-receptor antagonist in, 251P(ab)
- lung, relation between uptake ratios of ^{201}Tl SPECT, histopathological differentiation, grade of Na-K ATPase staining, 955

Adenosine

A₁ receptor antagonists, radiolabeled, for PET and SPECT, 142P(ab)

potential use of ^{11}C -KF15372 as A1 receptor ligand, PET, 1203

receptors, upregulation of, smooth muscle cells, localization of atherosclerotic lesions, 4P(ab)

SPECT, fixed and reversible defects during, prior infarction patients, 181P(ab)

stress ^{99m}Tc sestamibi SPECT, early poststress imaging, 59P(ab)

stress test, $99m\text{Tc}$ -tetrofosmin tomography and echocardiography, coronary artery disease, 178P(ab)

Adhesion molecule, integrin as a target, wide-spectrum immunoscintigraphy, 200P(ab)

Adrenal gland

incidentally discovered masses, cost-effectiveness, 158P(ab)

mass, evaluation by FDG-PET for metastatic disease, 141P(ab)

nonhypersecretory adenomas, uptake and retention of ^{11}C acetate, 15P(ab)

Adrenal infarction, depiction with NP-59 scintigraphy, aldosteronoma, 852

Adrenergic denervation, discrepancy in dual-tracer autoradiography, experimental myocardial infarctions, 680

Adrenergic innervation

arrhythmogenic right ventricular disease patients, 106P(ab)

norepinephrine release, isolated rat heart, 107P(ab)

Adrenergic receptors

^{18}F RS-15385-FP, PET, 40P(ab)

PET ligand, distributed nonlinear modeling of, 106P(ab)

Alpha-Adrenergic receptors, synthesis of ^{18}F atipamezole, 51P(ab)

Adult respiratory distress syndrome

differentiating from hydrostatic pulmonary edema, ^{67}Ga pulmonary leak index, 1316

early detection, ICAM-1, 196P(ab)

Advanced differentiated thyroid cancer, high-dose radioiodine therapy, ^{131}I -NaI, 1496

Adverse reactions, prevalence in nuclear medicine, 185

Aebersold Award, development of novel radiopharmaceuticals, Kenneth Krohn, 22N(9)

Aerosol deposition measurement, three-dimensional description using multimodality imaging, 873

Age-dependency, biokinetics of ^{99m}Tc -DMSA in

pediatric population, effects of renal pathology, 1331

Aging

abnormal, brain, radical-related disease, nuclear medicine in, 56P(ab)

cerebral atrophy and, effects on cerebral blood flow, 308P(ab)

cerebral glucose metabolism and, attention-deficit/hyperactivity disorder adults, changes related to, cortical blood flow activation response, 164P(ab)

clinical management of very elderly patients, myocardial perfusion SPECT, 69P(ab)

dopamine transporter imaging, comparative nirostriatal, 133P(ab)

effects on acetylcholine storage and release, ^{123}I -MIBI vesamicol receptor, 1192

effects with ^{123}I - β -CIT, 272P(ab)

extrastratial dopamine D2 receptor availability and, 281P(ab)

normal and pathological, comparison from point of carbon dioxide responsiveness, 165P(ab)

normal and schizophrenic, PET studies of impaired Wisconsin card sorting, 79P(ab)

normal process on striatal uptake values, ^{123}I -IPT SPECT imaging of CNS dopamine transporters, 1965

AIDS

see also Acquired immunodeficiency syndrome

Alagille syndrome, focal liver hyperplasia, assessment with hepatoreceptor and hepatobiliary imaging, 1365

ALCAPA syndrome, assessment bydobutamine stress ^{201}Tl SPECT and echocardiography, 748

Alcoholism, benzodiazepine receptors in, SPECT imaging of, 285P(ab)

Aldosteronoma, depiction with NP-59 scintigraphy, adrenal infarction, 852

Aliasing artifact, SPECT imaging, optimal number of views in 360-degree, 1740

Alpha-2 receptor blocker, abnormal ^{123}I -MIBG images in healthy subjects, diagnostic pitfalls related to sympathetic activity, 1686

Alpha-particle emitting radionuclide, preclinical characterization, 78P(ab)

Alveolar permeability, compartmental model for lung clearance of pertechnegas, 2066

degree of damage in cirrhosis, 437

Alzheimer's disease

see also Dementia

^{123}I IMZ distribution volume, as a measure of neuronal loss, 164P(ab)

^{99m}Tc HMPAO, absolute and relative quantitation with, 278P(ab)

automated classification of neural networks in brain SPECT, 195

carbon dioxide responsiveness, stereotaxic comparison, 165P(ab)

cerebral oxygen and glucose metabolism, uncoupling of, 275P(ab)

comparison of ^{99m}Tc -HMPAO and ^{99m}Tc -ECD images, 1749

discriminant value of semiquantitative SPECT, 404(Le)

earliest metabolic reduction, PET study, 163P(ab)

early detection, PET strategies, 79P(ab)

early diagnosis using radioactive analog method and PET, 649

FDG-PET scanning for evaluation of, 270P(ab)

glucose transport and phosphorylation

- determined by FDG-PET, 201
mapping AChE in human brain, PET and ¹⁸F PMP use in, 21P(ab)
metabolic impairment in, assessment with ¹⁸F FDG-PET, 275P(ab)
SPECT and histopathologic correlation, cerebral blood flow, 79P(ab)
study of medial temporal oxygen metabolism, PET, 1159
vesamicol receptor, ¹²³I MIV affinity for, 186P(ab)
- Ambulatory renal monitoring**, renal scan and, renal function after combined kidney and pancreas transplant, 293P(ab)
- American Board of Science in Nuclear Medicine**, 20th anniversary, 30N(5)
- American College of Nuclear Physicians**, ACNP/SNM government relations update, 20N(1)
- Amino acid infusion**, reduction of renal tubular reabsorption of radioconjugates, 837(ed)
- Amino acids**
as PET tracer, breast cancer, 86P(ab)
transport, concentration effects on ¹⁸F FDOPA uptake, PET, 109P(ab)
transporters of, ¹²³I IMT and OMIMT, SPECT, brain tumors, 201P(ab)
uptake, glucose metabolism and, brain tumors, 268P(ab)
- Amphetamine**, acute, effects on striatal dopamine system, 163P(ab)
- Amygdala-hippocampus**, lesions, neonatal and adult, ¹²³I β -CIT and ¹²³I IBZM SPECT, primate, 281P(ab)
- Amyloidosis**, myocardial, detection with ^{99m}Tc aprotinin, 185P(ab)
- Anatomic standardization**, depression Androgen receptor, evaluation of ¹⁸F-labeled ligands in baboons, prostate cancer, 1009
- Anesthesia**, during PET, binding of raclopride and NMSP, mouse brain, 279P(ab)
- Angina pectoris**, calcium blocker effects on outcome, 149P(ab)
- Angiography**
biplane, 3D coronary artery trees from, perfusion SPECT, 97P(ab)
coronary
myocardial perfusion imaging and, 3D-fusion image of, 218P(ab)
rest-stress myocardial perfusion imaging comparison to, 182P(ab)
nuclear, multiwire proportional gamma camera for, 52P(ab)
radionuclide
improvement in left ventricular ejection fraction and cardiac volume after bypass surgery, 93P(ab)
quantitative analysis of gated blood-pool images, 93P(ab)
- Angioplasty**
^{99m}Tc-sestamibi SPECT to detect restenosis, 1300
carotid, semiquantitative diamox rCBF brain SPECT, 89P(ab)
coronary, SPECT use in assessment of results, 126P(ab)
versus bypass surgery, thallium quantitative SPECT, 125P(ab)
- Angiotensin converting enzyme (ACE) inhibitor**, renography for detecting renovascular hypertension, consensus report, 1876
- Angiotensin receptors**
dietary sodium as a regulator of, imaged with ¹¹CL-159, 884, 47P(ab)
- E-3174, pharmacological potency and AT1 receptor occupancy of, 288P(ab)
impulse response function, validation of, 288P(ab)
- Angiotensin-II**, hypertensive chemotherapy, PET imaging to measure blood flow of hepatic tumors, 1522
- Angiotensin-II receptors**, in vivo labeling with ¹¹C-L-159, 884, 307
- Angular sampling**, value in clinical SPECT, 1915(le)
- Annexin V**, recombinant, ^{99m}Tc radio labeling of, arterial thrombus imaging, 29P(ab)
- Anterior cruciate ligament**
SPECT bone scintigraphy
knee injury, 1353
tears, knee bone scintigraphy with SPECT, 297P(ab)
- Anti-carcinoembryonic antigen antibody**
¹¹¹I-labeled, radioimmunotherapy, 168P(ab)
^{99m}Tc-labeled, tumor uptake with, 151P(ab)
treatment of medullary thyroid cancer, 243P(ab)
tumor targeting, radioimmunotherapy, 169P(ab)
- Anti-granulocyte antibody**, ^{99m}TcMN3 Fab
- Anti-intercellular adhesion molecule-1 antibody**, detecting early inflammation, ¹¹¹In, 656
- Anti-macrocycle antibodies**, response to radiometal chelating agents, lymphoma, 451
- Anti-platelet agents**, E5510, effects on platelet deposition in atherothrombotic lesions, ¹¹¹In assessment, 242P(ab)
- Anti-TAC dsFV**
¹⁸F FMB-labeled, hydrolyzable linkers with, 204P(ab)
⁶⁷Ga-labeled, biodistribution and catabolism, 152P(ab)
^{99m}Tc MAG₃-labeled, renal uptake and, 29P(ab)
- Antibiotics**, trovafloxacin, ¹⁸F measurement, PET study of *E. coli*-infected rabbits, 239P(ab)
- Antibody**, predictive doses from therapy using tracer studies, ¹³¹I, 1970
- Antibody labeling**, proteins, role of Tin-117, 195P(ab)
- Antigranulocyte immunoscintigraphy**, prostate cancer metastasis to bone, differential difficulties of superimposed osteomyelitis, 999
- Antimyosin antibody**
radiolabeled, detection of myocardial injury, 38P(ab)
V1-V3 specific, genetically engineered single-chain Fv of, mammalian system, 144P(ab)
- Antimyosin liposome membrane sealing therapy**, preservation of hypoxic cardiomyocyte viability, myocardium, 106P(ab)
- Antipsychotic agents**, striatal dopamine receptors, temporal binding characteristics and receptor occupancy, 11
- Antisense probes**
^{99m}Tc N-myc, human breast tumor hosted in SCID mice, 269P(ab)
^{99m}Tc-labeled, imaging myocardial mRNA of heat shockprotein-70 after bypass, pig, 96P(ab)
- Antistage-specific embryonic antigen-1**, imaging inflammatory diseases, neutrophils, 1789
- Aortic valve stenosis**, ¹⁸C acetate planar imaging of, 38P(ab)
- Aphasia**, primary progressive, ^{99m}Tc HMPAO SPECT, 165P(ab)
- Aplastic anemia**, bone marrow scintigraphy in hematologic disorders, ^{99m}Tc-antigranulocyte antibody, 978
- Appendicitis**, atypical acute, ^{99m}TcMN3 Fab fragment of anti-granulocyte antibody in, 162P(ab)
- Appetite**, glycemic response, gastric emptying in NIDDM, postprandial hunger, 1643
- ARA-C HD**, see cytarabine, high dose
- Aromatic amino acid decarboxylase**, endocrine pancreatic tumors, in vivo enzymatic activity, PET, 32
- Arrhythmias**
outcome in, left ventricular end-diastolic volume relations, 149P(ab)
ventricular, outcome prediction using SPECT perfusion imaging, 14P(ab)
- Arrhythmogenic right ventricular disease**, cardiac adrenergic activity in, 106P(ab)
- Arterial input function**, measurement, high temporal resolution, dynamic PET, 266P(ab)
- Arteriography**, detection and treatment of renovascular HTN, meta-analysis of costs, sensitivities, and specificities, 171
- Arteriovenous malformation**, spontaneous regression on PET, 1673
- Arthrography**
nuclear
combined scintigraphy and radiography for detecting hip prosthesis loosening, 62
radiographic
diagnosis of total hip prosthesis loosening, 62
- Artifacts**, wrap-around lung in 180 degree cardiac studies, SPECT, 1891
- Artificial neural networks**, automated diagnosis of Alzheimer's disease, brain SPECT, 195
- Astatine-211**
biotin conjugate labeled with, preparation and binding properties, 197P(ab)
human neuroblastoma xenograft model, athymic mice, 61P(ab)
- Astrocytoma**, visualized by ^{99m}Tc-ECD SPECT, 273
- Atherosclerosis**
carotid, ^{99m}Tc P280 clinical studies, 272P(ab)
localization of, upregulation of adenosine receptors on smooth muscle cells, 4P(ab)
macrophage density, FDG-PET imaging of, 38P(ab)
myocardial insulin resistance related to, insulin resistance syndrome patients, 38P(ab)
proliferating smooth muscle cells in, ¹¹¹In NC-Z2D3 imaging of, 49P(ab)
- Attenuation**, identification of gastrointestinal bleeding despite presence of barium, tagged RBC scan, 643
- Attenuation correction**
²⁰¹Tl myocardial perfusion, reversibility in patients with regional dyssynergy, 148P(ab)
²⁰¹Tl myocardial SPECT, dual-headed SPECT system, 30P(ab)
^{99m}Tc sestamibi SPECT, cardiac, 81P(ab)
^{99m}Tc sestamibi uniformity with, low likelihood for coronary artery disease, 148P(ab)
accurate, without transmission measurements, 18P(ab)
analytical nonuniform, truncated fan-beam cardiac SPECT imaging, 18P(ab)
automated model, functional PET brain imaging studies, 42P(ab)
breast size and shape, defect contrast in

- myocardial perfusion SPECT**, 216P(ab)
cardiac SPECT, fast iterative reconstruction algorithms for, 63P(ab)
clinical cardiac ^{201}TI SPECT perfusion imaging, 212P(ab)
combined scatter correction, evaluation with simultaneous transmission/emission SPECT system, 209P(ab)
comparison of supine and prone, ^{99m}Tc sestamibi myocardial perfusion SPECT, 81P(ab)
compensation of map errors, ^{99m}Tc sestamibi downscatter with ^{113}Gd transmission scanning, 215P(ab)
defect size, location, and contrast effects, cardiac SPECT, 210P(ab)
effect on defect reversibility, regional dyssynchrony patients, 175P(ab)
effects on ^{99m}Tc tetrofosmin SPECT, detection of viable myocardium, 180P(ab)
emission contamination, SPECT scanning line source transmission data, 19P(ab)
enhanced contour finding method, PET brain emission images, 172P(ab)
fast quantitative measurement, SPECT, 217P(ab)
image performance, simultaneous transmission/emission image system, 210P(ab)
improper, effect on accuracy of SPECT tumor imaging, 211P(ab)
interaction, myocardial SPECT perfusion imaging, 149P(ab)
iodine contrast media effects, quantitative SPECT with emission/transmission imaging systems, 218P(ab)
iterative filtered backprojection algorithm for, SPECT with fanbeam collimation, 214P(ab)
Metz intrinsic method, performance in parameter estimation tasks, 18P(ab)
PET scans, transmission to emission transformation in projection space, 155P(ab)
photon attenuation, correction of, myocardial perfusion imaging, 176P(ab)
postinjection transmission measurement, neurological FDG-PET, 128
reconstruction for, ^{99m}Tc sestamibi cardiac SPECT, 81P(ab)
scanning line source method for, using an anthropomorphic phantom, 211P(ab)
scatter and iterative, modified Wiener filter method for nonstationary resolution recovery, 210P(ab)
scatter compensation and, ^{201}TI SPECT, 80P(ab)
short AsF transmission CT for, cardiac SPECT, 210P(ab)
short transmission scans in, whole-body PET, 172P(ab)
transmission emission tomography, myocardial perfusion imaging comparison, 97P(ab)
uniformity in cardiac phantom, increasing levels of liver activity, 176P(ab)
using patient scatter body outlines, bone SPECT, 127P(ab)
with transmission image segmentation, whole-body PET, 8P(ab)
Attenuation histogram, noise reduction in ^{18}F -FDG-PET, 786
Auditory activation studies, PET, cochlear implantation and hearing subjects, 123P(ab)
Auger electron emitters
 applying in vitro approach to in vivo cancer therapy strategies, ^{125}I -IUDR and ^{125}I -IUDR, 6S(4)
 safety evaluation of radiolabeled IUDR, 13S(4)
 strategies for selective targeting, tumor cells, 3S(4)
 tumor targeting in bladder cancer, ^{125}I -IUDR, 315
 use of $^{5-125}\text{I}$ -IUDR in treatment of colorectal cancer with liver metastases, pharmokinetics and dosimetry, 29S(4)
Auger electrons
See Auger electron emitters
 decay, double-stranded DNA breaks induced by, 229P(ab)
 improved tumor-to-marrow radiation dose by clinical use of ^{123}I -A33, 1052
Automatic contour detection, in vivo estimation of receptor biochemistry, ^{99m}Tc -NGA kinetic modeling, 1896
Automatic motion correction, in vivo estimation of receptor biochemistry, ^{99m}Tc -NGA kinetic modeling, 1896
Autonomic neuropathy
 gastric emptying in patients with NIDDM, 1643
 myocardial abnormality of ^{123}I -MIBG in diabetic patients, cardiac denervation, 1985
Autonomous thyroid nodule, radioiodine therapy in patients with or without visible extranodular activity, 401(l)e
Autoradiography
 comparison of ^{18}F -Phe with ^{113}C -MET in tumor imaging, 320
 distribution of tritiated-FDG in breast cancer, correlation between glut-1 expression and FDG uptake, 1042
 dual tracer measurement, cardiac oxidative metabolism, 95P(ab)
 dual-isotope, middle cerebral artery occlusion, rats, 282P(ab)
 usefulness of ^{111}In -DTPA-Arg¹ substance P to visualize SPR+ processes, 108
Autoradiolysis, ^{90}Y immunoconjugates, 143P(ab)
Avidin, biochemical modification for two-step imaging and therapeutic procedures, in vitro and in vivo analysis, streptavidin, 1380
Avidin-antibody conjugate, radiolabeled biotin and, targeting of xenografted intraperitoneal tumor using, 200P(ab)
Avidin/biotin, tumor pretargeting and direct antibody labeling in uveal melanoma, quantitative comparison, 967
Avidin/inium-111-biotin, scintigraphy to detect prosthetic vascular graft infection, 55
Avidin/streptavidin, antibody-dependent signal amplification, tumor targeting, 343
Award winners, 1996 SNM fellowships, 20N(5)
Azidothymidine, labeled, for imaging cell proliferation, 240P(ab)
- B**
- B-cell lymphoma**, LYM-1 therapy for, 170P(ab)
 β -CIT, visualization of ischemic insult in caudate putamen, dopamine transporter changes, 1214
Backprojectors, valid matrices, iterative construction, 206P(ab)
Bacterial endotoxin test, for radiopharmaceuticals, evaluation of, 305P(ab)
Balloon test occlusion, assessment of neurological deficits, HMPAO SPECT, 551
Barium, positive ^{99m}Tc -RBC gastrointestinal bleeding scan after small-bowel
- study**, 643
Bartter's syndrome, renal scintigraphy as baseline and after captopril administration, Bartter's syndrome, 1688
Bayesian estimation, image reconstruction, cardiac PET, 130P(ab)
Beclomethasone, inhaled, deposition of, ^{99m}Tc labeling method for, 142P(ab)
Benign exertional headache, frontal hypoperfusion demonstrated by ^{99m}Tc -HMPAO SPECT, 1172
Benzamides, brain D2 tracer, first-pass extraction, brain, 279P(ab)
Benzodiazepine receptor
 analysis of ^{113}C -iomazenil cerebral binding kinetics, 699
brain
 quantitation, using partial saturation method, PET, FMZ, 5
 concentration, PET image after partial-saturation ^{113}C -FMZ injection, 76P(ab)
 distribution, chronic cerebrovascular disease, evaluation of neuronal cell loss, 133P(ab)
 quantitative assessment of, iomazenil SPECT, 374
 SPECT imaging of, alcoholics, 285P(ab)
 visualization of, ^{123}I NNC 13(long dash)8241 SPECT, 76P(ab)
- Beta-Adrenergic receptors**
 first delineation of, PET, brain, 11P(ab)
 in vivo imaging and quantifying compared to in vitro radioligand binding, pulmonary density using PET, 1275
 measurement of concentration, ^{18}F fluorocarazolol PET, 174P(ab)
 thoracic, ^{18}F fluorocarazolol PET use in, 71P(ab)
- Beta-Ray camera**, surgical, gamma-ray background for, 78P(ab)
- Bicarbonate dialysate**, effect on plasma renin activity and level changes, hemodialysis, 145P(ab)
- Bifunctional chelating agents**
 4-ICE, synthesis of, 72P(ab)
 for radioimmunotherapy, 167P(ab)
 improvement in, 72P(ab)
- Bifunctional ligand**, antibody conjugation and stable ^{99m}Tc labeling, kit formulation, 362
- Biliary atresia**, differentiation from neonatal jaundice, ^{99m}Tc disofenin cholescintigraphy in, 288P(ab)
- Biochemical validation study**, measurement of cortical AchE activity in Alzheimer's disease, 649
- Biodistribution**
 ^{111}In and ^{90}Y -labeled human IgM, intraperitoneal administration in mice with carcinomatosis, 1545
 biotinylated antibody FAB' fragment, co-localization with streptavidin, 151P(ab)
 three-dimensional fusion imaging in multidrug resistant tumors, 312
- Biokinetics**, of ^{99m}Tc -DMSA in children, effects of renal pathology and age differences, 1331
- Biomedical cyclotron**, production of high specific activity ^{64}Cu , 61P(ab)
- Biotin**
 ^{210}At conjugate-labeled, preparation and binding properties, 197P(ab)
 ^{64}Cu 13N4-macrocycle conjugates, radiolabeling and radiotracer kinetic studies, rats, 166P(ab)
 antibody-dependent signal amplification in tumor xenografts, avidin or

- streptavidin, 343
 radiolabeled, targeting of xenografted intraperitoneal tumor using, 200P(ab)
 streptavidin and avidin biochemical modification for two-step imaging and therapeutic procedures, in vitro and in vivo analysis, 1380
- Bispecific antibody**, ^{131}I -labeled bivalent hapten
- ^{99m}Tc -labeled conjugate of MTX, targeted delivery of antineoplastics to bone tumors, 105
effect on bone scintigraphy, 401(ie)
- Bladder cancer**
diagnosis and tumor targeting of bladder cancer with 5-iodo-2'-deoxyuridine, 315
- FDG-PET preliminary study in, 260P, 262P(ab)
intravesical administration of $^{131}\text{I}\text{dR}$, 315
intravesical infusion of $5\text{-}^{123}\text{I}\text{-IUDR}$, 16S(4)
- BLIP upgrade**, status report, 167P(ab)
- Blood flow**
cerebral, *see* Cerebral blood flow
cortical, activation response, aging related changes, 164P(ab)
myocardial. *see* Myocardial blood flow
PET imaging to evaluate sensitivity of hepatic tumor to hypertension chemotherapy, angiotensin-II, 1522
soft-tissue vascular anomalies, direct puncture scintigraphy, 183P(ab)
- Blood sampling**, quantitation of cerebral glucose utilization, FDG-PET, 221P(ab)
- Blood vessels**, wall, radiation dosimetry, 229P(ab)
- Blood-brain barrier**, changes in, RMP-7 injection, dynamic SPECT after, 252P(ab)
- Blood-pool imaging**
automated assessment of left ventricular ejection fraction and volumes by, versus gated MRI, 218P(ab)
gated
FDG-PET comparison, assessment of left ventricular function, 39P(ab)
kit prepared ^{99m}Tc DMP-HSA and ^{99m}Tc -labeled-red blood cells, 175P(ab)
sensitivity dependence on region definition, 149P(ab)
mathematical cardiac torso phantom for, volume and ejection fraction determination, 97P(ab)
radionuclide analyses of, response to vasoactive drugs, hepatic lobular dynamics, 244P(ab)
synthetic copolymer kit for, 198P(ab)
time-activity curve extraction, FDG-PET studies in small hearts, derivation of input function, 1717
use of ^{99m}Tc -labeled liposomes, compared with ^{99m}Tc -red cells, 1374
- BMIPP**, metabolic fate after etomoxir administration, canine myocardium, 1836
- Bone**
 ^{99m}Tc MDP SPECT, diagnosis of lumbar spine lesions., 127P(ab)
allograft reconstruction, osteosarcoma after, skeletal scintigraphy use in, 28P(ab)
benign and malignant masses, evaluation with FDG-PET, 140P(ab)
diseases, $99m\text{Tc}$ MDP scans in neurofibroma, plexiform neuroma and neurofibrosarcoma, Von Recklinghausen's neurofibromatosis, 1778
graft, viability, total hip replacement, FDG-PET evaluation of, 27P(ab)
metastases
 ^{99m}Tc effects on adriamycin toxicity in treatment, 32P(ab)
combined radionuclide therapy for treatment, 32P(ab)
diagnostic difficulties with superimposed osteomyelitis, prostatic cancer, 999 dose escalation of ^{186}Re -HEDP in breast cancer patients, 244
osseous metastases, pharmacoeconomic benefits of ^{89}Sr therapy, 31P(ab)
relief of pain with ^{186}Re -etidronate, prostate cancer patients, pain assessment diary, 1511
skeletal metastases
clinical outcome of ^{99m}Tc therapy, 31P(ab)
therapy with ^{99m}Tc or ^{131}Sm EDTMP, hepatic toxicity after, 31P(ab)
- SPECT**
attenuation correction for, using patient scatter body outlines, 127P(ab)
comparison to MRI in detection of vertebral metastases, 975
tumors, targeted delivery of antineoplastics, $99m\text{Tc}$ -labeled gem-bisphosphonate conjugate of MTX, 105
- Bone and soft-tissue tumor**, ^{99m}Tc MIBI scintigraphy, ^{67}Ga comparison within subject, 298P(ab)
- Bone marrow**
imaging
 ^{99m}Tc LL1, 239P(ab)
sulfur colloid, filtration effects, 240P(ab)
metastases
detected by ^{131}I scintigraphy, insular thyroid cancer, 633
noninvasive evaluation of, 982(ed)
regional dosimetry, measured relative depression in skeletal ^{99m}Tc uptake, 232P(ab)
scanning, granulocyte scintigraphy, detection of mandibular metastases, 266P(ab)
toxicity, in radioimmunotherapy, different predictive measures, 43P(ab)
dosimetry
regional variability of marrow-localizing antibody, 695
scintigraphy
evaluation of bone marrow status in hematologic disorders, ^{99m}Tc -antigranulocyte antibody, 978
toxicity
 ^{186}Re -HEDP in metastatic breast cancer, thrombocytopenia, 244
- Bone mineral density**
chronic dialysis effects, different methods, 104P(ab)
comparison, athletic and non-athletic Chinese male adolescents, 298P(ab)
diabetic polyneuropathy effects, 104P(ab)
dual-energy x-ray absorptiometry, measurements, 103P(ab), 13N(10)
femoral neck, lumbar spine comparison, with suspected osteoporosis, 103P(ab)
testosterone treatment effects, young males with delayed puberty, 103P(ab)
- Bone pain**
malignant, absorption of stannous diphosphonates to hydroxyapatite, 72P(ab)
metastatic, correlation of marrow suppression with marrow absorbed dose of Sn-117m(4+) DTPA, 102P(ab)
normal and metastatic, Sn-117m(4+) DTPA
- uptake and retention, 72P(ab)
- Bone scan**
application in sports medicine, 17N(12)
ABG-arthroplasty, hip, bone mineral density after, 103P(ab)
changing prostate-specific antigen levels related to, prostate cancer patients, 296P(ab)
diabetic renal osteodystrophy patients, 28P(ab)
diagnosis of spinal metastases, in cancer patients, 250P(ab)
granulocyte scintigraphy, detection of mandibular metastases, 266P(ab)
heparanase or collagenase activity correlation with, breast cancer patients, 127P(ab)
hot spots in, confirmation of osseous tumor spread and, 266P(ab)
preoperative assessment, mandibular invasion in oral cancer, 137P(ab)
- Bone scintigraphy**
 ^{99m}Tc -sestamibi, assessment of osseous tumor spread, 1526
chronic recurrent multifocal osteomyelitis, phyeal involvement in, children, 23P(ab)
concomitant lung and gastric uptake of ^{99m}Tc -MDP, sarcoidosis, 1530
diagnosing and staging Langerhans' cell histiocytosis, 1456
extensive photopenic osteomyelitis, septic arthritis, 1676
hungry bone syndrome following parathyroidectomy, 1371
procedure guidelines for, 1903
quantitative, leg length discrepancy, congenital growth disorders, 23P(ab)
usefulness and limitations of three-dimensional images, volume-rendering technique and SPECT, 1567
- Book reviews**
Atoms, Radiation and Radiation Protection, 2nd ed., 707
Cancer Therapy with Radiolabeled Antibodies, 194
Clinical Nuclear Cardiology, 707
Combined Scintigraphic and Radiographic Diagnosis of Bone and Joint Disease, 194
Medical Effects of Ionizing Radiation 1995, 707
Nuclear Medicine: Diagnosis and Therapy, 1922
Nuclear Medicine, 1921
Principles of Nuclear Medicine, 1922
Radiation Protection in the Health Sciences, 1921
Your Heart — An Owner's Manual, 22N(2)
- Bradykinin**, RMP-7 agonist of, measurement of changes in blood-brain barrier, SPECT, 252P(ab)
- Brain**
 ^{113}C β -CIT-FP and ^{113}C β -CIT-FE uptake, PET examination of, 284P(ab)
3D versus 2D PET, subjective image quality comparison, 74P(ab)
abnormal aging, radical-related disease, nuclear medicine in, 56P(ab)
abscess, immunoscintigraphy for, 241P(ab)
activation
median and phrenic nerve, ^{99m}Tc ECD SPECT and MRI with image registration, 8P(ab)
patterns in motor sequence learning, PET, 281P(ab)
prediction of recovery in poststroke aphasia, FDG-PET, 122P(ab)
activation response, aging related changes, 164P(ab)

- antioxidative ability**
 glutathione localization with ^{99m}Tc -meso-HMPAO, 1698
- atrophy, aging and cerebral blood flow**, 308P(ab)
- blood flow. see cerebral blood flow**
- cerebral glucose metabolism and peptide T in AIDS dementia**, 1177
- cerebral perfusion abnormalities in Sturge-Weber syndrome**, 81
- dopamine transporter, ^{18}F -labeled β -CIT-FP for PET**, 192P(ab)
- energy metabolism, pH, and vascular reactivity, mitochondrial encephalomyopathy**, 123P(ab)
- epileptic foci, contralateral cerebellar uptake**, 426
- fluid spaces, compartments and reaction volumes**, 126(ed)
- frontal area vascular response, orthostatic hypotension**, 1
- hemide cortication in, plasticity of the corticostratial pathway after**, 56P(ab)
- hypometabolism, epilepsy, FDG-PET**, 41P(ab)
- imaging**
 ester-derivatized TcO mixed ligand complex for, 188P(ab)
 ethical clinical practice guidelines, 1256
- infarction**
 cerebral ischemia with, ^{99m}Tc BMS-181321 detection of, 272P(ab)
 prediction after subarachnoid hemorrhage, CBF with ^{123}I IMP SPECT, 12P(ab)
- mapping, ECAT ART**, 74P(ab)
- metabolism, ^{99m}Tc ECD, properties of enzyme to catalyze**, 189P(ab)
- mid-sagittal plane, ^{99m}Tc ECD SPECT images in 6degrees of freedom**, 8P(ab)
- perfusion**
 cellular basis of ECD retention, ^{99m}Tc -HMPAO, 1694
- extraction and retention of ^{99m}Tc -ECD, SPECT and ^{18}O -water PET studies**, 1600
- SPECT-HMPAO accuracy in normal state, observations in pathological situations and redox state alterations**, 1413
- PET activation studies**
 ^{18}O water, classic conditioning of flexor reflex, 55P(ab)
 language function, left-handed subjects, 55P(ab)
- quantitation of benzodiazepine receptors using partial saturation**, 5
- radionecrosis, functional brain imaging with ^{99m}Tc HMPAO**, 259P(ab)
- SPECT**
 cerebral blood flow in depressed patients detected with ^{99m}Tc -HMPAO SPECT, electroconvulsive therapy, 1075
- clinical utilization of in acute ischemic stroke, thrombolysis**, 1259
- dipyridamole stress in evaluation of cerebral blood flow reserve, carotid artery stenosis**, 1595
- determination of dopamine receptor occupancy by antipsychotic RWJ-37796, striatal activity**, ^{123}I IBZM, 11
- evaluation of patients with pure photosensitive epilepsy, ^{99m}Tc -HMPAO**, 1755
- impact on clinical management decision**, 1070
- perfusion scans, visual interpretation in conjunction with statistical image analysis**, 275P(ab)
- traumatic injury, SPECT imaging after**, 275P(ab)
- tumors**
 ^{123}I IMT SPECT compared with ^{18}F FDG-PET, 157P(ab)
 ^{99m}Tc HMPAO localization of, 263P(ab) after radiotherapy, ^{201}Tl uptake and retention index value in, 255P(ab)
 amino acid analogs IMT and OMIMT as SPECT tracers for, 201P(ab)
 blood-brain barrier permeability changes, intra-arterial RMP7, ^{67}Ga EDTA PET study of, 146P(ab)
 childhood, ^{201}Tl avidity as an outcome predictor, 270P(ab)
 FDG-PET, local histology and prognostic value, 21P(ab)
 $\text{D}-\text{Dopa}$ as an amino acid tracer in detection of, extrapyramidal symptoms, 1180
 glucose metabolism and amino acid uptake in, 268P(ab)
 primary, ^{113}C THY, 157P(ab)
 SPECT and MRI comparison in assessment of, 272P(ab)
 thallium uptake indexes, comparative evaluation, 157P(ab)
 visualization of grade II astrocytoma, ^{99m}Tc -ECD SPECT, 273
- volume imaging head PENN-PET scanner, ultra high resolution**, 276P(ab)
- Brain and head dosimetry model, revised anthropomorphic representations**, 1226
- Brain injury, metabolic consequences and role of PET**, 1170(ed)
- Breast cancer**
 ^{18}F FDG-PET qualitative and quantitative assessment, 254P(ab)
 ^{18}F FTX PET with, 86P(ab)
 ^{99m}Tc MIBI and MRI comparison in detection of, 75P(ab)
 ^{99m}Tc MIBI scintimammography monitoring of treatment, 156P(ab)
 ^{99m}Tc recombinant human alpha-fetoprotein for diagnosis, 87P(ab)
 ^{99m}Tc scintimammography, SPECT and, 252P(ab)
 ^{99m}Tc sestamibi detection
 ^{186}Re -HEDP dose escalation in patients with bone metastases, 244
 accuracy of, 74P(ab)
 axillary lymph node involvement, 75P(ab)
 histopathologic correlation, 75P(ab)
 scintimammography, response to chemotherapy
 ^{99m}Tc tetrofosmin scintimammography use in diagnosis, 156P, 255P(ab)
 advanced, early response to therapy, evaluation by ^{113}C methionine PET, 256P(ab)
 axillary lymphadenopathy and, ^{99m}Tc sestamibi in evaluation of, 252P(ab)
 axillary node imaging, ^{99m}Tc sestamibi and ^{111}In pentetreotide imaging, 251P(ab)
 benign and normal tissue, FDG uptake in, 249P(ab)
 benign tumor, ^{99m}Tc sestamibi uptake correlation with histologic characteristics in, 250P(ab)
 biological disposition and imaging of radioiodinated alkylphosphocholine in rodents, 1540
 biopsied, sigma receptor binding sites in, 267P(ab)
 CEA-scan in diagnosis and staging, 238P(ab)
 comparison of four radiopharmaceuticals used in, 75P(ab)
 correlation of heparanase activity with bone scan findings, 127P(ab)
 detection in dense breasts after negative mammogram, scintimammography for, 269P(ab)
 detection with ^{99m}Tc -MIBI scintimammography, 626
- diagnosis with ^{99m}Tc alpha-fetoprotein and blood pool activity subtraction**, 148P(ab)
- dynamic ^{111}In -pentetreotide scintigraphy**, 622
- evaluation of preoperative chemotherapy using FDG-PET**, 931
- FDG-PET and scintimammography**, 265P(ab)
- FDG-PET for distinguishing between benign and malignant masses**, 99P(ab)
- FDG-PET, quantitative image analysis**, 99P(ab)
- imaging, prone or supine, comparison of sensitivity**, FDG-PET, 99P(ab)
- indeterminate mammograms, scintimammography or contrast-enhanced MRI use in**, 156P(ab)
- L-1- ^{14}C tyrosine as PET tracer for**, 86P(ab)
- limited-angular-view ML-EM pinhole SPECT for**, 214P(ab)
- localization of ^{111}In MX-DTPA humanized BrE-3MAB in**, 169P(ab)
- mammoscintigraphy with ^{99m}Tc -sestamibi**, 926
- metastatic, response to tamoxifen, PET assessment of**, 99P(ab)
- nuclear medicine use in studies, simulation tool for modeling cost effectiveness**, 301P(ab)
- palpable and nonpalpable, ^{99m}Tc sestamibi scintimammography in**, 259P(ab)
- pathologic features of, ^{99m}Tc sestamibi uptake correlation with**, 267P(ab)
- recurrent or metastatic, whole-body FDG-PET accuracy in**, 99P(ab)
- recurrent, whole-body FDG-PET in evaluation of**, 252P(ab)
- scintimammography accuracy, patient age and lesion histology effects**, 254P(ab)
- sensitivity of imaging with a new receptor-binding radiopharmaceutical**, 199P(ab)
- sigma-2 receptors as potential biomarkers for**, 87P(ab)
- small scintillation camera with photodiode readout for imaging of tumors**, 52P(ab)
- staging of the axilla, FDG-PET use in**, 307P(ab)
- stereotactic coordinates from ECT sinograms, radionuclide-guided biopsy**, 1562
- suspected, ^{99m}Tc MDP scintimammography accuracy in**, 155P(ab)
- SUV-lean and Glut-1 expression, FDG-PET**, 65P(ab)
- suspicious mammographic findings, CEA-scan and histopathological results**, 238P(ab)
- tumor, human, hosted in SCID mice, ^{99m}Tc N-mycantibody for imaging of**, 269P(ab)
- Breast carcinoma, distribution of tritiated-FDG, correlation between glut-1 expression and FDG uptake**, 1042
- Breast tumors**
 investigations with ^{18}F -FDG and SPECT, 615
 uptake of ^{99m}Tc -sestamibi, lymph nodes, 922
- Breast uptake, nonbreastfeeding thyroid cancer patients, radioiodine**, 26
- Breastfeeding**
 dose from after thallium-201 administration, 2079
 radioiodine uptake, 26
- Brown tumor, hungry bone syndrome following parathyroidectomy, bone scintigraphy**, 1371
- Buprenorphines, role in treatment of drug dependence, cerebral perfusion defects**, 2098(ie)

C

- Calcium blockers**, effects on outcome, angina pectoris, 149P(ab)
- Camera systems**
gamma camera devices, computer using real-time signal processing software, 206P(ab)
- myocardial perfusion studies, tomography, 208P(ab)
- Cancer**
see also specific type or site
¹¹C-thymidine metabolites, PET imaging, 290
enhanced FDG-PET imaging, emission computed tomography, 371
recurrent, assessment with FDG and L-methionine, 67P(ab)
- Cancer therapy**
development of growth factors as diagnostic and therapeutic radiopharmaceuticals, 197P(ab)
lutetium-177 radioisotope for, reactor production of, 166P(ab)
- Cannabinoid receptors**, ¹²³I AM251 binding to, brain, mouse, 187P(ab)
- Captopril**
baseline and post ACE-inhibition renal blood flow measurements, renovascular hypertension, 1652
transplant renography investigations, interpretation using neural network, 1649
- Captopril radionuclide renography**, renal artery aneurysms, pregnancy-related factors, 1368
- Captopril renography**, detection and treatment of renovascular HTN, meta-analysis of costs, sensitivities, and specificities, 171
- Carbon dioxide**, metabolites in tumor imaging, ¹¹C-thymidine, PET, 290
- Carbon-11**
high-affinity ligands, PET imaging, pulmonary cholinergic receptors, 108P(ab)
neuronal nitric oxide synthase labeled with, PET study, 201P(ab)
- Carbon-11 β-CNT**, PET, serotonin and dopamine transporter sites, brain, 40P(ab)
- Carbon-11 acetate**
adenosine and dobutamine combination, cardiac stress, 307P(ab)
clearance, nasopharyngeal carcinoma, 136P(ab)
compartmental model and, quantification of myocardial perfusion, PET, 83P(ab)
measurement of oxygen consumption, myocardial, 222P(ab)
metabolic changes in hypertrophic cardiomyopathy, PET, 572
PET, aortic valve stenosis, 38P(ab)
simple method of production, 341
simple preparation of 1-¹¹C-acetate, 341
- Carbon-11 alpha-methyl-tryptophan**
kinetics, estimation of serotonin synthesis rate, brain, 145P(ab)
PET, serotonin synthesis in human brain measured by, 113P(ab)
- Carbon-11 carbon dioxide**, synthesis of ¹¹C urea from, 51P(ab)
- Carbon-11 CH₃I**, gas phase production of, 194P(ab)
- Carbon-11 cholin**, brain uptake of, PET, 283P(ab)
- Carbon-11 CP-126,998**, studies of acetylcholinesterase, 41P(ab)
- Carbon-11-daunorubicin**, PET imaging of P-glycoprotein in tumors, ¹¹C-verapamil, multidrug resistance, 1571
- Carbon-11 deprenyl**, PET studies, cluster analysis use in, 42P(ab)
- Carbon-11-DOPA**, in vivo demonstration of decarboxylation, pancreatic tumors, 32
- Carbon-11 doxepin**, PET, artificial neural network decomposition of, 164P(ab)
- Carbon-11 flumazenil**, distribution volume estimate bias, non-immediate equilibrium state, 226P(ab)
- Carbon-11 FMAU**, preclinical studies, PET indicator of tumor proliferation, 107P(ab)
- Carbon-11 FMZ**
detection of viable neurons, ischemic penumbra, 76P(ab)
partial saturation injection, determination of benzodiazepine receptor concentration, 76P(ab)
- Carbon-11-glucose**, radiation absorbed dose estimates in adults, effects of hyperinsulinemia, 1668
- Carbon-11-HED**, PET imaging of neuroblastomas, 16
- Carbon-11 HDMI**, for cardiac norepinephrine transporter, 50P(ab)
- Carbon-11-hydroxyephedrine**, functional status of cardiac sympathetic neurons, ¹¹C-phenylephrine, PET, 1923
- Carbon-11 indometacin**, synthesis, brain studies of cyclo oxygenase, 192P(ab)
- Carbon-11-iomazenil**, modeling alternatives for cerebral kinetics, 699
- Carbon-11-KF15372**, potential use as adenosine A₁ receptor ligand, PET, 1203
- Carbon-11 L-159,884**
impulse response function of, validation of, 288P(ab)
potential PET tracer, in vivo labeling of angiotensin II receptors, 307
- Carbon-11 McN 5652**, loss of serotonin transporters, PET visualization of, 112P(ab)
- Carbon-11 MDL 100907**, suitability as serotonin radiotracer, kinetic analysis, baboon, 145P(ab)
- Carbon-11 methadone**, PET, baboon studies, 40P(ab)
- Carbon-11 methionine**
compared with ¹⁸F-FDG in detection of malignant tumors, PET, 1472
comparison with ¹⁸F-Phe for tumor imaging, 320
FDG comparison, residual or recurrent malignant tumor detection, 261P(ab)
high uptake in brain radiation necrosis, epileptic activity, 1174
parathyroid accumulation in hyperparathyroidism, PET, 1766
- PET**
delineation of cerebral glioma with, 259P(ab)
evaluation of early response to therapy, advanced breast cancer, 256P(ab)
potential as tracer for measuring liver protein synthesis, PET, 279
uptake in PET studies to detect brain tumors, ¹⁸F-Dopa, 1180
- Carbon-11 MHED**
metabolites of, measurement, 205P(ab)
reinnervation, orthotopic heart transplant, 70P(ab)
transport capacities and volumes, PET, during catecholamine stimulation, 70P(ab)
- Carbon-11-N-methylspiperone**, PET imaging of neuroreceptors, typical and atypical neuroleptics, 1122
- Carbon-11 PHEN**, sensitivity to neuronal monoamine oxidase activity, 1122
- kinetics in normal human heart, 70P(ab)
- Carbon-11 raclopride**
binding potential, estimation of, 280P(ab)
bidistribution and dosimetry, 231P(ab)
PET studies, dopamine microdialysis data and, dopamine D2 receptors, 77P(ab)
- Carbon-11 RTI-121**, PET, quantification of dopamine transporter, 109P(ab)
- Carbon-11 SKF 82957**, dopamine D1 agonist, evaluation for PET studies, 202P(ab)
- Carbon-11 THY**, detection of primary brain tumors, 157P(ab)
- Carbon-11 thymidine**
for imaging cell proliferation, 240P(ab)
monitoring of tumor response to chemotherapy, 67P(ab)
- Carbon-11 tyrosine**
evaluation of cytotoxic therapy, lung cancer, 265P(ab)
groin metastases in vulvar cancer patients, 263P(ab)
- Carbon-11 urea**, synthesis from ¹¹C carbon dioxide, 51P(ab)
- Carbon-11-methionine**
- Carbon-11-verapamil**, PET imaging of P-glycoprotein in tumors, ¹¹C-daunorubicin, multidrug resistance, 1571
- Carbon-13 urea breath test**, diagnosis of *H. pylori*, [L2]246P(ab)
- Carbon-14 aminopyrine breath test**, prediction of liver function, postoperative lethality, 114P(ab)
- Carbon-14 L-DOPA**, binding, ¹²³I β-CIT comparison, Parkinson's disease, 66P(ab)
- Carbon-14 urea breath test**
breath samples, simple liquid scintillation counter for analyzing, 207P(ab)
diagnosis of *H. pylori*, replacement of endoscopic biopsy, 246P(ab)
diagnosis, *Helicobacter pylori* gastritis, 114P(ab)
examination of fasting state, 1916(l)e)
- Carborundum pneumoconiosis**, ⁶⁷Ga and ^{99m}Tc DTPA assessment of, lung scintigraphy, 294P(ab)
- Carcinoembryonic antigen**
radioimmunotherapy of medullary thyroid cancer, 905
radioimmunotherapy with ¹³¹I-NP-4F(ab, 1504 radiolabeled antibodies to, detection of medullary thyroid cancer with, 9P(ab)
tumors expressing, radioimmunodetection and therapy in, 9P(ab)
- Carcinogenesis**, risk estimates and dosimetry of radioiodine therapy, multinodular goiters, 2072
- Carcinoid**
myocardial uptake of labeled somatostatin analog, carcinoid syndrome, 275
somatostatin-receptor scintigraphy, bronchial tumor with metastases, 1537
- Carcinoid tumor**
5-hydroxyindole acetic acid, urinary screening, scintigraphy and histopathology of hormonally active, 270
jugulo-tympanic region, methods of diagnosis, 270
metastatic, high-dose ¹³¹I MIBG therapy in, 237P(ab)
visualization of myocardial metastasis, ¹¹¹In-pentetreotide and fusion imaging, 1528
- Cardiac abnormalities**, SPECT myocardial perfusion imaging, ^{99m}Tc-sestamibi, 1285
- Cardiac glycosides**, ^{99m}Tc-Q12 and ²⁰¹Tl extraction

- and retention, effects of ouabain, 752
- Cardiac studies**, transmission smoothing, effects of attenuation in PET, 690
- Cardiac sympathetic nervous system**, myocardial imaging with ^{123}I -MIBG, right ventricular pressure overload, 1343
- Cardiomyopathy**
- ^{123}I -MIBG imaging in pheochromocytoma, excessive catecholamine effect on heart and lungs, pulmonary edema, 1361
 - auto-antibodies in, sarcoplasmic reticulum calcium ATPase inhibited by, 144P(ab)
 - development of, hypoxia effects on, hamster, 175P(ab)
 - dilated
 - β -blockade therapy in, ^{123}I MIBG scintigraphy for estimation, 183P(ab)
 - after beta-blocking therapy, ^{123}I MIBG myocardial images of, 3P(ab)
 - hypertrophic, assessed by PET with ^{13}C CGP 12177 and HED, 71P(ab)
 - idiopathic dilated, reduced coronary vasodilatory capacity in, 82P(ab)
 - left ventricular function in, ambulatory assessment during exercise, 181P(ab)
 - nonischemic, myocardial fatty acid uptake in, PET and ^{13}C palmitate, 39P(ab)
- Cardiomyoplasty**, functional evaluation, gated radionuclide angiography, 93P(ab)
- Cardiopulmonary bypass**
- l-arginine infusion during, reduction of neutrophil margination, 162P(ab)
 - platelet thrombus reduction, l-arginine , pig model, 240P(ab)
- Carotid artery**
- imbalance, effects on blood flow estimations with ^{15}O water PET imaging, 221P(ab)
 - preoperative test occlusion brain perfusion imaging, 415
- Carotid artery disease**, evaluation of cerebral hemodynamic and metabolic status, PET, 429
- Carotid stenosis**, unilateral, diamox ^{99m}Tc ECD SPECT in, 274P(ab)
- Cassen prize**, David Kuhl, recipient of, 23N(8)
- Catecholamine**, hormonally active carcinoid tumor in jugulo-tympanic region, 270
- Catecholamine uptake**, ^{18}F -PFBG accumulation by sympathetic nerve terminals in rat hearts, 2011
- Cationic amino acids**, solutions infused to reduce renal uptake of antibody fragments, 829
- Caudate putamen**, visualization of ischemic insult with B-CIT, 1214
- CB-PAO complex**, preparation and characterization, 187P(ab)
- CCT (RTI-131)**, PET imaging probes for dopamine terminals, CFT and CDCT, 1186
- CDCT (dichloropane)**, PET imaging probes for dopamine terminals, CFT and CCT, 1186
- Cell proliferation**, methyl- ^{14}C -thymidine for in vivo measurement of, 1048
- Cell-level dosimetry**, enhancement of radiation to nucleus, vesicular internalization of ^{123}I -A33, 1052
- Cellular uptake**
- ^{99m}Tc -HMPAO SPECT in oxido-reductive state, 1413
 - basis of ECD retention, brain perfusion, 1694
- Central nervous system lymphoma**, differentiating from toxoplasmosis in patients with AIDS, ^{201}TL SPECT, 1150
- Central nervous system tumors**, intratumoral administration of $5\text{-}^{123}\text{I}$ -IUDR, 19S(4)
- Cerebellum**, semi-quantitative analysis, brain SPECT imaging, 273P(ab)
- Cerebral angiography**, assessment of neurological deficits during balloon test occlusion, HMPAO SPECT, 551
- Cerebral artery**, stenosis, diamox SPECT assessment of, 274P(ab)
- Cerebral blood flow**
- ^{99m}Tc HMPAO SPECT, systemic lupus erythematosus patients, 163P(ab)
 - age versus cerebral atrophy effects, 308P(ab)
 - carotid imbalance effects, ^{15}O water PET imaging, 221P(ab)
 - change during executive function and declarative memory, ^{15}O water PET, 284P(ab)
 - frontal vascular response, raise-up test, orthostatic hypotension, 1
 - gender differences as a function of cognition, PET, 559
 - in dementias, SPECT and histopathologic correlation, 79P(ab)
 - ischemic stroke, studied by ^{99m}Tc HMPAO, 13P(ab)
 - measuring changes in, equilibrium ^{15}O water PET techniques, 283P(ab)
 - metabolic status in carotid artery disease, PET, 429
 - neurophysiological and neuropsychological dissection, working memory, PET study, 284P(ab)
 - normal percent variation, quantification, healthy subjects, 305P(ab)
 - pattern of ictal perfusion, temporoparieto-occipital junction seizures, SPECT, 1946
 - quantification of, ^{15}O water, 282P(ab)
 - quantitation with ^{64}Cu -PTSM and a three-compartmental model, PET, 1089
 - regional functional differences and resistance to degeneration, 1086
 - research, ECAT ART, 74P(ab)
 - SPECT
 - ^{99m}Tc HMPAO, 3D stereotactic surface projection, 215P(ab)
 - activation study, post-traumatic stress disorder, 285P(ab)
 - cerebral dysautoregulation in chronic autonomic failure, 277P(ab)
 - studies on motor activation, ^{15}O butanol and water compared with, 219P(ab)
- Cerebral blood flow and metabolism**, measured by PET in patients with severe diffuse brain injuries, 1166
- Cerebral blood volume**, estimation, rate constants in FDG compartment model analysis, 220P(ab)
- Cerebral cortex**, motor task activation of, PET and SPECT, 273P(ab)
- Cerebral glucose metabolism**, reproducibility of regional brain metabolic changes, benzodiazepine agonists, 1609
- Cerebral glucose utilization**, FDG-PET, a re-examination, 394
- Cerebral ischemia**
- acute stroke associated with, ^{99m}Tc BMS-181321 detection of, 272P(ab)
 - detection of viable neurons in, ^{15}O FMZ use in, 76P(ab)
 - focal, ^{123}I IMZ SPECT after, rats, 282P(ab)
 - rest/stress ^{99m}Tc HMPAO SPECT, 277P(ab)
- Cerebral oxygen metabolism**
- decreased in medial temporal lobe in patients with Alzheimer's disease, PET, 1159
 - regional functional differences, resistances to degeneration, 1086
- Cerebral perfusion**
- defects, improvement after buprenorphines, drug dependence, 2098(1e)
 - imaging, frontal vascular response, with raise-up test in orthostatic hypotension, ^{99m}Tc -HMPAO SPECT, 1
 - preoperative test occlusion of ICA, HMPAO brain SPECT, 415
 - reserve
 - combined transcranial Doppler and brain SPECT, 88P(ab)
 - double-injection protocol with acetazolamide, ^{99m}Tc -ECD, 2057
 - vasodilatory stress, ^{99m}Tc ECD stress, 88P(ab)
- Cerebrospinal fluid shunt**, radionuclide shuntogram, 406
- Cerebrovascular disease**
- ischemic, ^{123}I IMZ SPECT in, 12P(ab)
 - surgery effects, PET parameters for evaluation, 21P(ab)
- Cerebrovascular stress tests**, parenchymal versus vascular cerebral disease, 88P(ab)
- Certification exam**, offered in the field of nuclear cardiology, 13N(7)
- Cesium-137-citrate**, localization of radionuclides in testis, transferrin, 336
- CFT (WIN 35,428)**, PET imaging probes for dopamine terminals, CCT and CDCT, 1186
- CGP-12177**, PET quantification of beta-adrenoceptor density, comparison with radioligand binding assay, 1275
- Chapter Bowl**, winner of 1996 seventh annual challenge, 34N(9)
- Chelating agents**, ^{99m}Tc -DOTA, preparation of radioimmunoconjugate, 167P(ab)
- Chemotaxis**, re-appraisal of quality control of radiolabeled granulocytes, 863
- Chemotherapy**, colon cancer, ^{131}I -labeled MN-14 IgG anti-CEA MAb, 169P(ab)
- Chernobyl**, effects of radiation exposures, 24N(12)
- Children**, use of ^{99m}Tc -ECD SPECT as tool for investigation of epilepsy, 1106
- Cholecystitis**
- false-positive ^{131}I whole-body scans in patients with thyroid cancer, sebaceous cyst, 1690
 - hepatobiliary kinetics of ^{99m}Tc -IDA, linear system theory, 1323
 - morphine-augmentation as aid in diagnosis of patients with pericholecytic rim sign, 267
- Cholecystokinin analog**, normal gallbladder ejection fraction and, morphine augmentation of, 113P(ab)
- Cholecystokinin-octapeptide**, bolus versus continuous infusion, dynamic cholescintigraphy, 261
- Cholescintigraphy**
- ^{99m}Tc disofenin, biliary atresia, 288P(ab)
 - patients with Dubin-Johnson andRotor syndromes, 247P(ab)
- Cholinergic function**, dopamine antagonist-stimulated vesamicol receptor binding, effects of aging, 1192
- Cholinergic receptors**, PET imaging, ^{13}C high-affinity ligands for, 108P(ab)
- Cholinergic synaptic vesicle**, regulation of, 108P(ab)
- Cigarette smoking**, effects on lung permeability, ^{99m}Tc pertechnetate SPECT assessment of, 5P(ab)
- Cirrhosis**
- compensated and decompensated alcoholics,

- hepatic uptake of ^{99m}Tc
DISIDA, 245P(ab)
- ventilation and alveolar permeability, $^{99}\text{TC}-\text{DTPA}$, 437
- Clinical applications**, appropriateness of functional brain imaging, ethical clinical practice, 1256
- Cocaine**, binding sites, on dopamine transporter, PET imaging of, 65P(ab)
- Cognitive stimulation**, gender differences in cerebral blood flow, PET, 559
- Coincidence imaging**, dual-headed gamma camera, 223P(ab)
- Colchicine**, biodistribution evaluation using whole-body quantitative autoradiography, multidrug resistant tumors, 312
- Collapse**, left lower lobe, pseudosign versus stripe sign on perfusion scan, emphysema, 1682
- Collimators**
- 511 keV, physical evaluation of, WWW resource, 305P(ab)
 - characteristics, influence on quantification in SPECT, 1832
 - design, optimization by computer simulations of, 213P(ab)
 - electronic single-photon imaging device, theoretical performance limits, 119P(ab)
 - pinhole
 - improved scintimammography, 78P(ab)
 - positron and single photon emitter using, 215P(ab)
 - rotating slant-hole SPECT camera, phantom experiments with, 120P(ab)
 - testing, focusing quality of commercial fan-beam collimator, 207P(ab)
- Colon cancer**, metastatic to liver, staging with FDG-PET, 131P(ab)
- Colon transit**
- effects of opioid and opioid-like drugs measured by scintigraphy, 818
 - subtypes of prolonged colonic transit, colon transit scintigraphy in differentiation of, 247P(ab)
- Colorectal cancer**
- advanced primary and recurrent, FDG-PET role in, 132P(ab)
 - FDG-PET**
 - comparison with CT, 132P(ab)
 - diagnostic accuracy and cost-effectiveness, 132P(ab)
 - validation with surgical pathology, 131P(ab)
 - imaging with ^{99m}Tc 88BV59, totally human monoclonal antibody, 9P(ab)
 - intra-arterial infusion of 5^{-131}I -IUDR in liver metastases, 22S(4)
 - recurrence, whole-body FDG-PET for evaluation of, 258P(ab)
 - recurrent, whole-body FDG-PET detection of, 261P(ab)
 - treatment with hepatic artery infusion of 5^{-131}I -IUDR in patients with liver metastases, 25S(4)
- Colorectal-liver metastases**, ^{67}Cu PTSM PET use in, 54P(ab)
- Communication**
- effectively conveying radiation risks (part 1), 23N(6)
 - effectively conveying radiation risks (part 2), 20N(7)
- Compartmental analysis**, human kinetics of OMF in blood and striatum modeling of F-Dopa, 432
- Compartmental and deconvolutional analysis**,
- hepatobiliary kinetics of ^{99m}Tc -IDA analogs, linear systems theory, 1323
- Compartmental model analysis**, FDG, rate constants in, cerebral blood volume estimation, 220P(ab)
- Compartmental modeling**, Parkinson's disease, combined FDOPA and 3OMFD PET studies, 209
- Compartmental models**
- cerebellar data, serotonin-2 receptor binding potential, PET, 95
 - correlation between reaction volume and molecular lipophilicity, 118
- Compartments**, reaction volume, brain fluid spaces, 126(ed)
- Compressive goiter**, radioiodine risk estimates and dosimetry, carcinogenesis, 2072
- Computer simulation**, metal ion speciation in blood plasma, 379
- Computer-assisted image processing**, neural networks to diagnose Alzheimer's disease, brain SPECT, 195
- Computers**
- case-based reasoning system, automated interpretation of myocardial perfusion imaging, 178P(ab)
 - diagnosis assisted by, lung scans for pulmonary embolism, 124P(ab)
 - local density functional methods, ^{99m}Tc computational chemistry, 189P(ab)
 - Macin PET software application, 303P(ab)
 - modeling software, State Space Modeler (SSM), 303P(ab)
 - real-time signal processing software, building a gamma camera in, 206P(ab)
 - simulation tool for modeling cost effectiveness, nuclear medicine in lung and breast cancer studies, 301P(ab)
 - simulations, optimization of collimator design, 213P(ab)
 - software, package for PET quantification, 304P(ab)
 - V/Q scanning, for directing pulmonary angiography, 294P(ab)
- World Wide Web**
- digital department moves to, 172P(ab)
 - virtual reality markup language extensions and, cardiac SPECT and PET, 172P(ab)
- Congenital growth disorders**, leg length discrepancy, accurate prediction of, children, 23P(ab)
- Congenital heart disease**, false positive ventilation perfusion scan in patient with complex congenital heart disease, 1359
- Congress**
- NRC and challenging issues, ACNP/SNP update, 34N(10), 44N(11)
 - response to NAS-IOM report, 25N(7)
- Consensus reports**, on renal imaging, 1872, 1876, 1883
- Constipation**
- subtypes of prolonged colonic transit, colon transit scintigraphy in differentiation of, 247P(ab)
- Continuous acquisition**, comparison of continuous step-and-shoot versus step-and-shoot, SPECT, 2037
- Contractile reserve**, changes in myocardial blood flow and, 82P(ab)
- Contrast venography**, detection of deep venous thrombosis, ^{99m}Tc modified rt-PA, 744
- Copper-62-labeled human serum albumin-dithiosemicarbazone**, microcirculation in brain, PET, 1080
- Copper-62-PTSM**
- assessment of regional myocardial perfusion, PET, 1294
 - detection of electron transport failure, occlusion-reperfusion injury, 192P(ab)
 - PET, colorectal liver metastases, 54P(ab)
 - quantitation of cerebral perfusion, three-compartment model, 1089
 - triple-isotope technique to trace, 206P(ab)
 - use as a myocardial PET perfusion tracer compared with $^{15}\text{NH}_3$, 729
- Copper-64**
- anti-colon cancer monoclonal antibody, long-term studies of, 61P(ab)
 - bis(diphosphine) complexes, biological evaluation, 166P(ab)
 - carrier-free, isolated from ^{67}Ga waste, use in PET and therapy, 195P(ab)
 - dosimetric evaluation of, in ^{67}Cu in ^{67}Cu -2IT-BAT-Lym-1, radioimmunotherapy, 146
 - high specific activity, production using a biomedical cyclotron, 61P(ab)
 - retention of, clearance organs and, 71P(ab)
- Copper-64 13N4-macrocycle**, biotin conjugates, radiolabeling and radiotracer kinetic studies, rats, 166P(ab)
- Copper-64 BAT-2IT-NR-LU-10 Fab**, PET imaging and radioimmunotherapy with, 95P(ab)
- Copper-64 TETA octreotide**, radiotherapy studies of, tumor-bearing rats, 128P(ab)
- Copper-67**
- clinical doses of, radioassay, presence of ^{64}Cu impurity, gamma spectrometry, 199P(ab)
 - dosimetric evaluation of ^{64}Cu in, radioimmunotherapy, 146
 - measurement in presence of ^{64}Cu contaminant using dose calibrator, 302
- Copper-67 21T-BAT-LYM-1**, efficacy and toxicity of, mice implanted with Burkitt's lymphome, 128P(ab)
- Coronary artery disease**
- ^{201}Tl and ^{99m}Tc sestamibi comparison, women, 69P(ab)
 - ^{201}Tl reverse redistribution, clinical correlation, 735
 - ^{99m}Tc sestamibi SPECT, gating and, 149P(ab)
 - 3D coronary artery trees, from biplane angiography, perfusion SPECT, 97P(ab)
 - adenosine stress test, ^{99m}Tc tetrofosmin tomography and echocardiography, 178P(ab)
 - arbutamine and dobutamine stress testing, comparison with ^{99m}Tc sestamibi SPECT, 177P(ab)
 - catheterization, post-nuclear testing referral to, 68P(ab)
 - cavity dilatation, versus elevated lung heart ratio, exercise SPECT thallium, 183P(ab)
 - detection during dobutamine stress test, simultaneous perfusion tomography and radionuclide angiography, 1306
 - detection, sublingual nitroglycerine plus ^{99m}Tc -tetrofosmin use in, 302P(ab)
 - dipyridamole/rest ^{99m}Tc tetrofosmin, myocardial tomography, 58P(ab)
 - end-stage renal disease patients, detection with myocardial perfusion SPECT, 69P(ab)
 - fatty acid uptake in ischemic heart disease, ^{123}I -BMIPP SPECT, 1981
 - maximal microvascular dilator capacity, ^{15}N ammonia PET assessment of, 161P(ab)
 - metabolism and function relations, gated FDG-PET, 161P(ab)
 - myocardial perfusion imaging, correlation with

- cardiac serum markers, spontaneous angina, 58P(ab)
- nonreversible defects, cardiac risk and, diagnostic population, 182P(ab)
- normal rest ECG patients, SPECT in, 116P(ab)
- patients at risk for cardiac death, SPECT strategy for identification, economics of, 14P(ab)
- postoperative tachyarrhythmia in, innervation and perfusion mismatch as indicator of, 184P(ab)
- revascularization, ²⁰¹Tl rest-redistribution SPECT in prediction of improvement, 178P(ab)
- ROC analysis, ^{99m}Tc MIBI SPECT and ⁸⁹Rb PET, 160P(ab)
- SPECT evaluation, women, 182P(ab)
- treadmill exercise first-pass left ventricular ejection fraction, diagnostic value of, 180P(ab)
- vascular surgery, preoperative risk stratification in, 14P(ab)
- venous and arterial bypass grafts, attenuated coronary vasoconstrictive capacity and flow reserve, 82P(ab)
- wall motion in, rest motion analysis in gated SPECT, 115P(ab)
- Coronary artery stenosis**, resting perfusion and, detection of ischemia with FDG-PET, 174P(ab)
- Coronary flow reserve**
- hyperlipidemia, angiographically normal coronary arteries, 82P(ab)
 - maximal microvascular dilator capacity, ¹⁵N ammonia PET assessment of, 161P(ab)
 - PET studies in familial hypercholesterolemia, dipyridamole, 1937
 - simplified PET protocol, ⁸⁹Rb and ¹⁵N-ammonia, 1701
 - sympathetic neuron effects, heart transplant patients, 4P(ab)
- Coronary reperfusion**, acute, comparative analysis of ^{99m}Tc sestamibi and thallium, 160P(ab)
- Coronary stent**
- implantation, scintigraphic evaluation of, 126P(ab)
 - SPECT assessment of results, 126P(ab)
- Cost-effectiveness**
- decision tree sensitivity analysis, FDG-PET staging and management of non-small-cell lung carcinoma, 1428
 - diagnostic accuracy and, FDG-PET, colorectal cancer, 132P(ab)
 - diagnostic management strategies, adrenal incidentaloma, 158P(ab)
 - FDG-PET, management of solitary pulmonary nodule patients, 110P(ab), 111P(ab)
 - patients at risk for cardiac death, SPECT strategy for, 14P(ab)
 - PET, staging of small-cell lung cancer, 110P(ab)
 - preoperative risk stratification, vascular surgery patients, 14P(ab)
 - somatostatin receptor scintigraphy, 19P(ab)
 - stress echocardiography, versus nuclear myocardial perfusion imaging, 174P(ab)
 - stress myocardial perfusion imaging, stable angina, women, 68P(ab)
- Cost efficacy**, detection and treatment of renovascular HTN, meta analysis, 171
- CP96,345**, specific binding, substance P receptor expression with ¹¹¹In-DTPA-Arg⁻, substance P, 108
- Cross-talk correction method**, dual-isotope acquisition, myocardial perfusion SPECT
- dog study, 216P(ab)
- Crossed cerebellar hyperperfusion**, increased uptake of ^{99m}Tc HMPAO on ictal brain SPECT, 426
- CT**, evaluation of squamous cell carcinoma metastases, comparisons with other methods of assessment, 897
- Cyclooxygenase**, inhibition by indomethacin, inflammation imaging, brain, 192P(ab)
- Cystography**, neonatal hydronephrosis, 287P(ab)
- Cytarabine**, high dose, HMPAO SPECT scan abnormalities, children, 35P(ab)
- Cytokines**, enhancement of radioiodine uptake in cultural thyroid cancer cells, 646
- Cytosine deaminase**, gene therapy, in vitro studies using 5-fluorocytosine, 87
- D**
- D2 receptors**, ¹²³I-epidepride SPECT in pituitary adenomas, dopamine, 1931
- Deadtime**, multihead anger cameras, ¹³¹I dual-energy/window acquisition mode, 78P(ab)
- Decision analysis**, cost-effectiveness and accuracy of FDG-PET in non-small-cell lung cancer staging and management, 1428
- Deconvolution**, energy spectral, Compton-scatter correction in SPECT, 171P(ab)
- Deconvolution analysis**, suitability of renography, 403(ie)
- Deep venous thrombosis**
- ^{99m}Tc-P280 as thrombus imaging agent, 775
 - companion leg xenon imaging, part of routine V/Q scanning, 302P(ab)
 - detection with ^{99m}Tc P280-labeled peptide, 95P(ab), 294P(ab)
 - lung scanning in diagnosis of pulmonary embolism, 165
 - scintigraphic detection with ^{99m}Tc modified r-PA, 744
- Deferoxamine**, gallium complex, different concentrations and incubation conditions, 199P(ab)
- Degeneration**, of dopamine transporters, age-induced, 554
- Delayed gastric emptying**, right lateral and upright positioning in pediatric patient, ^{99m}Tc-sulphur colloid, 1356
- Delayed graft function**, renal allograft, ^{99m}Tc MAG3 clearance and, 292P(ab)
- Delayed imaging**, diagnostic utility of SPECT and 48-hour scanning in neuroblastoma, ¹²³I-MIBG, 1464
- Delivery protocol**, applying in vitro approach to in vivo cancer therapy strategies, ¹²³I-IUdR and ¹²³I-IUdR, 6S(4)
- Dementia**
- ^{99m}Tc HMPAO SPECT, acetazolamide test and, 273P(ab)
 - cerebral oxygen and glucose metabolism, uncoupling of, 275P(ab)
 - diagnosis orientation in, ^{99m}Tc ECD brain SPECT, 274P(ab)
 - functional brain image database system in, 164P(ab)
 - regional rate constants, dynamic FDG-PET studies in Parkinson's disease, 1115
- Densitometers**, impact on nuclear medicine, screening for osteoporosis with DEXA imaging, 13N(10)
- Department of Energy**, privatization of National Lab, 21N(11)
- Depression**
- glucose metabolism in brain, during REM sleep, 80P(ab)
 - limbic and prefrontal hypoperfusion in psychiatric patients, SPECT, 410
 - relapse, cerebral metabolic correlates for, FDG-PET, 80P(ab)
- Diabetes**
- cardiac denervation in, ¹²³I MIBG for assessment of, 150P(ab)
 - foot lesions, ¹⁸F FMISO PET scan assessment of, 27P(ab)
 - metabolic fate of ¹⁴C acetate, rat myocardium, 50P(ab)
 - MIBG imaging in silent myocardial ischemia, evaluation of sympathetic innervation, 712
 - regional abnormality of ¹²³I-MIBG, assessment of cardiac denervation, autonomic neuropathy, 1985
 - renal osteodystrophy, bone scan findings in, 28P(ab)
 - viable myocardium in, FDG-PET identification of, 39P(ab)
- Diabetic polyneuropathy**, effects on bone mineral density, 104P(ab)
- Diagnosis**, ¹²³I-IBZM SPECT, therapy in Parkinson's disease, 1112
- Diagnostic imaging**, simplified deoxyglucose utilization rate analysis, FDG-PET, 950
- Dialysis**, chronic, effects on bone mineral density, 104P(ab)
- Diastereomers**, improved method for radioiodination of ¹²³I-IQNB, SPECT, 2021
- Diazepam**, effect on skeletal muscle uptake of ¹⁸F-FDG, PET, 1127
- Differential diagnosis**, lung uptake on bone scan due to Wegener's vasculitis, 857
- Differentiated thyroid cancer**, procedure guideline for extended scintigraphy, 1269
- Diffuse brain injury**, cerebral hemodynamics and metabolism measured by PET, 1166
- Diphosphines**, ⁶⁷Cu, biological evaluation, 166P(ab)
- Dipyridamole**
- brain SPECT evaluation of cerebral blood flow reserve, carotid artery stenosis, 1595
 - correlation of ²⁰¹Tl SPECT with hemodynamic indices of myocardial dysfunction, 723
 - myocardial blood flow at rest and during loading dose, PET in familial hypercholesterolemia, 1937
 - myocardial perfusion imaging, patient weight effects, 177P(ab)
 - stress induced by, ⁸⁹Rb PET studies, anesthetized canine, kinetic studies, 146P(ab)
- Disseminated intravascular coagulation**, in metastatic prostate cancer, 401(ie)
- Distribution volume**
- estimate bias, from non-immediate equilibrium state, flumazenil kinetics, 226P(ab)
 - in vivo ligand-receptor interaction modeling, reaction volume, 118
- Diuresis renography**, standardized approach to investigating the dilated upper urinary tract, ^{99m}Tc-MAG3, 1872
- Diving illness**, detection with ^{99m}Tc-HMPAO SPECT and texture analysis, 1154
- DMP444**, potential thrombus imaging agent, 151P(ab)
- DNA**
- damage protection, double-stranded breaks induced by decay of ¹³¹I, 229P(ab)

- single-strand breaks
site-specific detection, MCF7 cells, 233P(ab)
synthesis of DNA-protective proteins, 233P(ab)
- transfer into lymphoma cells, T101-biotinylated-avidin-polylysineantibody complex, 62P(ab)
- triplexes, targeting of auger electron emitters, potential for cytotoxic therapy, 3S(4)
- DNA-level dosimetry**, treatment of colorectal cancer with liver metastases, ¹³¹I-IUDR, 29S(4)
- Dobutamine**
²⁰¹Tl myocardial scintigraphy, left bundle branch block patients, 177P(ab)
evaluation of simultaneous changes in left ventricular function and perfusion, ^{99m}Tc-sestamibi, 1306
- SPECT combined with, diagnostic accuracy, 58P(ab)
- stress ^{99m}Tc sestamibi uptake, magnitude of ischemia, dogs with coronary stenoses, 3P(ab)
- stress echocardiography
FDG-SPECT versus, function after revascularization, 59P(ab)
functional assessment of ALCAPA syndrome, 748
- stress testing
comparison with ^{99m}Tc sestamibi SPECT, 177P(ab)
myocardial assessment during peri-infarction and remote ischemic event, 201Tl SPECT, 1951
- Timing of thallium injections during dobutamine imaging, 193(l)e
- Dopa-decarboxylase**, putamenal, levodopa effects on, Parkinson's disease, 55P(ab)
- Dopamine**
¹²³I-epidepride SPECT, D2 receptor imaging in pituitary adenomas, 1931
asymmetric nigro-striatal function, sleep bruxism, ¹²³I IBZM SPECT, 271P(ab)
comparison of ¹²³I-epidepride and ¹²³I-IBZM, brain SPECT, 1589
- endogenous, synaptic concentration, SPECT measurement, resting state, 32P(ab)
marker of Parkinson's disease process, 216
- psychostimulant-induced release, PET studies of dopamine D2 receptors, 281P(ab)
- receptor occupancy by antipsychotic agent RW-37796, continuous ¹²³I IBZM infusion, SPECT determination, 11
- release, amphetamine-induced, aging effects, SPECT and ¹²³I IBZM, 33P(ab)
- transporter sites, ¹²³I- β -CIT and ¹²³IIBZM SPECT, primate, 281P(ab)
- Dopamine agonists**, ¹²³I-IBZM binding in Parkinson's disease, L-Dopa, 1112
- Dopamine D1 agonists**, ¹¹³C SKF 75670 and SKF 82957, evaluation for PET studies, 202P(ab)
- Dopamine D2 receptors**
¹¹³C raclopride PET studies, dopamine microdialysis data and, 77P(ab)
availability, integrity in Parkinson's disease, ¹²³I iodoluride SPECT, 22
- availability, opiate addicts, during naloxone precipitated withdrawal, 45P(ab)
- binding, with ¹²³I IBF SPECT, 281P(ab)
- extrastriatal, availability, aging effects, 281P(ab)
- NCQ-298, first-pass extraction, brain, 279P(ab)
- occupancy measurements, using no input function, 77P(ab)
- PET, psychostimulant-induced dopamine release and, 281P(ab)
vesamicol receptor binding sensitive to, intact striatum, 280P(ab)
- Dopamine D3 receptors**, design of, 193P(ab)
- Dopamine D4 receptors**
living primary brain, 113P(ab)
YM-43611 as potential radiotracer for, 50P(ab)
- Dopamine metabolism**, compartmental analysis, kinetics of OMFD in blood, striatum, PET, 432
- Dopamine receptors**
occupancy by antipsychotic RWJ-37796, continuous ¹²³I IBZM infusion, SPECT imaging, 11
- sensitivity, changes in synaptic dopamine, 203P(ab)
- SPECT imaging, clinical utility of, 1591(ed)
- Dopamine terminals**, low activity, Lesch Nyhan disease, PET study, 45P(ab)
- Dopamine transporter sites**, ¹²³I-IACFT SPECT in patients with Parkinson's disease, 1197
- Dopamine transporters**
¹²³I FP-CIT pharmacokinetics and dosimetry for evaluation, 65P(ab)
¹²³I-IPT SPECT imaging of, effects of aging on striatal uptake values, 1965
- ¹²³I IPT SPECT measurement, nonhuman primates, 66P(ab)
- ¹²³I IPT SPECT, Parkinson's disease, 273P(ab)
- ¹²³I IPT uptake values, SPECT, primates, 201P(ab)
- ¹⁸F-labeled β -CIT-FP for, PET, 192P(ab)
- altered densities, social phobia patients, 45P(ab)
- changes after ischemic insult in caudate putamen, visualization with β -CIT, 1214
- cocaine binding sites on, PET imaging of, 65P(ab)
- cocaine cogener for, SPECT exploration of, 186P(ab)
- comparative imaging with ¹²³I- β -CIT-FP SPECT and ¹⁸F-FDOPA-PET, Parkinson's disease, 1760
- decline with age, PET, 554
- dosimetry of IPT, SPECT, 151
- imaging agents, ^{99m}Tc-labeled tropanes as, 17P, 298P(ab)
- measurement using ¹²³I- β -CIT SPECT, evaluation of neuropsychiatric disease, 222
- methylphenidate induced high and, 44P(ab)
- quantification of, ¹¹³C RTI-121 and PET, 109P(ab)
- receptors and, SPECT measurement in alcoholics, 33P(ab)
- SPECT imaging of ¹²³I- β -CIT, 1129
- SPECT imaging, comparative nicrostriatal, 133P(ab)
- SPECT measurement in schizophrenia, 33P(ab)
- sustained cocaine abstinence, SPECT imaging, ¹²³I β -CIT, 44P(ab)
- synthesis, imaging with ¹⁸F-labeled FECT, 191P(ab)
- Dosage escalation**, ¹¹⁶Re-HEDP in breast cancer patients with bone metastases, 244
- Dose calibrator**, measurement of ⁶⁷Cu in presence of ⁶⁴Cu contaminant, 302
- Dose uptake ratio**, simplified deoxyglucose utilization rate analysis, FDG-PET, 950
- Dosimetry**
¹¹³In-CYT-356, labeled monoclonal antibodies, prostate cancer, 1583
- ¹³¹I anti-CEA antibodies, red marrow dose and myelotoxicity relations, 43P(ab)
- ¹³¹I treatment for differentiated thyroid cancer, risk due to exposure, 1860
- ¹³¹I, radiation dose to spinal cord, 90P(ab)
- ^{99m}Tc DMSA, tissue and cellular distribution, rat kidney, 231P(ab)
- ¹¹³Sn(4+) DTPA, correlation of marrow suppression with marrow absorbed dose, 102P(ab)
- ¹⁸F-FDOPA
bladder wall radiation dose, PET, 1850
- 3D quantitative, colloidal phosphorus-32, Bremsstrahlung SPECT, 90P(ab)
- biodistribution and
¹¹³C raclopride, 231P(ab)
- ^{99m}Tc NOET, normal humans, 229P(ab)
- ^{99m}Tc P748, 231P(ab)
- ^{99m}Tc P829, 90P(ab)
- cobalt-55, 2082
- cobalt-57, 2082
- comparisons of ^{99m}Tc-HYNIC-IgG with ¹¹³DTPA-IgG, 843
- determination of therapeutic activity, radioimmunotherapy, 43P(ab)
- dopamine transporter imaging, IPT, SPECT, 151
- dose from breastfeeding after thallium-201, 2079
- in newborns, FDG-PET, 387
- intraleisional radionuclide therapy, multimodality imaging and mathematical modeling, 228P(ab)
- marrow, hematologic toxicity in, different predictive measures, 43P(ab)
- patient-specific
¹¹³In/^{99m}Tc-labeled monoclonal antibody CC49, 90P(ab)
- 3D, Monte Carlo approach, 89P(ab)
- quantitative SPECT imaging and 3D-DFT convolution, 89P(ab)
- platelet count, relationship between bone marrow absorbed dose and toxicity, Rhenium-186-HEDP, MIRD model, 38
- potential, minimal residual disease, radiolabeled antibodies, 44P(ab)
- radiation
evaluation of ⁶⁷Cu in ⁶⁷Cu-21T-BAT-Lym-1, 146
- ¹³¹I sodium iodide safety concerns with dialysis, 229P(ab)
- trachea, 228P(ab)
- biodistribution and, effects of Lym-1 antibody preload on, lymphoma patients, 90P(ab)
- estimates for PET radiopharmaceuticals using primates, ¹¹³C arachidonic acid, 230P(ab)
- estimates for positron radiopharmaceuticals used in drug development, 228P(ab)
- estimates in primates for humans for DMP444, 232P(ab)
- exposure to staff from patients having vascular surgery, 230P(ab)
- irradiation of ¹³¹I, 305P(ab)
- organ S values for individual patients, 232P(ab)
- PET measurements of ⁶⁰Y EDTMP uptake, 227P(ab)
- regional bone marrow, measured relative depression in skeletal ^{99m}Tc uptake, 232P(ab)
- regional quantitation based on SPECT, 232P(ab)
- wall of blood vessels, 229P(ab)
- radioimmunodetection and therapy, CEA-expressing tumors, 9P(ab)
- risk estimates of radioiodine therapy, compressive goiter, 2072
- risk versus benefits in ¹³¹I-MIBG therapy, 1058

- small-scale alpha, red bone marrow, using histological images, 231P(ab)**
- tumor, radioimmunotherapy of CEA-expressing cancers, 231P(ab)**
- Double-injection protocol, cerebral perfusion reserve with Acetazolamide, ^{99m}Tc-ECD, 2057**
- Double-phase scanning, nodular thyroid malignancy, ^{99m}Tc-sestamibi, 1919(ie)**
- Drug dependence, role of buprenorphines in treatment, improvement in cerebral perfusion defects, 2098(ie)**
- Dual-energy x-ray absorptiometry bone mass measurements for osteoporosis, 13N**
- Dual-isotope acquisition**
 - enhanced cross-talk correction technique for myocardial perfusion SPECT dog study, 216P(ab)
 - positron and single photon emitter, using gamma camera and pinhole collimator, 215P(ab)
- Dual-isotope imaging**
 - impaired fatty acid metabolism and dyskinesis in hypertrophic cardiomyopathy, ¹²³I-BMIPP, 1679
 - evaluation of AIDS patients, 302P(ab)
 - simultaneous evaluation of metabolic state and myocardial perfusion, heart transplantation, 1990
- Dual-tracer autoradiography, ²⁰¹Tl and ¹²³I-MIBG, uptake discrepancy in experimental myocardial infarctions, 680**
- Dubin-Johnson syndrome, kinetic chole scintigraphy in evaluation of, 247P(ab)**
- Dynamic cholescintigraphy, inducing and describing gallbladder emptying, ejection fraction, 261**
- Dynamic imaging, ¹¹¹In-pentetreotide scintigraphy in breast cancer, 622**
- Dynamic study, pulmonary SPECT of ¹³³Xe washout, 807**
- Dyskinesis, hypertrophic cardiomyopathy, metabolic imaging with ¹²³I-BMIPP, 1679**
- E**
- ECAT ART, research in cerebral activation, 74P(ab)**
- Ectopic parathyroid adenomas, localization with ^{99m}Tc-MIBI scintigraphy, 631**
- Education**
 - and research as investment in the future, 17N(7)
 - continuing medical, 16N(4)
- Effective dose, radiation dosimetry of ^{99m}Tc-DMSA in pediatrics, 1336**
- Effective dose equivalent, ^{99m}Tc-DMSA, dosimetry in children, 1336**
- Effective half-life, hyperthyroidism treatment with ¹³¹I, 228**
- Effective renal plasma flow**
 - camera-based determination, complete dynamic scan data, 91P(ab)
 - glomerular filtration rate and, simultaneous estimation with ^{99m}Tc EC, 91P(ab)
 - radionuclides in nephrology, Committee on Renal Clearance report, 1883
- Ejection fraction**
 - comparison of planar and SPECT gated blood-pool studies, 1795
 - left ventricular
 - automated calculation, gated perfusion tomography, 213P(ab)
 - cardiac volumes and, improvement after bypass surgery, 93P(ab)
- determination with mathematical cardiac torso phantom for bloodpool imaging, 97P(ab) measured by ^{99m}Tc tetrofosmin gated SPECT, 179P(ab)
- normal children, 286P(ab)
- radial distribution of myocardial count rate density for measurement, 211P(ab)
- reproducibility from stress versus rest gated perfusion SPECT, 115P(ab)
- tomographic MUGA comparison to planar techniques, 92P(ab)
- treadmill exercise first pass radionuclide ventriculography, 93P(ab)
- myocardial wall motion and, gated FDG-PET examination of, 226P(ab)
- resting left ventricular, first-pass ²⁰¹Tl ventriculography, 181P(ab)
- tomographic, severely hypoperfused myocardium, image enhancement, 105P(ab)
- treadmill exercise first pass, detection of coronary artery disease, 180P(ab)
- Elbow, lymph node visualization, 1913(ie)**
- Electroconvulsive therapy, assessment of cerebral blood flow in depressed patients, ^{99m}Tc-HMPAO SPECT, 1075**
- Electron transport chain, mitochondrial, detection of failure with ⁶⁷Cu PTSM, 192P(ab)**
- Emission computed tomography**
 - breast cancer
 - stereotactic coordinates from ECT sinograms, radionuclide-guided biopsy, 1562
 - enhanced FDG-PET tumor imaging, 371
 - fatty acid uptake in ischemic heart disease in patients without prior MI, ¹²³I-BMIPP, 1981
- Emphysema**
 - lung volume reduction surgery, V/Q scans for evaluation, 5P(ab)
 - preoperative assessment, V/Q scintigraphy, 5P(ab)
 - scintigraphic perfusion defect stripe sign versus pseudostripe sign, lobar collapse, 1682
- Encephalomyopathy, mitochondrial, cerebral energy metabolism, pH, and vascular reactivity in, 123P(ab)**
- Endocrine pancreatic tumors, decarboxylation, in vivo demonstration of enzymatic activity observed with PET, 32**
- Endocrine tumors, ¹¹¹In-pentetreotide uptake, lymphoma, 916**
- Endoprosthesis, hip, bone mineral density after, time-course of, 103P(ab)**
- Endothelial cells, re-appraisal of quality control of radiolabeled granulocytes, 863**
- Endotoxemia, gram-negative, pulmonary migration of granulocytes, granulocyte-colony stimulating factor effects, 24P(ab)**
- Endotoxins, problems in FDG imaging, 199P(ab)**
- Energy spectrum, estimation of, multispectral images, SPECT, 171P(ab)**
- Enhanced contour finding method, attenuation correction, PET brain emission images, 172P(ab)**
- Enzyme replacement therapy, Gaucher's disease, scintigraphic monitoring of, 297P(ab)**
- Epibatidine**
 - ¹⁴C N-methylated analogs of, synthesis of high specific activity, 192P(ab)
 - analog of
 - central nicotinic acetylcholine receptors, 108P(ab)
 - radiotracer for studies of nicotinic cholinergic
- receptors, 6P(ab)
- Epilepride, dopamine D₂ receptor imaging in pituitary adenomas, SPECT, 1931**
- Epidermal growth factor, use in imaging of breast cancer, 199P(ab)**
- Epiglottitis, scintigraphy using ¹¹¹In-WBC in unsuspected cases, 76**
- Epilepsy**
 - definition of foci on ictal scan, crossed cerebellar hyperperfusion, 426
 - evaluation of ^{99m}Tc-ECD SPECT as investigational tool, pediatrics, 1106
 - extratemporal lobe
 - interictal brain SPECT in, 271P(ab)
 - localization of seizure foci, ^{99m}Tc ECD SPECT, 100P(ab)
 - hypometabolism, localization of, brain, FDG-PET, 41P(ab)
 - ictal and interictal ^{99m}Tc-bicisate brain SPECT, pediatric population, 1101
 - ictal cerebral blood flow, temporoparieto-occipital junction seizures, SPECT, 1946
 - ictal SPECT, ^{99m}Tc HMPAO or ECD, 100P(ab)
 - imaging regional cerebral blood flow at high flow levels, HMPAO, 661
 - intractable, surgical outcome, electrode data and, 100P(ab)
 - partial seizures, SPECT localization for postsurgical followup and invasive electrode data, 101P(ab)
 - partial, associated with vascular malformations, FDG-PET evaluation, 100P(ab)
 - pediatric, comparison of FDG-PET, SPECT, and MRI in, 269P(ab)
 - temporal lobe, presurgical localization of foci, ¹²³IIMZ SPECT for, 101P(ab)
- Esophageal cancer**
 - staging, FDG-PET, 135P(ab)
 - tumor imaging, ²⁰¹Tl SPECT imaging of, 248P(ab)
- Esophageal scintigraphy, optimizing results with ROC analyses, esophageal motility, 1799**
- Esophagitis, perfusion imaging, identifying a noncardiac cause of chest pain, 1285**
- Esophagus, reflux esophagitis, quantitative salioscintigraphies in, 245P(ab)**
- Estrogen, receptor-positive tumor, evaluation with ¹¹¹In DTPA estradiol, 264P(ab)**
- Estrogen receptors**
 - DNA single-strand breaks, site-specific detection, MCF7 cells, 233P(ab)
 - gallium-chelating ligands for, 194P(ab)
- Ethanol, percutaneous injection, radioiodine therapy comparison, hyperthyroidism, 255P(ab)**
- Ethylenedi cysteine isomers, comparison in rats and healthy volunteers, 46P(ab)**
- Etomoxir, metabolic fate of ¹²³I-BMIPP, canine myocardium, 1836**
- Euthyroid, ¹²³I uptake, stability of values, 805**
- Expectation maximization with ordered subsets, whole-body FDG-PET improvement with, 130P(ab)**
- Expert systems**
 - interpretation, myocardial perfusion imaging, 48P(ab)
 - interpreting cardiac ²⁰¹Tl SPECT studies, comparison with physician training, 179P(ab)
- External radiotherapy, treatment of metastatic thyroid cancer, 598**
- Extracellular fluid, solute distribution in, 91P(ab)**
- Extrapyramidal effects, temporal binding characteristics, receptor occupancy, antipsychotic agents, 11**

Extremity edema, ^{99m}Tc -albumin colloid lymphoscintigraphy, postoperative lymphocele discovered incidentally, 1517

F

F-DOPA, combined PET studies, Parkinson's disease, 30MFD, 209

Fab' fragments, reduction of renal uptake of monoclonal antibodies by amino acid infusion, 829

Factor analysis, FDG-PET studies in small hearts, derivation of input function, 1717

Factor analysis of dynamic structure (FADS), combination with SPECT for detection of abnormal parathyroid glands, ^{99m}Tc -sestamibi, 1773

Familial hypercholesterolemia, myocardial blood flow measurements with PET, dipyridamole, 1937

Fan-beam collimator, commercial, focusing quality of, 207P(ab)

Fatty acid metabolism

focal accumulation of ^{123}I -BMIPP in liposarcoma, 997

impairment in hypertrophic cardiomyopathy, metabolic imaging with ^{123}I -BMIPP, dyskinesis, 1679

metabolic fate of ^{123}I -BMIPP in myocardium after etomoxir administration, canine study, 1836

Fatty acids

3R-BMIPP isomer, heart uptake of, 6P(ab)

metabolic activity, myocardial function and, recovery in postperfusion myocardium, 37P(ab)

metabolism, myocardial serial change in utilization, acute MI, 185P(ab)

single injection of ^{123}I BMIPP, 185P(ab)

myocardial, PET and ^{13}C palmitate detection in cardiomyopathy patients, 39P(ab)

radiolabeled to predict functional outcome after myocardial infarction, 718

Fibromyalgia syndrome, abnormal CSF substance P, low ^{99m}Tc HMPAO uptake and, 276P(ab)

Filtering, fast quantitative measurement of attenuation map, SPECT, 217P(ab)

Flow tracers, lipophilic cationic, detection with microelectrode sensors, 205P(ab)

Flumazenil, FMZ affinity and benzodiazepine receptor concentration estimates using partial saturation method, 5

Flunarizine, Moyamoya disease, improved cerebral perfusion following therapy, ^{99m}Tc -HMPAO, SPECT, 84

Fluorine-18

5α -dihydrotestosterone, evaluation of 18F-labeled androgen receptor ligands in baboons, prostate cancer, 1009

5-Fluorouracil, biodistribution and metabolism, PET and MRI study comparison, 249P(ab)

mapping of dopamine transporters, PET and SPECT, 298P(ab)

pinhole SPECT, brain, Monte Carlo study, 120P(ab)

radiolabeled transferrin, iron metabolism in cell proliferation, tumor localization, 1408

Fluorine-18 altanserin, use in quantitative imaging of serotonin receptors, 109P(ab)

Fluorine-18 atipamezole, synthesis, biodistribution in rats, 51P(ab)

Fluorine-18 DOPA

examination of F-Dopa model, normal and

Parkinsonian subjects, 432

FDG-PET and, multiple system atrophy and Parkinson's disease, 271P(ab)

PET imaging to detect brain tumors, Parkinson's disease, 1180

statistical parametric mapping of, 271P(ab) uptake, amino acid transport effects, 109P(ab)

Fluorine-18 epibatidine analog

radioligand for imaging of, 11P(ab)

SPECT imaging of nicotinic acetylcholine receptors, baboon brain, 11P(ab)

Fluorine-18 FCAP, assessment of ACE activity, spontaneously hypertensive rat, 118P(ab)

Fluorine-18 FECT, dopamine transporter imaging with, monkey, 191P(ab)

Fluorine-18 FHPG, synthesis, imaging of viral infection and gene therapy, PET, 193P(ab)

Fluorine-18 fluoroacyclovir, probe for gene expression, PET, 193P(ab)

Fluorine-18 flurodeoxyglucose (FDG)

^{113}C methionine comparison, residual or recurrent malignant tumor detection, 261P(ab)

^{123}I BMIPPA comparison, uptake in ischemic heart disease, 184P(ab)

^{123}I IMT SPECT compared with, evaluation of brain tumors, 157P(ab)

abnormal colonic accumulation in pseudomembranous colitis, 1683

adrenal masses, evaluation for metastatic disease, 141P(ab)

brain

image misregistration, limits of visual analysis, 208P(ab)

quantitative evaluation of 3D PET, 219P(ab)

cancer dual study with ^{113}I whole-body scanning, 1468

cerebral glucose metabolism in HIV-1 seropositive subjects, PET, 1133

cerebral glucose utilization, during physiological stimulation, 223P(ab)

changes in function and regional glucose uptake, stunned porcine myocardium, PET, 2006

compared to sestamibi SPECT, localization of parathyroidism adenomas, hyperparathyroidism, 1809

compared with ^{113}C -MET in detection of malignant tumors, PET, 1472

comparison of ^{18}F -Phe with ^{113}C -Met in tumor imaging, 320

detection and treatment of ocular melanoma, 137P(ab)

diagnosis of malignant melanoma, comparison with scintigraphy, 137P(ab)

dual-isotope

myocardial viability, 261P(ab)

single acquisition SPECT, correction for downscatter, 137P(ab)

endotoxins in, 199P(ab)

evaluation of therapy on transplanted VX2 liver tumor, 296

focal pulmonary abnormalities, 36P(ab)

gastroesophageal cancers, preoperative staging, 135P(ab)

head and neck cancer

chemotherapy response in, 136P(ab)

value in preoperative workup, 136P(ab)

whole-body staging by, 136P(ab)

head and neck tumors, benign or malignant, 304P(ab)

high-energy slit aperture and pinhole SPECT, correcting aperture penetration, 7P(ab)

high uptake in brain radiation necrosis, epileptic activity, 1174

histogram sharpening method to reduce transmission noise, PET, 786

hyperparathyroidism after resection of parathyroid carcinoma, ^{99m}Tc -sestamibi-SPECT, 2000

inhaled drug deposition, labeling of fluticasone propionate particles in, 141P(ab)

interpretation of myocardial PET scans in hyperglycemia, 1713

L-methionine, assessment of cancer recurrence with, 67P(ab)

liver metastases, discordance with MRI scans, 253P(ab)

management of lymphoma, 139P(ab)

metabolic changes in hypertrophic cardiomyopathy, PET, 572

middle cerebral artery occlusion, viable and ischemic regions, rats, 282P(ab)

monitoring response of soft-tissue and musculoskeletal sarcoma to neoadjuvant therapy, PET, 1438

myocardial, comparison of viability studies, 177P(ab)

myocardial uptake of, comparison of PET and SPECT in dyssynergic myocardium, 1631

neural development studies, conscious infant primates, 55P(ab)

neurologic, signal-to-noise ratio in, comparison of reconstruction algorithms, 220P(ab)

neurological PET, postinjection transmission measurements of attenuation correction, 128

non-small-cell lung cancer, 259P(ab)

parameters, monitoring of non-Hodgkin's lymphoma, 138P(ab)

PET

compared to ^{99m}Tc -MIBI SPECT, evaluation of musculoskeletal sarcomas, 1476

derivation of input function, studies in small animal hearts, 1717

estimated radiation dose in neonates, 387

evaluation of preoperative chemotherapy in breast cancer, 931

glucose uptake by tongue and pharyngeal muscles, 1918(ie)

imaging of neuroblastomas, 16

position of photon-emitting objects in emission scanner, stereotactic coordinates, ECT sinograms in breast biopsy, 1562

preliminary study, bladder cancer patients, 260P(ab)

primary renal cancer visualization with, correlation with histopathological data, 64P(ab)

probability of malignancy in solitary pulmonary nodules, PET, 943

response to hyperthermic isolated limb perfusion for soft-tissue sarcoma, PET, 984

routine estimation of regional cerebral metabolic rates of glucose, 147P(ab)

sarcoma, tumor glucose metabolic rate and differential uptake ratio in, 140P(ab)

simplified deoxyglucose utilization rate analysis, PET, 950

skeletal muscle uptake, effect of oral diazepam, 1127

SPECT versus PET, cardiac, determination of myocardial viability, 60P(ab)

staging of high-risk cutaneous melanoma, 137P(ab)

staging, Hodgkin's disease, 139P(ab)

- statistical parametric mapping for assessment of brain, clinical validation of, 42P(ab)
- thoracic and upper abdominal tumors**, 36P(ab)
- tumor uptake**
- chronic hyperglycemia, 253P(ab)
 - hyperacute changes after stereotactic radiosurgery, 257P(ab)
- uptake**
- correlation of Glut-1 in pancreatic tumors, 248P(ab)
 - distribution of tritiated-FDG in breast cancer, correlation between glut-1 expression, 1042
 - expression of Glut-1 and, colon carcinoma, 248P(ab)
 - normal head and neck structures, 251P(ab)
 - proliferating cell nuclear antigen and, non-small cell lung cancer, 64P(ab)
 - Wortmannin effects on glucose utilization, 94P(ab)
- uptake and retention kinetics** in rat hearts, sympathetic nerve terminals, 2011
- uptake in laryngeal muscles**, speech-related visualization with PET, 1771
- whole-body**, staging of malignant melanoma, 138P(ab)
- whole-body PET**, physiological and artifactual versus pathological accumulations, 441
- Fluorine-18-fluorophenylalanine**, feasibility for tumor imaging compared with ¹³C-Met, 320
- Fluorine-18 fluoroproline**, tracer for collagen synthesis, 41P(ab)
- Fluorine-18 FMISO**
- imaging kit, hypoxic tissues, 72P(ab)
 - PET, assessment of diabetic foot lesions, 27P(ab)
 - uptake, evaluation of tumor hypoxic fraction using tumor:muscle ratios, 235P(ab)
- Fluorine-18 FQNPe**, preparation and biodistribution of, 193P(ab)
- Fluorine-18 FTHA**, fatty acid tracer retention, myocardial ischemia and hypoxia, 94P(ab)
- Fluorine-18 FTX**, PET, breast cancer, 86P(ab)
- Fluorine-18 holo-transferrin**, dynamic 3D-PET and, measurement of transferrin receptor kinetics, liver, 203P(ab)
- Fluorine-18 misonidazole**, PET, localization of liver hypoxia with, 200P(ab)
- Fluorine-18-OMFD**, plasma to striatum forward transport rate, compartmental analysis, 432
- Fluorine-18 orthocarbon**, preparation, PET imaging of new boron neutron capture therapy agents, 194P(ab)
- Fluorine-18 PFBG**
- PET, imaging of pheochromocytoma, dogs, 200P(ab)
- Fluorine-18 RS-15385-FP**, PET, alpha-1adrenergic receptor radioligand for, 40P(ab)
- Fluorine-18-setoperone**, alteration of 5-HT₂ receptors in unlesioned cortical areas, stroke, 1976
- Fluorine-18 trovafloxacin**, pharmacokinetics, PET study of *E. coli*-infected rabbits, 239P(ab)
- Fluorocytosine**, conversion to 5-fluorouracil, gene therapy with cytosine deaminase, 87
- Fluorodeoxyglucose (FDG)**
- breast tumor investigations with whole-body acquisition and SPECT, 615
 - cerebral glucose metabolism, reliability of scans before and after placebo infusions, PET, 1142
 - detection of brain tumors, Parkinson's disease, 1180
 - enhanced PET tumor imaging, emission computed tomography, 371
 - PET
 - determination of regional cerebral glucose utilization, 394
- Fluorodopa**, Parkinson's disease, PET data analysis, 421
- Focal liver hyperplasia**, assessment with hepatoreceptor and hepatobiliary imaging, Alagille syndrome, 1365
- Folate binding protein**
- concentration of GP38 in ovarian cancer, 665
 - radiopharmaceutical tumor targeting via receptor-mediated endocytosis of ⁶⁷Ga-DF, 1003
- Folate receptor**, concentration of FBP-GP38 in ovarian cancer, 665
- Forensics**, appropriateness of functional brain imaging, ethical clinical practice, 1256
- Fractionated cold kits**, reduced stability, quality control, 1913(Le)
- Free thyroxine estimate**, correction of, 144P(ab)
- Frontal area**, vascular response of orthostatic patients, 1
- Frontal lobe**, cerebral blood flow, gender differences as a function of cognition, 559
- Fulminant hepatic failure**, monitored by ^{99m}Tc-GSA, 641
- Functional indices**, assessment and diagnosis
- Furosemide**, standardized approach to investigating the dilated upper urinary tract, ^{99m}Tc-MAG3, International Consensus Committee on diuresis renography, 1872
- G**
- Gadolinium-3**, computer simulation of metal ion speciation, MRI contrast agents, 379
- Gadopentate**, interference with ⁶⁷Ga, tumor imaging, 198P(ab)
- Gallbladder**, morphine-augmentation in diagnosis of acute cholecystitis, pericholecystic rim sign, 267
- Gallbladder emptying**, dynamic cholescintigraphy, ejection fraction, 261
- Gallium**
- ligands for, estrogen receptor, 194P(ab)
 - scintigraphy
 - diagnosis of acute osteomyelitis, spine and sacroiliac, 297P(ab)
 - diagnosis of untreated *Pneumocystis carinii* pneumonia in AIDS patient, 293P(ab)
 - thallium and, disseminated mycobacterium avium complex, 242P(ab)
- Gallium-67**
- ²⁰¹Tl comparison, imaging of pediatric Hodgkin's disease, 285P(ab)
 - antitac DSFV fragment, biodistribution and catabolism, 152P(ab)
 - compared to ²⁰¹Tl imaging in salivary gland disorders, ^{99m}Tc, 1819
 - computer simulation of metal speciation in blood plasma, MRI contrast agents, 379
 - evaluation of ¹⁸F-labeled transferrin, tumor localizing agent, 1408
 - gadopentate interference with, tumor imaging, 198P(ab)
 - lung scintigraphy, assessment of carborundum prediction of response, after chemotherapy in lymphoma, 139P(ab)
 - pulmonary leak index in differentiating hydrostatic pulmonary edema from ARDS, noninvasive, 1316
 - radiolabeled liposomes for tumor imaging, 326
 - radiopharmaceutical tumor targeting with receptor-mediated endocytosis, 1003
 - scintigraphy, somatostatin receptor comparison, malignant lymphomas, 268P(ab)
 - with different deferoxamine concentrations and incubation conditions, 199P(ab)
- Gallium-67 citrate**
- hilar uptake, after CHOP chemotherapy for non-Hodgkin's lymphoma, 140P(ab)
 - uptake, benign hyperplasia, after chemotherapy for lymphoma, children, 256P(ab)
- Gallium-67 hydroxyaryl derivatives**, agents for lymphoma diagnosis, 196P(ab)
- Gallium-67-citrate**
- comparative study thallium versus gallium scintigraphy in lymphoma subgroups, uptake according to tumor grade, type, 46
 - scintigraphy for noninvasive detection of early tumor development, non-Hodgkin's lymphoma, 1524
 - sequential thallium and gallium chest scans, differentiating kaposi sarcoma from lymphoma and opportunistic infections in AIDS, 1662
- Gallium-68 EDTA**, brain tumor blood-brain barrier permeability changes, intra-arterial RMP7, 146P(ab)
- Gamma camera**
- accuracy of ^{99m}Tc-MAG3 clearance measurements, heart curve, 1281
 - building of, computer using real-time signal processing software, 206P(ab)
 - Compton scatter camera design, medical imaging of radiopharmaceuticals, 77P(ab)
 - dual-head
 - ^{99m}Tc MAG₃ clearance measurements with, 91P(ab)
 - coincidence mode imaging with, 223P(ab)
 - SPECT/PET, initial coincidence imaging with, 53P(ab) - high resolution miniaturized, bone tumor localization during surgery, 303P(ab)
 - mobile tomographic, acute perfusion studies in emergency room or intensive care unit, 120P(ab)
 - multiwire proportional, murine nuclear angiography with, 52P(ab)
 - positron and single photon emitter using, simultaneous acquisition technique for, 215P(ab)
 - renal uptake of ^{99m}Tc MAG₃, interobserver variance, 293P(ab)
- Ganglioneuroblastoma**, ¹¹¹In-pentetetotide imaging in children, 893
- Gastric antral vascular ectasias**, diagnosis with ^{99m}Tc-labeled red cell scans, case report, 854
- Gastric bleed sites**, amplitude images for detection of, 246P(ab)
- Gastric emptying**
- antral motility and, alterations in men and women, dynamic antral scintigraphy, 244P(ab)
 - effects of gastric acid suppressant drugs on, dynamic antral scintigraphy, 57P(ab)
 - effects of opioid and opioid-like drugs measured

- by scintigraphy, 818
 estimation of antral motility, new method, 57P(ab)
Gastric pacing, effects, patients with gastroparesis, 57P(ab)
 in early NIDDM, glycemic response, 1643
 management of patients with gastrointestinal disorders, 245P(ab)
 peristalsis and, scintigraphic imaging of, 56P(ab)
 postprandial glucose and insulin level relations, hypertensive subjects, 247P(ab)
 time, untreated Parkinson's disease patients, 245P(ab)
Gastric function, calculation methods of solid gastric emptying lag phase, 1639
Gastric motility, new method for estimation, 57P(ab)
Gastric pacing, effects on gastric emptying, patients with gastroparesis, 57P(ab)
Gastric physiology, calculation methods of solid gastric emptying lag phase, 1639
Gastritis, bile reflux during SPECT myocardial perfusion imaging, identifying noncardiac cause of chest pain, 1285
Gastroenteropancreatic tumors
 somatostatin receptor scintigraphy in, 253P(ab)
 staging and management, octreotide scans for, 20P(ab)
Gastroesophageal cancer, preoperative staging, ¹⁸F FDG-PET, 135P(ab)
Gastroesophageal reflux
 assessment of pediatric gastric emptying, right lateral and upright positioning, 1356
 gastric emptying studies in, 245P(ab)
Gastrointestinal adenocarcinomas, ¹²³I-VIP compared to ¹¹¹In-CYT-103 immunoscintigraphy, 1480
Gastrointestinal tract hemorrhage, ^{99m}Tc-RBC scintigraphy, clinical utility despite presence of barium, 643
Gated blood-pool scintigraphy, robust myocardial edge detection, left ventricular ejection fraction, 685
Gaucher's disease
 enzyme replacement therapy in, scintigraphic monitoring of, 297P(ab)
 lipid deposits in bone marrow, ^{99m}Tc sestamibi scintigraphy for evaluation, 297P(ab)
Gemcitabine, metabolic effects, prostate adenocarcinomas, rat, 265P(ab)
Gender differences
 alterations in gastric emptying and antral motility, dynamic antral scintigraphy, 244P(ab)
 in cerebral blood flow, role of cognitive state with PET, 559
 prognostic value of stress, ^{99m}Tc sestamibi SPECT, 14P(ab)
 serotonin synthesis, reduction in plasma tryptophan, 284P(ab)
 SPECT, evaluation of coronary artery disease in women, 182P(ab)
Gene expression
 imaging, living animals, PET reporter gene/reporter probe technology, 107P(ab)
 probe for, ¹⁸F fluoroacyclovir use in, 193P(ab)
Gene therapy
 cytosine deaminase acativity, in vitro studies using 5-fluorocytosine, 87
 evaluation, novel PET tracer for, 53P(ab)
HSV-TK, gamma camera imaging of, 53P(ab)
 imaging of viral infection and, synthesis of ¹⁸F FHPG synthesis, 193P(ab)
 metabolic effects, HSV thymidine kinase,
- hepatoma cells, 234P(ab)
 uptake of specific substrates, for HSV thymidine kinase, hepatoma cells, 235P(ab)
- Generator**
⁹⁰Y produced by, preparation of clinically useful radioconjugates, 195P(ab)
 radioisotope, based on microfiltration of ⁹⁰Y/⁸⁹Sr microfiltration, 194P(ab)
- Genetic risk**, assessment after ¹³¹I exposure, 612(ed)
- Geometric asymmetries**, in circular photomultipliers, PET block detector, 227P(ab)
- Gertsmann-Sträussler-Scheinker disease**, glucose metabolism in, PET study, 270P(ab)
- Glioblastoma**, transfection with CD gene, in vitro studies using 5-fluorocytosine, 87
- Glioblastoma multiforme**
¹⁸F BPA-F kinetics, PET, 279P(ab)
 boron neutron capture therapy in, PET determination of, 235P(ab)
- Glioma**
²⁰¹Tl scintigraphic localization, histological evaluation and proliferation markers, 265P(ab)
 delineation with ¹¹³C methionine PET, blood flow measurement and, 259P(ab)
 detection with ¹¹³C THY PET, 157P(ab)
FDG-PET in
 clinical grading scale, 263P(ab)
 local histology and prognostic value, 21P(ab)
 high-grade, high-dose focal radiotherapy, SPECT/CT-guided stereotactic biopsy after, 158P(ab)
 low-grade, presurgical speech-activated FDG-PET in, 270P(ab)
 malignant, therapy trial with ⁹T-biotin, 169P(ab)
 novel PET tracer for, evaluation of gene therapy, 53P(ab)
 proliferative capacity of, ²⁰¹Tl proliferating cell nuclear antigen and ⁶⁷Ki use in, 65P(ab)
 recurrent malignant, ²⁰¹Tl and ^{99m}Tc MIBI SPECT in, 260P(ab)
 recurrent, from radiation necrosis, FDG-PET in differentiation of, 157P(ab)
Glomerular filtration rate
⁵¹Cr EDTA estimation, comparison in clinical practice, 92P(ab)
 radionuclides in nephrology, Committee on Renal Clearance report, 1883
 use of single-sample adult technique in children, 1805
- Glucose**
 utilization, cerebral
 graphical analysis of FDG double injection, 223P(ab)
 quantitation in FDG-PET without blood sampling, 221P(ab)
- Glucose metabolic rate**, tumor, sarcoma, use of FDG in, 140P(ab)
- Glucose metabolism**
 Alzheimer's disease, dynamic FDG-PET, 201 and peptide T in AIDS dementia complex, FDG-PET, 1177
- cerebral
 aging effects, attention-deficit/hyperactivity disorder adults, 284P(ab)
 during REM sleep, depressed patients, 80P(ab)
 systemic lupus erythematosus, 21P(ab)
 uncoupling of, dementia, 275P(ab)
- detection of hexokinase activity in tumor cells, 192P(ab)
- Gertsmann-Sträussler-Scheinker disease**
 patients, PET study of, 270P(ab)
 individual tissues, quantitative FDG-PET imaging, 68P(ab)
- myocardial**, dichloracetate effects, 3P(ab)
 sensitivity of dynamic FDG-PET in Parkinson's disease, 1115
- simplified deoxyglucose utilization rate analysis, FDG-PET, 950
- skeletal muscle uptake of ¹⁸F-FDG, effect of oral diazepam, 1127
- Wortmannin effects on, FDG uptake measurement of, 94P(ab)
- Glucose transport**, Alzheimer's disease, dynamic FDG-PET, 201
- Glucose transport proteins**
 feasibility of targeting for tumor imaging, 1031
 targeting for tumor imaging, controversial issues, 1038(ed)
- Glucose uptake**
 by tongue and pharyngeal muscles, FDG-PET, 1918(ie)
 degree estimated by PET, stunned porcine myocardium, LV function, 2006
- Glucose-transporter 1 gene**
 FDG uptake and
 colon cancer, 248P(ab)
 pancreatic cancer, 248P(ab)
 histological differentiation in thyroid neoplasms, 248P(ab)
- Glucosylifosfamide**, biodistribution, prostate adeno carcinoma, 264P(ab)
- Glut**, facilitative and sodium dependent, mRNA expression in nude mice tumor xenografts, 254P(ab)
- Glut-1 expression**, distribution of tritiated-FDG in breast cancer, correlation to FDG uptake, 1042
- Glutathione**, regional localization in brain, use of ^{99m}Tc-meso-HMPAO as an imaging agent, 1698
- Glycemic control**, gastric emptying in patients with NIDDM, postprandial hunger, 1643
- Goiter**, differential diagnosis, 1745
- Government relations**, 16N(1), 20N(1), 34N(10), 44N(11), 24N(12)
 ACNP and SNM, endorsement of institute of medicine report, 18N(8)
- GP38**, quantitation of FBP in ovarian cancer, 665
- GPIIb/IIIa receptor**, use of ^{99m}Tc-P280 as thrombus imaging agent, 775
- Grade of differentiation**, relationship between Na-K ATPase staining and uptake ratios of ²⁰¹Tl SPECT, adenocarcinoma of lung, 955
- Granulocyte colony-stimulating factor**, thyrotoxicosis induced by contrast media, metastatic thyroid cancer, 1532
- Granulocytes**, pulmonary migration of, gram-negative sepsis, granulocyte-colony stimulating factor effects, 24P(ab)
- Graphical analysis**, cortical data, serotonin-2 receptor binding potential, PET, 95
- Graves' disease**
 effective half-life measurements of 131I, 228 rapid thyroid 131I turnover, hyperthyroidism, 1815
- Growth factors**, development of, diagnostic and therapeutic radiopharmaceuticals, 197P(ab)
- GSO**, scintillation detectors distributed on spheroid surfaces, PET brain imaging, 1219

Half-time hepatic excretion, extraction efficiency and excretion rate of 99m Tc-mebrofenin, hepatobiliary study in dogs, 1846

HAMA, *see* Human anti-mouse antibody

Head and neck cancer

- 111 Re-MAb conjugates for clinical radioimmunotherapy, 352
- chemotherapy response, evaluation with FDG-PET, 136P(ab)
- differentiation, SUV and time SUV curve on FDG-PET, 304P(ab)
- immunoresponse cell infiltration in, FDG uptake, 264P(ab)
- normal structures, FDG uptake, high resolution PET, 251P(ab)
- preoperative workup, FDG-PET value in, 136P(ab)
- squamous-cell carcinoma, detection of metastases with PET-TYR, MRI, and CT, 897
- squamous-cell, study of new tumor marker, CYFRA 21.1, 145P(ab)
- staging, whole-body PET-FDG imaging, 136P(ab)

Head and neck neoplasms, radiation treatment planning, 99m Tc-labeled monoclonal antibodies, SPECT, 1942

Health Care Financing Administration, physician guidelines, 24N(9)

Health Care Financing Administration (HCFA), proposed rule for 1997 physician fee schedule, Medicare, 29N(10)

Health insurance, portability bill, 29N(10)

Health Physics Society, position on low doses of radiation, 25N(7)

Heart

- adrenergic activity, arrhythmogenic right ventricular disease patients, 106P(ab)
- detection of myocardial metastasis of carcinoid tumor, 111 In-pentetrotide and fusion imaging, 1528
- failure, sympathetic activity after long-term overload, 160P(ab)
- imaging agent, 99m Tc Q compounds enhanced by ligandester groups, 188P(ab)
- oxidative metabolism, dual tracer autoradiographic measurement, 95P(ab)
- perfusion and metabolism studies, short-axis angle selection effects, 160P(ab)
- PET adrenoreceptor ligand, distributed nonlinear modeling of, 106P(ab)
- regional energy spectrum, in multispectral images, SPECT, 171P(ab)
- regional oxygen consumption 15 O kinetics, dog, 110P(ab) estimation by single-breath inhalation of 18 O, PET study, 146P(ab)
- respiratory motion in imaging, compensation for, 130P(ab)
- SPECT and PET, World Wide Web and virtual reality markup language extensions in, 172P(ab)
- transplantation. *see* Transplantation
- uptake and retention of MIBG, specific activity effects, 160P(ab)

Heart transplantation, evaluation of fatty acid metabolism and myocardial perfusion, dual-isotope study, explanted heart, 1990

Heat shock protein-70, imaging of, 99m Tc-labeled antisense probes, 96P(ab)

Heating techniques, 99m Tc sulfur colloids, lung uptake of, 197P(ab)

Helicobacter pylori

14 C breath samples, simple liquid scintillation counter for analyzing, 207P(ab)

diagnosis, 14 C urea breath test use in, 246P(ab)

gastritis, diagnosis with 14 C urea breath test, 114P(ab)

Helium-3

magnetic resonance imaging, human lungs, 296P(ab)

Hemangioma

hepatic, 99m Tc RBC imaging in, 114P(ab)

visualization on 111 In-octreotide scan, somatostatin receptors, Beckwith-Wiedemann syndrome, 1516

Hematologic disorder

evaluation of bone marrow status using 99m Tc-antigranulocyte antibody

scintigraphy, 978

Hematoporphyrin derivative

99m Tc-labeled, potential tumor imaging agent, 17P(ab)

Hematotoxicity, high-dose radioiodine therapy, advanced differentiated thyroid cancer, 131 I-NaI, 1496

Hemodialysis, plasma renin activity, active renin level changes and, 145P(ab)

Hemodynamics, indices of myocardial dysfunction, associated scintigraphy findings, 723

Heparanase, activity, correlation with bone scan findings, breast cancer patients, 127P(ab)

Hepatic cancer, 99m Y-lipiodol as potential therapeutic agent, 332

Hepatic extraction efficiency, 99m Tc-mebrofenin, hepatobiliary study in dogs, 1846

Hepatic infusion, use of 5'- 123 I-IUDR in treatment of colorectal cancer with liver metastases, 25S(4)

Hepatic metabolism, in vivo study of lipid metabolism with isomers of labeled fatty acid analogs, pPPA and oPPA, 1841

Hepatic receptor imaging

assessment of focal liver hyperplasia in Alagille syndrome, 1365

fulminant hepatitis monitored by 99m Tc-GSA, 641

Hepatobiliary imaging

assessment of focal liver hyperplasia in Alagille syndrome, 1365

extraction efficiency and excretion rate, 99m Tc-mebrofenin canine study, 1846

monitoring of graft and native liver functions post transplantation, 847

Hepatocellular carcinoma

angiotensin-II-induced hypertension

chemotherapy, PET imaging to measure hepatic blood flow, 1522

therapy management, FDG and 14 C ethanol PET, 68P(ab)

Hexokinase, activity, tumor malignancy relations, detection with glucose metabolism, 192P(ab)

High-resolution tomography, new approach for, 306P(ab)

High-dose iodine-131-sodium iodide therapy, advanced differentiated thyroid carcinoma, 1496

Hilar uptake, 67 Ga imaging, after CHOP chemotherapy, 140P(ab)

Hip prosthesis

orthopedic patient with polycystic kidney and liver disease, scintigraphic findings, 2062

loosening, diagnosed with nuclear arthrography, 62

Hodgkin's disease

pediatric, 203 Tl and 67 Ga comparison, 285P(ab)

whole-body PET-FDG staging of, 139P(ab)

Holmium-166 DOTMP, uptake, bone marrow ablation trial, 234P(ab)

HSV-tk, gene expression, gamma camera imaging with 131 I FIAU, 53P(ab)

Human anti-mouse antibody (HAMA), antibody responses to macrocyclic chelators, lymphoma, 451

Human breast tumor, 99m Tc-sestamibi uptake, correlation with multidrug resistance gene expression, 286

Human IgM, 111 In and 99m Y-labeled, intraperitoneal administration in mice with carcinomatosis, 1545

Human immunodeficiency virus

cerebral glucose metabolism in subjects with and without dementia, 1133

FDG-PET imaging of lymph nodes in, 162P(ab)

Hungry bone syndrome, increase in bone uptake following parathyroidectomy, bone scintigraphy, 1371

Hydrazinonicotinamide

99m Tc labeling of, optimization of mannitol formation, 143P(ab)

99m Tc-labeled, pyridinethiols and pyrimidinethiols asco-ligands for, 152P(ab)

Hydrocephalus, radionuclide shuntogram, shunt patency, 406

Hydronephrosis

diuresis renography

two-point postural drainage with, 46P(ab)

neonatal, cystographic investigation, 287P(ab)

Hydrostatic pulmonary edema, differentiating from ARDS, 67 Ga pulmonary leak index, 1316

Hydroxyamamide-based tetradeinate ligand, 99m Tc chelates with, HPLC analysis, 189P(ab)

Hyperbaric oxygen therapy, combined 111 I MIBG therapy, recurrent neuroblastoma, children, 287P(ab)

Hyperglycemia

chronic, tumor FDG uptake in, 253P(ab)

influence on interpretation of myocardial FDG-PET images, 1713

PET tumor tracers of, 64P(ab)

Hyperlipidemia, coronary flow reserve in, angiographically normal coronary arteries, 82P(ab)

Hyperparathyroidism

99m Tc-pertechnetate uptake by a parathyroid adenoma, 861

bone scintigraphy in hungry bone syndrome, brown tumor, 1371

FDG-PET and sestamibi-SPECT in recurrent postoperative parathyroid cancer, 2000

localization of mediastinal parathyroid adenoma, 1535

parathyroid 14 C-methionine accumulation, PET, 1766

parathyroidectomy guided by SPECT-MIBI and parathyroid measurements, 798

preoperative assessment with 99m Tc MIBI scintigraphy, 15P(ab)

Hypertension

determination of, correlation of slope of hepatic uptake of 99m Tc DISIDA, 245P(ab)

functional abnormalities in, gated SPECT, 115P(ab)

rapid gastric emptying in, postprandial glucose and insulin level relations, 247P(ab)

renovascular, diagnosis with captopril scintigraphy, 291P(ab)

spontaneous, 18 F FCAP assessment of ACE

- activity, rat, 118P(ab)
- Hyperthermic isolated limb perfusion**, evaluation of soft-tissue sarcoma with FDG-PET, 984
- Hyperthyroid**, ^{131}I uptake, stability of values, 805
- Hyperthyroidism**, ^{131}I treatment, effective half-life measurements, 228
- Plummer's disease, percutaneous ethanol injection or radioiodine therapy, 255P(ab)
- rapid thyroidal ^{131}I turnover, 1815
- Hypertrophic cardiomyopathy**, impaired fatty acid metabolism and dyskinesis in, ^{123}I -BMIPP, 1679
- primary metabolic impairment in, PET, 572
- Hypoxia**, in solid tumors, evaluation of ^{99m}Tc -labeled 2-nitroimidazole as a marker, 1023
- I**
- Image comparison**, data obtained at different times with different modalities, SPECT and PET, 137
- Image coregistration**, intra-study alignment effects, dynamic neuroreceptor ligand images, 220P(ab)
- multi-modal, using external fiducial markers, 219P(ab)
- PET-MRI, automatic and accurate method, 224P(ab)
- Image fusion**, ^{123}I MIBG, MRI and, integrated diagnosis of abdominal tumors, pediatric, 34P(ab)
- multimodality, automated system for, 125P(ab)
- Image processing technique**, calculation of amplitude images, gastric bleed sites, 246P(ab)
- Image quality**, decomposition of images, pinhole imaging system, 63P(ab)
- list-mode likelihood, 124P(ab)
- maximum-likelihood image reconstruction, from list-mode data, 124P(ab)
- Image reconstruction**, decreasing artifacts in SPECT, optimal number of views in 360-degree imaging, 1740
- Image registration**, automated algorithm for, brain SPECT, 98P(ab)
- automatic intensity scaling and, SPECT brain images, 213P(ab)
- median and phrenic nerve brain activation with ^{99m}Tc ECD SPECT and MRI, 8P(ab)
- automatic 3D, with nonframe-based headholder, PET and MRI, 303P(ab)
- dosimetry for intralesional radionuclide therapy, 228P(ab)
- interpretation of MRI and FDG-PET images, known or suspected brain tumors, 22P(ab)
- multimodality, automated system for, 125P(ab)
- Image resolution**, artifacts and, investigation in 3D PET, 73P(ab)
- Image segmentation**, multimodality, automated system for, 125P(ab)
- Imaging**, comparison of ^{123}I -VIP receptor scintigraphy and ^{111}In -CYT-103 immunoscintigraphy, localizing intestine adenocarcinomas and metastatic spread, 1480
- evaluation of the dopamine system of the human brain, PET, 1242
- resolution, quantitation of neuroreceptors, 1911(ie)
- Imunoconjugates**, two-step targeting, xenografted tumors, 203P(ab)
- Immunoglobulin**, imaging infection and inflammation with ^{99m}Tc -liposomes, Stealth, 1392
- Immunoreactivity**, prevention of radiolysis during labeling, monoclonal antibody protection, 1384
- Immunoscintigraphy**, ^{111}In CYT356, patterns of metastatic prostate cancer determined by, 10P(ab)
- ^{99m}Tc HIG, bone infection after orthopedic surgery and trauma, 127P(ab)
- ^{99m}Tc S12 Fab', localization of giant cellarteritis, 242P(ab)
- detection of brain abscess, 241P(ab)
- inflammatory bowel disease, monoclonal antibody against E-selectin, 114P(ab)
- monoclonal antibody BC-1, directed against oncofetal fibronectin, 238P(ab)
- three-step, evaluation of immunological response after, 238P(ab)
- tissue distribution of CD4 lymphocytes, 24P(ab)
- wide-spectrum, integrin as a target of, 200P(ab)
- Implanted ports**, injection of ^{89}Sr -chloride, 400(ie)
- Impotence**, pharmacologic treatment planning in, role of nuclear penogram, 288P(ab)
- In vivo imaging**, biochemical modification of streptavidin and avidin, 1380
- Indium-111**, incubation with In-111-octreotide, 2002 internalization of in human endocrine tumors, 2002
- lymphocyte scintigraphy, staging method for non-Hodgkin's lymphoma, 258P(ab)
- planar and SPECT imaging, quadruple energy window algorithm use in, 207P(ab)
- radiolabeled immunoglobulin therapy, intraperitoneal administration in rodents with peritoneal carcinomatosis, 1545
- radiolabeled liposomes for tumor imaging, 326
- role of ICAM-1 in inflammatory process, 656 versus ^{99m}Y , anti-tac monoclonal antibodies labeled with, biodistribution of, 234P(ab)
- Indium-111 biotin**, ^{99m}Y and, dual-isotope counting method, pretargeted cancer therapy, 144P(ab)
- Indium-111-colloid**, combined scintigraphy and radiology for detecting hip prosthesis loosening, 62
- Indium-111 DTPA**, polypeptides, hepatocyte metabolism of, 202P(ab)
- Indium-111-DTPA-D-Phe¹-octreotide**, systemic therapy in midgut carcinoid syndrome, 1519
- Indium-111 DTPA-estradiol**, evaluation, estrogen receptor-positive tumor, 264P(ab)
- Indium-111-DTPA-IgG**, biodistribution and dosimetry of ^{99m}Tc -HYNIC-IgG, comparisons, 843
- Indium-111 ICAM-1**, early detection of lung injury, 196P(ab)
- Indium-111 IgG**, comparison with ^{67}Ga scintigraphy, focal sites of infection and inflammation, 239P(ab)
- intraperitoneal retention of, peritonitis, different extent of fibrin formation, 2241P(ab)
- scintigraphic detection of inflammation and infection, ^{99m}Tc -Stealth-liposomes, 1392
- scintigraphy, evaluation of infections in the locomotor system, 128P(ab)
- Indium-111 KC-4G3**, EDTA effects on, prostate cancer patients, 198P(ab)
- Indium-111-leukocyte**, correlation with bone marrow scan in Paget's disease, 858
- Indium-111 NC-Z2D3**, imaging of proliferating smooth muscle cells, atherosclerotic lesions, 49P(ab)
- Indium-111-octreotide**, cost effective analysis of somatostatin receptor imaging, 886
- somatostatin receptor scintigraphy compared with conventional imaging in medullary thyroid cancer, 912
- Indium-111-oxinate-labeled granulocytes**, re-appraisal of quality control, ^{99m}Tc -HMPAO, 863
- Indium-111 pentetreotide**, axillary node imaging, breast cancer, 251P(ab) comparison
- ^{131}I MIBG, neuroblastoma patients, 34P(ab)
- comparison with ^{99m}Tc MDP, neuroblastoma patients, 34P(ab)
- detection of radiation pneumonitis, 584
- dynamic imaging in breast cancer, 622
- myocardial uptake in carcinoid syndrome, 275
- scintigraphy in children with neuroblast-derived tumors, 893
- somatostatin-receptor scintigraphy, metastasis from bronchial carcinoid, 1537
- SPECT accuracy of somatostatin receptor scintigraphy, abdominal carcinoid tumors, 1452
- tumor staging, neuro-endocrine and gastroenteropancreatic, 250P(ab)
- uptake
- benign hyperplasia, after chemotherapy for lymphoma, children, 256P(ab)
- growth hormone response and to octreotide and, in acromegaly, 159P(ab)
- uptake in endocrine tumors and lymphoma, 916
- visualization of myocardial metastasis, carcinoid heart disease, 1528
- Indium-111 platelets**, anti-platelet agent E5510effects, platelet deposition in atherosclerotic lesions, 242P(ab)
- Indium-111 polyclonal IgG**, comparison with ^{67}Ga scintigraphy, focal sites of infection and inflammation, 239P(ab)
- Indium-111 Stealth liposomes**, biodistribution and pharmacokinetics, solid tumors, 54P(ab)
- Indium-111 WBC**, scintigraphy, fever of unknown origin, 161P(ab)
- epiglottitis detected by ^{111}In -WBC scintigraphy, 76
- Indium-114m**, localization of radionuclides in testis, transferrin, 336
- Indomethacin**, ^{113}C -labeled, inflammation imaging, brain studies of cyclooxygenase, 192P(ab)
- Infection**, *E. coli*, pharmacokinetics of ^{18}F trovafloxacin, PET study of rabbits, 239P(ab)
- ^{99m}Tc leukotactic peptide, synthetic, 24P(ab)
- ^{99m}Tc -MIBI scintigraphy, pulmonary tuberculosis, 233
- ^{99m}Tc WBC imaging, comparison with ^{111}In WBC imaging, 204P(ab)
- bone, after orthopedic surgery and trauma, ^{99m}Tc HIG immunoscintigraphy in, 127P(ab)
- fever of unknown origin, ^{111}In WBC scintigraphy in, 161P(ab)
- locomotor system, evaluation with ^{111}In IgG scintigraphy, 128P(ab)
- osteomyelitis, localization with recombinant interleukin-8scintigraphy, 25P(ab)

- peritonitis, different extent of fibrin formation in, 1P retention of ^{111}In IgG, 224P(ab)
- platelet factor 4, ^{99m}Tc -P483H, 673
- prosthetic vascular graft, ^{99m}Tc HMPAO efficacy in, 163P(ab)
- radiodiagnostic agent for, ^{123}I IUDR role in, 187P(ab)
- scintigraphic detection of inflammation, ^{99m}Tc -labeled Stealth liposomes, 1392
- scintigraphic findings in orthopedic patient with polycystic kidney and liver disease, 2062
- use of streptavidin and labeled biotin in pretargeting approach, osteomyelitis, 1655
- viral, imaging of, synthesis of ^{18}F FHPG synthesis, 193P(ab)
- Inflammation**, scintigraphic detection of infectious process, ^{99m}Tc -labeled Stealth liposomes, 1392
- Inflammation imaging**
- ^{111}In in polyclonal IgG, comparison with ^{67}Ga scintigraphy, 239P(ab)
 - ^{99m}Tc HMPAO labeled white blood cell scans, detection of appendicitis in women, 241P(ab)
 - arthritis, ^{111}In anti-E-selectin monoclonal antibody, 128P(ab)
- Inflammatory bowel disease**
- immunolocalization of, monoclonal antibody against E-selectin, 114P(ab)
 - leukocyte scintigraphy to assess disease activity, 400(e)
 - pediatric, assessment with ^{99m}Tc HMPAO labeled with leukocytes, 287P(ab)
- Inflammatory diseases**, imaging with ^{99m}Tc -SSEA-1, neutrophils, 1789
- Information superhighway**, contacting specialists via the information superhighway, Newsbriefs, 24N(1)
- Inhalation injury**, detection by ^{99m}Tc DTPA radioaerosol, lung scintigraphy, 294P(ab)
- Institute of Medicine**
- IOM study supports state, not NRC, regulation of medical isotopes, 23N(2)
 - recommendations met with mixed reviews, 28N(6)
- Insular carcinoma**, comparative radionuclide imaging, ^{99m}Tc -(V)DMSA, 78
- Insular thyroid carcinoma**, bone marrow metastases detected by ^{131}I whole-body scintigraphy, 633
- Insulin resistance**, myocardial, coronary atherosclerosis and, 38P(ab)
- Integrin**, potential as a target, wide-spectrum immunoscintigraphy, 200P(ab)
- Intercellular adhesion molecule-1**, biodistribution of ^{111}In -labeled antibody, early detection of inflammation, 656
- Interferon- α -2b**, tumor uptake of radiolabeled monoclonal antibodies and, 151P(ab)
- Interleukin**, localization of infection, osteomyelitis, 25P(ab)
- Intermodality registration**, automated image technique for SPECT and PET, 137
- Internal dosimetry**
- ^{99m}Tc -DMSA in children, effective dose equivalent, 1336
 - revised anthropomorphic model of the adult head and brain, 1226
- Internet**
- case-based teaching files, 178
 - nuclear medicine review manual on, 304P(ab)
 - World Wide Web, physical evaluation of collimators, 305P(ab)
- Interventricular septum**, ^{123}I -MIBG imaging, evaluation of sympathetic nervous system in pulmonary hypertension, 1343
- Intestinal lymphangiectasia**, intestinal leakage of ^{99m}Tc -MDP, unexpected during bone scintigraphy, 639
- Intestine**, chronic inflammation, accumulation of ^{99m}Tc chemotactic peptides in, 239P(ab)
- Intra-arterial infusion**, tumor targeting with $5\text{-}^{123}\text{I}$ -IUDR in patients with liver metastases from colorectal cancer, 22S(4)
- Intraoperative detection**
- differentiated thyroid cancer, use of ^{131}I in, 52P(ab)
 - ion-implanted-silicon detector based probe, detection of beta emitters, 52P(ab)
- Intraoral squamous-cell carcinoma**, bone SPECT assessment of mandibular invasion, 42
- Intrapерitoneal administration**, ^{111}In and ^{90}Y -labeled human IgM, mice bearing carcinomatosis, 1545
- Intratumoral delivery**, ultrasound-guided radiotherapy with ^{90}Y -glass microspheres, liver cancer, 958
- Intratumoral injection**, brain tumor administration of $5\text{-}^{123}\text{I}$ -IUDR, 19S(4)
- Intravesical instillation**, locoregional administration of $5\text{-}^{123}\text{I}$ -IUDR in bladder cancer, 16S(4)
- Inulin**, measurement of solute distribution, in extracellular fluid, 91P(ab)
- Iodination**, monoclonal antibody, for ovarian cancer, 142P(ab)
- Iodine-120 MIBG**, production and labeling, newPET radiotracer, 191P(ab)
- Iodine-123**
- diagnostic accuracy, differentiated thyroid cancer, 236P(ab)
 - evaluation of thyroid cancer, comparison with ^{99m}Tc sestamibi
 - PK11195 labeled with, high affinity ligand for PET and SPECT, 6P(ab)
 - safety evaluation of radiolabeled IUDR, 13S(4)
 - sodium iodide capsules, thyroid uptake and dissolution, 197P(ab)
 - SPECT studies, serotonin transporter, 186P(ab)
 - uptake, stability of values over years, 805
- Iodine-123 β -CIT**
- aging effects with, 272P(ab)
 - binding, with clomipramine, striatum, serotonin dopamine interaction, 66P(ab)
 - calculation of measures of dopamine transporters, SPECT, 222
 - SPECT imaging of dopamine transporters, 1129
- Iodine-123 AM251**, binding to cannabinoid receptors, brain, mouse, 187P(ab)
- Iodine-123 BMIPP**
- ECG-gated SPECT, myocardial, ischemic heart disease patients, 304P(ab)
 - evaluation of myocardial viability in canines, 1403
 - fatty acid uptake in ischemic heart disease, patients without prior MI, 1981
 - focal accumulation in liposarcoma of the thigh, 997
 - heart uptake, rats, 6P(ab)
 - left ventricular hypertrophy, disturbed myocardial fatty acid metabolism in, 184P(ab)
 - metabolic imaging in hypertrophic cardiomyopathy, impaired fatty acid metabolism and dyskinesis, 1679
 - metabolism and kinetics of, in canine myocardium, 757
- metabolism, reflection of possible ischemia, 95P(ab)
- myocardial uptake, abnormal metabolic switching, fasting condition, 175P(ab)
- single injection, evaluation of myocardial perfusion and fatty acid metabolism, 185P(ab)
- uptake and washout kinetics, rat hearts, 94P(ab)
- Iodine-123 BMIPPA**, ^{18}F FDG comparison, uptake in ischemic heart disease, 184P(ab)
- Iodine-123 fatty acid**, evaluation of fatty acid metabolism and coronary perfusion, dual-isotope study during cardiac transplantation, 1990
- Iodine-123 FP-CIT**, evaluation of dopamine transporter system, 65P(ab)
- Iodine-123-5-iodo-6-nitroquipazine**, use as tracer for *in vivo* study of serotonergic neurons, SPECT, 1207
- Iodine-123-HuM195**, bone marrow dosimetry, regional variability, 695
- Iodine-123 IBZM**, SPECT, asymmetric nigrostriatal dopaminergic function in sleep bruxism, 271P(ab)
- Iodine-123 IDAB**, scintigraphy, visualization of ocular malignant melanoma, 268P(ab)
- Iodine-123-lodo-lisuride**, imaging striatal dopamine D2 receptors in parkinson's disease, 22
- Iodine-123-iodobenzamides**, tracers for the detection of melanotic melanoma, 1865
- Iodine-123-iodobenzamine**, binding in Parkinson's disease, treatment with dopamine agonists, 1112
- Iodine-123-lomazenil**, quantitative assessment of benzodiazepine receptors, SPECT, 374
- Iodine-123 IMP**
- autoradiography, regional cerebral blood flow measurement, scatter compensation for, 276P(ab)
 - CBF with, prediction of cerebral infarction after subarachnoid hemorrhage, 12P(ab)
 - hepatic distribution of blood flow, portal streamlining, scintigraphy, 51
- Iodine-123 IMT**, SPECT, evaluation of brain tumors, 157P(ab)
- Iodine-123 IMZ**
- benzodiazepine receptor distribution, chronic cerebrovascular disease, evaluation of neuronal cell loss, 133P(ab)
 - receptor imaging, as a measure of neuronal loss in Alzheimer's disease, 164P(ab)
- SPECT**
- ischemic cerebrovascular disease, 12P(ab)
 - presurgical localization of foci, temporal lobe epilepsy, 101P(ab)
- Iodine-123 interferon gamma**, inhalation scintigraphy, 5P(ab)
- Iodine-123 IPPA**
- ^{99m}Tc sestamibi comparison, myocardial perfusion imaging in coronary patients, 37P(ab)
 - myocardial viability assessment, observer variability, 184P(ab)
- SPECT**
- fasting and nonfasting, detection of myocardial viability, 150P(ab)
 - prediction of left ventricular function after coronary revascularization, 37P(ab)
- Iodine-123-IPT**, SPECT imaging of CNS dopamine transporters, effects of aging on striatal uptake values, 1965
- Iodine-123-IQNB**, improved method for radioiodination of, 2021

- Iodine-123 IUDR**
applying in vitro results to in vivo strategies, cancer therapy, 6S(4)
intratumoral administration in a patient with a brain tumor, 19S(4)
radiodiagnostic agent for infection, 187P(ab)
tumor targeting by intra-arterial infusion, liver metastases from colorectal cancer, 22S(4)
tumor therapy and diagnosis, preclinical studies, 10S(4)
- Iodine-123 MIBG**
¹³¹I MIBG and, neuroblastoma, children, 35P(ab)
abnormal myocardial images in healthy subjects, 1686
assessment of cardiac denervation, diabetic patients, 150P(ab)
cardiac imaging in patients with right heart overload, 1343
cerebral hypoperfusion in orthostatic hypotension, denervated heart, 1824
comparison to ¹³¹I MIBG, diagnosis of endocrine tumors, 243P(ab)
dosimetry in cancer therapy, risk versus benefits, 1058
effects of excessive catecholamines on heart and lungs, pheochromocytoma-induced cardiomyopathy and pulmonary edema, 1361
estimation of β -blockade therapy, dilated cardiomyopathy therapy, 183P(ab)
hepatic accumulation, neuroblastomas, PET scanning, 16
innervation and perfusion mismatch, postoperative tachyarrhythmia in coronary disease patients, 184P(ab)
long-term cardiac overload, sympathetic hyperactivity after, 160P(ab)
MRI and image fusion with, integrated diagnosis of abdominal tumors, pediatric, 34P(ab)
myocardial images, dilated cardiomyopathy patients after beta-blocking therapy, 3P(ab)
myocardial uptake and distribution, long QT syndrome patients, 37P(ab)
regional abnormality in diabetic hearts, autonomic neuropathy and cardiac denervation, 1985
scintigraphy, urinary screening, and histopathology of hormonally active carcinoid tumor, 270
utility of SPECT and delayed imaging in neuroblastoma, 1464
- Iodine-123 NNC 13—8241**, SPECT, visualization of benzodiazepine receptors, 76P(ab)
- Iodine-123-OIH**, exercise renography in untreated hypertension, 838
- Iodine-123 PHIPA 3—10**, long chain fatty acid, metabolically trapped, 49P(ab)
- Iodine-123 QNB**, SPECT, muscarinic receptors, 143P(ab)
- Iodine-123-tropane**, use as imaging agent, presynaptic dopamine transporters, 151
- Iodine-123 VIP**, receptor scanning, adenocarcinomas and endocrine tumors, gastrointestinal tract, 20P(ab)
- Iodine-124**, PET
- Iodine-124 IUDR**, imaging of tumor proliferation, 54P(ab)
- Iodine-125**
auger-electron emitting, positional changes, strand breaks on plasmid DNA after, 102P(ab)
localization of radionuclides in testis, transferrin, 336
safety evaluation of radiolabeled IUDR, 13S(4)
- Iodine-125 β -CIT**, binding, L-DOPA comparison, Parkinson's disease models, 66P(ab)
- Iodine-125 IMZ**, SPECT, focal cerebral ischemia, rats, 282P(ab)
- Iodine-125 Iododeoxyuridine**, antibody conjugates, preparation of, 196P(ab)
- Iodine-125 oligodeoxyribonucleotides**, radiotoxicity of, mammalian cells, 228P(ab)
- Iodine-125-IACFT**, preparation and biological evaluation of, SPECT agent for imaging dopamine transporter sites, 1197
- Iodine-125-IUDR**
applying in vitro results to in vivo strategies, cancer therapy, 6S(4)
intravesical infusion in patients with bladder cancer, 16S(4)
tumor therapy, preclinical animal studies, 10S(4)
- Iodine-125-MIBG**, discrepancy in dual-tracer autoradiography, comparisons with ²⁰¹Tl in experimental myocardial infarctions, 680
- Iodine-125-MIBT vesamicol receptor**, effect of aging on vesicular acetylcholine storage and release, 1192
- Iodine-131**
biological dosimetry thyroid carcinoma, risk due to exposure, 1860 concentration by the thymus, thyroid cancer, 1830 diagnostic accuracy, differentiated thyroid cancer, 236P(ab) distributions, brain tumor phantoms with pinhole SPECT, 212P(ab) dosimetry, radiation dose to spinal cord, 90P(ab) dual-energy-window acquisition mode, deadline, 78P(ab) effective half-life measurements in treatment of hyperthyroidism, 228 exposure to, pregnancy outcome in thyroid cancer patients, 606 false-positive whole-body scans in patients with thyroid cancer, cholecystitis and sebaceous cyst, 1690 high doses, parenchymal damage after, salivary gland scintigraphy in diagnosis of, 246P(ab) energy-based scatter corrections for scintillation camera techniques, window-based and spectrum-fitting methods, 2030 irradiation of, radiation dosimetry, 305P(ab) kinetics, scanning in thyroid cancer patients, 15P(ab) mononuclear blood cells with, synthesis of DNA-protective proteins, 233P(ab) outpatient therapy, thyroid diseases, NRC regulations, 243P(ab) prediction of radiation doses from therapy using tracer studies, labeled antibodies, 1970 scintigraphy compared to ²⁰¹Tl whole-body scans in differentiated thyroid cancer, concordance and discordance rates, 1487 therapy thymic uptake in the anterior mediastinum, 991 thyroid cancer, radiotoxicity after, micronucleus assay, 101P(ab) treatment absorbed dose to salivary glands in thyroid patients, 102P(ab) thyroid cancer in children and adolescents, 236P(ab)
- treatment of metastatic thyroid cancer, 598 treatment planning, based on radiation absorbed dose or patient size, 43P(ab) whole-body scanning in combination with ¹⁸F-FDG whole-body PET, thyroid cancer, 1468 whole-body scintigraphy in detection of marrow metastases, 633 whole-body scintigraphy, detection of recurrence or metastasis in differentiated thyroid carcinoma, 446
- Iodine-131 BZM**, melanoma imaging, 6P(ab)
- Iodine-131 exposure**, genetic risk assessment, 612(ed)
- Iodine-131 IdUMP**, preliminary SPECT study, tumor imaging in lung cancer patients, 248P(ab)
- Iodine-131 IETNIM**, as a marker for tumor hypoxia, predictor for radiosensitizing effect and, 253P(ab)
- Iodine-131 MIBG**
chemotherapy combined with, stage 4 neuroblastoma treatment, 237P(ab) comparison to ¹²³I MIBG, diagnosis of endocrine tumors, 243P(ab) high-dose therapy malignant pheochromocytoma patients, 237P(ab) metastatic carcinoid tumor patients, 237P(ab) neuroblastoma, survival after, 237P(ab) hyperbaric oxygen therapy combined with, recurrent neuroblastoma, children, 287P(ab) neuroblastoma followup, 34P(ab) scintigraphy in children with neuroblast-derived tumors, role of ¹¹¹In-pentetetotide, 893
- Iodine-131 sodium iodide**
¹²³I comparison, total body scan, thyroid cancer, 251P(ab), 301P(ab) radiation dose safety concerns with dialysis, 229P(ab) trachea, 228P(ab)
- Iododemercuration**, kit preparation of IUDR by demetallation, 1S(4)
- Iododeoxyuridine**
¹²⁴I-labeled, imaging of tumor proliferation, 54P(ab) antibody conjugates, preparation of, 196P(ab) auger electron emitter labeled, safety evaluation, 13S(4) cell kinetic measurements with, primary rectal cancer, 54P(ab) preparation by demetallation, kit formulation, 1S(4) treatment of colorectal cancer with liver metastases hepatic artery infusion, 25S(4) treatment of colorectal cancer with liver metastases, pharmacokinetics and dosimetry, 29S(4)
- Iododestannylation**, kit preparation of IUDR by demetallation, 1S(4)
- Iodohippuric acid**, metabolism, lysosomes, diagnostic and therapeutic purposes, 7P(ab)
- Iohexol**, contrast nephrotoxicity, renal scintigraphy, vascular occlusion versus ATN, 1828
- IQNP**
isomers of, stereochemistry, 186P(ab) Z-(R, R)-, imaging of muscarinic receptors, brain and heart, 202P(ab)
- Iron metabolism**, role in cell proliferation, ¹⁸F-labeled transferrin, 1408
- Iron-52 transferrin**, whole-body imaging with,

- PET scanner comparison with dual-headed gamma camera, 148P(ab)
- Iron-59**, localization of radionuclides in testis, transferrin, 336
- Ischemia**
- detection of ^{99m}Tc-nitroimidazole in myocardial tissue, 761
 - experimental, reperfusion damage and, evaluation with ^{99m}Tc glucarate and PYP, 119P(ab)
 - visualization of insult in caudate putamen, ¹²³I- β -CIT, 1214
- Isotopes**
- commercial production of, 21N(11)
 - production, transition metal analysis, 195P(ab)
- J**
- Janus**, origin of, 1272(ie)
- Jugular venous reflux**, superior vena cava syndrome, diagnosis and functional assessment with radionuclide venography, 1460
- K**
- Kalman filter**, 3D, enhancement of SPECT images, brain, 208P(ab)
- Kidney**
- ^{99m}Tc DMSA, tissue and cellular distribution, rat, 231P(ab)
 - cancer, correlation with histopathological data with FDG-PET imaging, 64P(ab)
 - chronic dialysis, effects on bone mineral density, 104P(ab)
 - extraction, ^{99m}Tc, role of protein binding in, 47P(ab)
 - function
 - complete dynamic scan data for camera-based determination, 91P(ab)
 - radiopharmaceuticals for evaluation, 17P(ab)
 - functional mass, renal scarring effects on, 290P(ab)
 - functional response, acetylcholine inhibition, scleroderma patients, 290P(ab)
 - intermittent hydronephrosis, modified lasix renogram, children, 23P(ab)
 - measuring function of, in children and adults, ^{99m}Tc-MAG3, 588
 - normal function, clearance of ^{99m}Tc MAG3, 293P(ab)
 - obstruction, diuretic MAG₃ scintigraphy in, 289P(ab)
 - plasma flow and glomerular filtration rate, simultaneous estimation with ^{99m}Tc EC, 91P(ab)
 - region of interest, renal uptake of ^{99m}TcMAG3, 293P(ab)
 - split function, calculation with ^{99m}TcMAG3, using patlak plot, 307P(ab)
- Kinetic modeling**
- ¹³C alpha-methyl-tryptophan, estimation of serotonin synthesis rate, brain, 145P(ab)
 - ¹³C MDL 100907, suitability as a serotonin radiotracer, baboon, 145P(ab)
 - ¹³C raclopride binding potential, estimation of, 280P(ab)
 - analysis of ¹³C-iomazenil binding, PET, 699
 - automatic preparation of radiopharmacokinetic data, ^{99m}Tc-NGA, 1896
 - dipyridamole-induced stress, ⁸⁹Rb PET studies, anesthetized canine, 146P(ab)
 - generation of parametric images, artificial neural networks, 220P(ab)
 - new muscarinic cholinergic ligand, PET, 10P(ab)
 - receptor concentration, dynamic PET data, 146P(ab)
 - tracer, effect of increased vascularity, 207P(ab)
- Kinetic rate constants**
- Alzheimer's disease, dynamic FDG-PET, 201
 - dynamic FDG-PET studies in Parkinson's disease, 1115
- Knee SPECT**, bone scintigraphy of anterior cruciate ligament injury, ^{99m}Tc-MDP, 1353
- Koposi sarcoma**, sequential thallium and gallium chest scans, differentiating from lymphoma and opportunistic infections, AIDS, 1662
- Krohn, Kenneth**, Aebersold Award, 22N(9)
- Krypton-81m**, determining regional pulmonary abnormalities in patients on mechanical ventilators, 239
- L**
- L-1-[¹⁴C]-tyrosine**, PET evaluation of squamous cell carcinoma metastases, comparisons with other methods of assessment, 897
- L-Arginine**, platelet thrombus reduction by, during cardiopulmonary bypass, pig model, 240P(ab)
- L-Dopa**, ¹²³I-IBZM binding in Parkinson's disease, reduction by dopamine agonists, 1112
- Labeled fatty acids**, lipid metabolism in the liver, pPPA and oPPA, 1841
- Labeling damage**, monoclonal antibody loss of immunoreactivity, prevention of, 1384
- Lag phase**, quantification for solid gastric emptying studies, 1639
- Langerhans' cell histiocytosis**, role of bone scintigraphy in diagnosing and staging, 1456
- Language processing**, ^{99m}Tc ECD SPECT study of, 280P(ab)
- Laryngeal muscles**, speech-related visualization of, ¹⁸F-FDG-PET, 1771
- Larynx**, uptake of ¹⁸F FDG by muscles, speech and, 282P(ab)
- Learning disability**, abnormal cerebral glucose metabolism and, children, PET study of, 286P(ab)
- Left bundle branch block**, septal metabolic mismatch, 1918(ie)
- Left ventricular ejection fraction**, edge detection method for gated radionuclide ventriculograms, 685
- Left ventricular function**
- ambulatory assessment, during exercise, idiopathic cardiomyopathy, 181P(ab)
 - ambulatory monitoring, amlodipine effects on myocardial ischemia, angina patients, 59P(ab)
 - assessment of volume, ECG-gated SPECT with ^{99m}Tc MIBI and tetrofosmin, 180P(ab)
 - automated assessment by blood pool imaging, versus gated MRI, 218P(ab)
 - automated ejection fraction calculation, gated perfusion tomography, 213P(ab)
 - chronic ischemic, ^{99m}Tl reinjection after exercise-redistribution imaging, 13P(ab)
 - end-diastolic volume, relation to outcome in arrhythmia patients, 149P(ab)
 - evaluation, ^{99m}Tc sestamibi, comparison with contrast ventriculography, 104P(ab), 105P(ab)
- hypertrophy**
- coronary artery disease and, radionuclide ventriculography and SPECT, 93P(ab)
 - coronary artery disease with, myocardial perfusion SPECT for, 182P(ab)
 - disturbed myocardial fatty acid metabolism in, 184P(ab)
- myocardial perfusion and, automated method for assessment**, 179P(ab)
- normal limits, from myocardial perfusion imaging, 105P(ab)
- perioperative cardiac events, risk stratification of, gated SPECT, 116P(ab)
- planar and SPECT blood-pool studies, ejection fraction, 1795
- quantification, both ²⁰¹Tl and ^{99m}Tc sestamibi gated SPECT, 104P(ab)
- wall motion, severe coronary artery disease, rest motion analysis in gated SPECT, 115P(ab)
- Lesch Nyhan disease**, low dopamine activity in, PET study, 45P(ab)
- Leukemia**
- acute, bone marrow transplant, ¹³¹I anti-CD45 antibody regimen prior to, 233P(ab)
 - regional dose variability of bone marrow-localizing antibody, 695
- Leukocytes**
- ^{99m}Tc HMPAO labeled with, pediatric patients with inflammatory bowel disease, 287P(ab)
 - ^{99m}Tc HMPAO scans, detection of appendicitis in women, 241P(ab)
 - ^{99m}Tc-P483H, developed from platelet factor 4 to detect infection, 673
 - labeled scintigraphy, evaluation of Charcot joint, 241P(ab)
 - labeling agent for, ^{99m}Tc phenylene imine phenol in, 188P(ab)
 - radiolabeling of
 - absence of plasma and erythrocytes, 84P(ab)
 - stabilized ^{99m}Tc HMPAO use in, 84P(ab)
- Levodopa**, effects on putamenal-dopa-decarboxylase activity, Parkinson's disease, 55P(ab)
- Ligand tracer**, binding, anesthesia effects, mouse brain, 279P(ab)
- Limb salvage surgery**, homograft scintigraphy in, pediatric, 286P(ab)
- Limbic system**, hypoperfusion in psychiatric illness, SPECT, 410
- Lipid metabolism**
- assessment of myocardial viability, ¹²³I-BMIPP imaging in canine model, 1403
 - in vivo study with isomers of labeled fatty acid analogs, pPPA and oPPA, hepatic metabolism, 1841
- Lipliodol**, labeled for hepatic artery injection, biodistribution in rats with hepatoma, 332
- Lipophilicity**, correlation with reaction volume, in vivo ligand-receptor model, PET, 118
- Liposarcoma**, focal accumulation of ¹²³I-BMIPP, thigh, 997
- Liposome**, radiolabeled for optimal tumor imaging, 326
- Liposomes**
- ¹¹¹In-labeled, biodistribution and pharmacokinetics, solid tumors, 54P(ab)
 - ^{99m}Tc-labeling, blood pool agents, 1374
- Liver**
- blood flow. *see also* Blood flow, liver
 - colorectal cancer, chemoembolization in, FDG-PET, 132P(ab)
 - function, ¹³C aminopyrine breath test, 114P(ab)

- hypoxia, imaging with ^{18}F misonidazole PET, 200P(ab)
 lobular dynamics, blood pool changes in response to vasoactive drugs, 244P(ab)
 metastases
 discordance between FDG-PET and MRI scans, pre and post therapy, 253P(ab)
 FDG-PET imaging of, 250P(ab)
 tracers used to assess protein synthesis, PET, 279
 experimental studies with ^{18}O and PET, 147P(ab)
 measurement, ^{18}O water and PET, dogs, 244P(ab)
Liver cyst, febrile patient with polycystic kidney and liver disease and hip prostheses, 2062
Liver malignancy, ultrasound-guided internal radiotherapy using ^{90}Y -glass microspheres, 958
Liver metastases, tumor targeting by intra-arterial infusion of $^{5-123}\text{I}$ -IUDR, colorectal cancer, 22S(4)
Liver perfusion scintigraphy, transjugularintrahepatic portosystemic shunts, compared with surgical shunts, in hypertension, 243P(ab)
Liver tumors, new treatment approaches, 963(ed)
Liver-heart artifact, early and delayed myocardial SPECT imaging, ^{99m}Tc -tetrofosmin, 1622
Lobar, collapsed left lower lung, differential diagnosis of stripe sign in perfusion scan, emphysema, 1682
Localization
 glutathione in brain, use of ^{99m}Tc -*meso*-HMPAO as an imaging agent, 1698
 pattern of ictal perfusion in seizures originating in the posterolateral cortex, SPECT, 1946
Locoregional administration
 auger emitters, ^{123}I -IUDR and ^{123}I -IUDR, preclinical animal cancer studies, 10S(4)
 intra-arterial infusion of $5-123\text{I}$ -IUDR in patients with liver metastases from colorectal cancer, 22S(4)
 intravesical infusion of $5-123\text{I}$ -IUDR in patients with bladder cancer, 16S(4)
Lorazepam
 regional brain metabolic responses to, reproducibility for, 76P(ab)
 reproducibility of regional brain metabolic changes, 1609
Lossy compression, effect on parameter estimation, PET, 125P(ab)
Lung
 concomitant lung and gastric uptake in bone scintigraphy, sarcoidosis, 1530
 disease, ^{18}FDG imaging of, 36P(ab)
 endobronchial stent implantation, by V/Q scanning, quantification of, 36P(ab)
 low probability scans, review of six-month mortality in, 117P(ab)
 nodules
 ^{99m}Tc sestamibi to distinguish malignant from benign, 35P(ab)
 ^{99m}Tc tetrofosmin utility in, 111P(ab)
 FDG-SPECT diagnosis of, 36P(ab)
 solitary, FDG-PET, cost-effectiveness of, 110P(ab), 111P(ab)
 pulmonary angiograms with and without scans, comparison of lung scan criteria and, 118P(ab)
 respiratory gated FDG-PET, thoracic and upper abdominal tumor imaging, 36P(ab)
 scans, pulmonary embolism, pattern recognition
- systems with synthetic discriminant function, 124P(ab)
 scintigraphy
 guidelines for pulmonary embolism, 1906
 detection of superior vena cava clot, collateral flow to liver, 1826
 severe trauma, accumulation of ^{99m}Tc chemotactic peptides in, 240P(ab)
 ventilation
 dynamic pulmonary SPECT, 133Xe washout, 807
 incidence of abnormalities in cirrhosis, 437
- Lung cancer**
 ^{99m}Tc MIBI imaging, CT and FDG-PET comparison, 260P(ab)
 assessment of mediastinal involvement with ^{99m}Tc -sestamibi SPECT, 938
 cytotoxic therapy, evaluation with ^{113}C tyrosine PET, 265P(ab)
 differentiating benign from malignant lesions, FDG-PET, 121P(ab), 122P(ab)
 FDG-PET, simplified deoxyglucose utilization rate analysis, 950
 hilar and mediastinal lymph node metastases in, ^{99m}Tc MIBI evaluation, 263P(ab)
 mediastinal lymph node metastases and, FDG-PET in the detection of, 122P(ab)
 mediastinal staging, FDG-PET, 121P(ab)
 non-small cell
 ^{18}F FDG-PET staging of, 259P(ab)
 FDG uptake with proliferating cell nuclear antigen, Ki-67 and DNA ploidy pattern, 64P(ab)
 nodal staging with FDG-PET and CT, 121P(ab)
 preoperative nodal staging and detection with FDG-PET, 249P(ab)
 staging, PET and CT comparison, 260P(ab)
 nuclear medicine use in studies, simulation tool for modeling cost effectiveness, 301P(ab)
 patient management with whole-body FDG-PET, 121P(ab)
 primary
 ^{99m}Tc tetrofosmin SPECT in, 264P(ab)
 detection with ^{99m}Tc tetrofosmin, 35P(ab)
 primary and metastatic, ^{201}Tl and ^{99m}Tc MIBI SPECT of, 296P(ab)
 sequential follow-up PET FDG scanning, after radiation treatment, 261P(ab)
 small cell
 chemotherapy, ^{99m}Tc sestamibi as predictor of response, 67P(ab)
 iodinated bombesin analogues, 185P(ab)
 metastases and, somatostatin receptor scintigraphy in diagnosis, 20P(ab)
 solitary lesion
 ^{201}Tl SPECT differentiation of benign and malignant, 268P(ab)
 ^{99m}Tc MIBI, ^{99m}Tc DMSA and ^{201}Tl comparison, 268P(ab)
 staging, CT and FDG-PET scans for, 249P(ab)
 SUV-lean and Glut-1 expression, FDG-PET, 65P(ab)
 tumor imaging, preliminary SPECT study of I^d UMP, 248P(ab)
- Lung uptake**, ^{99m}Tc -MDP bone scan in Wegener's vasculitis, 857
Lung uptake assessment, ^{113}In -pentetreotide, detection of radiation pneumonitis, 584
Lutetium-177, reactor production of, cancer therapy, 166P(ab)
Lutetium-177-CC49, intraperitoneal radioimmunotherapy of ovarian cancer, 1491
Lyme disease, perfusion abnormalities in, ^{99m}Tc HMPAO brain SPECT detection of, 270P(ab)
Lymph node
 FDG-PET imaging, in HIV patients, 162P(ab)
 involvement in the porta hepatis, papillary thyroid cancer, 993
 tumor-involved, size limitations in detection of 2D and 3D PET, 98P(ab)
 uptake of ^{99m}Tc -sestamibi, breast tumors, 922
 visualization in elbow region, 1913(ie)
Lymphangioscintigraphy, transport index in, evaluation of peripheral lymphedema, 183P(ab)
Lymphedema
 peripheral, evaluation using a transport index, lymphangi scintigraphy, 183P(ab)
 upper extremity, classification via lymphoscintigraphy, 261P(ab)
Lymphoceles, ^{99m}Tc -albumin colloid lymphoscintigraphy, evaluation of limb edema, 1517
Lymphocytes
 CD4, tissue distribution, determination with immunoscintigraphy, 24P(ab)
 labeling, damages induced by ^{99m}Tc HMPAO, 101P(ab)
Lymphoma
 ^{111}In -pentetreotide, endocrine tumors, 916
 ^{67}Ga hydroxaryl derivatives, agents for diagnosis, 196P(ab)
 after chemotherapy, prediction of response by ^{67}Ga scintigraphy, 139P(ab)
 antibody responses to macrocycles, 451
 B-cell, enhanced retention of radionuclides by, ^{99m}Y -labeled monoclonal antibody, 151P(ab)
 BCL1, radioimmunotherapy with bispecific antibodies and ^{131}I -labeled bivalent haptens, 129P(ab)
 brain, AIDS patients, ^{201}Tl SPECT detection of, 258P(ab)
 comparison of ^{201}Tl and ^{67}Ga scintigraphy, 46
 FDG-PET for management of, 139P(ab)
 malignant
 somatostatin receptor and ^{67}Ga scintigraphy comparison, 268P(ab)
 whole-body FDG-PET in detection of extent of, 262P(ab)
 non-Hodgkin's
 FDG-PET parameters for monitoring of, 138P(ab)
 hilar uptake on ^{67}Ga citrate after CHOP chemotherapy, 140P(ab)
 low grade, ^{201}Tl scintigraphy in, 258P(ab)
 somatostatin receptor scintigraphy in staging of, 19P(ab)
 stage with ^{113}In lymphocyte scintigraphy, 258P(ab)
 pediatric, MIBI scintigraphy in, 139P(ab)
 pericardial imaging in AIDS, ^{67}Ga , 995
 radiolabeled Lym-1, biodistribution and radiation dosimetry of, 90P(ab)
Lymphoscintigraphy
 ^{99m}Tc colloidal albumin, sentinel node identification, 259P(ab)
 ^{99m}Tc dextran 70 for, 143P(ab)
 ^{99m}Tc sulfur colloid for, 84P(ab)
 ^{99m}Tc sulfur colloid, reduced particle size, 301P(ab)
 ^{99m}Tc -sulfur colloid, preparation parameters, particle size distribution and stability, 1575
 classification, upper extremity lymphedema, 261P(ab)

drainage to triangular intermuscular space nodes, melanoma, 964
evaluation of limb edema, ^{99m}Tc -albumin colloid, lymphocele, 1517
lymphatic mapping in cutaneous melanoma, 972
melanoma, sentinel node identification, ^{99m}Tc sulfur colloid, 307P(ab)
noninvasive long-term followup, after lymph vessel transplant, 25P(ab)
with sulfur colloid, identification of sentinel node in malignant melanoma, 138P(ab)

Lysine

favorable effects of, biodistribution of ^{99m}Tc dsFv, 129P(ab)
pharmacokinetics of, effects on ^{123}I anti-Tac dsFv antibody accumulation, kidney, 203P(ab)
reduction of renal uptake of ^{111}In -DTPA-octreotide, sodium maleate, 1388

M

MAb425. ^{99m}Tc -labeling of bifunctional ligands, 362

Macrocyclic chelators, antibody response in lymphomas., 451

MAG3. captopril transplant renography, interpretation using a neural network, 1649

Magnetic resonance imaging (MRI)

comparison to bone SPECT in detection of vertebral metastases, 975
complex and unresolved issues related to myocardial viabilities assessment, 794
evaluation of squamous cell carcinoma metastases, comparisons with other methods of assessment, 897

Magnetic resonance spectroscopy

^{99m}Tc MAA lung scintigraphy and, measurement of focal pulmonary flow, 304P(ab)
5-fluorouracil biodistribution and metabolism, comparative animal study, 249P(ab)
fluorouracil pharmacokinetics, liver metastases from colorectal carcinoma, 257P(ab)
hyperpolarized ^2H , human lungs, 296P(ab)
prostate adenocarcinoma, glucosylifosfamide biodistribution in, 264P(ab)
transmission scans, image fusion method for adjustment of, 209P(ab)
use of F-Dopa as an amino acid tracer in detection of brain tumors, 1180

Major depression. assessment of cerebral blood flow with ^{99m}Tc -HMPAO SPECT, electroconvulsive therapy, 1075

Mammography

indeterminate, further study with scintimammography or contrast-enhanced MRI, 156P(ab)
microcalcifications without mass, ^{99m}Tc MDP scintimammography in, 156P(ab)

Managed care. regulate managed care industry, New York, 33N(10)

Management. myocardial perfusion imaging, effect on diagnostic and clinical decisions, 1618

Mandible. intraoral squamous-cell invasion, SPECT, 42

Mandibular metastases. detection, bone and bone marrow/granulocyte scintigraphy, 266P(ab)

Manpower. nuclear medicine physician requirements, projections for future, 15N(5)

Mathematical models. PET quantitation of

myocardial fatty acid metabolism, ^{14}C -palmitate, 1723

Maxillary sinus, sinusitis, involvement in nasopharyngeal carcinoma, FDG-PET in, 262P(ab)

MDX210. ^{99m}Tc -labeling of bifunctional ligands, 362

Media, focus on Alzheimer's diagnosis with PET, 33N(5)

Medial temporal lobe, decreased oxygen metabolism in Alzheimer's disease, PET, 1159

Mediastinal lymph nodes, assessment with ^{99m}Tc -sestamibi SPECT, lung cancer, 938

Mediastinum, thymic uptake of ^{131}I , 991

Medicare, impact of HCFA's proposed rule for 1997 physician fee schedule, 29N(10)

Medicare reform, SNM response to budget cuts, 16N(1)

Medullary thyroid cancer

bispecific antibody and ^{131}I -labeled bivalent hapten dosimetry, two-step targeting, small-cell lung cancer, 1853

comparison of octreotide scintigraphy and conventional imaging, 912

treatment with ^{131}I -labeled anti-CEA antibodies, 905

Melanoma

^{123}I -iodobenzamides as tracers for detection of, 1865

cutaneous, FDG-PET staging of, 137P(ab)

imaging with radioiodinated benzamides, 6P(ab)
lymphatic drainage to triangular intermuscular space nodes, 964

malignant

^{201}Tl whole-body imaging with, 256P(ab)

^{99m}Tc MIBI scintigraphic evaluation, 266P(ab)

metastatic, FDG-PET in diagnosis, comparison with scintigraphy, 137P(ab)

ocular, visualization with ^{123}I IDAB scintigraphy, 268P(ab)

sentinel node in, lymphoscintigraphy use in identification, 138P(ab)

whole-body FDG-PET staging of, 138P(ab)

ocular, FDG-PET detection and treatment of, 137P(ab)

radioimmuno scintigraphy with monoclonal antibody, 252

receptors for α -MSH peptide, imaging with, 191P(ab)

reproductibility of lymphoscintigraphy for lymphatic mapping, 972

staging of, ^{99m}Tc -labeled synthetic peptides with somatostatin receptors, 138P(ab)

Memory loss, blood flow decrease, hippocampus, SPECT evaluation, 285P(ab)

Meningioma, suspected, somatostatin receptor scintigraphy or MRI in, 257P(ab)

Merit, useful technique in treatment of cancer, 1914(e)

Meta-analysis, renovascular HTN, 171

Metabolism, and hemodynamics in carotid artery disease, PET, 429

Metaiodobenzylguanidine (MIBG)

evaluation of cardiac sympathetic innervation, imaging in silent myocardial ischemia, 712

long-term cardiac overload, sympathetic hyperactivity after, 160P(ab)

scintigraphy, suspected

pheochromocytoma, 158P(ab)

uptake and retention, specific activity effects, heart, 160P(ab)

Metal speciation, ^{67}Ga citrate and MRI contrast agents, computer simulation, 379

Metastases

squamous cell carcinoma, detection of metastases with PET-TYR, MRI, and CT, 897

thyroid cancer, treatment with radioactive iodine and external radiotherapy, 598

Metastasis, lymph node involvement in the porta hepatis, papillary thyroid cancer, 993

Metastatic liver cancer, angiotensin-II-induced hypertension chemotherapy, PET imaging to evaluate hepatic blood flow, 1522

Methotrexate, antineoplastic delivery to bone tumors, ^{99m}Tc labeled gem-bisphosphonate conjugate, 105

Methyl iodide, ^{131}C , gas phase production of, 194P(ab)

Mibolerone, ^6F androgen receptor ligands in baboons, prostate cancer, 1009

Micronucleus, radiotoxicity after ^{131}I therapy, thyroid cancer, 101P(ab)

Midgut carcinoid, ^{111}In -DTPA-D-Phe¹-octreotide, systemic radionuclide therapy, 1519

Migraine, spontaneous, PET rCBF studies in, 279P(ab)

Mild head injury, one-year follow-up, predictive capacity of ^{99m}Tc -HMPAO SPECT, 1605

Minimal degree, renographic characteristics of stenosis in renovascular disease, 594

Mitochondria, electron transport chain, detection of failure with ^{63}Cu PTSM, 192P(ab)

Mitochondrial and cell membrane potentials, kinetics

Mitochondrial function, metabolic fate of ^{123}I -BMIPP in canine myocardium, etomoxir provocation, 1836

Modeling, in emission tomography, abstraction versus reality, 1241(ed)

Modified lasix renogram, intermittent hydronephrosis, children, 23P(ab)

Molecular modeling, muscarinic receptor-ligand binding, 279P(ab)

Molybdenum-99m

domestic supply, 34N(9)

update on molybdenum-99m supply, 25N(1)

Monoamine oxidase, neuronal activity, ^{14}C PHEN kinetics in human heart, 70P(ab)

Monoclonal antibodies

^{111}In anti-E-selectin, imaging arthritis, 128P(ab)

^{111}In -labeled, EDTA effects on, prostate cancer patients, 198P(ab)

^{99m}Tc -labeled, CDR-grafted, enhanced retention of radionuclides by B-lymphoma using, 151P(ab)

^{99m}Tc 88BV59

imaging of colorectal cancer, 9P(ab)

imaging of ovarian cancer, 9P(ab)

^{99m}Tc -labeling of bifunctional ligands, 362

absorbed dose from ^{111}In -CYT-356, prostate cancer diagnostics, 1583

antibody-dependent signal amplification in tumor xenografts, avidin or streptavidin, 343

anti-tac, ^{111}IN versus ^{90}Y labeled with, biodistribution, 234P(ab)

biotinylated antibody FAB

fragment, co-localization with streptavidin, 151P(ab)

BW 431/26, 362

CEA-scan, evaluation of suspicious mammographic findings, 238P(ab)

directed against oncofetal fibronectin, validation in animal models and patients, 238P(ab)

fragments, radiometal-conjugated, overcoming nephrotoxicity in therapy, 96P(ab)

- imaging, staging recurrent prostate cancer, 10P(ab)
iodinated, or ovarian cancer, 142P(ab)
MOV18
in vitro quantitative autoradiography, concentration of FBP-GP38 in ovarian cancer, 665
myelosuppression and therapeutic potential of ^{90}Y , colonic cancer xenograft models, 168P(ab)
prevention of radiolysis during labeling, 1384
prostate cancer staging, 11N(4)
radioimmunoscintigraphy in patients with malignant melanoma, staging, 252
radioimmunotherapy and chemotherapy, ^{131}I -labeled MN-14 IgG anti-CEA MAb, colon cancer, 169P(ab)
radioimmunotherapy of medullary thyroid cancer, 905
radioimmunotherapy with ^{131}I -NP-4 F(ab')₂ anti-CEA antibody, small-volume tumors, 1504
reduction of renal uptake by amino acid infusion, 829
successful radioimmunotherapy, micro and occult metastases, SCID mouse model, 44P(ab)
T101-biotinylated-avidin-polylysine complex, transfer of DNA into lymphoma cells, 62P(ab)
vesicular internalization, enhancement of radiation dose to nucleus, 1052
Monte Carlo simulations, analysis of scatter contributions, PET, 2024
Monte Carol approach, patient-specific dosimetry, 89P(ab)
Morphine, augmentation, normal gallbladder ejection fraction and, after intravenous scincalide, 113P(ab)
Motion correction
cardiac creep, rest/stress myocardial perfusion studies, 131P(ab)
multihead SPECT, 214P(ab)
respiratory, compensation for, cardiac imaging, 130P(ab)
volumetric approach, ^{15}N ammonia cardiac PET, 131P(ab)
Motor stimulation, patterns of brain activation, ^{15}O water PET, 281P(ab)
Moyamoya disease
assessment of cerebral perfusion following therapy with flunarizine, 84
evaluation of posterior circulation, ^{99m}Tc -HMPAO SPECT and MRI, 1613
pediatric, evaluation of surgical outcome with diaxon SPECT, 89P(ab)
MRI, see Magnetic resonance imaging
 α -MSH, see Peptides
Multidrug resistance
 ^{99m}Tc sestamibi hepatic clearance, genetic factors in, 262P(ab)
 ^{99m}Tc TcN-NOET and sestamibi uptake, cancer cellines sensitive and resistant to chemotherapy, 189P(ab)
breast tumor cells
 ^{99m}Tc -tetrofosmin as substrate for P-glycoprotein, ^{99m}Tc -MIBI, 1578
development in breast tumor cells, ^{99m}Tc -sestamibi, 286
identification in tumors using ^{14}C -CHC, three-dimensional fusion imaging, 312
P-glycoprotein expression, solid tumors, evaluation with ^{99m}Tc sestamibi, 67P(ab)
P-glycoprotein overexpression, chemotherapy failure, cancer patients, 71P(ab)
PET imaging agents of, 51P(ab)
PET imaging of P-glycoprotein in tumors, ^{113}C -daunorubicin and ^{113}C -verapamil, 1571
protein associated with, ^{99m}Tc sestamibi as a transport substrate of, 247P(ab)
tumors, accumulation of ^{99m}Tc MIBI, 118P(ab)
Multidrug resistance associated protein, ^{99m}Tc sestamibi uptake mediated by, cancer cell lines, 233P(ab)
Multimodality imaging, three-dimensional description of pulmonary deposition of aerosols, 873
Multinodular goiter, dosimetry and risk estimates of radioiodine therapy, carcinogenesis, 2072
Multiple energy radionuclides, multiple energy reconstruction, SPECT, 171P(ab)
Multiple sclerosis, white matter lesions in, FDG-PET, 22P(ab)
Muscarinic receptors
improved method for radioiodination of ^{123}I -IQNB, SPECT, 2021
kinetic analysis, PET, 10P(ab)
ligand binding, molecular modeling of, 279P(ab)
myocardial, upregulation of, heart denervation and, 70P(ab)
preparation and biodistribution of ^{18}F -FQNPe, 193P(ab)
SPECT imaging, ^{123}I QNB for, 143P(ab)
 $Z-(\text{R}, \text{R})\text{-IQNP}$ imaging, brain and heart, 202P(ab)
Muscles, effect of oral diazepam, ^{18}F -FDG-PET, 1127
Mycobacterium avium complex, disseminated, review of gallium and thallium scans and autopsy findings, 242P(ab)
Myelodysplastic syndrome, bone marrow scintigraphy in hematologic disorders, ^{99m}Tc -antigranulocyte antibody, 978
Myeloma
 ^{99m}Tc MDP in evaluation of, diffuse marrow increase, 267P(ab)
 ^{99m}Tc -sestamibi uptake, 1001
evaluation, ^{99m}Tc MIBI characteristics in, 269P(ab)
Myocardial blood flow
 ^{113}C acetate and, compartmental model and, 83P(ab)
assessment with generator-produced ^{64}Cu -PTSM and PET, 1294
changes in, contractile reserve and, 82P(ab)
collateral, downscatter correction for dual isotope SPECT imaging, 216P(ab)
comparisons of ^{64}Cu -PTSM with $^{15}\text{NH}_3$ as PET perfusion tracers, 729
estimates, ^{15}O water PET, 221P(ab)
idiopathic dilated cardiomyopathy, reduced coronary vasodilatory capacity in, 82P(ab)
measurement with ^{15}N ammonia PET, 174P(ab)
PET studies in detection of familial hypercholesterolemia, dipyridamole, 1937
reproducibility of ^{15}N -ammonia PET measurements of, resting and hyperemic states, 1626
venous and arterial bypass grafts, attenuated coronary vasodilatory capacity and flow reserve, 82P(ab)
Myocardial imaging, bile reflux during, identifying noncardiac cause of chest pain, 1285
Myocardial infarction
acute phase of reperfusion, serial change in fatty acid utilization during, 185P(ab)
acute, assessment of salvaged myocardium by ^{99m}Tc tetrofosmin, 126P(ab)
adenosine sestamibi SPECT in, implications of fixed and reversible defects, 181P(ab)
coronary angioplasty, reverse redistribution of ^{99m}Tc sestamibi after, 181P(ab)
dobutamine ^{201}TI -SPECT for assessment of peri-infarction and remote ischemia, 1951
dual-tracer autoradiography, ^{123}I -MIBG and ^{201}TI , 680
functional risk area, assessed by ^{99m}Tc tetrofosmin, 58P(ab)
recovery of fatty acid metabolic activity and function, postperfusion myocardium, 37P(ab)
SPECT with pinhole collimator, rats, 159P(ab)
Myocardial ischemia
 ^{201}TI and ^{99m}Tc -tetrofosmin uptake comparison, severe systolic dysfunction and low flow, 1398
amlodipine effects, angina patients, ambulatory left ventricular function monitoring, 59P(ab)
assessment of reperfused myocardium, ^{99m}Tc HL91 use in, 94P(ab)
changes in function and regional glucose uptake, stunned porcine myocardium, PET, 2006
detection, ^{15}S homocysteine thiolactone, 49P(ab)
fatty acid tracer retention during, comparison, 94P(ab)
gated SPECT, FDG SPECT comparison, 60P(ab)
identification by ^{123}I BMIPP, 95P(ab)
quantitative FDG-PET detection of, 174P(ab)
swine model, ^{99m}Tc glucarate uptake in, 50P(ab)
Myocardial metabolism
impairment in hypertrophic cardiomyopathy, 572
interpreting cardiac FDG-PET images, influence of blood glucose, 1713
Myocardial perfusion
ouabain effects on ^{99m}Tc -Q12 and ^{201}TI extraction and retention, 752
three-dimensional spillover and recovery correction, PET, 767
Myocardial perfusion imaging
 ^{123}I IPPA and ^{99m}Tc sestamibi comparison, in coronary patients, 37P(ab)
 ^{15}N ammonia data fitting, parameter estimation stability, 224P(ab)
motion correction in, volumetric approach, 131P(ab)
 ^{15}O water, use of factor analysis in, 147P(ab)
 ^{201}TI attenuation and scatter compensation in, 80P(ab)
attenuation correction effects on defect reversibility, 148P(ab)
combined attenuation correction and scatter correction for, 30P(ab)
phantom studies, small-lesion detectability in, 213P(ab)
results of attenuation and scatter correction in, 212P(ab)
simultaneous acquisition of transmission and emission data, 80P(ab)
 ^{201}TI and ^{99m}Tc sestamibi comparison, coronary artery disease, women, 69P(ab)
 ^{201}TI versus dobutamine echocardiography, chronic left ventricular dysfunction, 126P(ab)
 ^{99m}Tc Q12, rat hearts during hypoxia, acidosis,

- and ischemia reperfusion, 49P(ab)
^{99m}Tc sestamibi comparison with ^{99m}Tc tetrofosmin, uptake, 48P(ab)
^{99m}Tc sestamibi SPECT
 anterior defect location with, 14P(ab)
 gating and, detection of coronary artery disease, 149P(ab)
 prognostic value of stress in, gender differences, 14P(ab)
^{99m}Tc sestamibi, automated method for assessment of left ventricular function, 179P(ab)
^{99m}Tc SPECT, correlation with cardiac serum markers, spontaneous angina, 58P(ab)
^{99m}Tc-labeled compounds, uptake in human breast cancer cell lines, 190P(ab)
 adenosine stress ^{99m}Tc sestamibi, early post-stress imaging, 59P(ab)
 automated interpretation of, case-based reasoning system, 178P(ab)
 blood flow and coronary endothelial function, after heart transplant, 83P(ab)
 cavity dilatation, versus elevated lung heart ratio, 183P(ab)
 comparison, attenuation correction, 97P(ab)
 coronary angiography and 3D-fusion image, 218P(ab)
 coronary artery disease evaluation, women, 182P(ab)
 cross-talk correction method, dual-isotope acquisition, 216P(ab)
 defect contrast in, effect of breast size and shape, 216P(ab)
 detection of coronary artery disease, end-stage renal disease patients, 69P(ab)
 dipyridamole for, patient weight effects, 177P(ab)
 dipyridamole/rest ^{99m}Tc tetrofosmin, assessment of coronary artery disease, 58P(ab)
 dobutamine ²⁰¹Tl, left bundle branch block patients, 177P(ab)
 dual-isotope, downscatter correction for, study of collateral circulation, 216P(ab)
 effect on diagnostic and clinical management, 1618
 errors due to partial volume effects, contractile movement and, 215P(ab)
 exercise-induced ischemia, chronic left ventricular dysfunction patients, 25P(ab)
 expert system interpretation, 48P(ab)
 extracardiac activity on, scatter correction and attenuation correction in, 214P(ab)
 false-positive, obese male patients, 178P(ab)
 fully automatic processing system, knowledge-based image understanding, 97P(ab)
 gamma camera images, ^{99m}Tc NOET kinetics, ischemic myocardium at rest, 107P(ab)
 gated both ²⁰¹Tl and ^{99m}Tc sestamibi, quantification of left ventricular function, 104P(ab)
 hypertensive patients, functional abnormalities, 115P(ab)
 perioperative cardiac events, risk stratification of, 116P(ab)
 postexercise, rest motion analysis in, 115P(ab)
 stress versus rest, reproducibility of left ventricular ejection fraction from, 115P(ab)
 tomographic ejection fraction, severely hypoperfused myocardium, 105P(ab)
 inferior wall evaluation, full versus empty stomach, 1916(lc)
 interpretation, physician training level effects, 179P(ab)
 kinetic parameters, input function shape and image acquisition, 8P(ab)
 left ventricular hypertrophy patients, coronary artery disease in, 182P(ab)
 mobile tomographic gamma camera, emergency room or intensive care unit use, 120P(ab)
 motion correction, for cardiac creep, 131P(ab)
 nonreversible defects, cardiac risk and, diagnostic population, 182P(ab)
 normal limits of left ventricular function, 105P(ab)
 rest-stress, comparison to coronary angiography, 182P(ab)
 resting ^{99m}Tc sestamibi SPECT, post injection times, 48P(ab)
 risk assessment, patients with submaximal exercise, 182P(ab)
 rotating planar projection views, interaction with attenuation correction, 149P(ab)
 scanning line source method, using an anthropomorphic phantom, 211P(ab)
 simultaneous evaluation, perfusion and fatty acid metabolism, 185P(ab)
 SPECT
 clinical management of very elderly patients, 69P(ab)
 correction of photon attenuation in, 176P(ab)
 stress ^{99m}Tc sestamibi/rest ²⁰¹Tl, regional dyssynergy patients, 175P(ab)
 stress, stable angina in women, cost analysis of, 68P(ab)
 TcN-NOET, metabolite analysis, after injection in rats, 188P(ab)
 ventricular arrhythmias, life-threatening, outcome prediction, 14P(ab)
 versus stress echocardiography, cost-effectiveness, 174P(ab)
 with ectomography, collimator design, 208P(ab)
 wrap-around lung effect, attenuation artifacts in SPECT, 189I
Myocardial SPECT, early and delayed ^{99m}Tc-tetrofosmin imaging, liver-heart artifact, 1622
Myocardial stunning, changes in LV function and regional glucose uptake, 18-FDG-PET, 2006
Myocardial uptake, of labeled somatostatin analog in carcinoid syndrome, 275
Myocardial viability
 comparison between FDG-PET and FDG-SPECT, dyssynergic myocardium, 1631
 evaluation of perfusion and metabolic state, isotope study, 1990
 evaluation with ¹²³I-BMIPP in canines, 1403
 predictions of functional outcome, BMIPP and sestamibi scintigraphy, 718
Myocardial viability assessment, discussion of complex and unresolved issues, state-of-the-art technologies, 794
Myocardium
¹²³I BMIPP uptake and washout kinetics, rat, 94P(ab)
 amyloid involvement, detection with ^{99m}Tc aprotinin, 185P(ab)
 blood flow. *see* Blood flow
 collateral circulation, downscatter correction for dual isotope SPECT imaging, 216P(ab)
 diabetic, metabolic fate of ¹⁴C acetate in, rat, 50P(ab)
 flow reserve, sympathetic neuron effects on, heart transplant patients, 4P(ab)
 glucose metabolism, dichloracetate effects, 3P(ab)
 injury, aortic regurgitation, antimyosin antibody-mediated detection, 38P(ab)
metabolism
¹²³I BMIPP comparison with ¹⁸F FDG, 184P(ab)
 fasting condition, negative uptake of ¹²³I BMIPP, 175P(ab)
metabolism and kinetics of ¹²³I-BMIPP in canine tissue, 757
necrotic, subcellular distribution of ^{99m}Tc glucarate, 175P(ab)
oxygen consumption, ¹⁴C acetate for measurement of, 222P(ab)
quantitative polar map of, correction for partial volume effectin, 153P(ab)
thickening, reversible ischemia, gated tomographic polar map Fourier amplitude images, 105P(ab)
thorax phantom, dynamic functional SPECT, 219P(ab)
uptake and distribution of ¹²³I MIBG, long QTsyndrome patients, 37P(ab)
viability
¹²³I IPPA prediction of left ventricular function after coronary revascularization, 37P(ab)
²⁰¹Tl and ¹⁸F FDG SPECT assessment of, 39P(ab)
^{99m}Tc sestamibi SPECT and histology correlation, 26P(ab)
 accuracy of thallium defects, 25P(ab)
 assessment with gated SPECT ^{99m}Tc tetrofosmin during dobutamine administration, 116P(ab)
 attenuation correction effects on ^{99m}Tc tetrofosmin SPECT, 180P(ab)
 comparison of ²⁰¹Tl and ^{99m}Tc MIBI reinjection tomography in, 308P(ab)
 comparison of ^{99m}Tc sestamibi, tetrofosmin, and stress reinjection ²⁰¹Tl for, 26P(ab)
 detection with ¹²³I IPPA SPECT, 150P(ab)
 diabetes mellitus patients, FDG-PET identification of, 39P(ab)
 dual-isotope simultaneous acquisition with ^{99m}Tc tetrofosmin and ¹⁸F FDG, 60P(ab)
 FDG cardiac SPECT versus PET, 60P(ab)
 image quality of FDG SPECT after glucose, 60P(ab)
 long-chain fatty acid ¹²³I PHIPA 3—10, 49P(ab)
 multicenter trial of ^{99m}Tc tetrofosmin SPECT, 26P(ab)
 observer variability in assessment with ¹²³I IPPA, 184P(ab)
 post-redistribution reinjection of ²⁰¹Tl for, 47P(ab)
 stress-redistribution-reinjection ²⁰¹Tl SPECT, 179P(ab)

N

- N-Acetyl aspartate**, NMR spectroscopic maps of, cerebral ischemia measured by, 277P(ab)
Na-K ATPase, relation between grade of histopathological differentiation, uptake ratios of ²⁰¹Tl SPECT in adenocarcinoma of lung, 955
Narcolepsy, semiquantitative rCBF brain SPECT in, 165P(ab)
Nasopharyngeal carcinoma
¹⁴C acetate clearance in, 136P(ab)
 evaluating primary disease and differentiating residual/recurrent disease from therapy changes, ²⁰¹Tl and ^{99m}Tc-sestamibi SPECT, 1956
 maxillary sinus involvement from sinusitis, FDG-PET in, 262P(ab)

- pre and post therapy, 99m Tc sestamibi and 201 Tl evaluation, 257P(ab)
- National Atomic Museum**, Exhibit planned for nuclear medicine at the National Atomic Museum, 15N(1)
- Neck ultrasonography**, detection of recurrence or metastasis in differentiated thyroid carcinoma, 446
- Needle biopsy**, stereotactic coordinates from ECT sinograms, breast cancer, 1562
- Neonatal cholestasis**, hepatobiliary kinetics of 99m Tc-IDA analogs, linear systems theory, 1323
- Neonates**, estimating radiation dose, FDG-PET, 387
- Neoplasms**
 - 18 F-labeled transferrin, iron metabolism in cell proliferation, localizing tumors, 1408
 - FDG uptake in soft-tissue sarcomas, PET, 257
- Nephrotoxicity**
 - contrast-induced, role of radionuclide renal scan, vascular occlusion versus ATN, 1828
 - therapy with radiometal-conjugated MAb fragments, peptides and, 96P(ab)
- Neural development studies**, FDG-PET, conscious infant primates, 55P(ab)
- Neural networks**
 - decomposition of 11 C doxepin PET image sequences, 164P(ab)
 - interpretation of captopril transplant renography, renal artery stenosis, 1649
 - generation of parametric images with, 220P(ab)
- Neuroactivation studies**, working memory, 284P(ab)
- Neuroblastoma**
 - 113 In pentetetreotide comparison with 131 I MIBG, 34P(ab)
 - comparison with 99m Tc MDP, 34P(ab)
 - 113 In-pentetetreotide imaging in children, 893
 - 131 I MIBG and 123 I MIBG imaging, children, 35P(ab)
 - 131 I MIBG therapy, survival after, 237P(ab)
 - 131 I MIBG, followup, 34P(ab)
 - human xenograft model, athymic mice, 210 At in, 61P(ab)
 - PET hydroxyephedrine imaging, 16
 - recurrent, combined 131 I MIBG therapy and hyperbaric oxygen, children, 287P(ab)
 - SPECT and delayed planar imaging, 123 I-MIBG, 1464
 - stage 4, treatment with 131 I MIBG and chemotherapy combined, 237P(ab)
- Neuroendocrine tumors**
 - cost effective analysis of somatostatin receptor imaging, 886
 - diagnosis, 131 I MIBG compared with 123 IMIBG, 243P(ab)
 - internalization of In-111 in humans, 2002
 - staging, value of 113 In pentetetreotide in, 250P(ab)
- Neurofibroma**, 99m Tc MDP bone scans, neurofibromatosis, 1778
- Neurofibromatoses**, type 1, pediatric, FDG-PET, 265P(ab)
- Neurofibrosarcoma**, 99m Tc MDP bone scans in neurofibromatosis, 1778
- Neuroimaging**, comparison of 123 I-epidepride and 123 I-IBZM, dopamine receptors, 1589
- Neurological illnesses**, evaluation of the dopamine system of the human brain, PET, 1242
- Neurology**
 - pediatric, utility of FDG-PET use in, 286P(ab)
 - postinjection transmission measurements for attenuation correction, FDG-PET, 128
- Neuronal death**, change in the dopamine transmitter after insult in caudate putamen, β -CIT, 1214
- Neuropeptide receptor imaging**, of schwannoma, 1272(l)e
- Neuroreceptor occupancy**, PET measurements of, typical and atypical neuroleptics, 1122
- Neuroreceptors**, quantitation of, need to increase imaging resolution, 1911(l)e
- Neurotransmitters**, comparison of 123 I-epidepride and 123 I-IBZM, dopamine receptor imaging, 1589
- evaluation of the dopamine system of the human brain, PET, 1242
- Neutrophil**
 - imaging inflammatory diseases, antistage-specific embryonic antigen-1, 1789
 - inhibition by L-arginine, normothermic cardiopulmonary bypass, 162P(ab)
- NHS-BAT ester**, antibody conjugation and stable 99m Tc labeling, 362
- Nicotine acetylcholine receptors**
 - imaging, brain, baboon, 11P(ab)
 - PET ligand for study of, epibatidine analog, 108P(ab)
 - radioligand for imaging of, 11P(ab)
- Nicotinic receptors**
 - binding, PET measurement of, 11P(ab)
 - SPECT radiotracer for, analog of epibatidine, 6P(ab)
 - studies with 11 C n-methylated analogs of epibatidine, 192P(ab)
- Nigrostriatal dopaminergic function**, FDOPA and 3OMFD PET, combined studies in Parkinson's disease, 209
- Nitric oxide**, neuronal, 14 C-labeled, PET study, 201P(ab)
- Nitrogen-13 ammonia**
 - cardiac PET, motion correction in, volumetric approach, 131P(ab)
 - PET, measurement of myocardial blood flow, age and oxygen consumption effects, 174P(ab)
 - simplified PET protocol for determining coronary flow and flow reserve, 87 Rb, 1701
 - use as a myocardial PET perfusion tracer compared with 64 Cu-PTSM, 729
- Nitroimidazole**, status of hypoxia in solid tumors, 99m Tc, 1023
- Noise reduction**, histogram sharpening of attenuation images, 18 F-FDG-PET, 786
- Non-Hodgkin's lymphoma**, transition from orbital pseudotumor, 67 Ga-citrate scintigraphy, 1524
- Non-small-cell lung carcinoma**, decision tree analysis for cost-effectiveness in staging and management, FDG-PET accuracy, 1428
- Nonisotopic exchange**, 123 I-iodobenzamides for the detection of melanotic melanoma, 1865
- Nonisotropic spatial resolution**, improved collimator design, SPECT and planar scintigraphy, 1417
- Nonstationary**, scatter subtraction-restoration in high-resolution PET, 2040
- Norepinephrine analog**, 113 C MHED, PET, presynaptic sympathetic nervous function studies, 205P(ab)
- Norepinephrine transporter**
 - cardiac, 14 C HDMI as potential radiotracer for, 50P(ab)
 - evaluation of 14 C-phenylephrine, MAO-sensitive
- marker of sympathetic neurons in cardiac tissue, 1923
- Normal data files**, quantitative analysis of SPECT images, 201 Tl, 99m Tc-sestamibi, 99m Tc-tetrofosmin, and 99m Tc-furifosmin, 1783
- NP-59 scintigraphy**, simultaneous depiction of aldosteronoma and adrenal infarction, 852
- NRC**, See Nuclear Regulatory Commission
- Nuclear arthrography**, radiography and scintigraphy to diagnose loosened hip prosthesis, 62
- Nuclear Education in Medicine Association**, proposed standard for residents, 33N(9)
- Nuclear medicine**
 - clinical function, impact of turn-key PACS, 208P(ab)
 - commentary of 100th anniversary, evaluation of radiation research, 18N(10)
 - experiment design, optimal image sampling schedule, 227P(ab)
 - issues in nuclear technology assessment, 000
 - European organizations, 26N(11)
 - review manual on the Internet, 304P(ab)
 - robotics, remote preparation of radioactive doses, 205P(ab)
 - therapeutic, with 90 Sr or 131 Sm EDTMP, skeletal metastases, 31P(ab)
- Nuclear oncology**, advances in 1996, 885
- Nuclear Regulatory Commission**, Institute of Medicine study supports state regulation of medical isotopes over NRC, 23N(2)

O

- Obesity**, effects on false positive scans, myocardial perfusion imaging, 178P(ab)
- Occipital meningioma**, discordant uptake on brain SPECT images, 99m Tc-HMPAO and 99m Tc-MIBI, 1183
- Octreotide scans**
 - staging and management, gastroenteropancreatic tumor patients, 20P(ab)
 - subcutaneous cavernous hemangioma visualization, Beckwith-Wiedemann syndrome, 1516
- Oligodeoxyribonucleotides**, [L_2] 123 I-labeled, radiotoxicity in mammalian cells, 228P(ab)
- Oligonucleotides**, auger strategies, potential for cytotoxic therapy, 3S(4)
- Opiates**, addiction, dopamine D2 receptor availability during naloxone precipitated withdrawal, 45P(ab)
- Opioid drugs**, effects on whole-gut transit measured by scintigraphy, 818
- Opioid receptors**, mu, binding, in cocaine abusers, SPM, 45P(ab)
- Opportunistic infections**, differential diagnosis with sequential thallium and gallium chest scans, kaposi sarcoma, lymphoma in AIDS, 1662
- Oral cancer**, preoperative assessment, role of bone scanning in, 137P(ab)
- Orbital pseudotumor**, transition into lymphoma, 67 Ga-citrate scintigraphy, 1524
- Orthostatic hypotension**
 - cerebral hypoperfusion, denervated myocardium, 99m Tc-HMPAO brain SPECT, 1824
 - maladaptation of frontal vascular response, 1
- Osseous metastasis**, procedure guideline for treatment of bone pain, 881

- Osseous tumor**, metastases, hot spots in bone scintigraphy and, 266P(ab)
- Osteoarthritis**, induced, ^{99m}Tc pertechnetate, uptake mechanism of, rat, 298P(ab)
- Osteoarthropathy**, infected versus noninfected, 706
- Osteomyelitis**
- acute, spine and sacroiliac, gallium scintigraphy of, 297P(ab)
 - Charcot joint, labeled leukocyte/marrow scintigraphy in, 241P(ab)
 - chronic recurrent multifocal, phyeal involvement in, children, 23P(ab)
 - infection imaging with streptavidin and ¹¹¹In-biotin, pretargeting, 1655
 - interpretational confusion, ¹¹¹In-WBC uptake correlation with bone marrow scan in Paget's disease, 858
 - recombinant interleukin-8 scintigraphy, localization of infection, 25P(ab)
- Osteoporosis**
- bone mass measurement, impact of densitometers on nuclear medicine, DEXA, 13N(10)
 - suspected, bone mineral density measurement in femoral neck or lumbar spine, 103P(ab)
- Osteosarcoma**
- after allograft reconstruction, skeletal scintigraphy use in, 28P(ab)
 - effect of chemotherapy, ²⁰¹Tl scintigraphic assessment, 1444
- Ovarian cancer**
- ¹¹¹I-labeled MN-14 IgG anti-CEA MAb, radioimmunotherapy with, 168P(ab)
 - imaging with ^{99m}Tc 88BV59, totally human monoclonal antibody, 9P(ab)
 - intraperitoneal radioimmunotherapy, ¹⁷⁷Lu-CC49, 1491
 - iodinated monoclonal antibody for, 142P(ab)
- Ovarian carcinoma**
- concentration of FBP-GP38, in vitro quantitation autoradiography, 665
 - unexpected pleuroperitoneal migration of ³²P-chromic phosphate therapy, 636
- Oxidation**, PET quantitation of myocardial fatty acid metabolism, ¹⁻¹³C-palmitate, 1723
- Oxygen**, cerebral, uncoupling of, dementia, 275P(ab)
- Oxygen-15**
- clinical studies, dual-PET system for noninvasive quantification, 110P(ab)
 - kinetics, estimating regional oxygen consumption, canine heart, 110P(ab)
 - single-breath inhalation, estimation of regional oxygen consumption, human heart, PET study, 146P(ab)
- Oxygen-15 butanol**
- cerebral blood flow studies compared with, motor activation, 219P(ab)
 - kinetics, PET neuroactivation studies, 222P(ab)
- Oxygen-15 water**
- cerebral blood flow studies compared with, motor activation, 219P(ab)
 - detection of brain tumors, Parkinson's disease, 1180
 - factor analysis, myocardial perfusion assessment with, 147P(ab)
 - kinetics, PET neuroactivation studies, 222P(ab)
 - metabolism, depletion of vascular reserve effects, 277P(ab)
- PET**
- investigation of panic disorder, 225P(ab)
 - liver perfusion studies, 147P(ab)
 - measurement of regional hepatic blood flow, 244P(ab)
- measuring changes in cerebral blood flow, 283P(ab)
- vascular tracer activity effects, 280P(ab)
- presurgical speech-activated FDG-PET, low grade gliomas, 270P(ab)
- quantitative imaging, 226P(ab)
- P**
- P-glycoprotein**, ^{99m}Tc-sestamibi imaging for diagnosing multidrug resistance, breast tumor cells, 286
- PACS**, *see* Picture and archiving communication system
- Paget's disease**
- diagnosis with ¹¹¹In-leukocyte and ^{99m}Tc-sulfur colloid uptake, 858
 - FDG-PET appearance of, 27P(ab)
 - FDG-PET differentiation from osteoblastic metastases of prostate, 27P(ab)
- Pain**
- acupuncture and, effects on brain functions, ^{99m}Tc HMPAO SPECT imaging, 278P(ab)
 - bone metastases, ¹⁵³Sm EDTMP as a palliative agent, 32P(ab)
 - central processing of, in trigeminal neuralgia, 278P(ab)
- Pain response**, effectiveness of ¹¹⁰Re-etidronate in metastatic bone pain, daily pain diary kept by patients with prostate cancer, 1511
- Painful osseous metastases**, radiopharmaceutical dosage and response, 249(ed)
- Palmitate**, quantitation of myocardial fatty acid metabolism, PET, 1723
- Pancreas**
- cancer, classification by FDG-PET, 140P(ab)
 - in vivo enzymatic activity of endocrine tumors, PET, 32
- Panda and lambda signs**, sarcoidosis, 4P(ab)
- Paragangliomas**, diagnosis of carcinoid tumor in jugulo-tympanic region, 270
- Parallel-hole collimators**, improved spatial resolution, SPECT and planar scintigraphy, 1417
- Parameter estimation**, loss compression effectson, PET, 125P(ab)
- Parathyroid**, FDG-PET and sestamibi SPECT comparisons, hyperparathyroidism, 1809
- Parathyroid adenoma**, ^{99m}Tc-sestamibi SPECT localization, 1535
- Parathyroid carcinoma**, FDG-PET and sestamibi-SPECT, hyperparathyroidism, 2000
- Parathyroid gland**
- ^{99m}Tc pertechnetate/sestamibi subtraction, dual-phase ^{99m}Tc sestamibi, and SPECT comparison, 15P(ab)
 - ^{99m}Tc sestamibi detection of pathology, in hyperparathyroidism, 158P(ab)
 - dual versus single isotope imaging, 16P(ab)
 - evaluation of primary and secondary hyperparathyroidism, ^{99m}Tc sestamibi scintigraphy, 243P(ab)
- hyperparathyroidism, preoperative assessment with ^{99m}Tc MIBI scintigraphy, 15P(ab)
- lesion localization, SPECT versus planar imaging, preoperative, 242P(ab)
- nodules, ^{99m}Tc tetrofosmin and MIBI imaging of, 159P(ab)
- PET and ¹¹¹C-methionine accumulation, hyperparathyroidism, 1766
- scintigraphic detection of pathology, histopathology and, in
- hyperparathyroidism, 159P(ab)
- Parathyroid hormone measurements**, combined with ^{99m}Tc-MIBI SPECT as guide to parathyroidectomy, 798
- Parathyroid hyperfunction**, ^{99m}Tc-MIBI scintigraphy to identify functional autonomy, 565
- Parathyroid hyperplasia**, functional autonomy in secondary hyperparathyroidism, identification with ^{99m}Tc-MIBI scintigraphy, 565
- Parathyroid scintigraphy**, increased accuracy with ^{99m}Tc-MIBI, FADS, and SPECT, 1773
- Parathyroidectomy**
- guided by SPECT-MIBI and parathyroid measurements, 798
 - increase in bone uptake, bone scintigraphy in hungry bone syndrome, 1371
- Parkinson's disease**
- 3OMFD, combined PET studies in Parkinson's disease, 209
 - ¹²³I IPT SPECT dopamine transporter imaging in, 273P(ab)
 - ¹⁴C L-DOPA binding, ¹²³I β -CIT comparison, 66P(ab)
 - clinical significance of striatal DOPA decarboxylase activity, PET, 216
 - combined FDOPA and 3OMFD PET studies, 209
 - comparative dopaminergic imaging, ¹²³I- β CIT-FP SPECT and ¹⁸F-FDOPA PET, 1760
 - comparison of cocaine congeners as imaging probes for dopamine terminals, PET, 1186
 - determination of regional rate constants, dynamic FDG-PET, 1115
 - differentiation from progressive supranuclear palsy, ¹²³I β -CIT basal ganglia distribution in, 133P(ab)
 - dopamine transporters in ¹²³I β -CIT brain SPECT in, 134P(ab)
 - SPECT imaging, ¹²³I use in, 133P(ab)
 - F-Dopa PET in detection of brain tumors, 1180
 - fluorodopa PET data analysis, nigrostriatal dopaminergic function, 421
 - kinetics of ¹²³I iodolisuride, striatal binding, 22
 - multiple system atrophy and, ¹⁸F DOPA and FDG-PET use in, 271P(ab)
 - neural degeneration and graft survival, PET and MRS use in, primate model, 66P(ab)
 - preparation and biological evaluation of ¹²³I-IACFT for SPECT imaging, 1197
 - putamenal dopa-decarboxylase activity in, levodopa effects on, 55P(ab)
 - striatal signal in, ¹²³I FP-CIT SPECT use in, 134P(ab)
 - treatment with dopamine agonists, ¹²³I-IBZM binding, SPECT, 1112
 - untreated, gastric emptying time and gastric motility in, 245P(ab)
- Partial volume correction**
- binding potential measurements, ¹¹C raclopride PET, 283P(ab)
 - MRI-based, for brain FDG-PET images, 42P(ab)
- Partial volume effect**
- correction for
 - including contractile movement, myocardial SPECT, 215P(ab)
 - quantitative polar map of myocardium, 153P(ab)
- MRI-based correction for**, PET, 154P(ab)
- Mueller-Gaertner correction**, brain PET, 225P(ab)

- reducing effect of, activity quantitation with OS-MLEM SPECT, 153P(ab)
- Particle deposition**, use of ^{99m}Tc -DTPA in determining regional abnormalities in ventilated patients, 239
- Particle size distribution**, ^{99m}Tc -sulfur colloid for lymphoscintigraphy, preparation parameters, stability, 1575
- Pathology**, evaluation of fatty acid metabolism and myocardial perfusion, heart transplantation, 1990
- Patient management**, utility of cerebral SPECT imaging impact on clinical decisions, 1070
- Patlak method**, ^{99m}Tc MAG3 renal scintigraphy, 291P(ab)
- Pediatric acute pyelonephritis**, ^{99m}Tc -DMSA renal SPECT in diagnosing and monitoring, 1349
- Pediatric gastric emptying**, right lateral and upright positioning, 99m sulphur colloid, 1356
- Pediatrics**
 - ^{111}In -pentetreotide scintigraphy, neuroblast-derived tumors, 893
 - ^{131}I MIBG and ^{123}I MIBG imaging, neuroblastoma, 35P(ab)
 - ^{99m}Tc -DMSA studies in urinary tract infection, 823
 - abdominal tumors, integrated diagnosis, ^{123}I MIBG, MRI and image fusion, 34P(ab)
 - assessment of renal uptake of ^{99m}Tc DMSA, planar posterior-view method, 291P(ab)
 - biokinetic behavior of ^{99m}Tc -DMSA, effects of renal pathology and age differences, 1331
 - chronic recurrent multifocal osteomyelitis, phseal involvement in, scintigraphy, 23P(ab)
 - estimating glomerular filtration rate, using single-sample adult technique in children, 1805
 - evaluation of renal parenchyma, ^{99m}Tc MAG3 SPECT, 23P(ab)
 - high risk neonates, ^{99m}Tc ECD brain SPECT in, 22P(ab)
 - ictal and interictal ^{99m}Tc -bicisate brain SPECT identification of epileptogenic foci, 1101
 - inflammatory bowel disease, ^{99m}Tc HMPAO labeled with leukocytes, 287P(ab)
 - intermittent hydronephrosis, modified lasix renogram, 23P(ab)
 - learning disability, abnormal cerebral glucose metabolism and, PET, 286P(ab)
 - left ventricular ejection fraction in, 286P(ab)
 - leg length discrepancy, accurate prediction of, congenital growth disorders, 23P(ab)
 - limb salvage procedures, homograft scintigraphy, 286P(ab)
 - lymphoma, MIBI scintigraphy in, 139P(ab)
 - moyamoya disease, evaluation of surgical outcome with diamox SPECT, 89P(ab)
 - noninvasive quantification of renal function, gamma camera using ^{99m}Tc -MAG3, 71
 - primitive neuroectodermal CNS tumors, somatostatin receptor scintigraphy, 286P(ab)
 - pyelonephritis, cortical lesions in, ^{99m}Tc -MAG3 and ^{99m}Tc GH comparison in, 287P(ab)
 - radiation dosimetry of ^{99m}Tc -DMSA, effective dose equivalent, 1336
 - radionuclide salivagram, pulmonary disease and medical conditions predisposing to aspiration, 22P(ab)
 - recurrent neuroblastoma, combined ^{131}I MIBG therapy and hyperbaric oxygen, 287P(ab)
 - thymic hyperplasia, ^{111}In pentetetotide and ^{67}Ga citrate uptake in, lymphoma, 256P(ab)
 - tumors, MIBG scintigraphy in, 288P(ab)
 - urinary tract infection, renal outcomes after, 46P(ab)
- Penicillin**, induced focal seizures in rats, HMPAO as cerebral blood flow tracer, 661
- Penis**, hemodynamic impotence, radioisotope penile plethysmography role in, 292P(ab)
- Penogram**, nuclear, role in treatment planning for impotence, 288P(ab)
- Pentetreotide**
 - biodistribution and dosimetry, 230P(ab)
 - uptake, somatostatin receptor-positive tissues, 141P(ab)
- Peptide nucleic acid**, ^{99m}Tc -labeled, hybridization of, 203P(ab)
- Peptide T**, and glucose metabolism in AIDS dementia complex, FDG-PET, 1177
- Peptides**
 - α -MSH, receptors in melanoma, imaging with, 191P(ab)
 - ^{105}Rh -tetraethylmacrocyclic conjugate, bombesin analogue, 61P(ab)
 - ^{111}In DTPA octreotide and others, delivery to lysosomes, liver, kidneys, and target tissues, 302P(ab)
 - ^{111}In DTPA polypeptides, hepatocyte metabolism of, 202P(ab)
 - ^{99m}Tc leukotactic, novel approach to infection imaging, 24P(ab)
 - ^{99m}Tc P748, biodistribution and dosimetry, 231P(ab)
 - ^{99m}Tc P829, biodistribution and dosimetry, 230P(ab)
 - ^{99m}Tc -labeled based on ternary ligand system, 29P(ab)
 - comparison to challenge with cysteine, 150P(ab)
 - inflammation imaging, 152P(ab)
 - bombesin iodinated analogues, small cell lung cancer, 185P(ab)
 - radioiodinated analogue, as a potential radiotherapeutic agent, 186P(ab)
 - chemotactic, ^{99m}Tc accumulation in chronic intestinal inflammation, 239P(ab)
 - accumulation in lung, severe trauma effects, 240P(ab)
 - potential use of ^{99m}Tc -P587 and ^{99m}Tc -P829 as radiotracers for detection of SSTR-expressing tumors, 1016
 - radiolabeled, canine model of intra-arterial thrombus, 152P(ab)
 - rhodium-bound hormone, structure and function, 96P(ab)
 - synthesis, radiolabeling of polypeptide sequences during, 198P(ab)
- Percutaneous transluminal coronary angioplasty**, reverse redistribution of ^{99m}Tc -sestamibi, with SPECT imaging, prediction of artery patency and wall motion status, 1289
- Perfusion**, pseudostripe sign in lobar collapse, differential diagnosis, emphysema, 1682
- Pericardial lymphoma**, ^{67}Ga imaging, AIDS, 995
- Peripheral nerve neoplasms**, ^{99m}Tc MDP bone scans, neurofibromatosis, 1778
- Peripheral vascular disease**, flow characteristics, evaluated by direct puncture scintigraphy, 183P(ab)
- Peristalsis**, gastric, scintigraphic imaging of, 56P(ab)
- Peritonitis**, *see* Infection
- Permeability surface area product**, ^{99m}Tc -ECD extraction and retention, dynamic SPECT and ^{18}O -water PET, 1600
- Permeability-surface area product**, brain perfusion SPECT, correction for nonlinear relationship of tracer flow and uptake, 1237
- Pertechnegas**
 - compartmental model for alveolar clearance of, 2066
 - transition from technegas, 1917(ie)
- PET**, *see* Positron emission tomography
- PET transmission noise**, histogram sharpening method to reduce noise in PET, ^{18}F -FDG, 786
- Pharmacokinetics**
 - DMP444, potential thrombus imaging agent, 151P(ab)
 - of cobalt-55, 2082
 - of cobalt-57, 2082
- Pharmacologic stress**, reproducibility of ^{15}N -ammonia PET measurement of myocardial blood flow, resting and hyperemic states, 1626
- Pharmacological challenge**, reproducibility of regional brain metabolic changes, lorazepam induced responses, 1609
- Pharmacology**, evaluation of the dopamine system of the human brain, PET, 1242
- Phenyltropane**, PET, serotonin and dopamine transporter sites, brain, 40P(ab)
- Pheochromocytoma**
 - ^{131}I -MIBG dosimetry in cancer therapy, 1058
 - malignant, high-dose ^{131}I MIBG therapy in, 237P(ab)
 - PET imaging, ^{18}F PFGB use in, dogs, 200P(ab)
 - suspected, MIBG scintigraphy in, 158P(ab)
 - tumor characterization and effects of excessive catecholamines on heart and lungs, ^{123}I -MIBG imaging, 1361
- Phobia**, social, altered dopamine transporter densities in, 45P(ab)
- Phospholipid synthesis**, study of PET tracers to assess liver protein synthesis, 279
- Phosphorous-32-phosphate pleural**
 - radioactivity, unexpected migration of intraperitoneal therapy for ovarian carcinoma, 636
- Photonic activation**, ^{99m}Tc -HMPAO brain SPECT, evaluation of patients with pure photosensitive epilepsy, 1755
- Photodiode detectors**, Sherbrooke Avalanche Photodiode PET Scanner, performance of, 170P(ab)
- Photopenic osteomyelitis**, bone scintigraphic findings, septic arthritis, 1676
- Physiological accumulations**, differentiating uptake pattern in muscles from pathological lesions, whole body PET scans, 441
- Picture Archiving and Communication Systems**
 - on-line teaching-reference file, filmless nuclear medicine department, 307P(ab)
 - turn-key, nuclear medicine clinic function and, 208P(ab)
- Pinhole collimator**, high-resolution thyroid tomography, SPECT, 2017
- Pinhole magnification**, ^{99m}Tc -DMSA scintigraphy to detect pyelonephritis in piglets, comparison of planar and SPECT imaging, 1731
- Pituitary adenomas**, dopamine D2 receptor imaging, ^{123}I -epidepride and SPECT, 1931

- Pituitary glands, ¹¹¹In-DTPA-octreotide uptake, SPECT,** 1449
- PK receptor ligand, high affinity, PET and SPECT,** 6P(ab)
- Placebo, cerebral glucose metabolism during pharmacologic studies, paired FDG-PET scans,** 1142
- Planar collimator, improved spatial resolution in SPECT and planar scintigraphy,** 1417
- Planar imaging**
- comparative methods for quantifying thyroid volume, SPECT, 1421
 - SPECT and delayed 48-hour scanning in neuroblastoma, ¹³¹I-MIBG, 1464
- Planar-concave collimator, improved spatial resolution, SPECT and planar scintigraphy,** 1417
- Plasma volume, measurement with ⁶⁷Cu-HSA-DTS, regional HCT to assess cerebral circulation,** 1080
- Platelet count, relationship between absorbed dose and toxic dose of ¹¹¹Re-HEDP,** 38
- Plethysmography, penile, evaluation of penile hemodynamic impotence,** 292P(ab)
- Pleural effusion**
- patterns on V/Q lung scans, 296P(ab)
 - ventilation/perfusion scan interpretation for acute pulmonary embolus, 1310
- Pneumocystis carinii, localization difficulty, detecting infection and inflammation with ^{99m}Tc-Stealth-liposomes,** 1392
- Poisson noise, accurate treatment of, reconstruction of brain SPECT,** 218P(ab)
- Polar map, myocardium, correction for partial volume effect in,** 153P(ab)
- Polyethylene glycol**
- ^{99m}Tc-labeled liposomes for blood pool imaging, ventriculography, 1374
 - detecting acute infection and inflammation with ^{99m}Tc-liposomes, Stealth, 1392
- Polypeptides, radioiodination of, diagnostic and therapeutic purposes,** 7P(ab)
- Porta hepatis, metastasis of papillary thyroid cancer,** 993
- Portal streamlining, mapping of hepatic blood flow distribution by scintigraphy, ¹³¹I IMP, 51**
- Positron camera, 2D/3D acquisition capability, isotropic spatial resolution and, evaluation of,** 170P(ab)
- Positron emission tomography (PET)**
- 5-HT2 receptors, post-stroke changes in unlesioned cortical areas, PET, 1976
 - ¹¹C β -CIT-FP and ¹¹C β -CIT-FE uptake, human brain, 284P(ab)
 - ¹¹C acetate
 - cardiac, heart transplant patients, 161P(ab)
 - uptake and retention, adrenal adenomas, 15P(ab) - ¹¹C CGP 12177 and HED, hypertrophic cardiomyopathy assessed by, 71P(ab)
 - ¹¹C deprenyl, cluster analysis use in, 42P(ab)
 - ¹¹C doxepin, artificial neural network decomposition of, 164P(ab)
 - ¹¹C DTBZ and, equilibrium versus compartmental analysis, 109P(ab)
 - ¹¹C HED uptake, ischemia-induced inhibition, isolated rat heart, 107P(ab)
 - ¹¹C MDL 100, 907
 - cerebral serotonin receptor occupancy, 112P(ab)
 - imaging cerebral serotonin receptors, 112P(ab) - ¹¹C methadone, baboon studies, 40P(ab)
 - ¹¹C methionine, evaluation of early response
- totherapy, advanced breast cancer, 256P(ab)
 - ¹¹C PMP, mapping AChE in human brain, Alzheimer's disease, 21P(ab)
 - ¹¹C raclopride
 - correction for partial volume effects on binding, 283P(ab)
 - estimation of binding potential, 280P(ab) - ¹²³I MIBG, production and labeling, 191P(ab)
 - ¹⁴N ammonia
 - data fitting, parameter estimation stability, 224P(ab)
 - myocardial blood flow measurement, age and oxygen consumption relations, 174P(ab) - ¹⁵N ammonia assessment of maximal microvascular dilator capacity, coronary disease, 161P(ab)
 - ¹⁷O study, regional oxygen consumption, human heart, 146P(ab)
 - ¹⁷O water
 - estimation of myocardial blood flow, 221P(ab)
 - investigation of panic disorder, 225P(ab)
 - measurement of regional hepatic blood flow, 244P(ab)
 - motor task activation of cerebral cortex, 273P(ab)
 - patterns of brain activation in motor sequence learning, 281P(ab)
 - quantitative imaging, 226P(ab)
 - vascular tracer activity effects, 280P(ab)
 - visual selective attention to orientation and spatial frequency, 306P(ab) - ¹⁸O, cerebral blood flow change during executive function and declarative memory, 284P(ab)
 - ¹⁸OCO₂ steady-state method compared with SPECT, use of permeability-surface model for nonlinear correction of brain perfusion, 1237
 - ¹⁸F BPA-F, kinetics, glioblastoma, 279P(ab)
 - ¹⁸F DOPA, statistical parametric mapping of, 271P(ab)
 - ¹⁸F FDHT staging, prostate cancer, 87P(ab)
 - ¹⁸F fluorocarazolol, measurement of beta-adrenergic receptor concentration, 174P(ab)
 - ¹⁸F misonidazole, localization of liver hypoxia with, 200P(ab)
 - ¹⁸F orthocarbon, imaging of new boron neutron capture therapy agents, 194P(ab)
 - ¹⁸F transferrin, biodistribution in nude mice models, 118P(ab)
 - ¹⁸F-FDG
 - derivation of input function, small animal hearts, 1717
 - determining regional cerebral glucose determination, 394
 - imaging of soft-tissue sarcoma, 257 - ¹⁸F-FDG and ^{99m}Tc-MIBI SPECT, comparison of diagnostic accuracy in musculoskeletal sarcomas, 1476
 - ¹⁸F-FDG uptake by laryngeal muscles, speech-related visualization, 1771
 - ¹⁸F-FDG, estimated radiation dose to newborns, 387
 - ¹⁸F-labeled β -CIT-FP, for dopamine transporter, 192P(ab)
 - ¹⁸F-Phe versus ¹¹C-Met in tumor imaging, 320
 - ¹⁸Cu BAT-21T-NR-LU-10 Fab as an agent for, 95P(ab)
 - ⁶⁷Ga EDTA study, blood-brain barrier permeability changes, brain tumor, 146P(ab)
 - ⁸⁵Rb studies, dipyridamole-induced stress, 146P(ab)
- anesthetized canine, 146P(ab)
 - 1-¹¹C-acetate, simple method of production, 341
 - 1-¹¹C-glucose, absorbed dose estimates in adults, hyperinsulinemia, 1668
 - 2D and 3D, tumor-involved lymph nodes, size limitations indetection of, 98P(ab)
 - 2D- and 3D-, detectability of small lesions, 220P(ab)
 - 3D ¹⁵O water brain activation studies, scatter correction for, 227P(ab)
 - 3D whole-body
 - 2D comparison, image quality, brain, 74P(ab)
 - acquisitions parameters for, 73P(ab)
 - activity outside the FOV, signal-to-noise loss, 73P(ab)
 - FDOPA scans for, with scatter correction, 73P(ab)
 - resolution and artifacts in, 73P(ab) - 5-fluorouracil biodistribution and metabolism, comparative animal study, 249P(ab)
 - activation studies
 - ¹⁷O water, classic conditioning of flexor reflex, 55P(ab)
 - language function, left-handed subjects, 55P(ab) - activation/deactivation patterns, brain, SPM95 sensitivity to, 41P(ab)
 - adenosine and dobutamine combination, cardiac stress, 307P(ab)
 - Alzheimer's disease
 - decreased medial temporal oxygen metabolism, 1159
 - glucose transport and phosphorylation, 201 - analysis of binding kinetics, ¹¹C-iomazenil, 699
 - analysis of scatter contributions, Monte Carlo-based calculations, 2024
 - appropriateness of functional brain imaging, ethical clinical practice, 1256
 - assessment of regional myocardial perfusion, ¹¹Cu-PTSM and PET, 1294
 - attenuation correction of, brain emission images, 172P(ab)
 - auditory activation studies, cochlear implantation and hearing subjects, 123P(ab)
 - automated interstudy image, registration method, comparison of datasets with SPECT, 137
 - automated search for significant elements in, 209P(ab)
 - autoradiography and, binding studies of serotonin receptors, human and monkey, 112P(ab)
 - bladder wall radiation dose, ¹⁸F-FDOPA, 1850
 - block detector technology, for SPECT imaging, 119P(ab)
 - block detector, circular photomultipliers in, geometric asymmetry effects, 227P(ab)
 - brain
 - FMZ, pons, noninvasive quantitation of benzodiazepine receptors, 5
 - hydroxyephedrine imaging of neuroblastoma, 16
 - measurement of AchE activity in Alzheimer's disease using radioactive analog method, 649
 - Mueller-Gaertner partial volume correction in, 225P(ab)
 - regional radioactivity quantitation in blood flow, 222P(ab)
 - serotonin receptors in, 108P(ab) - camera for high temporal and spatial resolution, design aspects, 85P(ab)
 - cardiac, Bayesian image reconstruction for, 130P(ab)

- carrier-free ^{64}Cu , isolated from
 $^6\text{Gawaste}$, 195P(ab)
 CBF studies, spontaneous migraine, 279P(ab)
 central processing, vestibular system, stimulus-induced differences of, 122P(ab)
 cerebral blood flow
 evaluation of cerebral hemodynamic and metabolic status, carotid artery disease, 429
 gender differences as a function of cognition, 559
 cerebral glucose metabolism in HIV-1 seropositive subjects, AIDS dementia complex, 1133
 changes in LV function and regional glucose uptake, myocardial stunning in porcine studies, 2006
 coincidence imaging, dual head gamma camera, 53P(ab)
 comparative nigrostriatal dopaminergic imaging in Parkinson's disease, SPECT, 1760
 comparison of ^{18}F -FDG and ^{11}C -MET, malignant tumor detection, 1472
 comparison with dual-headed gamma camera, whole-body imaging with ^{57}Fe transferrin, 148P(ab)
 comparison with SPECT, myocardial uptake of ^{18}F -FDG, dyssynergic myocardium, 1631
 comparisons of cocaine congeners for dopamine terminals, 1186
 complex and unresolved issues related to myocardial viability assessment, 794
 coronary flow and flow reserve, simplified protocol using ^{82}Rb and ^{15}N -ammonia, 1701
 correction for attenuation, smoothing during transmission processing on cardiac scans, 690
 cortical 5-HT₂ serotonergic receptors, post-stroke changes, 1976
 CT comparison, mediastinal and extrathoracic staging of non-small cell lung cancer, 260P(ab)
 data fitting, parameter estimation, 304P(ab)
 decarboxylation of carbon-11-DOPA, endocrine pancreatic tumors, in vivo enzymatic activity demonstration, 32
 decision tree analysis, cost-effectiveness in staging and management of non-small-cell lung cancer, 1428
 decline in dopamine transporters with age, 554
 detector design, LSO scintillator crystals and photodiode readout, 85P(ab)
 dichloracetate effects, myocardial glucose metabolism, 3P(ab)
 dopamine transporter occupancy, methylphenidate induced high and, 44P(ab)
 dopamine transporter, cocaine binding sites on, 65P(ab)
 dual system, noninvasive quantification of ^{15}O clinical studies, 110P(ab)
 dynamic
 estimation of serotonin synthesis rate, brain, 145P(ab)
 kinetic modeling of, estimation of receptor concentration by, 146P(ab)
 stochastic algorithm for parameter estimation in, 222P(ab)
 earliest metabolic reduction, Alzheimer's disease, 163P(ab)
 early detection of Alzheimer's disease, 79P(ab)
 ECAT EXACT HR+, performance characteristics, 221P(ab)
 estimation of serotonin-2 receptor binding potential, ^{18}F -setoperone, 95
 evaluation of ^{11}C -phenylephrine, MAO-sensitive marker of sympathetic neurons in cardiac tissue, 1923
 evaluation of ^{18}F androgen receptor ligands in baboons, prostate cancer, 1009
 evaluation of hepatic blood flow, angiotensin-II-induced hypertension chemotherapy, 1522
 evaluation of preoperative chemotherapy in breast cancer patients, FDG, 931
 F-Dopa as an amino acid tracer for detection of brain tumors, extrapyramidal symptoms, 1180
 fast iterative image reconstruction, performance evaluation, 154P(ab)
 FDG
 cerebral glucose metabolism, reliability of scans before and after placebo infusions, 1142
 enhanced tumor imaging, emission computed tomography, 371
 ^{13}C ethanol and, hepatocellular carcinoma, 68P(ab)
 2D- and 3D comparison, 226P(ab)
 3D, quantitative evaluation, brain imaging, 219P(ab)
 abnormal cerebral glucose metabolism, children, 286P(ab)
 advanced primary and recurrent colorectal cancer, 132P(ab)
 after differentiated thyroid cancer, 134P(ab)
 appearance of Paget disease, 27P(ab)
 assessment of breast tumors, 254P(ab)
 breast cancer response to tamoxifen, 99P(ab)
 breast cancer, staging of the axilla, 307P(ab)
 breast imaging, prone and supine, 99P(ab)
 breast, quantitative image analysis, 99P(ab)
 cancellous bone graft viability in total hip replacements, 27P(ab)
 cerebral metabolic correlates for depressive relapse, 80P(ab)
 classification of pancreatic tumors, 140P(ab)
 colorectal cancer, hepatic, chemoembolization in, 132P(ab)
 correlation of GLUT-1 glucose transporters with FDG uptake in, 248P(ab)
 detection and treatment of ocular melanoma, 137P(ab)
 detection of lung cancer and mediastinal lymph node metastases, 122P(ab)
 detection of myocardial ischemia, 174P(ab)
 diagnosis of malignant melanoma, comparison with scintigraphy, 137P(ab)
 diagnostic accuracy and cost-effectiveness, colorectal cancer, 132P(ab)
 diagnostic evaluation of dementia, 270P(ab)
 differentiating benign from malignant lesions, lung, 121P(ab), 122P(ab)
 differentiation of benign from malignant bone and soft tissue lesions, 140P(ab)
 evaluation of adrenal masses for metastatic disease, 141P(ab)
 evaluation of renal cell carcinoma, 141P(ab)
 F-Dopa and, Parkinson's disease, 271P(ab)
 for distinguishing between benign and malignant breast masses, 99P(ab)
 gated, assessment of left ventricular function, 39P(ab)
 glioma, clinical grading scale for, 263P(ab)
 head and neck cancer
 head and neck tumor differentiation, 304P(ab)
 identifying tumor hypoxia, ^{99m}Tc HL91 and, 87P(ab)
- imaging atherosclerotic macrophage density by, 38P(ab)
 immunoresponsive cell infiltration and, head and neck cancer, 264P(ab)
 impact of image registration, brain tumors, 22P(ab)
 liver metastases, 250P(ab)
 locally recurrent and metastatic thyroid cancer, 135P(ab)
 lung and breast cancer, 65P(ab)
 lymph nodes, HIV patients, 162P(ab)
 management of lymphoma, 139P(ab)
 management of solitary pulmonary nodule patient, 110P(ab), 111P(ab)
 mediastinal staging of lung cancer, 121P(ab)
 metabolic impairment in Alzheimer's disease, 275P(ab)
 monitoring non-Hodgkin's lymphoma, 138P(ab)
 monitoring of tumor response to chemotherapy, 67P(ab)
 myocardial viability assessed by, 39P(ab)
 myocardial wall motion and ejection fraction, 226P(ab)
 nasopharyngeal carcinoma, maxillary sinus involvement from sinusitis, 262P(ab)
 neurofibromatoses type 1, pediatric patients, 265P(ab)
 nodal staging of non-small cell lung cancer, 121P(ab)
 noninvasive method for quantitating mice input functions, 147P(ab)
 normal extracranial head and neck structures, 251P(ab)
 Pagets disease or osteoblastic metastases of prostate, 27P(ab)
 partial epilepsy with vascular malformations, 100P(ab)
 partial volume correction method for, MRI-based, 42P(ab)
 patient management of non-small-cell lung cancer, 121P(ab)
 pediatric neurology patients, 286P(ab)
 prediction of recovery in poststroke aphasia, 122P(ab)
 preliminary study, bladder cancer patients, 262P(ab)
 preoperative nodal staging and detection of non-small-cell lung cancer, 249P(ab)
 quantitation of cerebral glucose utilization without blood sampling, 221P(ab)
 recurrent colorectal cancer, comparison with CT, 132P(ab)
 recurrent differentiated thyroid cancer, 134P(ab)
 recurrent malignant glioma from radiation necrosis, 157P(ab)
 relation to local histology and prognostic value, glioma, 21P(ab)
 relationship between metabolism and function in coronary artery disease, 161P(ab)
 renal cancer, correlation with histopathological data, 64P(ab)
 residual testicular cancer after chemotherapy, 256P(ab)
 respiratory gated, thoracic and upper abdominal tumor imaging, 36P(ab)
 sequential follow-up scanning, lung cancer, 261P(ab)
 SPECT and MRI comparison, pediatric epilepsy, 269P(ab)
 staging of colon cancer metastatic to liver, 131P(ab)
 staging of esophageal cancer, 135P(ab)
 staging of high-risk cutaneous

- melanoma, 137P(ab)
 staging of Hodgkin's disease, 139P(ab)
 staging of malignant melanoma, 138P(ab)
 staging of pulmonary neoplasms, 249P(ab)
 tumor glucose utilization, primary rectal cancer, 54P(ab)
 uptake in benign and normal breast tissue, 249P(ab)
 uptake, laryngeal muscles with speech, 282P(ab)
 validation with surgical pathology, colorectal cancer, 131P(ab)
 viable myocardium, diabetes mellitus patients, 39P(ab)
 white matter lesions, stable multiple sclerosis, 22P(ab)
 chemotherapy response in, 136P(ab)
 value in preoperative workup, 136P(ab)
 whole-body staging, 136P(ab)
 discordance with MRI scans, 253P(ab)
 colorectal cancer recurrence, 258P(ab)
 detection of extent of malignant lymphoma, 262P(ab)
 detection of recurrent or metastatic breast cancer, 99P(ab)
 evaluation of suramin therapy, metastatic prostate cancer, 267P(ab)
 expectation maximization with ordered subsets, 130P(ab)
 recurrent breast cancer, 252P(ab)
 recurrent colorectal cancer, 261P(ab)
 feasibility of scintillation detector distribution on a spheroidal surface, brain imaging, 1219
 fluorine-18-6-fluorodopa, reproducibility and discriminating ability in Parkinson's disease, 421
 fluorocarazol, thoracic β -adrenergic receptors, heart, 71P(ab)
 fluorocarazolol, delineation of β -adrenoceptors in human brain, 11P(ab)
 fluorouracil pharmacokinetics, liver metastases from colorectal carcinoma, 257P(ab)
 forward transport rates for F-Dopa and OMFD, compartmental analysis, 432
 functional brain image database system, in dementia, 164P(ab)
 functional brain imaging, automated attenuation correction model for, 42P(ab)
 functional brain mapping, signal-to-noise ratio in, 223P(ab)
 gene therapy with cytosine deaminase, conversion of 5-FC to 5-FU, 87
 glioblastoma multiforme, boron neutron capture therapy in, 235P(ab)
 glucose metabolism
 Gertsmann-Straussler-Scheinker disease patients, 270P(ab)
 individual tissues, 68P(ab)
 hepatoma cells
 metabolic effects of gene therapy with HSV thymidine kinase, 234P(ab)
 uptake of specific substrates for HSV thymidine kinase, 235P(ab)
 high-resolution camera, transformable field of view, 85P(ab)
 high-resolution detectors, feasibility studies of, high magnetic field environments, 85P(ab)
 high sensitivity/high spatial resolution scanner, small field of view, 86P(ab)
 hyperperfusion and hypermetabolism in brain radiation necrosis, MET and FDG uptake, 1174
 hypertrophic cardiomyopathy, metabolic changes, 572
 image reconstruction, MRI-constrained, 223P(ab)
 imaging agents of human multidrug resistance P-glycoprotein, 51P(ab)
 imaging of P-glycoprotein in tumors, ^{113}C -daunorubicin and ^{113}C -verapamil, multidrug resistance, 1571
 in vivo quantification of pulmonary beta-adrenoceptor density, CGP-12177, 1275
 infant, shielding to correct scatter from outside the field-of-view, 226P(ab)
 labeling of angiotensin II receptors, ^{113}C -L-159,884, 307
 ligands, antagonists for serotonin receptors, 204P(ab)
 liver
 protein synthesis, feasibility study on PET tracers, 279
 local statistics, analytic computation and sample estimation, 155P(ab)
 lossy compression, effects on parameter estimation, 125P(ab)
 MacinPET, 303P(ab)
 maximum-likelihood image reconstruction, from list-mode data, 124P(ab)
 McN5652, impulse response function and kinetic modeling with, 33P(ab)
 measurement of cell proliferation, methyl- ^{14}C -thymidine, 1048
 measurement of plasma volume and regional cerebral hematocrit, ^{67}Cu -HSA-DTS, 1080
 measurement, nicotinic receptor binding, 11P(ab)
 measurements of cerebral hemodynamics and metabolism in patients with severe diffuse brain injuries, 1166
 medical insurance coverage policies for studies and for diagnostic use, 948(ed)
 metabolic consequences of acute brain trauma, 1170(ed)
 metabolism of ^{113}C -thymidine, tumor imaging, 290
 micropet, small animal imaging, 86P(ab)
 monitoring response of soft-tissue and musculoskeletal sarcoma to neoadjuvant therapy, ^{18}F -FDG, 1438
 MRS and, evaluation of neural degeneration and graft survival, Parkinson's disease model, 66P(ab)
 myocardial blood flow at rest and dipyridamole loading, familial hypercholesterolemia, 1937
 myocardial muscarinic receptors, up-regulation of, heart denervation and, 70P(ab)
 myocardial perfusion tracers, ^{67}Cu -PTSM compared with $^{15}\text{NH}_3$, 729
 myocardial perfusion, ^{67}Cu PTSM complexes produced by a generator for, 308P(ab)
 neural development studies, conscious infant primates, 55P(ab)
 neuroactivation studies, ^{15}O water and butanol kinetics in, 222P(ab)
 neurological FDG, postinjection transmission measurements, attenuation correction, 128
 neuroreceptor occupancy, patterns in subjects treated with typical and atypical antipsychotic drugs, 1122
 nonpeptide angiotensin antagonist E-3174, pharmacological potency, 288P(ab)
 nonstationary scatter subtraction-restoration, reducing spillover effects in high-resolution studies, 2040
 optimal sampling schedule, nuclear medicine measurement, 227P(ab)
 outcome of temporal lobe epilepsy surgery, 1094
 parallel reconstruction tool for, penalized weighted least square algorithms in, 154P(ab)
 parathyroid L- ^{113}C -methionine accumulation, hyperparathyroidism, 1766
 Parkinson's disease
 clinical significance of striatal DOPA decarboxylase activity, 216
 combined FDOPA and 3OMFD studies, 209
 partial volume effects in, MRI-based correction for, 154P(ab)
 phantom measurements, production of ^{85}Sr isotope, 166P(ab)
 pharmacokinetic studies, measurement of arterial input function, 266P(ab)
 potential use of ^{113}C -KF15372, adenosine A₁ receptor ligand, 1203
 probability of malignancy in solitary pulmonary nodules, ^{18}F -FDG, 943
 quantitation of cerebral perfusion with ^{67}Cu -PTSM and three-compartmental model, 1089
 quantitative imaging
 ^{123}I , 1557
 quantitative protein synthesis rate determination, without arterial sampling, 225P(ab)
 radiation dose estimates, primates, ^{14}C arachidonic acid, 230P(ab)
 radiolabeled A₁ adenosine receptor antagonists as ligands for, 142P(ab)
 reaction volume, in vivo ligand-receptor model, 118
 receptor studies, tissue model for, 224P(ab)
 regional differences in cerebral blood flow in oxidative metabolism, 1086
 reporter gene/reporter probe technology, imaging gene expression in living animals, 107P(ab)
 reproducibility of measurements of myocardial blood flow, resting and hyperemic states, 1626
 response to hyperthermic isolated limb perfusion for soft-tissue sarcoma, ^{18}F -FDG, 984
 retracted-SEPTA data, accurate 3D reconstruction with, 225P(ab)
 scatter correction techniques, high-resolution imaging, 2046
 Sherbrooke avalanche photodiode PET scanner, performance of, 170P(ab)
 short-axis angle selection, effect on quantitation of myocardial uptake, 160P(ab)
 simplified deoxyglucose utilization rate analysis, 950
 spontaneous regression of intracranial arteriovenous malformation, 1673
 squamous cell carcinoma metastases, uptake of L-1- ^{14}C -tyrosine, comparisons with other methods of evaluations, 897
 staging of small cell lung cancer, cost-effectiveness of, 110P(ab)
 striatal dopamine system, acute methamphetamine and amphetamine effects, 163P(ab)
 targeting glucose transport proteins for tumor imaging, 1031
 three-dimensional correction for spillover and recovery of myocardial images, 767
 time course of regional brain activation, serotonin release, ^{15}O water use in, 123P(ab)

- transmission measurements in, 19P(ab)
transmission scans, image fusion method for adjustment of, 209P(ab)
transmission to emission transformation, in projection space, 155P(ab)
transport capacities and volumes of ¹³C MHED, during catecholamine stimulation, 70P(ab)
trigeminal neuralgia, central processing of pain in, 278P(ab)
tumor tracers, normal and elevated media glucose levels, 64P(ab)
visceral pain, normal and pathologic perception of, regional cerebral activity in, 123P(ab)
volume imaging scanner, ultra high resolution, 276P(ab)
whole body
 3D elastic transformation in registration of, 130P(ab)
 attenuation correction using short transmission scans, 172P(ab)
 attenuation correction with transmission image segmentation, 8P(ab)
 distinguishing pathological from physiological and artifactual FDG accumulations, 441
- Positron volume imaging**, singles-based, scatterin, 172P(ab)
- Postconcussion syndrome**, ^{99m}TcHMPAO SPECT use in, 278P(ab)
- Post-traumatic stress disorder**, regional cerebral blood flow SPECT activation study in, 285P(ab)
- Posterior circulation**, SPECT and MRI evaluations of, moyamoya disease, 1613
- Postinjection transmission**, measurement for attenuation correction, neurological FDG-PET studies, 128
- Postural cerebral hypoperfusion**
 frontal area vascular reponse, ^{99m}Tc-HMPAO SPECT, 1
 in patients with orthostatic hypotension, denervated myocardium, 1824
- Practice guidelines**
 appropriateness of functional brain imaging, 1256
 for bone pain treatment, 881
 for bone scintigraphy, 1903
 for general imaging procedures
 nuclear medicine computer systems, 2087
 scintillation cameras, 2087
 SPECT imaging, 2089
 for imaging with radiopharmaceuticals, 2092
 for lung scintigraphy, 1906
 for thyroid scintigraphy, 1264
 for thyroid uptake measurement, 1266
- Prefrontal cortex**, hypoperfusion in psychiatric illness, SPECT, 410
- Pregnancy outcome**, exposure to ¹³¹I in thyroid cancer patients, 606
- Pregnancy-related complications**, radionuclide captopril renography, renal artery aneurysms, 1368
- Preoperative chemotherapy**
 assessment of effect on osteosarcoma using ²⁰¹Tl scintigraphy, 1444
 evaluation of, using FDG-PET studies in breast cancer patients, 931
- Presynaptic neuron**, use of ¹⁴C-KF15372 in detecting degeneration of, adenosine A₁ receptor ligand, 1203
- Pretargeting**, infection imaging with streptavidin and ¹¹¹In-biotin, osteomyelitis, 1655
- Primary hyperparathyroidism**
 comparison of FDG-PET and sestamibi-
- SPECT, 1809
 localization of ectopic parathyroid adenomas, ^{99m}Tc-MIBI, 631
- Primary sensorimotor cortex**, regional functional differences in cerebral blood flow, oxidative metabolism, 1086
- Primary visual cortex**, regional functional differences in cerebral blood flow, oxidative metabolism, 1086
- Primitive neuroectodermal CNS tumors**, children, somatostatin receptor scintigraphy in, 286P(ab)
- Probability of reversible myocardial ischemia**, myocardial perfusion imaging, diagnostic and management strategy, 1618
- Procedure guidelines**
 bone pain treatment, 881
 bone scintigraphy, 1903
 extended scintigraphy for differentiated thyroid cancer, 1269
 general imaging, 2087
 imaging with radiopharmaceuticals, 2092
 lung scintigraphy, pulmonary embolism, 1906
 methodology for procedural directives in nuclear medicine, 878
 thyroid scintigraphy, 1264
 thyroid uptake measurement, 1266
- Prognosis**, thyroglobulin as tumor marker, use after thyroideectomy and prior to ablative radioiodine therapy, 1962
- Prolactin**, levels measured by scan findings, radioiodine breast uptake in non-breastfeeding women, 26
- Prostate**, ^{99m}Tc-labeled antibodyCYT-351, conjugation, labeling and clinical studies, 96P(ab)
- Prostate cancer**
 adenocarcinoma
 gemcitabine effects in, 265P(ab)
 glucosylfisfamide biodistribution in rats, 264P(ab)
 bone metastasis with superimposed osteomyelitis, diagnostic difficulties, 999
 EDTA effects on ¹¹¹In KC-4G3, 198P(ab)
 evaluation of ¹⁸F androgen receptor ligands in baboons, 1009
 human dosimetry
 diagnostic doses of ¹¹¹In-CYT-356 in prostate cancer patients, 1583
 marrow suppression as result of ⁸⁹Sr, DIC, 401(l)e
 metastatic
 patterns determined by ¹¹¹In CYT356 immunoscintigraphy, 10P(ab)
 suramin therapy, evaluation with FDG-PET, 267P(ab)
 pain relief of bone metastasis with ¹⁸Re-etidronate, pain assessment diary, 1511
 recurrent, monoclonal antibody imaging for staging of, 10P(ab)
 sigma receptor binding sites in tumor cells, 205P(ab)
 simultaneous dual energy SPECT imaging of, 217P(ab)
 staging with ¹⁸F FDHT, 87P(ab)
 staging with monoclonal antibody scan, 11N(4)
- Prostate-specific antigen**, changing levels, serial bone scans, prostate cancer patients, 296P(ab)
- Prostatectomy**, transurethral, renal functional changes after, ^{99m}Tc EC diagnosis of, 289P(ab)
- Prosthetic vascular graft infection**, diagnosis with avidin/¹¹¹In-biotin imaging, 55
- Protein**, labeling with cyclopentadienyltricarbonyl technetium, 28P(ab)
- Protein leak**, differentiating hydrostatic pulmonary edema from ARDS, noninvasive, bedside dual-radionuclide method, 1316
- Protein synthesis**, PET tracer assessment in liver, L-1-¹⁴C Tyr and L-Me-¹⁴C Met, 279
- Pseudomembranous colitis**, abnormal colonic accumulation of 18F-FDG, 1683
- Psychiatric illnesses**, evaluation of the dopamine system of the human brain, PET, 1242
- Puberty**, delayed, testosterone treatments on bone mineral density, 103P(ab)
- Pulmonary edema**, ¹²³I-MIBG imaging in pheochromocytoma, excessive catecholamine effect on heart and lungs, cardiomyopathy, 1361
- Pulmonary embolism**
 acute, V/Q scans, chest radiographic findings and, 117P(ab)
 clinical diagnosis of, 295P(ab)
 companion leg Xenon imaging, part of routine V/Q scanning, 302P(ab)
 computer assisted V/Q assessment for directing pulmonary angiography, 294P(ab)
 prevalence of recurrence, 295P(ab)
 criteria for diagnosis of, DTPA aerosol use in, 295P(ab)
 diagnostic value of small perfusion defects on ventilation/perfusion lung scans, 1313
 DMP 444 as potential imaging agent, 119P(ab)
 evaluating criteria for low probability interpretation of ventilation-perfusion scans, 577
 imaging, ^{99m}Tc P748, 231P(ab)
 low probability lung scans, review of six-month mortality in, 117P(ab)
 lung scanning in diagnosis of pulmonary embolism, 165
 lung scans for, pattern recognition systems with synthetic discriminant function, 124P(ab)
 massive, prognosis after, 117P(ab)
 matched ventilation, perfusion, and chest radiographic defects, detection of, 1636
 patient stratification by cardiopulmonary status, V/Q scan, 570
 procedure guidelines for lung scintigraphy, 1906
 pulmonary angiograms with and without lung scans, comparison of lung scan criteria and, 118P(ab)
 ventilatory imaging, ^{99m}Tc pertechnegas and ¹³³Xe comparison, 116P(ab)
- Pulmonary embolus**, pleural effusion and ventilation/perfusion scan interpretation, 1310
- Pulmonary hypertension**, myocardial imaging with ¹²³I-MIBG, right heart sympathetic neuronal function, 1343
- Pulmonary leak index**, noninvasive differentiation of hydrostatic pulmonary edema from ARDS, ⁶⁷Ga, 1316
- Pulmonary scintiscans**
 diagnosis of pulmonary embolism, patient stratification by cardiopulmonary status, 570
 positive predictive value of triple-matched defects, detection of acute pulmonary embolism, 1636
- Pulmonary tuberculosis**, detection follow-up, ^{99m}Tc-MIBI scintigraphy, 233
- Pure photosensitive epilepsy**, brain SPECT
- Pyelonephritis**
 comparison of planar (pinhole) and SPECT imaging in piglets, ^{99m}Tc-DMSA, 1731

pediatric, cortical lesions in, 99m Tc MAG₃ and 99m Tc GH comparison, 287P(ab)

Pyridinethiols, co-ligand for 99m Tc-labeled hydrazinonicotinamide conjugated peptides, 152P(ab)

Pyrimidinethiols, co-ligand for 99m Tc-labeled hydrazinonicotinamide conjugated peptides, 152P(ab)

Q

Quality assessment, interlaboratory program, Dept. of Veterans Affairs, Nuclear Medicine Service, 306P(ab)

Quality control, improved flood sourceuniformity, chelation of 113 In, liquid-filled plexiglass tank, 211P(ab)

Quantification

benzodiazepine receptor concentration and FMZ affinity, partial saturation method, PET measurement in pons, 5
biodistribution of 111 In-pentetreotide, endocrine tumors and lymphoma, 916
comparison of planar and SPECT normal data files, 201 Tl, 99m Tc-sestamibi, 99m Tc-tetrofosmin, and 99m Tc-furlosommin, 1783
reappraisal of quantitative esophageal scintigraphy, ROC analyses, 1799

Quantitation

Metz intrinsic attenuation correction method, performance in parameter estimation tasks, 18P(ab)
nonlinear tasks, performance for, at low SNR, 124P(ab)
parameter estimation tasks, evaluation of SPECT scatter compensation methods, 29P(ab)
protein synthesis rate determination, PET without arterial sampling, 225P(ab)
regional radioactivity, spatial variability of, PET brain scans, 222P(ab)
single projection method, determination of radionuclide uptake, 209P(ab)
time-activity curve slope, as a diagnostic guide, 206P(ab)

Quantitative imaging

123 I with PET, 1557
Quantitative measurements, influence of collimator design, SPECT, 1832

R

Radiation dose, from breastfeeding after thallium-201, 2079

Radiation dosimetry

evaluation of 67 Cu in 67 Cu-2IT-BAT-Lym-1, 146
predictive doses from therapy using tracer studies, 131I-labeled antibodies, 1970

Radiation fear, role of nuclear physician in communicating risk, 11N(2)

Radiation necrosis, hyperperfusion and hypermetabolism with epileptic activity, PET and SPECT, 1174

Radiation pneumonitis, imaging with 113 In-pentetreotide, 584

Radiation risk, responsibility to communicate medical radioactive hazards, 1915(le)

Radiation therapy

103 Rh with tetraether ligands, 165P(ab)
 113 I, thyroid adenoma, absorbed dose estimate by 131 I before, 230P(ab)
 113 Re RC-160, regional tumor treatment strategy, 236P(ab)
high-dose focal, high-grade gliomas,

SPECT/CT-guided biopsy after, 158P(ab)
organ S values for individual patients, 232P(ab)
sequential pulmonary effects of, detection by 99m TcDTPA radioaerosol inhalation lung scintigraphy, 234P(ab)

studies of 67 Cu TETA octreotide, tumor-bearing rats, 128P(ab)
unsealed source, for solid tumors, 235P(ab)

Radiation treatment planning, squamous head and neck cancer, immuno-SPECT, 99m Tc-labeled monoclonal antibodies, 1942

Radioactive waste, possible low-level site in Texas, 33N(5)

Radioaerosol

99m Tc DTPA inhalation lung scintigraphy, detection of pulmonary effects of radiation therapy, 234P(ab)

99m Tc DTPA lung scintigraphy acute inhalation injury in fire victims, 294P(ab)

clearance, systemic lupus erythematosus, 295P(ab)
criteria for diagnosis of pulmonary embolism, 295P(ab)

Radiochemical yield, optimum pH for, from stannylated precursors, 187P(ab)

Radiocontaminant, assay calculation of 67 Cu and 64 Cu, ionization chamber dose calibrator, 302

Radioimmunoassay

thyroid hormone binding ratio, free thyroxine estimate and, 144P(ab)

V1-V3 specific antimyosin antibody, genetically engineered single chain Fv of, mammalian system, 144P(ab)

Radioimmunoconjugates, monoclonal antibody CC49 labeled with 47 Sc, pre-clinical evaluation, 150P(ab)

Radioimmunodetection, therapy, CEA-expressing tumors, 9P(ab)

Radioimmunoscopy

CEA-scan, diagnosis and staging of breast cancer, 238P(ab)

NHS-BAT ester for antibody conjugation and 99m Tc labeling, 362

preparation of 113 Re-MAG3-MAb conjugates, head and neck cancer, 352
radiation treatment planning in squamous head and neck cancer, SPECT, 1942

staging cutaneous malignant melanoma, 252

Radioimmunotherapy

113 In MX-DTPA humanized BrE-3MAB, in advanced breast cancer, 169P(ab)

131 I anti-CEA antibodies, red marrow dose and myelotoxicity relations, 43P(ab)

131 I-labeled chimeric G250 monoclonal antibody, renalcell carcinoma patients, 169P(ab)

67 Cu anti-colon cancer monoclonal antibody, intact and combination, 61P(ab)

67 Cu BAT-2IT-NR-LU-10 Fab as an agent for, 95P(ab)

67 Cu 21T-BAT-LYM-1, mice implanted with Burkitt's lymphoma, 128P(ab)

99m T labeling of monoclonal antibody macrocyclic chelator conjugates for, 62P(ab)

99m Y combined with anti-EGFr c225, nude mice with human breast tumors, 167P(ab)

99m Y DOTA therapeutic enhancement with taxol, treatment of human breast tumors in nude mice, 129P(ab)

acute leukemia, bone marrow transplant, 131 Ianti-CD45 antibody regimen prior to, 233P(ab)

alpha-particle emitting radionuclide, preclinical

characterization, 78P(ab)

anti-CEA murine MN-14 F(ab)₂ as potential agent for, tumor targeting, 169P(ab)

B-cell lymphoma, enhanced retention of radionuclides by, 99m Tc-labeled monoclonal antibody, 151P(ab)

bifunctional chelating agent for, 167P(ab)

bispecific antibodies and 131 I-labeled bivalentaptens, BCL1

lymphoma, 129P(ab)

bone marrow dosimetry, regional variability, 695

CEA-expressing cancers

131 I-labeled anti-CEA monoclonal IgG, 168P(ab)

tumor dosimetry with 131 I-labeled CEA and anti-mucin monoclonal antibodies, 231P(ab)

CEA-producing cancers, 131 I-labeled anti-CEA monoclonal antibody, 168P(ab)

colon cancer, 131 I-labeled MN-14 IgG anti-CEA MAb, 169P(ab)

determination of radionuclide uptake, single projection method for, 209P(ab)

dosimetric evaluation of 67 Cu in 67 Cu-2IT-BAT-Lym-1, 146

dosimetric potential, minimal residual disease, radiolabeled antibodies, 44P(ab)

generator produced 90 Y, chemical form, clinically useful

radioconjugates, 195P(ab)

intraperitoneal administration of 177 Lu-CC49, ovarian cancer, 1491

loss of immunoreactivity during labeling, prevention of radiolysis of monoclonal antibodies, 1384

LYM-1 therapy, B-lymphocytic malignancies, 170P(ab)

micro and occult metastases, SCID mouse model, 44P(ab)

ovarian cancer, 131 I-labeled MN-14 IgG anti-CEA MAb, 168P(ab)

patient-specific dosimetry

113 In/ 90 Y-labeled monoclonal antibodyCC49, 90P(ab)

quantitative SPECT imaging and 3D-DFT convolution, 89P(ab)

prediction of radiation doses from therapy, tracer studies using 131 I-labeled antibodies, 1970

preparation of 113 Re-MAG3-MAb conjugates, head and neck cancer, 352

small-scale alpha dosimetry, red bone marrow, using histological images, 231P(ab)

therapeutic activity, simplified method for determination of, 43P(ab)

treatment for medullary thyroid cancer, 131 I-labeled Anti-CEA antibodies, 905

treatment planning, based on radiation absorbed dose or patientsize, 43P(ab)

use of 131 I-NP-4 F(ab)₂ anti-CEA antibody in patients with small volume tumors, 1504

Radioindium-labeled substance P, visualization of SP receptor-positive organs, 108

Radioiodinated phospholipid ethers, biological distribution and imaging, rat mammary tumor models, 1540

Radioiodine

breast uptake in non-breastfeeding thyroid

cancer patients, whole body scanning, 26

intravesical administration of 131 IUDR for bladder

cancer, 315

therapy

autonomous thyroid nodule, 401(le)

dosimetry and risk estimates of, multinodular

- goiters, 2072
 prognostic value of thyroglobulin after thyroidectomy, thyroid cancer, 1962
 uptake enhanced by tumoricidal cytokines in cultured thyroid cancer cells, 646
- Radioisotope dilution technique.** ^{99m}Tc -Q12 and ^{201}Tl extraction and retention, effects of ouabain, 752
- Radiolabeled aerosols**, deposition and regional ventilation, ^{99m}Tc -DTPA, 239
- Radiolabeled antibody fragments**, improved prospects for cancer therapy, peptides, 834(ed)
- Radiolabeled biotin**, imaging osteomyelitis, streptavidin, 1655
- Radioligand binding**, in vitro comparison with in vivo receptors, PET, 1275
- Radiotherapy**
- decomposition, $^{99m}\text{YDOTA}$ -biotin, 166P(ab)
 - prevention of, protection of monoclonal antibodies during labeling, 1384
- Radionuclide angiography**, simultaneous perfusion tomography during dobutamine stress, 1306
- Radionuclide clearance**, formula to measure renal function in children and adults, ^{99m}Tc -MAG3, 588
- Radionuclide gastric emptying**, lag phase quantification, time-activity curves, first appearance of bowel activity, modified power exponential, 1639
- Radionuclide imaging**
 - ^{201}Tl and ^{99m}Tc -tetrofosmin uptake comparison, cardiac low flow state and systolic dysfunction, 1398
 - investigations of breast tumors, ^{18}F -FDG and SPECT, 615
 - morphine-augmentation in gallbladder nonvisualization, pericholecystic rim sign, 267
- Radionuclide studies**, monitoring of graft and native liver functions post transplantation, 847
- Radionuclide therapy**
 - risk versus benefits in cancer therapy, ^{131}I -MIBG dosimetry, 1058
 - use of ^{99m}Y -glass microspheres for liver malignancy, 958
- Radionuclide venography**, diagnosis and functional assessment in superior vena cava syndrome, jugular venous reflux, 1460
- Radionuclides**
 - combination therapy, bone metastases, 32P(ab)
 - compartmental model for lung clearance, pertechnegas, 2066
 - medical use discussed with SNM and ACNP presidents, NRC chairman, 29N(5)
 - unauthorized use, new NRC rule, 15N(6)
- Radiopharmaceutical synthesis**, simple preparation of ^{14}C -acetate, 341
- Radiopharmaceutical therapy**, pleuroperitoneal migration of ^{32}P -chromic phosphate, ovarian cancer, 636
- Radiopharmaceuticals**
 - 20-minute bacterial endotoxin test for, 305P(ab)
 - chelating ligand in ^{99m}Tc , solid phase chemistry method for removal of excess, 189P(ab)
 - comparison of four, imaging of breast cancer, 75P(ab)
 - distribution localization, high resolution miniaturized gamma camera use in, 303P(ab)
 - effect of administration on Schilling test performance, 1995
 - inhaled beclomethasone, deposition of, ^{99m}Tc labeling method for, 142P(ab)
 - positron, radiation absorbed dose estimates for, 228P(ab)
 - prevalence of adverse reactions, 185
 - prior administration, effects on Schilling test, 162P(ab)
 - rapid preparation method for ^{99m}Tc bicisate, 142P(ab)
 - receptor-binding, sentinel node imaging, 118P(ab)
- Radiopharmacokinetic modeling**, index of hepatic function, Tc-NGA, receiver operating characteristics, 160
- Radiosurgery**, stereotactic, hyperacute changes in tumor FDG uptake after, 257P(ab)
- Radiotherapy**, evaluation of therapeutic effects on VX2 liver tumor, FDG-PET, 296
- Radiotoxicity**, ^{131}I -labeled oligodeoxyribonucleotides, mammalian cells, 228P(ab)
- Raise-up test**, with ^{99m}Tc -HMPAO brain SPECT to study cerebral perfusion in orthostatic patients, 1
- Rapid thyroidal iodine-131 turnover**, hyperthyroidism, 1815
- Rat heart**, kinetics of ^{18}F -PFBG, catecholamine uptake, 2011
- rCBF**, imaging during focal seizure activity, HMPAO, 661
- Reaction volume**
 - compartments, brain fluid spaces, 126(ed)
 - in vivo ligand-receptor interaction modeling, lipophilicity, 118
- Receiver operating characteristic analysis**, effect on lesion detection, hepatic SPECT, 30P(ab)
- Reappraisal of quantitative esophageal scintigraphy**, motility disorders, 1799
- Receiver operating characteristics**
 - kinetic analysis of Tc-NGA, detection of hepatocellular disease, 160
 - use of ^{99m}Tc -HMPAO SPECT and texture analysis to detect decompression illness in divers, 1154
- Receptor binding**, ^{99m}Tc -labeled peptides, somatostatin, 1016
- Receptor-binding radiopharmaceuticals**, diagnostic performance in hepatocellular disease, 160
- Receptor-mediated endocytosis**, radiopharmaceutical targeting, ^{67}Ga -DF-Folate, 1003
- Receptors**, free ligand concentration heterogeneity, reaction volume, 118
- Reconstruction**
 - 3D iterative filtered backprojection algorithm for, SPECT with fan beam collimation, 214P(ab)
 - accelerated
 - 3D SPECT, dual matrix ordered subsets, 62P(ab)
 - SPECT, fast line search strategy, 62P(ab)
 - Bayesian image, cardiac PET, 130P(ab)
 - brain SPECT, reconstruction of brain SPECT Poisson noise, 218P(ab)
 - decomposition of images, pinhole imaging system, 63P(ab)
 - fast iterative algorithms, attenuation correction of cardiac SPECT, 63P(ab)
 - fast iterative PET, performance evaluation, 154P(ab)
- FBP and OS-EM comparison**, signal-to-noise ratio in neurologic FDG-PET, 220P(ab)
- iterative**
 - 180 degree data, 217P(ab)
 - 3D depth-dependent point response in, 153P(ab)
 - rapid 3D projection in, using Gaussian diffusion, 63P(ab)
 - valid backprojection matrices, 206P(ab)
- list-mode likelihood**, 124P(ab)
- local statistics of PET**, analytic computation and sample estimation, 155P(ab)
- maximum-likelihood image**, from list-mode data, 124P(ab)
- ML-EM algorithm**, retracted-SPETA PET data, 225P(ab)
- MRI-constrained PET**, newly-developed, 223P(ab)
- multiple energy**, MLEM use in, SPECT, 171P(ab)
- ordered subset**, elliptical orbits and, effects on SPECT 3D spatial resolution, 63P(ab)
- parallel tool for PET data**, penalized weighted least square algorithms in, 154P(ab)
- phantom experiments**, with rotating slant-hole SPECT camera, 120P(ab)
- spillover artifacts in PET**, additive models and seeded region growth, 224P(ab)
- truncated projection data**, L-shaped dual detector system, myocardial SPECT, 210P(ab)
- Recovery correction**, suppression of spillover due to limited resolution, myocardial PET, 767
- Recurrent tumor**, comparison of ^{18}F -FDG and ^{113}C -MET PET, 1472
- Red blood cells**
 - ^{99m}Tc -labeled, label stability over time, 199P(ab)
 - Ultratag kit, splitting of, use in cardiac first pass studies, 83P(ab)
- Reference tissue model**, PET receptor studies, 224P(ab)
- Region of interest**
 - nonstationary resolution recovery for, SPECT, 153P(ab)
 - rough edges, approach to variance reduction, 155P(ab)
- Regional cerebral blood flow**
 - comparison of ^{99m}Tc -HMPAO and ^{133}Xe by SPECT, acetazolamide, 1735
 - permeability-surface model, nonlinear correction of brain perfusion, SPECT, 1237
 - predictive capacity of ^{99m}Tc -HMPAO SPECT, 12 months after mild head injury, 1605
 - SPECT and MRI evaluation of posterior circulation in patients with moyamoya disease, 1613
- Regional cerebral metabolic rates of glucose**, routine estimation, FDG-PET, 147P(ab)
- Regional hematocrit**, measurement with ^{67}Cu -HSA-DTC, assessment of cerebral circulation, 1080
- Regional skeletal metabolism**, sex specific and age-related changes in bone metabolism, ^{99m}Tc -HMDP, 815
- Regional ventricular function**, correlation of ^{201}Tl reverse redistribution with coronary lesion, wall motion abnormality, and tissue viability, 735
- Renal artery aneurysms**, radionuclide captopril renography, postpartum, 1368
- Renal artery stenosis**
 - ACE-inhibition in, captopril renography after, 46P(ab)
 - renographic characteristics in renovascular disease, 594

- renography in diagnosis, aspirin versus captopril renography**, 289P(ab)
- Renal cell carcinoma**
evaluation, whole-body FDG-PET, 141P(ab)
radioimmunotargeting, ¹¹¹I-labeled chimeric G250 monoclonal antibody, 169P(ab)
- Renal circulation**, exercise renography in untreated hypertensive patients, 838
- Renal clearance**
accuracy of measurements using precordial gamma camera curve, ^{99m}Tc-MAG3, 1281 estimation, modified countingmethod for estimation of ^{99m}Tc MAG3, 291P(ab) radionuclides in nephrourology, Committee on Renal Clearance report, 1883
- Renal cyst**, febrile patient with polycystic kidney and liver disease, scintigraphic findings, 2062
- Renal failure**, contrast-induced nephrotoxicity, role of radionuclide renal scan, vascular occlusion versus ATN, 1828
- Renal function**
biokinetics of ^{99m}Tc-DMSA, pediatrics, 1331 noninvasive quantification using ^{99m}Tc-MAG3 and gamma camera in children, 71
- Renal hypertension**, exercise renography in untreated subjects, 838
- Renal imaging**, ^{99m}Tc-DMSA SPECT, cortical scintigraphy in normal volunteers, 1346
- Renal plasma flow**, gamma camera renography in children, 71
- Renal scintigraphy**, baseline and after captopril administration, Barter's syndrome, 1688
- Renal tubular re-uptake**, reduction with sodium maleate or lysine administration, ¹¹³In-DTPA-octreotide, 1388
- Renal uptake reduction**, effects of amino acid infusion on monoclonal antibody fragments, 829
- Renogram**, contrast-induced nephrotoxicity, vascular occlusion versus ATN, 1828
- Renography**
^{99m}Tc EC, after transurethral prostatectomy, 289P(ab)
aspirin versus captopril, diagnosis of renal artery stenosis, 289P(ab)
captopril, ACE-inhibition in renovascular hypertension, 46P(ab)
characteristics in renovascular disease, stenosis, 594
detection of renovascular hypertension, ACE inhibition, consensus report, 1876
diuresis
2-point postural drainage with, assessment of hydronephrosis, 46P(ab)
interpretation of, using feed forward neural network, ^{99m}Tc-MAG3 captopril investigations, 1649
suitability for deconvolution analysis, 403(ie)
- Renovascular hypertension**, baseline and postcaptopril renal blood flow measurements, essential hypertension, 1652
- Renovascular hypertension**
ACE inhibitor renography, consensus report, 1876
detection and therapy, meta-analysis of costs, sensitivities, specificities, 171
radionuclide captopril renography, postpartum renal artery aneurysms, 1368
- Reperfusion**, detection of ^{99m}Tc-nitroimidazole in myocardial tissue, 761
- Reperfusion injury**, changes in function and regional glucose uptake, stunned porcine myocardium, PET, 2006
- Reproducibility**, myocardial edge detection for gated-pool scintigraphy, 685
- Reproducibility studies**
dopamine D2 receptor binding, with ¹²³I IBF SPECT, 281P(ab)
regional brain metabolic responses to lorazepam, 76P(ab)
renal uptake of ^{99m}Tc MAG₃, semiautomated and manual regions of interest, 293P(ab)
- Research**
and education as investment in the future, 17N(7)
future plans in nuclear medicine research, 16N(2)
- Residual disease**, ²⁰¹Tl and ^{99m}Tc-sestamibi SPECT, nasopharyngeal carcinoma pre- and post-therapy changes, 1956
- Restenosis**, detection after successful PTCA, ^{99m}Tc-sestamibi SPECT, 1300
- Retention index**, differential diagnosis of toxoplasmosis and CNS lymphoma in patients with AIDS, ²⁰¹TL SPECT, 1150
- Retinal metastases**, somatostatin-receptor scintigraphy, bronchial carcinoid, 1537
- Reverse redistribution**, indications for thallium reinjection, 742(ed)
- Rhenium**
detection with microelectrode sensors, 205P(ab)
peptide hormone, structure and function, 96P(ab)
- Rhenium complexes**, serotonin receptor binding, improvement of receptor selectivity and blood-brain transfer, 16P(ab)
- Rhenium-186**, rapid separation from Tungsten target, 196P(ab)
- Rhenium-186-HEDP**
dose escalation in breast cancer patients, bone metastases, 244
efficacy in prostate cancer patients with metastatic bone pain, pain assessment diary, 1511
palliation of metastatic bone pain, 38
- Rhenium-186-labeled monoclonal antibody**, clinical radioimmunotherapy, head and neck cancer, 352
- Rhenium-188**
direct labeling of proteins with, role of TIN-117m in, 195P(ab)
RC-160 somatostatin analog labeled with, regional tumor radiotherapy, 236P(ab)
- Rhodium-105**
tetrahydroacridine conjugate, bombesin analogue, 61P(ab)
tetraether ligands with, 165P(ab)
- Right ventricular hypertrophy**, evaluation of sympathetic nervous system, ¹²³I-MIBG cardiac imaging in pulmonary hypertension, 1343
- ROC analysis**, ^{99m}Tc MIBI SPECT, coronary artery disease, 160P(ab)
- Rotor syndrome**, kinetic cholescintigraphy in evaluation of, 247P(ab)
- Rubidium-82**, simplified PET protocol for determining coronary flow and flow reserve, ¹⁵N-ammonia, 1701
- S**
- S-values**, revised adult head and brain model for dosimetry, 1226
- Salivary gland**
absorbed dose of radioiodine, thyroid patients, 102P(ab)
function, parenchymal damage after treatment with high doses of ¹³¹I, 246P(ab)
quantitative scintigraphies, patients with reflux esophagitis, 245P(ab)
- Salivary glands**, ²⁰¹Tl imaging versus ⁶⁷Ga imaging, ^{99m}Tc, 1819
- Samarium-153 EDTMP**, as palliative agent, bone metastases patients, 32P(ab)
- Sarcoidosis**
lung and gastric uptake in bone scintigraphy, ^{99m}Tc-MDP uptake, hypercalcemia, 1530
- Sarcoma**
comparison of ¹⁸F-FDG-PET and ^{99m}Tc-MIBI SPECT, diagnostic accuracy, 1476 FDG-PET evaluation, response to hyperthermic isolated limb perfusion, 984 monitoring neoadjuvant therapy response, ¹⁸F-FDG-PET, 1438 tumor glucose metabolic rate anddifferential uptake ratio, FDG use in, 140P(ab)
- Sarcoplasmic reticulum**, calcium ATPase, inhibition in cardiomyopathy, 144P(ab)
- Scaled subprofile model**, cerebral glucose metabolism in HIV-1 seropositive subjects, AIDS dementia complex, 1133
- Scandium-47**, monoclonal antibody CC49 labeled with, pre-clinical evaluation, 150P(ab)
- Scatter components**
Monte Carlo-based analysis of PET contributions, 2024 subtraction-restoration in high-resolution PET, nonstationary, 2040
- Scatter correction**
Monte Carlo-based calculations, PET, 2024 scintillation camera imaging of ¹³¹I, window-based and spectrum-fitting techniques, 2030 subtraction-restoration in high-resolution PET, nonstationary, 2040
- Scatter correction techniques**
3D iterative, nonuniform attenuating media, SPECT, 216P(ab)
3D PET without, dynamic FDOPA scans for, 73P(ab)
attenuation correction and, extra-cardiac activity on myocardialperfusion SPECT, 214P(ab)
attenuation correction combined with ²⁰¹Tl cardiac SPECT, 30P(ab)
simultaneous transmission/emission SPECT system, 209P(ab)
dual photopeak window method, digital stationary dedicated brain camera, 77P(ab)
effect on lesion detection, hepatic SPECT, 30P(ab)
energy spectral deconvolution use in, Compton-scatter correction, 171P(ab)
estimation method, fan-beam SPECT, 30P(ab)
invertibility and noise properties, multiple energy window projection data, SPECT, 7P(ab)
limitations of, 171P(ab)
models for high-resolution PET, 2046 outside the field-of-view, infant PET scans, 226P(ab)
shared charge collection effects, Compton camera performance, 170P(ab)
signal and noise tradeoffs with 3D PET ¹⁵O water brain activation studies, 227P(ab)
singles-based PVI transmission imaging, 172P(ab)
SPECT methods, evaluation by parameter estimation tasks, 29P(ab)

- Scatter subtraction**, ^{113}In planar and SPECT imaging, quadruple energy window algorithm use in, 207P(ab)
- SCH 23390**, binding of dopamine D1 and D2 receptor radioligands, 203P(ab)
- Schilling test**
effect of radiopharmaceutical administration, analysis and recommendations, 1995 performance, prior radiopharmaceutical administration on, 162P(ab)
- Schizophrenia**
dopamine transporter in, SPECT measurement of, 33P(ab)
functional frontal eye field impairment, ^{99m}Tc ECD SPECT study, 283P(ab)
impaired Wisconsin card sorting, PET studies of aging, 79P(ab)
- Schwannoma**, neuropeptide imaging of, 1272(l)e
- Scintigraphy**
 ^{111}In WBC, fever of unknown origin, 161P(ab)
 ^{99m}Tc sestamibi, detection of parathyroid pathology in hyperparathyroidism, 158P(ab)
achalasia, botulinum toxin effects, 57P(ab)
antral, gastric emptying, effects of gastric acid suppressant drugs on, 57P(ab)
bone
diagnosis of prosthetic hip loosening, with radiography, 62
effect of bisphosphonate, 401(l)e
gallium bone scintigraphy, 193(l)e
colon transit, subtypes of prolonged colonic transit, 247P(ab)
direct puncture, flow characteristics of soft-tissue vascular anomalies, 183P(ab)
hepatobiliary
after orthotopic liver transplant, 302P(ab)
comparison with ^{99m}Tc PMT and GSA, liver cirrhosis with jaundice, 244P(ab)
histopathology and immunohistochemical correlation, abnormal parathyroid pathology, 159P(ab)
homograft, pediatric limb salvage surgery, 286P(ab)
inhalation, ^{123}I interferon gamma in treatment, 5P(ab)
leukocyte
disease activity in inflammatory bowel disease, 400(l)e
lung, exercise, quantitative analysis of V/Q ratio, 296P(ab)
lymphoma
comparison of ^{67}Ga and ^{201}TI , tumor grade, type, sensitivity of uptake, 46
MAG3 diuretic, acute renal obstruction, 289P(ab)
- MIBG**
childhood tumors, 288P(ab)
imaging in silent myocardial ischemia, evaluation of sympathetic innervation, 712
- MIIBI**, prognosis in pediatric lymphoma, 139P(ab)
- noninvasive detection of early tumor development**, from pseudotumor into lymphoma, ^{67}Ga -citrate, 1524
- per-rectal portal**
hepatic blood flow distribution, mesenteric vein mapping, ^{123}I IMP scintigraphy to detect portal streamlining, 51
- perfusion**, implantation of coronary stent, 126P(ab)
- somatostatin receptor**, staging of melanoma, 138P(ab)
- surgical beta ray camera**, gamma-ray background for, 78P(ab)
use to diagnose and localize infected cysts, patient with polycystic kidney and liver disease and hip prostheses, 2062
- using a radiolabeled somatostatin analog**
compared with conventional imaging in medullary thyroid carcinoma, 912
- ventilation**, ^{133}Xe , tympanum and paranasal sinuses, 4P(ab)
visualization of SP receptor-positive organs, ^{113}In -DTPA-Arg¹, SP, 108
- whole-body**
differentiated thyroid carcinoma, follow-up evaluation, 446
- Scintillation camera**, small, with photodiode readout, imaging of breast tumors, 52P(ab)
energy-based scatter corrections, window-based and spectrum-fitting techniques, 131I, 2030
- Scintimammography**
 ^{99m}Tc MDP(ab)
diagnostic accuracy in suspected breast cancer, 155P(ab)
mammographic microcalcifications without mass, 156P(ab)
 ^{99m}Tc MIBI, planning and monitoring treatment for breast cancer, 156P(ab)
 ^{99m}Tc sestamibi
histopathologic correlation in detection of breast cancer, 75P(ab)
palpable and nonpalpable breast tumors, 259P(ab)
 ^{99m}Tc tetrofosmin, diagnosis of breast cancer and lymph node metastases, 156P(ab)
accuracy, patient age and lesion histology effects on, 254P(ab)
collimator design, imaging geometry and, 78P(ab)
cost-effectiveness of, breast cancer in dense breasts after negative mammogram, 269P(ab)
detection of primary breast cancer, ^{99m}Tc -MIBI, 626
- FDG-PET** and, diagnosis of breast cancer, 265P(ab)
planar with sestamibi, SPECT improvement on accuracy of, 252P(ab)
semiquantitative, or contrast-enhanced MRI, further evaluation of indeterminate mammograms, 156P(ab)
small scintillation camera, with photodiode readout, imaging of breast tumors, 52P(ab)
- Scleroderma**, acetylcholine inhibition in, renal functional response to, 290P(ab)
- Sebaceous cyst**, false-positive ^{113}I whole-body scans in patients with thyroid cancer, cholecystitis, 1690
- Seizures**, quantification of normal percent variation, cerebral blood flow, 305P(ab)
- Semiconductor detectors**
improvement of SPECT resolution, FASTSPECT concept, 301P(ab)
multiplexer readout for high-resolution imaging, 53P(ab)
- Sensitivity analysis**, cost-effectiveness of FDG-PET in non-small-cell lung cancer staging and management, decision tree analysis, 1428
- Sentinel lymph nodes**, drainage to triangular intermuscular space nodes, melanoma on the back, 964
- Sentinel node**
identification
- ^{99m}Tc colloidal albumin, lymphoscintigraphy, 259P(ab)
early stage melanoma lymphoscintigraphy, ^{99m}Tc sulfur colloid, 307P(ab)
lymphoscintigraphy for lymphatic mapping in cutaneous melanoma, 972
- receptor-binding radiopharmaceuticals** for, 118P(ab)
- Septal metabolic mismatch**, left bundle branch block, 1918(l)e
- Septic arthritis**, extensive photopenic osteomyelitis, bone scintigraphy, 1676
- Serotonin**
 ^{113}C MDL 100907 as a radiotracer, kinetic analysis, 145P(ab)
diagnosis of normally active carcinoid tumor, paragangliomas, 270
dopamine interaction, ^{123}I β -CIT binding in striatum with clomipramine, 66P(ab)
release, ^{18}O water, time course of regional brain activation, PET imaging of, 123P(ab)
synthesis
brain, measured by PET and ^{113}C - α -MT, 113P(ab)
reduction in plasma tryptophan and, males and females, 284P(ab)
synthesis rate, estimation by ^{113}C - α -methyltryptophan kinetics, brain, 145P(ab)
- Serotonin receptors**
 ^{113}C MDL 100, 907 imaging, PET, 112P(ab)
 ^{99m}Tc -labeled, as imaging agents, 190P(ab)
antagonists for, 204P(ab)
binding studies, human brain, autoradiography and PET in monkey brain, 112P(ab)
binding technetium and rhenium complexes, improvement of receptor selectivity and blood-brain transfer, 16P(ab)
occupancy
after single dose of ^{113}C MDL 100, 907, 112P(ab)
ziprasidone treatment effects, PET analysis of, 33P(ab)
quantitative imaging, ^{18}F altanserin use in, 109P(ab)
selective imaging, PET, ^{113}C MDL 100907 for, 108P(ab)
- Serotonin system**, radioligand for, radiosynthesis binding affinity and biodistribution of, 40P(ab)
- Serotonin transporters**
fenfluramine and MDMA-induced loss of, PET visualization of, 112P(ab)
impulse response function, kinetic model and, $^{113}\text{CMcN}5652$, 33P(ab)
measures of in vivo binding to, INQUIP SPECT, 1207
SPECT study using ^{123}I , 186P(ab)
- Serotonin-2 receptors**, PET estimation of binding potential, F-setoperone, 95
- Shunt malfunction**, radionuclide shuntogram, hydrocephalus, 406
- Shutogram**, reliability in management of hydrocephalic patients, 406
- Sigma receptors**
binding sites
biopsied solid breast tumors, 267P(ab)
prostate tumor cells, 205P(ab)
probes, radioiodinated arylethylenediamines, 7P(ab)
- Sigma-2 receptors**, as biomarkers, breast cancer, 87P(ab)
- Signal augmentation**, antibody-dependent in tumor xenografts, biotinylated monoclonal antibody, avidin, streptavidin, 343

- Signal-to-noise ratio**
 effect of partition coefficient, permeability surface product, and radioisotope on, PET, 223P(ab)
- tomographic region of interest, approach to variance reduction, 155P(ab)**
- Silent myocardial ischemia, evaluations of sympathetic innervation, ¹²³I-MIBG, 712**
- Simultaneous dual-isotope imaging, influence of downscatter, ²⁰¹Tl and ^{99m}Tc-PYP SPECT, 781**
- Single-blood sample method, estimating glomerular filtration rate, feasibility of using adult technique in children, 1805**
- Single-chain Fv antibody fragments, radiolabeling with ^{99m}Tc for diagnostic imaging, 868**
- Single-photon emission computed tomography (SPECT)**
¹⁸F-FDG and SPECT, investigations of breast tumors, 615
^{99m}Tc, brain, acquisition time in the performance of, 273P(ab)
^{99m}Tc-DMSA scintigraphy, detection of pyelonephritis in piglets, pinhole magnification, 1731
^{99m}Tc DMSA uptake, kidneys, assessment of reproducibility, 290P(ab)
^{99m}Tc ECD
 brain images, mid-sagittal plane, 8P(ab)
 localization of seizure foci, extratemporal epilepsy, 100P(ab)
 study of cerebral perfusion reserve, 88P(ab)
 study of language processing, 280P(ab)
^{99m}Tc-HMPAO
 assessment of neurological deficits during balloon test occlusion, 551
 detection of decompression illness in sports divers, 1154
^{99m}Tc HMPAO
 brain, systemic lupus erythematosus patients, 163P(ab)
 postconcussion syndrome, 278P(ab)
 specific regions of left hemispheric dysfunction, 165P(ab)
^{99m}Tc-HMPAO, predictive capacity of scan 12 months after mild head injury, 1605
^{99m}Tc MAG3, evaluation of renal parenchyma, 23P(ab)
^{99m}Tc-MIBI and 18F-FDG-PET, comparison of diagnostic accuracy in musculoskeletal sarcoma, 1476
^{99m}Tc-sestamibi, assessment of osseous tumor metastases, 1526
^{99m}Tc-sestamibi, bile reflux during myocardial perfusion imaging, identifying noncardiac cause of chest pain, 1285
^{99m}Tc sestamibi
 cardiac
 reconstructions for, 81P(ab)
 scatter, attenuation and resolution, 81P(ab)
 supine vs right lateral imaging, 48P(ab)
^{99m}Tc sestamibi and 201Tl, quantifying perfusion defects, 178P(ab)
^{99m}Tc with dipyridamole, early and delayed imaging comparison, 180P(ab)
¹¹¹In-DTPA octreotide uptake, measurement in normal and abnormal pituitary glands, 1449
¹²³I-BMIPP metabolism and kinetics in canine myocardium, 757
¹²³I bCIT, dopamine transporter during cocaine abstinence, 44P(ab)
¹²³I FP-CIT, striatal signal in Parkinson's disease, 134P(ab)
- ¹²³I IBZM and, aging effects on amphetamine-induced dopamine release, 33P(ab)
- ¹²³I IPT dopamine transporter, Parkinson's disease, 273P(ab)
- ¹²³I IPT dosimetry, imaging dopamine transporters, 151
- ¹²³I-IPT imaging of CNS dopamine transporters, effects of aging on striatal uptake values, 1965
- ¹²³I-MIBG imaging of neuroblastoma, delayed 48-hour scans, 1464
- ¹²³I QNB, imaging of muscarinic receptors, 143P(ab)
- ¹²³I IPT measurement, dopamine transporter, nonhuman primates, 66P(ab)
- ¹³³Xe, motor task activation of cerebral cortex, 273P(ab)
- 180 degree data, use of iterative reconstruction in, 217P(ab)
- ²⁰¹Tl
 childhood brain tumors, 270P(ab)
 interpretation, physician training level effects on, 179P(ab)
 lymphoma and infectious intracranial lesions, AIDS patient, 276P(ab)
- ²⁰¹Tl chloride or ^{99m}Tc sestamibi, intracranial lesions in AIDS, 277P(ab)
- ²⁰¹Tl imaging of astrocytoma, 273
- ²⁰¹Tl rest-redistribution, revascularization after CAD, 178P(ab)
- 3D spatial resolution, ordered subset reconstruction effects, 63P(ab)
- accelerated image reconstruction
 dual matrix ordered subsets, 62P(ab)
 fast line search strategy, 62P(ab)
- accurate attenuation correction, without transmission measurements, 18P(ab)
- adenosine sestamibi, implications, fixed and reversible defects, prior MI, 181P(ab)
- appropriateness of functional brain imaging, ethical clinical practice, 1256
- assessment of results, coronary stents, 126P(ab)
- attenuation artifacts, wrap-around lung effect in cardiac imaging, 1891
- automated 3D registration algorithm, brain, 98P(ab)
- automated interstudy image, registration method, comparison of data sets with PET, 137
- automated search for significant elements in, 209P(ab)
- bone, ^{99m}Tc MDP, diagnosis of lumbar spine lesions, 127P(ab)
- bone
 mandibular invasion, squamous-cell carcinoma, 42
- brain
^{99m}Tc ECD, patients with acute stroke, 13P(ab)
 3D stereotactic surface projection, 215P(ab)
 accurate treatment of Poisson noise, 218P(ab)
 after traumatic injury, 275P(ab)
 automatic registration and intensity scaling in, 213P(ab)
 comparison with MRI, brain tumor patients, 272P(ab)
 perfusion defect after synangiosis surgery, 274P(ab)
 quantitative, transmission CT image quality for, 212P(ab)
 semi-quantitative analysis, pons as reference point, 273P(ab)
 use of 3D Kalman filter for evaluation, 208P(ab)
- brain
¹²³I IBZM infusion, regional brain activity,
- striatal effects of antipsychotic agent RWJ-37796, 11
- Alzheimer's disease, automated neural networks, 195
- astrocytoma visualized by ^{99m}Tc-ECD SPECT, 273
- dipyridamole stress in evaluation of cerebral blood flow reserve, carotid artery stenosis, 1595
- favorable review from neurology panel, 14N(7)
- identification of epileptogenic foci in children, ictal and interictal studies with ^{99m}Tc-bicisate, 1101
- imaging of dopamine transporters, ¹²³I-B-CIT, 1129
- limbic, paralimbic, and prefrontal hypoperfusion in depressive patients, 410
- measurement of dopamine transporters, ¹²³I-B-CIT, 222
- Sturge-Weber syndrome, ^{99m}Tc-HMPAO SPECT, 81
- vascular response in frontal area of patients with orthostatic hypotension, 1
- Bremsstrahlung
 3D quantitative dosimetry of colloidal phosphorus-32, 90P(ab)
- cardiac
 attenuation correction of, short AsF transmission CT for, 210P(ab)
 compensation for attenuation and 2D detector response, 18P(ab)
 compensation of attenuation map errors, 215P(ab)
 defect size, location, and contrast effects, 210P(ab)
 fan-beam, attenuation correction in, 18P(ab)
 kinetic parameters, input function shape and image acquisition, 8P(ab)
 scatter and iterative attenuation correction in, 210P(ab)
- CBF, cerebral dysautoregulation in chronic autonomic failure, 277P(ab)
- cerebral arteriospasm, after subarachnoid hemorrhage, 12P(ab)
- cerebral blood flow, dementias, 79P(ab)
- cerebrovascular stress tests, parenchymal versus vascular cerebral disease, 88P(ab)
- collimator design, influence on quantification, 1832
- combination with FADS for detection of abnormal parathyroid glands, ^{99m}Tc-sestamibi, 1773
- comparative methods for quantifying thyroid volume, planar imaging, 1421
- comparative nigrostriatal dopaminergic imaging in Parkinson's disease, PET, 1760
- comparison of ^{99m}Tc-HMPAO and ^{99m}Tc-ECD images, 1749
- comparison with PET, myocardial uptake of ¹⁸F-FDG, dyssynergic myocardium, 1631
- complex and unresolved issues related to myocardial viability assessment, 794
- Compton camera performance, shared charge collection effects, 170P(ab)
- Compton-scatter correction in, energy spectral deconvolution, 171P(ab)
- concurrent changes in left ventricular function and volumes, perfusion tomography and radionuclide angiography during dobutamine stress, 1306
- continuous step-and-shoot versus step-and-shoot acquisition, 2037
- depth-dependent response, recursive blur models for, 153P(ab)

- detection of ventilatory abnormalities, distribution of ^{133}Xe washout, 807
 diagnosing and monitoring pediatric acute pyelonephritis, 1349
diamox
 middle cerebral artery stenosis, 274P(ab)
 surgical outcome, moyamoya disease in children, 89P(ab)
 unilateral carotid stenosis patients, 274P(ab)
dipyridamole thallium perfusion scintigraphy, correlation with hemodynamic indices, 723
discordant MIBI and HMPAO uptake, recurrent occipital meningoia, 1183
discriminant value in mild Alzheimer's disease, 404(le)
dobutamine stress ^{201}Tl and echocardiography to assess ALCAPA syndrome, 748
dopamine D2 receptor imaging in pituitary adenomas, ^{123}I -epidepride, 1931
dopamine transporter, ^{123}I IPT uptake values, primates, 201P(ab)
dopamine transporters and receptors, alcoholics, 33P(ab)
dual energy, prostate cancer, 217P(ab)
dual-headed system, practical method for attenuation correction, 30P(ab)
dual-isotopic imaging, influence of downscatter, 781
dual-isotope, single acquisition, correction for downscatter, 31P(ab)
dynamic functional, thorax phantom for, 219P(ab)
dynamic, estimation, sampling rate effects, 98P(ab)
ECG-gated, assessment of left ventricular volume, 180P(ab)
evaluation of ^{99m}Tc -ECD as investigational tool in childhood epilepsy, 1106
evaluation of posterior circulation in moyamoya disease, MRI, 1613
fan-beam, cardiac, scatter response function for, 30P(ab)
FDG
 after glucose, myocardial viability, 60P(ab)
 functional outcome after revascularization, 59P(ab)
 lung nodules, 36P(ab)
 myocardial viability, 60P(ab)
 prediction of function recovery, after bypass surgery, 176P(ab)
 versus dobutamine stress echocardiography, after revascularization, 59P(ab)
frontal hypoperfusion in benign exertional headache, ^{99m}Tc -HMPAO, 1172
gated blood-pool imaging
 comparison with planar gated blood-pool studies, left ventricular ejection fraction, 1795
 left ventricular ejection fraction and volume, 97P(ab)
 quantitative analysis of, 93P(ab)
 sensitivity dependence on region definition, 149P(ab)
gated, measurement of left ventricular ejection fraction, 179P(ab), 211P(ab)
high-resolution thyroid pinhole tomography, thyroid gland, 2017
hippocampus, blood flow decreases with memory loss, 285P(ab)
hyperperfusion and hypermetabolism in brain radiation necrosis, ^{201}Tl chloride, 1174
imaging of benzodiazepine receptors, in alcoholism, 285P(ab)
imaging of dopamine receptors, 1591(ed)
 improved accuracy of somatostatin receptor scintigraphy, abdominal carcinoid tumors, 1452
improved method for radioiodination of ^{123}I -IQNB, 2021
improvement on plantar scintimammography, breast cancer, 252P(ab)
inferior wall attenuation, scar, 81P(ab)
interictal brain, value in extra-temporal lobe epilepsy, 271P(ab)
iterative reconstruction of, using Gaussian diffusion, 63P(ab)
kinetic behavior of ^{99m}Tc -ECD, regional cerebral blood flow measured by ^{15}O -water PET, 1600
knee, anterior cruciate ligament tears, 297P(ab)
left ventricular hypertrophy patients, coronary artery disease in, 182P(ab)
line source transmission data, correcting for emissioncontamination, 19P(ab)
localization of mediastinal parathyroid adenoma, ^{99m}Tc -sestamibi, 1535
localization of partial seizures, epilepsy, 101P(ab)
measurement of dopamine synaptic concentration, resting state, 32P(ab)
measurement of dopamine transporter, in schizophrenia, 33P(ab)
measurements of regional cerebral blood flow, comparisons of ^{99m}Tc -HMPAO and ^{133}Xe , acetazolamide, 1735
MIBI biodistribution, experimental phantom based on, 154P(ab)
multi-modal coregistration, using external fiducial markers, 219P(ab)
multihead, motion correction for, 214P(ab)
multiple energy reconstructions in, 171P(ab)
multiple energy window projection data in, invertibility of, 7P(ab)
myocardial
see also Myocardial perfusion imaging
 comparison of viability studies, 177P(ab)
 correction of photon attenuation in, 176P(ab)
 false positives in obese male patients, 178P(ab)
 reconstruction of truncated projection data, 210P(ab)
 rotating planar projection views, 149P(ab)
myocardial perfusion, typical angina and normal angiograms, women, 306P(ab)
nonuniform attenuating media for 3D iterative scatter compensation, 216P(ab)
optimal number of views in 360-degree imaging, decreasing artifacts, 1740
OS-MLEM, reducing influence of partial volume effect with, 153P(ab)
P-glycoprotein overexpression, chemotherapy failure, cancer patients, 71P(ab)
Parkinson's disease
 ^{123}I -IBZM binding, reduction by dopamine agonists but not L-Dopa, 1112
Parkinson's disease, ^{123}I iodolisuride, striatal dopamine D₂ receptors, 22
perfusion images, proportional stereotactic atlas for, 217P(ab)
permeability-surface model, nonlinear correction of brain perfusion, 1237
PET block detector technology for, 119P(ab)
pinhole
 ^{18}F , brain, Monte Carlo study, 120P(ab)
 brain tumor phantoms, ^{131}I distributions in, 212P(ab)
 detection of breast tumors, 214P(ab)
 high energy slit aperture and, 7P(ab)
prostate cancer with bone metastasis, superimposed osteomyelitis, diagnostic difficulties, 999
quantitative
 diagnostic accuracy, anti-ischemic medications in, 58P(ab)
 errors due to partial volume effects, 215P(ab)
 iodine contrast media effects on transmission data, 218P(ab)
quantitative assessment of benzodiazepine receptors, 374
radiation treatment planning in squamous head and neck cancer, radioimmunoscinigraphy, 1942
radiolabeled A₁ adenosine receptor antagonists as ligands for, 142P(ab)
rCBF study, post-traumatic stress disorder, 285P(ab)
regional cerebral blood flow measurement, scatter compensation for, 276P(ab)
regional energy spectrum, in multispectral images, 171P(ab)
regional radioactivity quantitation based on, 232P(ab)
renal function, pregnancy-induced hypertension effects, 290P(ab)
renal imaging with ^{99m}Tc -DMSA, normal volunteers, 1346
resolution, improvement of, FASTSPECT concept, 301P(ab)
ROI activity estimation in, nonstationary resolution recovery for, 153P(ab)
scatter correction, limitations of, 171P(ab)
semiquantitative diamox rCBF brain, carotid angioplasty, 89P(ab)
semiquantitative rCBF, in narcolepsy, 165P(ab)
stereotactic biopsy guided by, after radiotherapy for glioma, 158P(ab)
stress cerebral perfusion, image subtraction in, 276P(ab)
summing rapid acquisitions, bladder filling artifact and, 212P(ab)
thallium, risk assessment, patients with submaximal exercise, 182P(ab)
three-dimensional bone scan images usefulness and limitations, volume-rendering technique, 1567
transcranial Doppler combined with, assessment of cerebrovascular reserve, 88P(ab)
transmission imaging, multiple line sources for, 120P(ab)
transmission measurements in, 19P(ab)
tumor imaging, improper attenuation/emission registration on, 211P(ab)
tumor pretargeting and direct antibody labeling in uveal melanoma, quantitative comparison, 967
visual interpretation, statistical image analysis with, 275P(ab)
with angiography and transcranial Doppler, vasospasm, 12P(ab)
with pinhole collimator, myocardial infarction in rats, 159P(ab)
with somatostatin receptor scintigraphy, gastroenteropancreatic tumors, 256P(ab)
Skeletal muscle, interpreting myocardial FDG-PET images, influence of hyperglycemia, 1713
Small bowel transit, effects of opioid and opioid-like drugs measured by scintigraphy, 818
Small-cell lung cancer, bispecific antibody and ^{131}I -labeled bivalent hapten dosimetry, two-step targeting, medullary thyroid cancer, 1853
Small-volume disease, radioimmunotherapy with ^{131}I -NP4 F(ab')₂, 1504

- Sn-117m(4+) DTPA**
 absorption, stannous diphosphonates to hydroxyapatite, 72P(ab)
 correlation of marrow suppression with marrow absorbed dose, bone pain, 102P(ab)
 uptake and retention, bone pain, 72P(ab)
- SNM, see Society of Nuclear Medicine**
- Society of Nuclear Medicine**
 43rd annual meeting, budget planning, 24N(4)
 annual meeting
 review of instrumentation developments, cameras, and computer systems, 25N(9)
 Denver 1996, features of 43rd annual meeting, medical problem solving, 11N(8)
 government relations update, 20N(1)
 strategic plan, 22N(1)
- Sodium**, dietary, regulator of angiotensin receptors imaged with ^{13}C L-159, 884, 47P(ab)
- Sodium maleate**, reduction of renal uptake of ^{113}In -DTPA-octreotide, lysine, 1388
- Soft tissue**, benign and malignant masses, evaluation with FDG-PET, 140P(ab)
- soft-tissue sarcomas**, PET imaging, ^{18}F FDG, 257
- Solid-state detector**, intraoperative probe, detection of beta emitters, 52P(ab)
- Solitary pulmonary nodules**, probability of malignancy and preoperative staging, ^{18}F FDG-PET, 943
- Somatostatin analogs**
 octreotide derivatives, labeled with ^{99m}Tc , 29P(ab)
 radiolabeled, comparative studies with six, 20P(ab)
- Somatostatin receptor imaging**
 cost effective analysis, 886
 evaluation of ^{99m}Tc -P587 and ^{99m}Tc -P829 in detection of SSTR-expressing tumors, 1016
- Somatostatin receptor scintigraphy**, visualization of abdominal carcinoid tumors, ^{113}In -pentetrotide SPECT, 1452
- Somatostatin receptors**
 ^{99m}Tc -labeled synthetic peptides with, staging of melanoma, 138P(ab)
 expression, clinical immunology, 24P(ab)
 imaging, clinico-pathologic correlation, 255P(ab)
 overexpression of In-111-octreotide in human neuroendocrine tumors, 2002
 primitive neuroectodermal CNS tumors, children, 286P(ab)
 scintigraphy
 ^{67}Ga comparison, malignant lymphomas, 268P(ab)
 compared with MRI, suspected meningioma, 257P(ab)
 cost-effective analysis of, 19P(ab)
 diagnosis of small cell lung cancer and metastases, 20P(ab)
 gastroenteropancreatic tumors, additional value of SPECT in, 256P(ab)
 gastroenteropancreatic tumors, 253P(ab)
 staging of non-Hodgkin lymphomas, 19P(ab)
 subcutaneous cavernous hemangioma, ^{113}In -octreotide imaging, Beckwith-Wiedemann syndrome, 1516
 tissues positive for, visualization by pentetrotide, rats, 141P(ab)
- Specific binding**, tissue distribution, metabolism of ^{111}In -labeled analogs, gamma-camera scintigraphy, 108
- SPECT**, see Single-photon emission computed tomography
- Spectrometry**, gamma, clinical doses of ^{67}Cu , presence of "Cu impurity, 199P(ab)
- Spectrum-fitting technique**, energy-based scatter corrections for scintillation images of ^{131}I , window-based technique, 2030
- Spherical geometry**, PET cerebral imaging, GSO scintillation detectors, 1219
- Spillover artifacts**, corrections for, PET with additive models and seeded region growth, 224P(ab)
- Spinal metastases**, diagnosis on routine bonescintigraphy, in cancer patients, 250P(ab)
- Spontaneous regression**, intracranial arteriovenous malformation, 1673
- Squamous-cell carcinoma**
 ^{99m}Tc -sestamibi SPECT to assess osseous tumor metastases, 1526
 tumor cell line, uptake of ^{99m}Tc MIBI and tetrofosmin comparison, 254P(ab)
- Standardized arterial input function**, quantitative assessment of benzodiazepine receptors, SPECT, 374
- Standardized uptake value**, time-activity curveslope, 206P(ab)
- Standards**, outcome and cost in nuclear medicine, 1073(ed)
- Stannylated precursors**, radioiodination yields from optimum pH for, 187P(ab)
- Statistical parameter mapping**
 brain activation/deactivation patterns, sensitivity of, 41P(ab)
 FDG-PET brain scans, clinical validation of, 42P(ab)
 mu opioid receptor binding, analysis in cocaine abusers, 45P(ab)
- Statistical parametric imaging**, temporal lobe epilepsy, outcome of surgery, 1094
- Statistics**, analytic computation and sample estimation, local statistics of PET, 155P(ab)
- Step-and-shoot**, compared with continuous step-and-shoot mode, SPECT, 2037
- Stereoisomers**, IQNP isomers, 186P(ab)
- Stereotactic biopsy**, radionuclide-guided, coordinates from sinograms, breast cancer, 1562
- Stereotaxy**
 carbon dioxide responsiveness, comparison of normal and pathological aging, 165P(ab)
 proportional atlas, interpretation of SPECT perfusion images, 217P(ab)
- Steroids**, fluticasone propionate particles, labeling in FDG-PET studies, 141P(ab)
- Stochastic algorithm**, parameter estimation, dynamic PET, 222P(ab)
- Stomach**, concomitant lung and gastric uptake in bone scintigraphy, sarcoidosis, 1530
- Streptavidin**
 biochemical modification for two-step imaging and therapeutic procedures, in vitro and in vivo analysis, avidin, 1380
 imaging osteomyelitis, ^{113}In -biotin, 1655
- Striatum**, dopamine D4 receptors in, baboon, 113P(ab)
- Stripe sign**, differential diagnosis in perfusion lung scan, lobar collapse, 1682
- Stroke**, changes in cortical 5-HT₂ serotonergic receptors, PET, 1976
- Strontium-142**, a positron emitter for uptake monitoring, ^{13}Sm EDTMP therapy, 51P(ab)
- Strontium-153 EDTMP**, therapy, ^{143}Sm a positron emitter for uptake monitoring of, 51P(ab)
- Strontium-83**, production, PET phantom measurements and, 166P(ab)
- Strontium-89**
 adriamycin toxicity and, treatment of androgen-dependent prostate cancer, 32P(ab)
 injected through implanted ports, 400(ie)
 procedure guideline for treatment of bone pain, 881
 therapy
 skeletal metastatic disease, 31P(ab)
 symptomatic osseous metastases, pharmacoeconomic benefits of, 31P(ab)
- Sturge-Weber syndrome**, ^{99m}Tc -HMPAO SPECT, 81
- Subacute thyroiditis**, differential diagnosis, 1745
- Subarachnoid hemorrhage**
 cerebral arteriospasm after, SPECT diagnosis of, 12P(ab)
 cerebral infarction after, CBF with ^{123}I IMP SPECT, 12P(ab)
 vasospasm after, brain SPECT with angiography and transcranial Doppler, 12P(ab)
- Subcutaneous metastases**, somatostatin-receptor scintigraphy, bronchial carcinoid, 1537
- Substance P receptor**, in vitro and in vivo studies with ^{113}In -DTPA-Arg¹, SP, 108
- Subtraction-restoration**, nonstationary scatter kernels, high-resolution PET, 2040
- Sulfur colloid**, filtered, bone marrow imaging properties of ^{99m}Tc , 240P(ab)
- Superior vena cava clot**, lung scan detection of, collateral flow to liver, 1826
- Superior vena cava syndrome**, diagnosis and functional assessment, radionuclide venography, 1460
- Swallowing**, medical conditions predisposing to aspiration, radionuclide salivagram, children, 22P(ab)
- Sympathetic innervation**, imaging in silent myocardial ischemia, 712
- Sympathetic nerve activity**, subclinical variants of, diagnostic pitfalls in interpreting myocardial MIBG images, 1686
- Sympathetic nervous system**
 clinical evaluation of ^{11}C -phenylephrine, MAO-sensitive marker of cardiac neurons, 1923
 denervated rat heart, absence of uptake of MIBG, 106P(ab)
- Systemic lupus erythematosus**
 brain and CNS involvement, FDG-PET, 21P(ab)
 lung clearance test in, ^{99m}Tc DTPA aerosol, 295P(ab)
- Systemic radionuclide therapy**, ^{113}In -DTPA-D-Phe¹-octreotide, treatment in midgut carcinoid syndrome, 1519

T

- Teaching files**, internet for case-based presentations, 178
- Techetium-99m-HMPAO**, ictal brain SPECT, crossed cerebellar hyperperfusion, 426
- Technegas**, transition to pertechnegas, 1917(ie)
- Technetium complexes**
 serotonin receptor binding, improvement of receptor selectivity and blood-brain transfer, 16P(ab)
 technepine, labeling the dopamine transporter, brain, 17P(ab)
- Technetium-99m**
 ^{99m}Tl imaging versus ^{67}Ga imaging in salivary gland disorders, 1819
 chelators
 hydroxyamamide-based tetradentate, 189P(ab)

method for creating small ligands linked to targeting components, 190P(ab)
small neutral, new one-step ligand synthesis for preparation of, 191P(ab)
synthesis by a simplified route and evaluation of, 190P(ab)

solid phase chemistry method for removal of excess, 189P(ab)

chemotactic peptides
 accumulation in chronic intestinal inflammation, 239P(ab)
 accumulation in lung, severe trauma effects, 240P(ab)

computational chemistry, local density functional methods in, 189P(ab)

correlation with cardiac serum markers, spontaneous angina, 58P(ab)

ester-derivatized, brain imaging, 188P(ab)

labeled marker of solid tumor hypoxia, nitroimidazole, 1023

labeled somatostatin receptor-binding peptides, 1016

labeling of bifunctional ligands, conjugation chemistry, immunoactivity, kit formulation, 362

model chelators for, synthesis and radiochemical studies of, 28P(ab)

modeling, molecular mechanics investigation of, 16P(ab)

new octreotide derivatives labeled with, 29P(ab)

peptide conjugates, based on ternary ligand system, 29P(ab)

peptide labeled with, inflammation imaging, 152P(ab)

peptides labeled with, comparison to challenge with cysteine, 150P(ab)

prostate antibody CYT-351, conjugation, labeling and clinical studies, 96P(ab)

protein labeling with cyclopentadienyltricarbonyl technetium, 28P(ab)

radiolabeled liposomes for tumor imaging, 326

radiolabeling single chain Fv antibody fragments, 868

red blood cell scan, clinical utility despite intestinal barium, 643

renal tubular agents, renal extraction of, role of protein binding in, 47P(ab)

serotonin receptors labeled with, as imaging agents, 190P(ab)

transmission source, ²⁰¹Tl myocardial scintigraphy, 80P(ab)

Technetium-99m aerosol, labeling method, inhaled beclomethasone, 142P(ab)

Technetium-99m alpha-fetoprotein
 blood pool activity subtraction and, diagnosis of breast cancer, 148P(ab)
 recombinant, imaging of breast cancer xenografts, 87P(ab)

Technetium-99m antibody conjugates, intracellular processing of, 239P(ab)

Technetium-99m-anti-NCA-95, bone marrow scintigraphy in hematologic disorders, ^{99m}Tc-antigranulocyte antibody, 978

Technetium-99m aprotinin, detection of amyloid involvement, myocardial, 185P(ab)

Technetium-99m ATN-10, potential tumor imaging agent, 17P(ab)

Technetium-99m biccisate
 ictal and interictal brain SPECT, refractory epilepsy in children, 1101
 rapid preparation method for, 142P(ab)

Technetium-99m BMS-181321, detection of cerebral ischemia, associated with acute

stroke, 272P(ab)

Technetium-99m dextran 70, clinical grade, for lymphoscintigraphy, 143P(ab)

Technetium-99m-diphosphonate, bone tumors, biodistribution studies of ^{99m}Tc-labeled MTX-BP conjugate, 105

Technetium-99m disofenin, cholescintigraphy, biliary atresia, 288P(ab)

Technetium-99m DMP 444, protein binding, thrombosis imaging agent, 202P(ab)

Technetium-99m DMP-HSA, kit prepared, gatedblood pool imaging, 175P(ab)

Technetium-99m DMSA
 assessment of renal function, pregnancy-induced hypertension effects, 290P(ab)
 assessment of renal scarring
 parenchymal function and, 290P(ab)
 reduction of functional renal mass and, 290P(ab)
 assessment of renal uptake, children, planar posterior-view method, 291P(ab)
 biokinetic behavior of, effects of renal pathology and age differences, 1331
 comparison with ²⁰¹Tl and ^{99m}Tc MIBI, solitary pulmonary lesion, 268P(ab)
 detection of acute pyelonephritis in piglets, SPECT versus pinhole DMSA imaging, 1731
 radiation dosimetry in children, body surface area, 1336
 renal SPECT imaging in normal volunteers, 1346
 renal SPECT in diagnosing and monitoring acute pyelonephritis, pediatrics, 1349
 SPECT, uptake, kidneys, assessment of reproducibility, 290P(ab)
 studies in pediatric urinary tract infection, 823

Technetium-99m dsFv, biodistribution, favorable effects of lysine in, 129P(ab)

Technetium-99m DTPA
 determining regional ventilation, tracheostomized patients, 239
 lung scanning in diagnosis of pulmonary embolism, 165
 lung scintigraphy, assessment of carborundum pneumoconiosis, 294P(ab)
 radioaerosol inhalation lung scintigraphy, detection of pulmonary effects of radiation therapy, 234P(ab)
 radioaerosol, lung scintigraphy, acute inhalation injury, 294P(ab)

Technetium-99m EC
 captopril scintigraphy, diagnosis of renovascular hypertension, 291P(ab)
 simultaneous estimation, effective renal plasma flow and glomerular filtration, 91P(ab)

Technetium-99m ECD
 brain SPECT
 acute stroke, 13P(ab)
 high risk neonates, 22P(ab)
 statistical parametric mapping and, 79P(ab)
 cellular retention of, brain perfusion, 1694
 diamox SPECT, unilateral carotid stenosis patients, 274P(ab)
 double-injection protocol for cerebral perfusion reserve, Azetazolamide, 2057
 extraction and retention of, dynamic SPECT and ^{15O}-water PET, 1600
 ictal SPECT, epileptogenic zones, 100P(ab)
 leukocyte labeling with, absence of plasma and erythrocytes, 84P(ab)
 neuroactivation studies, paradigm for smooth pursuit eye movement, 283P(ab)
 properties of enzyme to catalyze, 189P(ab)
 SPECT, diagnosis orientation in dementia, 274P(ab)
 SPECT images in Alzheimer's disease, comparison with ^{99m}Tc-HMPAO, 1749
 use as investigational tool in childhood epilepsy, 1106
 visualization of grade II astrocytoma, 273

Technetium-99m-furifosmin, quantitative comparison of planar and SPECT normal data files, ²⁰¹Tl, ^{99m}Tc-sestamibi, and ^{99m}Tc-tetrofosmin, 1783

Technetium-99m-galactosyl-neoglycoalbumin, index of hepatic function, radiopharmacokinetic modeling, 160

Technetium-99m glucarate
 evaluation of reperfusion damage, experimental ischemia, 119P(ab)
 subnuclear localization, necrotic myocardium, 175P(ab)
 uptake, swine model of demand ischemia, 50P(ab)

Technetium-99m GSA
 comparison with ^{99m}Tc PMT, hepatobiliary scintigraphy, liver cirrhosis with jaundice, 244P(ab)
 diagnosis and follow-up study of fulminant hepatic failure, 641

Technetium-99m HIG, immunoscintigraphy, boneinfection after orthopedic surgery and bone trauma, 127P(ab)

Technetium-99m HL91, hypoxia avid imagingagent, assessment of reperfused myocardium, 94P(ab)

Technetium-99m-HMDP, age-related changes in bone scintigraphy, 815

Technetium-99m HMPAO
 absolute and relative quantitation with, Alzheimer's disease, 278P(ab)
 assessment of neurological deficits during balloon test occlusion, 551
 brain
 SPECT, vascular response in frontal area of orthostatic patients with measure of BP, plasma norepinephrine during raise-up test, 1
 brain SPECT
 Alzheimer's disease, automated neural networks, 195
 detection of perfusion abnormalities in Lyme disease, 270P(ab)
 evaluation of patients with pure photosensitive epilepsy, 1755
 statistical parametric mapping and, 79P(ab)
 cellular basis of ECD, brain perfusion, 1694
 cerebral blood flow in depressed patients, electroconvulsive therapy, 1075
 cerebral blood flow, ischemic stroke, 13P(ab)
 cerebral hypoperfusion in orthostatic hypotension, denervated myocardium, 1824
 compared with ¹³³Xe measurements of regional cerebral blood flow, Diamox, 1735
 detection, prosthetic vascular graft infection, 163P(ab)
 discordant results compared with ^{99m}Tc-MIBI uptake, recurrent occipital meningioma, 1183
 fractionation, stannous ion augmentation technique, 84P(ab)
 functional brain imaging, detection of cerebral radionecrosis, 259P(ab)
 ictal SPECT, epileptogenic zones, 100P(ab)
 imaging cerebral blood flow at high flow levels, penicillin induced seizures in rats, 661
 labeled white blood cell scans, detection of appendicitis in women, 241P(ab)

- localization in brain tumors, 263P(ab)
 low uptake, abnormal CSF substance P and, in fibromyalgia syndrome, 276P(ab)
 predictive capacity of SPECT, one-year follow-up after mild head injury, 1605
 preoperative brain perfusion imaging, identifying risk of infarction with temporary occlusion of ICA, 415
 pyrophosphate-spiked, subdispensed, kinetic and stability studies, 83P(ab)
 re-appraisal of quality control of labeled granulocytes, 863
 rest-stress SPECT, cerebral ischemia measured by, 277P(ab)
 scan abnormalities, cytarabine high dose, children, 35P(ab)
SPECT
 acetazolamide test and, evaluation of dementia, 273P(ab)
 cerebral blood flow, systemic lupus erythematosus patients, 163P(ab)
 demonstration of frontal hypoperfusion in benign exertional headache, 1172
 images in Alzheimer's disease, comparison with ^{99m}Tc-ECD, 1749
 MRI evaluation of posterior circulation, moyamoya disease, 1613
 outcome after synangiosis surgery, 274P(ab)
 oxido-reductive state, cellular retention, 1413
 perfusion images, proportional stereotactic atlas for, 217P(ab)
 post concussion syndrome, 278P(ab)
 regional brain function, pain and acupuncture effects, 278P(ab)
 specific regions of left hemispheric dysfunction, 165P(ab)
 Sturge-Weber syndrome, 81
 texture analysis to detect decompression illness, 1154
 stabilized, radiolabeling leukocytes, 84P(ab)
 use of ^{99m}Tc-labeled liposomes for blood pool imaging, compared with ^{99m}Tc-red cells, 1374
 white blood cell labeling, lymphocyte damages induced by, 101P(ab)
- Technetium-99m-HYNIC-IgG**, biodistribution and dosimetry compared with ¹¹¹In-DTPA-IgG, 843
- Technetium-99m-IDA**, hepatobiliary kinetics of, quantification by linear systems theory, 1323
- Technetium-99m-labeled monoclonal antibodies**, radiation treatment planning in squamous head and neck cancer, immuno-SPECT, 1942
- Technetium-99m-labeled peptide**, thrombus imaging, use of ^{99m}Tc-P280, 775
- Technetium-99m-liposomes**
 blood-pool imaging, compared with ^{99m}Tc-red cells, 1374
 scintigraphic detection of inflammation and infection, ^{99m}Tc-Stealth-liposomes, 1392
- Technetium-99m LL-EC**, comparison in rats and healthy volunteers, 46P(ab)
- Technetium-99m LL1**, potentially new bone marrow imaging agent, 239P(ab)
- Technetium-99m MAA**
 lung perfusion scintigraphy, measurement of focal pulmonary flow, 304P(ab)
 lung scan detection of superior vena cava clot, collateral flow to liver, 1826
 lung scanning in diagnosis of pulmonary embolism, 165
- Technetium-99m MAG3**
^{99m}Tc EC combination, promising renal tubular function agent, 17P(ab)
 accuracy of clearance measurements obtained with gamma camera heart curve, 1281
 assessment of renal scarring, parenchymal function and, 290P(ab)
 calculation of split renal function with, using patlak plot, 307P(ab)
 clearance
 dual-headed gamma camera without plasma samples, 91P(ab)
 normal renal function, 293P(ab)
 renal allograft, 292P(ab)
 diagnosis of renal transplant rejection, comparison with core needle biopsy, 289P(ab)
 dilated upper urinary tract, standardized approach to diuresis renography, International Consensus Committee, 1872
 exercise renography in untreated hypertension, 838
 fractional renal uptake of, graphical analysis, 292P(ab)
 graphic (Patlak) method in, renal scintigraphy, 291P(ab)
 measurement of renal function in children and adults, 588
 modified renal counting method in, estimation of renal clearance, 291P(ab)
 radiolabeling of disulfide stabilized fragment, effects on renal uptake, 29P(ab)
 renal scintigraphic appearance in Bartter's syndrome, captopril administration, 1688
 renal uptake
 gamma camera method, 293P(ab)
 semiautomated and manual regions of interest, 293P(ab)
 renograms, living related donor and recipient kidney transplant evaluation, 292P(ab)
SPECT, evaluation of renal parenchyma, 23P(ab)
- Technetium-99m MDP**
 characteristics, multiple myeloma, 267P(ab)
 combined scintigraphy and radiography for detecting hip prosthesis loosening, 62
 lung uptake on bone scan in Wegener's vasculitis, 857
 renal scintigraphy in evaluation of pediatric nephrological disease, 71
 scintimammography, mammographic microcalcifications without mass, 156P(ab)
 SPECT bone scintigraphy of anterior cruciate ligament, knee injury, 1353
 unexpected intestinal leakage in primary intestinal lymphangiectasia, 639
- Technetium-99m-mebrofenin**, hepatic extraction efficiency and excretion rate, hepatobiliary study in dogs, 1846
- Technetium-99m-meso-hexamethyl propyleneamine oxime**, imaging agent for glutathione localization in brain, assessment of antioxidative ability, 1698
- Technetium-99m MIBG**, absence of uptake, denervated rat heart, 106P(ab)
- Technetium-99m MIBI**
²⁰¹Tl comparison, detection of viable myocardium, 308P(ab)
 accumulation and modulation, multidrug resistant tumors, 118P(ab)
 biodistribution, quantitative SPECT, experimental phantom based on, 154P(ab)
 bone and soft tissue tumors, ⁶⁷Ga comparison within subject, 298P(ab)
- brain SPECT, recurrent malignant glioma, 260P(ab)
 breast cancer, MRI comparison, 75P(ab)
 combined with parathyroid measurements as guide to parathyroidectomy, 798
 comparison with ²⁰¹Tl and ^{99m}Tc DMSA, solitary pulmonary lesion, 268P(ab)
 discordant results compared with ^{99m}Tc-HMPAO uptake, recurrent occipital meningioma, 1183
 dual versus single isotope imaging, parathyroid scintigraphy, 16P(ab)
ECG-gated SPECT, myocardial, ischemic heart disease patients, 304P(ab)
 evaluation of multiple myeloma, diffuse marrow increase in, 269P(ab)
 functional autonomy in secondary hyperparathyroidism, 565
 gated, comparison with FDG, diagnosis of myocardial ischemia, 60P(ab)
 localization of ectopic parathyroid adenoma, 631
 lung cancer
 CT and FDG-PET comparison, 260P(ab)
 hilar and mediastinal lymph node metastases in, 263P(ab)
 preoperative assessment, hyperfunctional parathyroid glands, 15P(ab)
 scintigraphy in pulmonary tuberculosis, 233
 scintimammography, planning and monitoring treatment for breast cancer, 156P(ab)
 scintimammography in detection of primary breast cancer, 626
SPECT, primary and metastatic lung cancer, 296P(ab)
 tetrofosmin and, thyroid and parathyroid nodules, 159P(ab)
 uptake
 in human breast cancer cell lines, 190P(ab)
 tumor cell line, comparison with tetrofosmin, 254P(ab)
 uptake mechanics, compared with ^{99m}Tc-tetrofosmin, ²⁰¹Tl in tumor cell lines, 1551
- Technetium-99m-NGA**, automatic preparation of radiopharmacokinetic data, estimation of receptor biochemistry, 1896
- Technetium-99m nitrolimidazole**
 cardiomyopathy, hypoxia effects, hamster, 175P(ab)
 detection of ischemic and reperfused myocardium, 761
- Technetium-99m NOET**
 biodistribution and dosimetry, normal humans, 229P(ab)
 kinetics, gamma camera images, ischemic myocardium at rest, 107P(ab)
- Technetium-99m P280**
 activated platelet specific techtide, studies of carotid atherosclerosis, 272P(ab)
 peptide imaging, deep vein thrombosis, 95P(ab), 294P(ab)
- Technetium-99m-P483H**, detection of occult infection and inflammation, platelet factor 4, 673
- Technetium-99m P829**, biodistribution anddosimetry, 230P(ab)
- Technetium-99m pertechnegas**, ¹³³Xecomparison, ventilatory imaging in suspected pulmonary emboli, 116P(ab)
- Technetium-99m pertechnetate**
 SPECT, smoking effects on lung permeability, 5P(ab)
 uptake by parathyroid adenoma, 861
 uptake mechanism, induced osteoarthritis,

- rat, 298P(ab)
- Technetium-99m phenylene imine phenol**, as aleukocytes labeling agent, 188P(ab)
- Technetium-99m PNA**, hybridization of, 203P(ab)
- Technetium-99m polymer**, synthetic copolymerkit, blood pool imaging, 198P(ab)
- Technetium-99m-pyrophosphate**, influence of downscatter in dual-isotope imaging, ^{201}TI , 781
- Technetium-99m Q complexes**, cardiac myocyteuptake, enhanced by ligand ester groups, 188P(ab)
- Technetium-99m Q12**
- ^{201}TI extraction and retention, effects of ouabain, 752
 - kinetics, hypoxia, acidosis, and ischemia reperfusion, rat hearts, 49P(ab)
- Technetium-99m RBC**
- diagnosis of gastric antral vascular ectasia, case report and ROL, 854
 - hepatic hemangioma, 114P(ab)
 - label stability over time, 199P(ab)
- Technetium-99m-rt-PA**, detection of deep vein thrombosis, 744
- Technetium-99m sestamibi**
- ^{201}TI comparison
 - acute coronary reperfusion, 160P(ab)
 - detectin of coronary artery disease in women, 69P(ab)
 - recognition of hibernating myocardium, 26P(ab)
 - adenosine stress, SPECT, early post-stress imaging, 59P(ab)
 - anterior defect location with, 14P(ab)
 - arbutamine and dobutamine stress testing comparison, coronary artery disease, 177P(ab)
 - attenuated corrected stress, supine and prone comparison, myocardial perfusion SPECT, 81P(ab)
 - axillary node imaging, breast cancer, 251P(ab)
 - bile reflux during cardiac imaging, identifying a noncardiac cause of chest pain, 1285
 - breast cancer
 - axillary lymphadenopathy and, 252P(ab)
 - diagnostic accuracy of, 74P(ab)
 - scintimammography, histopathologic correlation, 75P(ab)
 - axillary lymph node involvement, 75P(ab)
 - breast density effects, 74P(ab)
 - clearance, hepatic, genetic factors in, 262P(ab)
 - combined with BMIPP to predict functional outcome after myocardial infarction, 718
 - compared to FDG-PET, localization of parathyroid adenomas, hyperparathyroidism, 1809
 - comparisons with ^{201}TI imaging in evaluation of thyroid tumors, 901
 - correlation with histologic characteristics, benign breast tumor, 250P(ab)
 - detection of parathyroid pathology, hyperparathyroidism, 158P(ab)
 - diagnose multidrug resistance to chemotherapies in breast tumor cells, 286
 - differentiated thyroid cancer, postoperative follow-up, 236P(ab)
 - dipyridamole and, early and delayed imaging comparison, 180P(ab)
 - dopamine stress, magnitude of ischemia, dogs with coronary stenoses, 3P(ab)
 - evaluating primary disease and differentiating residual/recurrent disease from therapy changes, nasopharyngeal carcinoma,
- ^{201}TI , 1956
- evaluation of left ventricular function, comparison with contrast ventriculography, 104P(ab), 105P(ab)
 - evaluation of thyroid cancer, comparison with radioiodine, 137P(ab)
 - fractionation, stannous ion augmentation technique, 84P(ab)
 - gated imaging, automated method for assessment of left ventricular function, 179P(ab)
 - lipid deposits in bone marrow, Gaucher's disease patients, 297P(ab)
 - malignant melanoma, primary and recurrent, 266P(ab)
 - mammoscintigraphy in suspected breast cancer, 926
 - parathyroid scintigraphy, evaluation of primary and secondary hyperparathyroidism, 243P(ab)
 - position of photon-emitting objects in emission scanner, stereotactic coordinates, ECT sinograms in breast biopsy, 1562
 - pre and post therapy evaluation, nasopharyngeal carcinoma, 257P(ab)
 - prognostic value of stress in, gender differences, 14P(ab)
 - property of being a substrate for P-glycoprotein similar to ^{99m}Tc -tetrofosmin, multidrug resistant breast cancer cells, 1578
 - pulmonary nodules, malignant or benign, coccidioidomycosis and, 35P(ab)
 - quantifying perfusion defects, single photon tomography, 178P(ab)
 - quantitative comparison of planar and SPECT normal data files, ^{201}TI , ^{99m}Tc -tetrofosmin, and ^{99m}Tc -furiosmin, 1783
 - recurrent hyperparathyroidism after resection of parathyroid carcinoma, ^{18}F -FDG-PET, 2000
 - resting SPECT, postinjection times, 48P(ab)
 - reverse redistribution, after coronary angioplasty in acute myocardial infarction, 181P(ab)
 - reverse redistribution of, following PTCA in acute myocardial infarction, 1289
 - scintimammography
 - breast cancer response to chemotherapy, 252P(ab)
 - breast cancer, SPECT improvement on, 252P(ab)
 - palpable and nonpalpable breast tumors, 259P(ab)
 - small-cell lung cancer, predictor of response to chemotherapy, 67P(ab)
 - solid tumors, determination of P-glycoprotein in, 67P(ab)
 - SPECT
 - ^{18}F -FDG-PET, comparison of diagnostic accuracy in musculoskeletal sarcomas, 1476
 - assessment of mediastinal involvement in lung cancer, 938
 - detection of restenosis after successful PTCA, 1300
 - imaging, preoperative parathyroid lesion localization, 242P(ab)
 - localization of mediastinal parathyroid adenoma, 1535
 - myocardial viability, 26P(ab)
 - parathyroid scintigraphy, FADS, 1773
 - subtraction, dual-phase, or SPECT, comparison of parathyroid imaging, 15P(ab)
 - supine vs right lateral imaging, comparison with coronary arteriography, 48P(ab)
 - transport substrate, human multidrug resistance-associated protein, 247P(ab)
- uniformity, improved with attenuation correction, low likelihood for coronary artery disease, 148P(ab)
- uptake
- cancer cell lines resistant to chemotherapy, multidrug resistant associated protein, 233P(ab)
 - cancer cell lines sensitive and resistant to chemotherapy, 189P(ab)
 - correlation with pathologic features, breast cancer, 267P(ab)
 - uptake in breast tumor and lymph nodes, 922
 - uptake in myeloma, 1001
 - utility of SPECT imaging with tumor-specific tracers, assessment of osseous tumor spread, 1526
- Technetium-99m sulfur colloid**
- assessment of gastric emptying in pediatric population, use of right lateral and upright positioning, 1356
 - correlation with ^{111}In -WBC uptake in Paget's disease, 858
 - lung uptake, microwave versus boiling preparations, 197P(ab)
 - preparation and evaluation, lymphoscintigraphy studies, 84P(ab)
 - radiopharmaceutical for lymphoscintigraphy, preparation parameters, particle size distribution and stability, 1575
 - reduced particle size, lymphoscintigraphy, 301P(ab)
- Technetium-99m TBIDA**, hepatobiliaryscintigraphy, after auxiliary liver transplant, 113P(ab)
- Technetium-99m TcN-NOET**
- neutral, metabolite analysis, after injection in rats, 188P(ab)
 - uptake, cancer cell lines sensitive and resistant to chemotherapy, 189P(ab)
- Technetium-99m tetrofosmin**
- ^{201}TI and, ECG-gated dual-isotope myocardial SPECT, 308P(ab)
 - ^{99m}Tc sestamibi and ^{201}TI comparison, myocardial viability assessment, 26P(ab)
 - ^{99m}Tc sestamibi comparison, myocardial uptake, 48P(ab)
 - assessment of salvaged myocardium from onset to reperfusion, 126P(ab)
 - early and delayed myocardial SPECT imaging, liver-heart artifact, 1622
 - dipyridamole and, early and delayed imaging comparison, 180P(ab)
 - dipyridamole/rest, assessment of coronary artery disease, 58P(ab)
 - during dobutamine administration, assessment of myocardial viability, 116P(ab)
 - functional risk area assessed by, infarct size, myocardial infarction, 58P(ab)
 - gated SPECT, measurement of left ventricular ejection fraction, 179P(ab)
 - MIBI and, thyroid and parathyroid nodules, 159P(ab)
 - multicenter trial, myocardial viability, 26P(ab)
 - multidrug resistant breast cancer cells, substrate for P-glycoprotein, ^{99m}Tc -MIBI, 1578
 - primary lung cancer detection, 35P(ab)
 - quantitative comparison of planar and SPECT normal data files, ^{201}TI , ^{99m}Tc -sestamibi, and ^{99m}Tc -furiosmin, 1783
 - scintimammography
 - diagnosis of breast cancer and lymph node metastases, 156P(ab)
 - suspicion of breast cancer, 255P(ab)
 - SPECT, primary lung tumor, 264P(ab)

- sublingual nitroglycerine plus, detection of severely ischemic but viable myocardium, 302P(ab)
- uptake compared to ^{201}TL , cardiac low flow state and systolic dysfunction, 1398
- uptake compared with $^{99\text{m}}\text{Tc}$ -MIBI and ^{201}TL , tumor cell lines, 1551
- uptake, tumor cell line, comparison with MIBI, 254P(ab)
- utility, detection of small pulmonary nodules, 111P(ab)
- Technetium-99m tropones**, as dopamine transporter imaging agents, 17P(ab)
- Technetium-99m WBC**, infection imaging, comparison with ^{111}IN WBC imaging, 204P(ab)
- Technetium-99m-(V)DMSA**, insular carcinoma of thyroid, 78
- Technetium-labeled monoclonal antibody**, clinical radioimmunotherapy, head and neck cancer, 352
- Telemedicine**, advantages and problems, age of filmless imaging departments, 19N(9)
- Temporal lobe epilepsy surgery**, outcome predicted by statistical parametric imaging, PET, 1094
- Temporoparieto-occipital junction seizures**, ictal SPECT, cerebral blood flow, 1946
- Test occlusion**, preoperative prediction of ICA sacrifice, HMPAO SPECT, 415
- Testicular cancer**, residual, after chemotherapy, FDG-PET imaging of, 256P(ab)
- Testis**, radionuclide uptake, role of transferrin, 336
- Testosterone**, treatment, young males with delayed puberty, effect on bone mineral density, 103P(ab)
- TFMPP**, radiosynthesis binding affinity and biodistribution of, serotonin system, 40P(ab)
- Thallium-201**
 - ^{113}I scintigraphy comparison, differentiated thyroid cancer, after surgery, 135P(ab)
 - ^{67}Ga comparison, imaging of pediatric Hodgkin's disease, 285P(ab)
 - $^{99\text{m}}\text{Tc}$ tetrofosmin and, ECG-gated dual-isotopemyocardial SPECT, 308P(ab)
 - $^{99\text{m}}\text{Tc}$ -Q12 and ^{201}TL extraction and retention, effects of ouabain, 752
 - $^{99\text{m}}\text{Tc}$ sestamibi comparative analysis, acute coronary reperfusion, 160P(ab)
 - 24-hour images, redistribution/reinjection, 47P(ab)
 - brain SPECT differential diagnosis of toxoplasmosis and CNS lymphoma in patients with AIDS, 1150
 - recurrent malignant glioma, 260P(ab)
 - cerebral hypoperfusion in orthostatic hypotension, denervated myocardium, 1824
 - comparative assessment of four different uptake indexes, brain tumor, 157P(ab)
 - comparative study of thallium versus gallium scintigraphy in lymphoma subgroups, gallium uptake according to tumor grade, type, 46
 - compared to ^{67}Ga imaging in salivary gland disorders, $^{99\text{m}}\text{Tc}$, 1819
 - comparison to $^{99\text{m}}\text{Tc}$ -tetrofosmin uptake, cardiac low flow state and systolic dysfunction, 1398
 - comparison with $^{99\text{m}}\text{Tc}$ MIBI and $^{99\text{m}}\text{Tc}$ DMSA, solitary pulmonary lesion, 268P(ab)
 - comparisons with $^{99\text{m}}\text{Tc}$ -MIBI in evaluation of thyroid tumors, 901
 - dipyridamole, radiation exposure to OR staff after vascular surgery patients, 230P(ab)
 - dipyridamole-thallium perfusion scintigraphy, correlation with hemodynamic indices of myocardial dysfunction, 723
 - discrepancy in dual-tracer autoradiography, comparisons with ^{123}I -MIBG in experimental myocardial infarctions, 680
 - dobutamine stress test and echocardiography to assess ALCAPA syndrome, 748
 - evaluating primary disease and differentiating residual/recurrent disease from therapy changes, nasopharyngeal carcinoma, 99mTc -sestamibi SPECT, 1956
 - exercise-induced ischemia, viability patterns and, chronic left ventricular dysfunction patients, 25P(ab)
 - gallium and, disseminated mycobacterium avium complex, 242P(ab)
 - influence of downscatter in dual-isotope imaging, $^{99\text{m}}\text{Tc}$ -PYP SPECT, 781
 - myocardial imaging, women with typical angina and normal coronary angiograms, 306P(ab)
 - myocardial SPECT, phantom studies, small-lesion detectability in, 213P(ab)
 - perfusion abnormalities in ischemic heart disease, detection of metabolic abnormalities with ^{123}I -BMIPP SPECT, 1981
 - post-redistribution reinjection of, assessment of myocardial viability, 47P(ab)
 - pre and post therapy evaluation, nasopharyngeal carcinoma, 257P(ab)
 - prediction of outcome, recurrent thyroid cancer, 16P(ab)
 - proliferating cell nuclear antigen and ^{67}Ki , cellular localization, C6 gliomas, 65P(ab)
 - quantifying perfusion defects, SPECT, 178P(ab)
 - quantitative comparison of planar and SPECT normal data files, $^{99\text{m}}\text{Tc}$ -sestamibi, $^{99\text{m}}\text{Tc}$ -tetrofosmin, and $^{99\text{m}}\text{Tc}$ -furiosmin, 1783
 - quantitative SPECT, prediction of outcome in emory angioplasty versus surgery trial, 125P(ab)
 - reinjection, after exercise-redistribution imaging, chronic ischemic left ventricular dysfunction, 13P(ab)
 - rest-redistribution SPECT
 - functional outcome after revascularization, 59P(ab)
 - prediction of functional improvement after revascularization, 178P(ab)
 - rest-redistribution, $^{99\text{m}}\text{Tc}$ sestamibi comparison, recognition of hibernating myocardium, 26P(ab)
 - scintigraphic localization, proliferation markers and, glioma, 265P(ab)
 - scintigraphy, dobutamine echocardiography, chronic left ventricular dysfunction, 126P(ab)
 - SPECT
 - detection of brain lymphomas, AIDS patients, 258P(ab)
 - differentiation of benign and malignant solitary pulmonary lesion, 268P(ab)
 - dobutamine stress test for assessment of peri-infarction and remote ischemia, myocardial infarction, 1951
 - esophageal cancer, 248P(ab)
 - relation of delayed scan uptake ratio and grade of histopathological differentiation in adenocarcinoma of lung, Na-K ATPase expression, 955
 - stress-redistribution-reinjection, residual activity or defect reversibility, 179P(ab)
 - stress reinjection, prediction of function recovery, after bypass surgery, 176P(ab)
 - stress-induced reversible and mild-moderate irreversible defects, myocardial viability and, 25P(ab)
 - timing of thallium injection during dobutamine imaging, 193(ie)
 - uptake and retention index, brain tumors after radiation therapy, 255P(ab)
 - uptake mechanisms, compared with $^{99\text{m}}\text{Tc}$ -tetrofosmin, $^{99\text{m}}\text{Tc}$ -MIBI in tumor cell lines, 1551
 - uptake, tumor cell line, 64P(ab)
 - ventriculography, estimation of resting left ventricular ejection fraction, 181P(ab)
 - whole-body scan compared to ^{131}I scintigraphy in differentiated thyroid cancer, concordance and discordance rates, 1487
 - whole-body imaging, malignant melanoma patients, 256P(ab)
- Thallium-201 scintigraphy**, correlation with coronary lesion, wall motion abnormality and tissue viability, reverse redistribution, 735
- Thallium-201-chloride**
 - effect of chemotherapy in osteosarcoma, scintigraphic assessment, 1444
 - high uptake in brain radiation necrosis, epileptic activity, 1174
 - scintigraphy, low grade non-Hodgkin's lymphoma, 258P(ab)
 - sequential thallium and gallium chest scans, differentiating kaposi sarcoma from lymphoma and opportunistic infections in AIDS, 1662
 - visualization of grade II astrocytoma SPECT, 273
- Therapeutic monitoring**, response of soft-tissue and musculoskeletal sarcoma to neoadjuvants, ^{18}F -FDG-PET, 1438
- Therapeutic nuclear medicine**, prediction of radiation doses, tracer studies with ^{131}I -labeled antibodies, 1970
- Three-compartment modeling**, quantitation of cerebral blood flow with ^{67}Cu -PTSM, PET, 1089
- Three-dimensional acquisition**, nearly isotropicspatial resolution and, new positron camera, 170P(ab)
- Three-dimensional analysis**, description of pulmonary deposition of aerosols using multimodality imaging, 873
- Three-dimensional fusion imaging**, ^{14}C -CHC biodistribution, multidrug resistant tumors, 312
- Three-dimensional imaging**
 - spheroid PET with GSO scintillation detectors, cerebral studies, 1219
 - usefulness and limitations, bone scintigraphy with volume-rendering technique and SPECT, 1567
- Thromboembolic disease**
 - diagnostic value of small perfusion defects in suspected pulmonary embolism, ventilation/perfusion scan, 1313
 - V/Q lung scan interpretation, patient stratification by cardiopulmonary status, 570
- Thromboembolism**
 - DMP 444 as potential imaging agent, 129P(ab)
 - evaluating criteria for low probability interpretation of ventilation-perfusion

- scans**, 577
matched ventilation, perfusion, and chest radiographic defects, detection of pulmonary embolism, 1636
phase I trial of DMP 444, 117P(ab)
Thrombolysis, clinical utilization of in acute ischemic stroke, brain SPECT, 1259
Thrombosis imaging, evaluation of 99m Tc-P280, in vitro receptor-binding affinity and clearance, 775
Thrombus imaging
 chelate 99m Tc radiolabeling of r-annexin V, 29P(ab)
 DMP 444 as potential agent, 129P(ab)
 plasma protein binding assay, ultrafiltration use in, 202P(ab)
 potential imaging agent, DMP444, 151P(ab)
 radiolabeled peptides for, 152P(ab)
Thymic hyperplasia, 111 Inpentetretotide and 67 Ga citrate uptake in, after chemotherapy for lymphoma, children, 256P(ab)
Thymidine
 in vivo measurement of cell proliferation, PET, 1048
 marker of tumor proliferation, 262P(ab)
 metabolites in PET imaging, tumor, tissue proliferation, 290
 uptake studies, preservation of hypoxic cardiomyocyte viability by antimyosin liposome membrane sealing, 106P(ab)
Thymus
 131 I uptake in anterior mediastinum, 991
 iodine concentration in thyroid cancer, 1830
Thyroglobulin, comparison of two htG-IRMAs in, differentiated thyroid cancer, 144P(ab)
Thyroglobulin
 concordance and discordance between diagnostic 131 I and 201 Tl scintigraphy, differentiated thyroid cancer, 1487
 detection of recurrence or metastasis in differentiated thyroid carcinoma, 446
 prognostic value in thyroid cancer, use after thyroidectomy and prior to ablation with 131 I, 1962
Thyroid
 adenoma, nodular and extranodular tissue, absorbed dose estimate by 123 I imaging before radiotherapy, 230P(ab)
 comparative methods for quantifying volume, planar imaging and SPECT, 1421
 high-resolution pinhole tomography, SPECT, 2017
 metastatic insular carcinoma, 99m Tc-(V)DMSA, 78
 nodules, 99m Tc tetrofosmin and MIBI imaging of, 159P(ab)
 somatostatin-receptor scintigraphy, bronchial carcinoid with metastases, 1537
 stability of thyroid radioiodine uptake values, 805
 uptake of radioiodide from sodium iodide capsules, 197P(ab)
Thyroid cancer
 123 I- and 131 I-labeled sodium iodide total body scan, comparison, 251P(ab)
 131 I treatment, in children and adolescents, 236P(ab)
 131 I and 123 I sodium iodide comparison, total body scanning, 301P(ab)
 131 I kinetics in, hypothyroidism, 15P(ab)
 99m Tc sestamibi evaluation, comparison with radioiodine, 137P(ab)
 absorbed dose of radioiodine, salivary gland, 102P(ab)
 biological dosimetry in patients treated with
- 131 I**, 1860
differentiated
 after surgery, 201 Tl and 131 I scintigraphy comparison, 135P(ab)
 comparison of two htG-IRMAs in, 144P(ab)
 FDG-PET as followup, 134P(ab)
 postoperative management, 236P(ab)
 recurrent, FDG-PET for detection, 134P(ab)
 use of 131 I in intraoperative detection of, 52P(ab)
enhancement of radioiodine uptake by tumoricidal cytokines, 646
false-positive 131 I whole-body scans, cholecystitis and sebaceous cyst, 1690
histological differentiation, increased GLUT-1 expression and, 248P(ab)
isolated porta hepatis metastasis, 993
locally recurrent and metastatic, FDG-PET imaging of, 135P(ab)
medullary
 detection with radiolabeled antibodies to carcinoembryonic antigen, 9P(ab)
 radiolabeled monoclonal antibodies against CEA, 243P(ab)
prognostic value of thyroglobulin, use after thyroidectomy and prior to ablative radioiodine therapy, 1962
radiotoxicity after 131 I therapy, micronucleus assay, 101P(ab)
recurrent, prediction of outcome with 201 Tl, 16P(ab)
solid tumors, unsealed source radiation therapy for, 235P(ab)
undifferentiated, accuracy of 123 I and 131 I in diagnosis of, 236P(ab)
Thyroid carcinoma
 131 I and 201 Tl whole-body scintigraphy comparisons, distant metastases and residual activity, 1487
 alternating 18 F-FDG-PET and 131 I whole-body scanning, 1468
 effectiveness of combined diagnostic modalities, 446
 external radiation and radioactive iodine treatment for metastasis, 598
 thymic uptake of 131 I in mediastinum, 991
 thyrotoxicosis induced by contrast media in metastatic thyroid carcinoma, abnormal ectopic thyroid tissue, 1532
Thyroid diseases, 131 I outpatient therapy, NRC regulations, 243P(ab)
Thyroid hormone binding ratio, correction of, 144P(ab)
Thyroid malignancy, double-phase scanning, 99m Tc-sestamibi, 1919(le)
Thyroid scans, 99m Tc-pertechnetate uptake by a parathyroid adenoma, 861
Thyroid scintigraphy, procedure guideline for, 1264
Thyroid tumors, 99m Tc-MIBI scintigraphy compared with 201 Tl imaging, 901
Thyroid uptake measurement, procedure guideline for, 1266
Thyroidectomy, comparison of 131 I and 201 Tl whole-body scintigraphy, detection of distant metastases and residual activity, 1487
Thyrotoxicosis, induced by iodinated contrast media in metastatic thyroid carcinoma, abnormal ectopic tissue, 1532
Time-activity curves, FDG-PET determination of, mice, 147P(ab)
Tomographic multigated analysis, leftventricular ejection fraction, comparison to planar
- techniques**, 92P(ab)
Tongue, glucose uptake in FDG-PET, 1918(le)
Total-body scanning, iodine concentration by the thymus, thyroid cancer, 1830
Toxic nodular goiter, effective half-life measurements of 131 I, 228
Toxicity, platelet decrease, bone marrow absorbed dose of 116 Re-HEDP, bone metastasis, 38
Toxoplasmosis, differentiating from CNS lymphoma by 201 Tl SPECT, AIDS, 1150
Trace metal analysis, isotope production, 195P(ab)
Tracers, PET quantitation of myocardial fatty acid metabolism, ^{1-13}C -palmitate, 1723
Transarterial internal radiation therapy, biodistribution of 90 Y-lipiodol in rats with hepatoma, 332
Transcatheter arterial embolization, evaluation of therapy on VX2 liver tumor, FDG-PET, 296
Transferrin
 18 F-labeled, iron metabolism in cell proliferation and rapidly growing cancers, tumor-localization, 1408
 18 F-labeled, PET, biodistribution in nude mice models, 118P(ab)
 receptor kinetics, measurement with dynamic 3D -PET and 18 F Tf, liver, 203P(ab)
 receptor mediated endocytosis, uptake of radionuclides by testis, 336
Transjugular intrahepatic portosystemic shunt, liver perfusion scintigraphy before and after, portal hypertension, 243P(ab)
Transmission computed tomography, image quality for quantitative SPECT, 212P(ab)
Transmission smoothing, quantitative cardiac PET scans, effects of attenuation, 690
Transmission/emission imaging
 simultaneous, incorporating a scanning transmission line source, performance of, 210P(ab)
 SPECT and PET comparison, 19P(ab)
 SPECT, multiple line sources for, 120P(ab)
Transplant, interpretation of captopril renography using a neural network, renal artery stenosis, 1649
Transplantation
 bone marrow
 166 Ho DOTMP ablation trial, 234P(ab)
 acute leukemia, 131 I anti-CD45 antibody regimen prioro, 233P(ab)
 heart
 blood flow and coronary endothelial function after, 83P(ab)
 cardiac PET with 113 C acetate, 161P(ab)
 incidence and time course of reinnervation in, 70P(ab)
 sympathetic neuron effects on basal myocardium blood flows and flow reserve, 4P(ab)
 kidney
 99m Tc MAG3 clearance and delayed graft function, 292P(ab)
 living related donor and recipient renogram evaluation, 292P(ab)
 rejection, 99m Tc MAG3 renogram or coreneedle biopsy in diagnosis, 289P(ab)
 Statistical Neuronet in evaluation, 92P(ab)
 kidney and pancreas, evaluation of renal function after, renal scan and ARM use in, 293P(ab)
 lymph-vessel, lymphoscintigraphy for non-invasive long-term followup, 25P(ab)
 monitoring of graft and native liver functions, FAMIS, 847

- neural**, Parkinson's disease, PET and MRS evaluation of degeneration and graft survival, 66P(ab)
- auxiliary**, ^{99m}Tc TBIDO hepatobiliary scintigraphy of, 113P(ab)
- orthotopic**, hepatobiliary scintigraphy after, 302P(ab)
- Treatment planning**, prediction of radiation doses, tracer studies with ^{131}I -labeled antibodies, 1970
- Triangular intermuscular space**, drainage of lymph nodes on the back, melanoma, 964
- Tropane**, derivatives, exclusive dopamine transporter visualization agent, 186P(ab)
- Tubular reabsorption**, ^{67}Ga -labeled anti-TAC dsFV, 152P(ab)
- Tumor**
- cell line, ^{201}Tl uptake mechanisms in, 64P(ab)
 - cells, hexokinase activity in, 18F Acetyl-FDG, 192P(ab)
 - evaluation of ^{99m}Tc -labeled 2-nitroimidazole as marker of hypoxia, 1023
 - grading, soft-tissue sarcomas, FDG-PET, 257
 - hypoxia
 - ^{111}I IETNIM as a marker for, predictor for radiosensitizing effect and, 253P(ab)
 - ^{18}F FMISO imaging of, 72P(ab)
 - ^{99m}Tc HL91 for identification, correlation with FDGPET, 87P(ab)
 - imaging
 - ^{123}I -iodobenzamides as tracers for detection of melanotic melanoma, 1865
 - criteria for optimal results, radiolabeled liposomes, 326
 - enhanced FDG-PET, 371
 - evaluation of ^{99m}Tc -labeled somatostatin receptor-binding peptides, 1016
 - focal accumulation of ^{111}I -BMIPP in liposarcoma, 997
 - glucose transport proteins for targeting, PET, 1031
 - radiopharmaceutical targeting via receptor-mediated endocytosis of ^{67}Ga -DF-Folate, 1003
 - localization, biological disposition and imaging of radioiodinated alkylphosphocholine in rodents, breast tumors, 1540
 - mandibular invasion, squamous-cell carcinoma, bone SPECT, 42
 - markers
 - characterization of cancer, 204P(ab)
 - CYFRA 21.1, squamous cell carcinoma, head and neck, 145P(ab)
 - proliferation, ^{201}Tl scintigraphic localization of gliomas, 265P(ab)
 - thymidine as, 262P(ab)
 - targeting
 - antibody-dependent signal amplification, 343
 - xenografted tumors, streptavidin and antibody fragment, 203P(ab)
 - therapy and diagnosis
 - ^{123}I -IUDR and ^{123}I -IUDR, preclinical animal studies, 10S(4)
 - xenografts
 - nude mice, Glut mRNA expression in, 254P(ab)
 - necrosis factor, response to hyperthermic isolated limb perfusion for soft-tissue sarcoma, FDG-PET, 984
 - proliferating, ^{123}I IUDR imaging of, 54P(ab)
- Tumor-associated glycoprotein 72**, ^{123}I -VIP receptor scintigraphy and ^{111}In -CYT-103 immunoscintigraphy comparisons, 1313
- gastrointestinal adenocarcinomas**, 1480
- Tumor-seeking agents**, biochemical markers for cancer, 204P(ab)
- Two-dimensional echocardiography**, complex and unresolved issues related to myocardial viability assessment, 794
- Two-step targeting**, bispecific antibody and ^{131}I -labeled bivalent hapten dosimetry, two-step targeting, small-cell lung cancer, 1853
- Tyrosine**, potential as tracer for measuring liver protein synthesis, PET, 279
- U**
- Ultratag RBC kit**, splitting of, use in cardiac first pass studies, 83P(ab)
- Uniformity flood**, chelation of ^{111}In , liquid-filled plexiglass tank, 211P(ab)
- Upright test**, see *Raise-up test*
- Uremic secondary hyperparathyroidism**, ^{99m}Tc -MIBI scintigraphy to identify functional autonomy, 565
- Urinary bladder**, filling artifact, summing rapid SPECT acquisitions and, 212P(ab)
- Urinary tract infection**
 - ^{99m}Tc -DMSA imaging in pediatric population, 823
 - renal outcomes after, children, 46P(ab)
- Urine pH**, reduction of re-uptake of ^{111}In -DTPA-octreotide, administration of lysine or sodium maleate, 1388
- Uveal melanoma**, quantitative comparison of three-step pretargeting method with conventional radioimmunoscintigraphy, 967
- V**
- Validation**, test-retest differences in cerebral glucose metabolism, FDG-PET, 1142
- Vascular graft**, prosthetic, infection, ^{99m}Tc -HMPAO efficacy in, 163P(ab)
- Vascular reserve**, depletion of, oxygen metabolism and, 277P(ab)
- Vasoactive drugs**, blood pool changes in response to, hepatic lobular dynamics, 244P(ab)
- Vasoactive intestinal peptide**
 - receptor antagonist, ^{123}I -labeled, binding, adenocarcinomas, 251P(ab)
 - receptor scan sensitivity compared to ^{111}In -CYT-103 immunoscintigraphy, gastrointestinal adenocarcinomas, 1480
- Vasomotor reserve**, single day split dose stresscerebral perfusion SPECT, image subtraction in, 276P(ab)
- Vasospasm**, after subarachnoid hemorrhage, brainSPECT with angiography and transcranial Doppler, 12P(ab)
- Ventilation/perfusion**
 - detection of acute pulmonary embolism, chest radiographic findings and, 117P(ab)
 - emphysema
 - lung volume reduction surgery, 5P(ab)
 - preoperative assessment, 5P(ab)
 - endobronchial stent implantation by, quantification of, 36P(ab)
 - for directing pulmonary angiography, 294P(ab)
 - lung scan
 - diagnostic value of small perfusion defects in suspected pulmonary embolism, 1313
 - evaluating criteria for low probability interpretation, 577
- misdiagnosis of pulmonary embolism in complex congenital heart disease**, 1359
- patient stratification by cardiopulmonary status**, 570
- revision of interpretive criteria for acute pulmonary embolus, pleural effusion size, 1310
- triple-matched defects in the detection of acute pulmonary embolism, chest radiographic abnormalities, 1636
- patterns, pleural effusions, 296P(ab)
- pulmonary embolism, prevalence of recurrence, 295P(ab)
- quantitative analysis of ratio, exercise lung scintigraphy, 296P(ab)
- Ventriculography**
- first-pass, estimation of resting left ventricular ejection fraction, 181P(ab)
 - radionuclide evaluation in cardiomyoplasty, 93P(ab)
 - SPECT and, evaluation of left ventricular hypertrophy, 93P(ab)
 - treadmill exercise first-pass, normal limits of, 93P(ab)
 - use of ^{99m}Tc -labeled liposomes for blood-pool imaging, compared with ^{99m}Tc -red cells, 1374
- Vertebral metastasis**, comparison of bone SPECT and MRI in detection of, 975
- Vertebrobasilar insufficiency**, ^{99m}Tc HMPAO brain perfusion SPECT, enhanced with acetazolamide, 88P(ab)
- Vesamicol receptor**
 - ^{123}I MIV affinity for, Alzheimer's disease, 186P(ab)
 - binding, dopamine D2 receptor-sensitive, intact striatum, 280P(ab)
- Vesico-ureteric reflux**, ^{99m}Tc -DMSA imaging in pediatric urinary tract infection, 823
- Vesicular internalization**, enhancement of radiation dose to nucleus, ^{123}I -labeled A33 monoclonal antibody, 1052
- Vesicular monoamine transporter**, assessment of, equilibrium versus compartmental analysis, 109P(ab)
- Vestibular stimulation**, differences in central processing, 122P(ab)
- Virtual surgery**, Nuclear medicine lays the groundwork for virtual surgery, 25N(2)
- Visceral pain**, normal and pathologic perception of, regional cerebral activity in, PET, 123P(ab)
- Visual analysis**, limits of, in image misregistration of brain ^{18}F FDG-PET-MRI study, 208P(ab)
- Visual selective attention**, orientation and spatial frequency, ^{18}O water PET, 306P(ab)
- Volume estimation**, quantification using planar imaging and SPECT, thyroid phantoms, 1421
- Volume rendering**, three-dimensional bone scintigraphy, usefulness and limitations, SPECT, 1567
- Vulvar cancer**, groin metastases in, detection with ^{14}C tyrosine PET, 263P(ab)
- VX2 tumor**, FDG-PET evaluation of therapy, 296
- W**
- Wegener's vasculitis**, lung uptake on ^{99m}Tc -MDP bone scan, 857
- Whole-body acquisition**, combined scans and FDG-SPECT in breast tumor

- investigations, 615
- Whole-body scan**
false-positive findings due to cholecystitis and sebaceous cyst in thyroid cancer patients, ^{131}I , 1690
role in radioiodine breast uptake in nonbreastfeeding thyroid cancer patients, 26
- Whole-body skeletal uptake**, age-related changes in bone metabolism, $^{99\text{m}}\text{Tc}$ -HMDP, 815
- Window-based technique**, energy-based scatter corrections for scintillation images of ^{131}I , spectrum-fitting technique, 2030
- World Wide Web**
digital department moves to, 172P(ab)
internet for case-based teaching files, 178
virtual reality markup language extensions and, cardiac SPECT and PET, 172P(ab) X
- X**
- Xenon-133**
compared with $^{99\text{m}}\text{Tc}$ -HMPAO measurements of regional cerebral blood flow, SPECT, 1735
ventilation scintigraphy, tympanum and paranasal sinuses, 4P(ab)
- Y**
- YM-43611**, ^{18}F fluorinated substituted benzamide analog of, radiotracer for dopamine D4 receptors, 50P(ab)
- Yttrium-86 EDTMP**, PET measurements of uptake, calculation of radiation dose for ^{153}Sm EDTMP based on, 227P(ab)
- Yttrium-90**
immunoconjugates, autoradiolysis of, 143P(ab)
combined with anti-EGFr c225, nude mice with human breast tumors, 167P(ab)
 ^{111}In biotin and, dual isotope counting method, pretargeted cancer therapy, 144P(ab)
 ^{89}Sr and, proposed radioisotope generator based on microfiltration, 194P(ab)
chelation, preparation of radioimmunoconjugate, 167P(ab)
labeling of lipiodol, biodistribution in rats with hepatoma, 332
labeling of monoclonal antibody macrocyclic chelator conjugates, for radioimmunotherapy, 62P(ab)
myelosuppression and therapeutic potential,
- Z**
- Ziprasidone**, serotonin receptor occupancy and, PET analysis, 33P(ab)



**CONTEMPORARY
HEALTHCARE
AND THE ETHIC
OF MEDICINE:
WHAT IS A
PHYSICIAN TO DO ?**

April 13-15, 1997

The Drake Hotel—Chicago, IL

Practitioners, ethicists, medical policy makers, and representatives of managed care are invited to meet together to re-examine the ethic of medicine as a profession and to consider challenges to ethical practice that physicians may encounter as a result of the rapid changes in the organization and financing of healthcare.

Sponsored by:
The Council of Medical Specialty Societies and
the American Academy of Otolaryngology—Head and Neck Surgery Foundation

Confirmed Speakers:
Saul Bellow, Roger J. Bulger, MD, Christine K. Cassel, MD, J. Lee Dockery, MD, John M. Eisenberg, MD, Jeremy Lazarus, MD, George D. Lundberg, MD, Mary H. McGrath, MD, MPH, Martin F. McKneally, MD, PhD, Lynn Peterson, MD, Edmund D. Pellegrino, MD, Raymond Scalettar, MD, and John Santa, MD

CME Credit
The American Academy of Otolaryngology—Head and Neck Surgery Foundation (AAO-HNSF) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The AAO-HNSF designates this educational activity for a maximum of 13 hours in category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

**For more information or to request registration materials, call
(847) 295-3456 or FAX (847)295-3759.**

JNM

DIRECT RESPONSE

Advertisers for December 1996

Listed below are the companies that have advertised in this issue. Simply circle the numbers of those companies you are interested in, fill out the information below, and mail or FAX this to the Society of Nuclear Medicine, Advertising Department, 1850 Samuel Morse Drive, Reston, VA 20190, Fax 703-708-9015. We will forward this information to the advertiser(s).

Reader Svc.No.	Advertiser		Telephone No.	Page(s)
1	ADAC Laboratories	Milpitas, CA	800/538-8531	4A-5A
10	Amersham, Medi-Physics, Inc.	Arlington Heights, IL	708/593-6300	15A-16A
23	Capintec, Inc.	Ramsey, NJ	800/631-3826	2A
31	Data Spectrum	Chapel Hill, NC	919/732-6300	19A
34	Du Pont Company	No. Billerica, MA	800/343-7851	20A-22A
82	Immunomedics	Morris Plains, NJ	800/327-7211	13A
110	Mallinckrodt Medical, Inc.	St. Louis, MO	314/895-2000	9A-12A
140	Ones Medical Services	Goffstown, NH	800/438-6637	25A
145	Park Medical Systems	Peabody, MA	508/977-6868	Inside Back Cover
181	Siemens Medical Systems, Inc.	Hoffman Estates, IL	708/304-7252	Inside Front Cover-1A
192	Toshiba Medical Systems	Tustin, CA	800/521-1968	Back Cover



SNM Meetings



SNM Membership Information



SNM Book Order Information

YOUR NAME: _____ TITLE: _____

INSTITUTION: _____ DEPT: _____

ADDRESS: _____

CITY: _____ STATE: _____ ZIP: _____

PHONE: _____ FAX: _____

PRIMARY SPECIALTY: _____ SECONDARY SPECIALTY: _____

CHECK ONE ANSWER IN EACH CATEGORY

Employer

- Hospital
- 500 patients plus
- 300-499 patients
- 200-299 patients
- 100-199 patients

Employer

- Private Clinic
- R&D Commercial
- University
- Government
- Other _____

Purchase Authority

- Recommend
- Specify
- Purchase

Reason for Inquiry

- Immediate Purchase
- General Information
- Budgeting Information

SNM Member

- Yes
- No

JNM/JNMT Subscriber

- Yes
- No